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Chapter I. General Introduction: Psychosis in Alzheim er’s disease
1. General Introduction: Psychosis in Alzheimer’s disease
A number of behavioural symptoms are commonly displayed by Alzheimer’s 
disease (AD) sufferers. Behavioural disturbances in AD can include affective 
symptoms, agitation, aggression and psychosis (Burns et al. 1990a; Burns et al. 
1990b; Burns et al. 1990c). Alois Alzheimer was the first to document psychosis in 
the disease bearing his name, during his description of the clinical presentation of 
a patient upon admission to the Frankfurt asylum in 1906 (Alzheimer 1995; 
Schneider and Dagerman 2004).
“Sometimes she greets the doctor as if he were a visitor.. .on other 
occasions she screams that he wants to cut her open.. .on others yet she 
fears him as a threat to her honour as a woman., .she seems to have 
auditory hallucinations. Often she screams for many hours in a homble
voice”
In this classic case of 51 year old Auguste D[eter], who presented with focal 
cognitive deficits, Alzheimer identifies both symptoms of psychosis, delusions and 
hallucinations, in addition to activity disturbances and aggression (Reisberg et al. 
1987a). Psychosis is a mental state involving hallucinations and/or delusions (van 
Os et al. 2000). Hallucinations are disturbances of perception that occur without 
cause in the real world (Behrendt 1998). They can occur in any sensory form 
(sound, sight, touch, taste and smell). Delusions are irrational yet strongly held 
personal beliefs held despite contradictory evidence, which result from an inability 
to separate real from unreal experiences, and are unexplained by the person's 
cultural background (Manschreck 1996). Psychosis in Alzheimer’s disease is 
common, often resulting in increased severity of functional and cognitive deficits 
(Jeste et al. 1992; Stern et al. 1994a), increased rate of decline (Neumann et al. 
2001; Wilson et al. 2000), earlier institutionalisation (Borson and Raskind 1997; 
Steele et al. 1990) and increased caregiver distress (Donaldson et al. 1998; Craig 
et al. 2005). Evidence suggests that psychotic symptoms in AD are heritable and 
may characterise a distinct and more severe disease subtype. Identification of 
genetic variation associated with Alzheimer’s disease with psychosis (AD+P) will
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further our understanding of the disease mechanisms which underlie behavioural 
features of AD and may have implications for other complex genetic disorders 
where psychosis is common.
1.1 Alzheimer’s disease
Alzheimer’s disease is a devastating neurodegenerative disorder, afflicting 
approximately 30 million individuals worldwide (Sanchez 2009). AD accounts for 
60-80% of late-onset dementia cases. In England and Wales there are thought to 
be approximately 700,000 AD cases (Comas-Herrera et al. 2007), with 180,000 
new cases of dementia reported each year (Matthews and Brayne 2005). In 
addition to the detrimental effects to sufferers, AD also causes severe distress for 
family members and caregivers, and places a massive burden on the economy 
(Lowin et al. 2001). The direct cost of AD to the United Kingdom is over 17 billion 
pounds a year (Comas-Herrera et al. 2007). With the oldest sector of the 
population expected to increase by 68% in the developed world (United Nations
2008), current projections suggest that by 2020 more than a billion people over the 
age of 65 will live in Europe (The Harvard School of Public Health 1996). Given 
AD is an age dependent disease, the escalating growth of the elderly population 
means that the economic and societal costs of the disease will increase over the 
coming years (Souetre et al. 1999; Villareal and Morris 1999).
Histopathological examination of brain tissue at post mortem is the only 
definitive method of diagnosing AD. However, this is problematic, with only 50% to 
60% of individuals meeting neuropathological criteria for AD having experienced 
cognitive decline (Knopman et al. 2003). Probable diagnosis of AD is generally 
based on physical examination, patient history and detailed cognitive assessment. 
The fourth edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV) (American Psychiatric Association, 1994) and the National Institute of 
Neurological and Communication Disorders and Stroke and the Alzheimer’s 
disease and Related Disorders Associations (NINCDS-ADRDA) (McKhann et al. 
1984) criteria are generally used in both research and clinical settings to make a 
diagnosis of Alzheimer’s disease. Both require deficits in memory and one other 
area of cognition, including aphasia, apraxia, agnosia and executive functioning,
3
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further stipulating that these difficulties should cause significant decline in 
functional abilities and activities of daily living. DSM-IV and NINCDS-ADRDA 
criteria also stipulate that the illness should be characterised by an insidious onset 
and gradual decline in cognitive and functional abilities, and that competing causes 
of dementia are ruled out. The reliability and validity of DSM-IV and NINCDS- 
ADRDA criteria for AD have been found to be good (O’Conner et al. 1996), with 
known validity for AD pathology (i.e. positive predictive value of 92-95% ) (Becker 
et al. 1994; Foy et al. 2007; Gearing et al. 1995; Holmes et al. 1999).
Neuroimaging may compliment the standard approaches, and serves to identify 
vascular contributions and other potentially treatable conditions (Kantarci and Jack 
2003).
The chief symptoms of Alzheimer's disease are progressive decline of 
memory and other higher mental functions, such as cognitive decline, nominal and 
comprehensive dysphasia, dyspraxia, agnosia, impairment of executive functioning 
and behavioural disturbances (Desai and Grossberg 2005; White and Clare 2002). 
Although many of these symptoms will not be present at the time of diagnosis, 
most AD sufferers will experience the majority if not all of these symptoms during 
the course of their illness (Havard 2005). In the early stages of Alzheimer's disease 
when the cells in the hippocampus degenerate, short-term memory begins to 
decline accompanied by deficits in learning and recalling new information. The 
ability to perform routine tasks also declines. As Alzheimer's disease spreads 
through the cerebral cortex judgment declines, emotional outbursts may occur and 
language is impaired, from anomia in the early stages to complete aphasia as the 
illness progresses. Advancement of the disease leads to increased deficits in 
executive function (Baudic et al. 2006; Rainville et al. 2002), and behaviour 
changes such as wandering and agitation. Visuospatial difficulties can often 
become apparent, manifesting as geographical disorientation or difficulty with 
copying figures in cognitive testing (Cummings and Cole 2002). Motor disturbances 
are common in the later stages of disease development, including gait changes, 
rigidity and seizures (McKhann et al. 1984). The ability to recognize faces and to 
communicate is completely lost in the final stages of disease. Patients lose bowel 
and bladder control, and eventually need constant care, frequently being bed 
bound (Villareal and Morris 1999). Without treatment those with AD usually survive 
for between 7 and 10 years after the onset of symptoms (Bracco et al. 1994;
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Larson et al. 2004), although it can take 20 years or more for the disease to run its 
course. A notable clinical variation in AD is age at onset (AAO). AD can present at 
anytime from 30 to 90+ years of age. A distinction is often made between those 
with disease onset before and after the age of 65, supported by both DSM-IV and 
NINCDS-ADRDA criteria. Those with a disease onset of less than 65 years are 
termed as early onset AD (EOAD); this form of the disease is rare, accounting for 
approximately 5% of AD sufferers. Both early and late onset cases share the 
clinical and neuropathological features of AD. However, early onset forms of the 
disease have been found to be characterised by shorter survival, more rapid 
cognitive deterioration, more severe language disturbances, and more severe AD 
related neuropathology (Koss et al. 1996; Sevush et al. 1993; Villareal and Morris 
1999).The most compelling evidence for a distinction between early and late onset 
AD comes from genetic findings, discussed in section 1.1.1.
There is currently no cure for AD. Cholinesterase inhibitors and A/-methyl d- 
aspartate receptor-targeted therapies are presently the only forms of medication 
available in the UK. Medication may provide modest benefits to cognition, activities 
of daily living and behaviour, and can provide temporary stabilisation of the rate of 
decline (Desai and Grossberg 2005). These treatments do not benefit all AD 
sufferers and their positive effects are usually temporary (Cummings and Cole
2002), meaning that there is an urgent need for more effective therapeutic 
interventions.
1.1.1. Genetics of Alzheimer’s disease
AD is generally categorised as sporadic or familial (Ashford and Mortimer
2002). The term familial is reserved for cases in which a clear pattern of autosomal 
dominant inheritance is observed, or for cases carrying known EOAD causing 
genetic mutations. Familial cases usually present with the disease before 65 years 
of age. Sporadic cases have a complex polygenic mode of inheritance (Ashford 
and Mortimer 2002), constitute around 95% of AD cases, and usually present after 
the age of 65. To date, the most significant discoveries in the genetic aetiology of 
AD have come from the rare autosomal dominant forms of disease. Mutations in 
the genes encoding p-Amyloid Precursor Protein (APP) on chromosome 21 (Goate 
etal. 1991), presenilin 1 (PSEN1) on chromosome 14 (Sherrington et al. 1995) and
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presenilin 2 (PSEN2) on chromosome 1 (Levy-Lahad et al. 1995; Rogaev et al. 
1995; Sherrington et al. 1995) have been found to cause AD in families with early- 
onset autosomal dominant forms of the disease. Most of the pathogenic mutations 
in the APP and presenilin genes are associated with abnormal processing of APP, 
which leads to the overproduction of toxic amyloid-beta 42 peptide (A(342) found in 
senile plaques (Kamboh 2004). Together, mutations in these genes account for 
approximately 50% of early onset AD cases, with the main contribution from 
PSEN1 (Tandon et al. 2000). These genes show no consistent evidence for 
involvement in the aetiology of late-onset AD (LOAD). Our understanding of the 
genetics of this more common form of AD remains much less complete (Lambert et 
al. 2004).Nu merous population based twin studies have been conducted and 
generally support heritability estimates for AD from 58-79% (Gatz et al. 2006), 
whilst family based studies consistently find the presence of one or more affected 
family members to be a strong risk factor for the disease (Fratiglioni et al. 1993; 
Jarvik et al. 1996; Martinez et al. 1998; Sleegers et al. 2004; van Duijn et al. 1991). 
To date, Apolipoprotein E (APOE) situated on chromosome 19 is the only gene to 
show consistent evidence of contributing to risk for both EOAD and LOAD. There 
are three common alleles of the APOE gene e2 , e3 and e4, resulting from amino 
substitutions (Arg and Cys) at positions 112 and 158 of the protein (Lambert et al.
2002). In normal populations the e3 allele is the most frequent, whilst e4 occurs 
slightly more often than the e2 allele (Hendrie 1998). The e4 allele of APOE 
displays replicable association with AD in hundreds of diverse case-control 
samples (Corder et al. 1993; Myers et al. 1996; Reiman et al. 2007), and pedigree 
cohorts (Saunders et al. 1993). The findings have been remarkably consistent with 
only a few studies, largely in selective populations, failing to find an association 
(Ashford et al. 2003; Raber et al. 2004). Carrying an e4 allele increases the risk for 
AD in an allele dose-dependent manner and is associated with an earlier age at 
onset of the disease, with the strongest effect below 70 years (Corder et al. 1993). 
In Caucasian populations, individuals who carry the e4 allele are three 
(heterozygotes) to eight (homozygotes) times more likely to develop AD than 
individuals who do not harbour the e4 allele (Corder et al. 1993). Conversely 
bearing a e2 allele confers protection against the disease (Farrer et al. 1997). This 
effect is not simply due to the absence of the e4 allele (Talbot et al. 2004). In fact, 
Corder and colleagues (Corder et al. 1994) reported that up to 23% of the risk of
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AD in their sample was attributable to the absence of APOE z2. Thus, APOE 
genotype is an important biologic marker for AD susceptibility. However, 
possession of the z4 allele is not sufficient to develop the disease. As many as 
50% of people who have two copies of z4 and survive to age 80 years are not 
cognitively impaired (Lambert et al. 2002). In fact, variation at the APOE locus 
accounts for less than half the genetic variation in liability to LOAD (Harold et al.
2003). Estimates of population risk attributable to APOE have ranged from 12% to 
57% (Harold et al. 2009; Nalbantoglu et al. 1994; Seshadri et al. 1995; Slooter et 
al. 1998), with the most recent estimates lying at the lower end of the range (Harold 
et al. 2009). In addition to the e2 and e4 alleles, polymorphisms in the APOE 
promoter region have been implicated with susceptibility to AD, however the results 
of these associations are often contradictory (Bullido et al. 1998; Lambert et al. 
2002; Lambert et al. 1998; Song et al. 1998; Wang et al. 2000). The biological 
mechanism by which APOE increases the risk of developing AD is not well 
understood. A number of studies have reported that the APOE z4 allele is 
associated with increased senile plaque and neurofibrillary tangle formation 
(Ghebremedhin et al. 2001), and a reduction in choline acetyltransferase in brains 
of AD patients (Schmechel et al. 1993). Since APOE modulates clearance and 
aggregation of Ap as well as other neuropathological changes, it has been difficult 
to elucidate the exact pathological mechanism behind the observed Ap phenotypes 
in human and animal studies. Prevailing data suggest that the main effect of APOE 
isoforms on risk for AD is via the effect of APOE on Ap metabolism, influencing the 
time of onset of Ap deposition in both brain parenchyma and vasculature (Kim et 
al. 2009). Additionally, the e4 isoform is not very efficient at catalyzing proteolytic 
breakdown of the Ap peptide (Jiang et al. 2008), suggesting a mechanism to 
increase vulnerability to Alzheimer's disease in individuals with that gene variation 
(Jiang et al. 2008). Other potential mechanisms, such as the differential modulation 
of neurotoxicity and tau phosphorylation by APOE isoforms as well as its role in 
synaptic plasticity and neuroinflammation, have not been ruled out. Inconsistent 
results among studies have made it difficult to define whether the APOE z4 allele 
represents a gain of toxic function, a loss of neuroprotective function, or both (Kim 
et al. 2009).
There remains a large percentage of the genetic risk for AD unaccounted for 
(Daw et al. 2000; Myers and Goate 2001). Over the past 16 years, since the
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identification of the APOE  locus, tremendous effort has been put into identifying 
these genes. Linkage analyses have generally proved inconclusive with most 
evidence implicating a region of chromosome 10 (Bertram et al. 2000; Ertekin- 
Taner et al. 2000; Farrer et al. 2003; Li et al. 2002; Myers et al. 2000).Findings 
from candidate gene association analyses have generally been negative, 
inconclusive or contradictory (Bertram and Tanzi 2004; Brookes and Prince 2005; 
Kamboh 2004). Most association studies have been restricted to genes which are 
both functional and positional candidates for AD (e.g. functional candidate genes 
within regions of linkage). However, very few of these associations have positively 
replicated when analysed in independent samples, increasing the possibility that 
these are ‘false positive’ findings (Brookes and Prince 2005). The recent evolution 
of genome-wide association studies (GWAS) has brought new hope to the field of 
AD genetics, with the identification and replication of one novel susceptibility locus 
and significant evidence for two additional loci (Harold et al. 2009; Lambert et al.
2009). The history of GWAS in AD is discussed more thoroughly in chapter 5. 
Despite these recent advances, a large amount of the genetic variation of AD is yet 
to be explained. Rare variation and/or alternative genetic elements such as copy 
number variation may explain a proportion of the missing genetics. However, it is 
possible that phenotypically distinguishable forms of AD, such as psychosis, could 
be linked to specific susceptibility loci. Therefore, utilising sample subsets with a 
narrow range of clinical variation may offer a suitable method to identify 
susceptibility loci for more homogenous forms of disease (Freimer and Sabatti
2003).
1.1.2. Neuropathology and Neurochemistrv of Alzheimer’s disease
Two kinds of microscopic damage develop in the AD brain; amyloid/senile 
plaques and neurofibrillary tangles. Neuron degeneration and synaptic loss are 
additional neuropathological hallmarks of the disease (Cummings and Cole 2002; 
Kamboh 2004). Amyloid plaques are abnormal extracellular structures which can 
be found throughout the AD brain, often particularly concentrated in the temporal 
lobes (Honig and Chin 2001). They consist predominantly of peta-amyloid, a 40- to 
42-amino-acid peptide derived from cleavage of the p-amyloid precursor protein 
(APP) (Abraham 2001). The APP protein is present in almost all tissues, and
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undergoes three alternative steps of cleavage by a-, p- and y-secretase enzymes. 
When cut by a-secretase and then y-secretase, APP generates a harmless 
peptide. However, when cut by P-secretase and then y -secretase, APP generates 
peptides of 39 to 43 amino acids, of which Ap42 accounts for about 10%. Ap42 is 
neurotoxic and involved in the formation of senile plaques in AD brains (Selkoe 
2001 ).A dditional proteins, aberrant neuronal cell processes (neuritis), reactive 
astrocytes and microglial cells are also contained within the amyloid plaques. 
Neurofibrillary tangles are abnormal intracellular structures located in various parts 
of the brain, occupying the cell body and extending into the dendrites. They are 
composed of dense arrays of paired helical filaments which are composed of a 
hyperphosphorylated form of the microtubule-associated protein tau (Honig and 
Chin 2001). The number of neurofibrillary tangles seen post-mortem has been 
shown to correlate with the degree of dementia during life (Honig and Chin 2001). 
However, synaptic loss is currently the best pathologic correlate of cognitive 
decline, and synaptic dysfunction is evident long before synapses and neurons are 
lost (Coleman et al. 2004). Neuronal loss or atrophy in the nucleus basalis, locus 
ceruleus and raphe nuclei of the brainstem leads to deficits in cholinergic, 
noradrenergic and serotonergic neurotransmitters and neuromodulators 
(Cummings and Cole 2002). In particular, the level of choline acetyltransferase is 
markedly reduced, typically in the hippocampus, substantia inominata, locus 
cereleus, and tempoparietal and frontal corticies (Hauw and Duyckaerts 2001;
White and Clare 2002). The current criteria for pathological diagnosis of definite AD 
require the presence of both amyloid plaques and neurofibrillary tangles (Reagan 
Institute Working Group 1997).
1.1.3. Environmental Risk Factors for Alzheimer’s disease.
In addition to genetics, numerous other risk factors for AD have been 
reported, of which increasing age, female sex and low levels of education are the 
most consistent. Increasing age is the most notable non-genetic risk factor for AD. 
However, prevalence estimates have tended to vary across studies (Hebert et al. 
1995; Ott et al. 1995). Multi centre meta-analyses have found the incidence of AD 
rises with age (Jorm and Jolley 1998; Launer et al. 1999; Matthews and Brayne
2005), with rates differing according to ethnicity and the diagnostic criteria used
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(Jorm and Jolley 1998). Population based samples have also been used to 
determine age specific incidence rates for AD in a variety of populations of differing 
ethnicity (Bachman et al. 1993; Canadian Study of Health and Aging 1994; Di 
Carlo et al. 2002; Fillenbaum et al. 1998; Fratiglioni et al. 1997; Ganguli et al. 2000; 
Guo et al. 1999; Havlik et al. 2000; Hebert et al. 1995; Hendrie et al. 2001; Kawas 
et al. 2000; Newman et al. 2005; Paykel et al. 1998; Tang et al. 2001; von Strauss 
1999; Waite et al. 2001; Yoshitake et al. 1995). On the whole most studies report 
incidence rates of AD between 1% and 3% in those aged around 65, rising to over 
40% among those aged over 85. Across experimental designs, there is a general 
consensus that the risk of AD increases exponentially with age, with incidence 
rates approximately doubling every five years up to 90+ years of age (Kukull et 
al.2002).
Numerous studies report female sex as a risk factor for AD (Brayne et al. 
1995; Fratiglioni et al. 1997; Hagnell et al. 1992). For example, in a longitudinal 
study by Brayne and colleagues, the incidence of Alzheimer's disease was 
increased 2.2-fold in females compared to males (Brayne et al. 1995). However, 
many findings are contradictory, and are likely to be imprecise (Ruitenberg et al.
2001), with prevalence estimates biased by the differential life expectancy of males 
and females (Bonsignore et al. 2002). Some large studies have suggested that the 
differential risk to males and females may be restricted to very old age (Launer et 
al. 1999; Ruitenburg et al. 2001). While several studies have reported no difference 
in the prevalence of dementia according to sex (Bachman et al. 1993; Ganguli et 
al. 2000; Letenneur et al. 1994a; Paykel et al. 1994; Rocca et al. 1998).
Low levels of education have been reported to increase the risk of 
developing AD in population (Ott et al. 1995; Qiu et al. 2001), longitudinal 
(Canadian Study of Health and Aging 1994; Di Carlo et al. 2002; Mortimer et al. 
2003; Schmand et al. 1997; Zhang et al. 1990) and cross sectional studies (Hill et 
al. 1993; Katzman 1993; Mortel et al. 1995; Risch 2000; Stern et al. 1994b). The 
cognitive reserve hypothesis proposes that education/mental activity might 
enhance the brains reserves by increasing synaptic density in the neocortical 
cortex. (Katzman 1993; Stern et al. 1994b). However, a number of large studies 
have failed to find a relationship between education and AD (Cobb et al. 1995; 
Fratiglioni et al. 1991; Paykel et al. 1994). Numerous lifestyle factors differ 
according to education which are likely to bias findings if not successfully
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accounted for (Winkleby et al. 1992). For example, socioeconomic status and 
disease diagnosis (Evans et al. 1997; Winkleby et al. 1992), as those with a higher 
education tend to perform better on neuropsychological tests (Qiu et al. 2001,
Stem et al. 1994b). Other, less well supported risk factors include smoking 
(Bowirrat et al. 2001, Lee 1994; Letenneur et al. 1994b), head injury (Launer et al. 
1999; Nicoll et al. 1995; Canadian Study of Health and Aging 1994), depression 
(Devanand et al. 1996; Speck et al. 1995), cardiovascular risk factors (Luchsinger 
and Mayeux 2004) and oestrogen replacement therapy (Henderson et al. 1994; 
Schmidt etal. 1996).
1.2. Psychosis in Alzheimer’s disease
AD has long been known to be accompanied by a variety of behavioural and 
psychological symptoms (Reisberg et al. 1987b). The type, severity and prevalence 
of behavioural symptoms vary greatly and they are not generally believed to be an 
inevitable consequence of disease progression (Cummings 2000; Sweet et al.
2003). Psychotic symptoms in AD are defined as delusions and/or hallucinations 
that are not attributable to other causes such as intoxication or delirium (Mintzer 
and Targum 2003). Development of psychosis is common in patients with AD 
(Bassiony et al. 2000; Jeste et al. 1992; Paulsen et al. 2000b). With the estimated 
prevalence ranging from approximately 40% (Ropacki and Jeste 2005) to over 60% 
(Ballard et al. 1995; Cook et al. 2003). Delusions and hallucinations both seem to 
develop more readily within a 1 to 2 year span and incidence seems to plateau 
after 3 years (Paulsen et al. 2000b), with the development of psychosis subsiding 
before 5 years of follow-up (Chen et al. 1998). Psychotic symptoms rarely seem to 
persist after several months, however exceptions to this standard have been 
acknowledged (Ropacki and Jeste 2005), and once present psychosis may recur 
or persist for several years (Jeste and Finkel 2000). In contrast to the progressive 
worsening of cognitive and functional changes in AD, behavioural and 
psychological symptoms peak in occurrence at some point prior to the final stage of 
AD (Ropacki and Jeste 2005). One hypothesis is that non-cognitive symptoms 
decrease in severe dementia because the AD brain can no longer articulate the 
symptoms. Psychosis in AD has been found to associate with many serious
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consequences including; severe functional (Stern et al. 1994a) and cognitive 
deficits (Jeste et al. 1992), increase in rate of decline (Wilson et al. 2000), earlier 
institutionalisation (Steele et al. 1990) and an increase in caregiver distress 
(Donaldson et al. 1998).
Delusions are the most common psychotic symptom in AD with a 
prevalence of around 36% in AD cases (Ropacki and Jeste 2005). The most 
frequent form of delusion in AD is misidentification. For example, the belief that 
one’s home is not one’s home, that a family member is someone else, that images 
on the television are actually people present in the house, or even that the person 
in the mirror is not oneself (Cook et al. 2003). Delusions of theft are also frequent. 
Delusions in AD are typically simple and non-bizarre and seem to differ somewhat 
from the more complex and bizarre delusions seen in patients with schizophrenia 
(Jeste and Finkel 2000). Hallucinations in AD occur less frequently, with an 
estimated prevalence of approximately 18% (Ropacki and Jeste 2005), and often 
co-occur with delusions. Hallucinations in AD are primarily visual and secondarily 
auditory in nature (Cook et al. 2003), with estimated prevalence of 18.7% and 9.2% 
respectively (Ropacki and Jeste 2005).
At post-mortem subjects with psychosis have been found to have increased 
amyloid plaque deposition and a 2.3-fold greater density of neocortical 
neurofibrillary tangles than subjects without psychosis (Farber et al. 2000; Marshall 
et al. 2006; Tekin et al. 2001; Zubenko et al. 1991). Increased levels of abnormal 
paired helical tau protein filaments in entorhinal and temporal cortices have also 
been documented in AD+P (Mukaetova-Ladinska et al. 1993). Although, a 
conflicting study showing no significant differences in neurofibrillary tangle or 
amyloid plaque density or distribution in AD+P has been reported (Sweet et al. 
2002a). As the majority of studies report similar observations it is likely that AD 
patients experiencing psychosis do have a greater amyloid plaque and 
neurofibrillary tangle burden compared to AD patients without psychosis. Although 
the implications of these observations are unclear, it has been suggested that 
psychosis in AD represents a more severe form of disease (Sweet et al. 2002b).
Neuroimaging investigations have found interesting changes in brains of 
patients with AD+P compared to AD patients and controls. The frontal (Kotrla et al. 
1995a; Lopez et al. 2001; Mega et al. 2000; Mentis et al. 1995; Staff et al. 1999;
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Sultzer et al. 1995; Sultzer et al. 2003), caudal anterior cingulated (Mega et al.
2000; Mentis et al. 1995; Sultzer et al. 1995; Sultzer et al. 2003), temporal (Hirono 
et al. 1998a; Lopez et al. 2001; Mentis et al. 1995; Ponton et al. 1995; Starkstein et 
al. 1994; Sultzer et al. 2003), parietal (Kotrla et al. 1995a; Mega et al. 2000), and 
occipital (Hirono et al. 1998a) lobes and striatum (Mega et al. 2000) have 
demonstrated abnormalities in a number of metabolism or perfusion imaging 
studies (Meeks et al. 2006; Fukuhara et al. 2001). Moran and colleagues have 
reported a whole brain, voxel-based imaging study which finds sex differences in 
AD+P (Moran et al. 2008), supporting sex as a risk factor for AD and AD+P. 
However, these findings have not, to date, been replicated, and there is no 
structural imaging data to support the observations. Also, there are several reports 
of sex differences in healthy older subjects (Good et al. 2001; Gur et al. 1995;
Jones et al. 1998; Li et al. 2004a; Slosman et al. 2001). Structural imaging of AD+P 
patients has revealed an increase in frontal and temporal asymmetry (Geroldi et al.
2002). For example, a magnetic resonance imaging (MRI) study indicated a 
relationship between delusions and white matter changes in LOAD (Lee et al.
2006). Significant associations with white matter changes and delusional 
misidentification were identified in frontal, right parieto-occipital, and left basal 
ganglia regions (Lee et al. 2006). While white matter changes are common in 
patients with AD (Scheltens et al. 1992; Scheltens et al. 1995; Fazekas et al. 1996; 
Filippini et al. 2009), the changes documented in psychosis appear distinct (Lee et 
al. 2006). Despite many studies using modest sample sizes (often less than 50 
subjects), the results of the majority of imaging studies in AD+P appear robust with 
good consistency and reproducibility across groups. In many cases, the findings of 
these studies also appear to correlate well with the clinical presentation of a more 
severe form of disease. Therefore supporting the suggestion that psychosis in AD 
is a distinct subtype of AD and warrants independent investigation.
1.2.1. Development of Psychosis in Alzheimer’s disease
There are two theories of psychosis development in AD (Hirono et al. 
1998b). For both theories, the AD patient who develops psychosis may have an 
underlying predisposition to the psychosis phenotype. This psychosis has not
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developed earlier in life due to avoidance of other ‘risk’ factors, or has been 
unmasked by the loss of compensatory mechanisms due to neuronal loss, amyloid 
plaque and neurofibrillary tangle formation and neurodegeneration. The first theory 
of psychosis development in AD suggests that psychosis develops on the 
‘background’ of AD (Hirono et al. 1998b). As such, AD patients with psychosis 
develop AD by the same mechanism, and therefore through common genetic and 
environmental risk factors, as AD patients without psychosis. However, once AD 
has developed genetic and environmental risk factors for psychosis manifest in the 
presentation of a psychotic phenotype. The genes which promote psychosis in AD 
are modifying the disease phenotype and are thus referred to as ‘modifier’ genes. 
We would expect to identify psychosis modifier genes through comparison of allele 
and genotype frequencies in AD cases with psychosis (AD+P) against AD cases 
without psychosis (AD-P).
The second theory proposes that AD with psychosis is a divergent sub-form 
of AD which develops from risk factors for both psychosis and AD (Hirono et al. 
1998b). Thus, the genetic risk factors involved in the aetiology of AD+P are distinct 
from the genetic risk factors involved in aetiology of AD per se, although both forms 
of disease may share common risk factors. This may be termed the ‘disease 
subtype’ theory. Due to the possible overlap in the genetic aetiology of AD+P and 
AD, the ‘disease subtype’ theory is best analysed by comparison of allele and 
genotype frequencies in AD cases with psychosis against control individuals.
1.2.2. Classification of Alzheimer’s disease with Psychosis
In general, there is controversy about how best to categorise behavioural 
symptoms in AD. DSM-IV guidelines do assess behavioural symptoms in AD, but 
suggest the use of additional coding to fully encapsulate non-cognitive phenotypes. 
However, specific guidelines for the diagnosis and classification are not available. 
Numerous rating scales have been created to assess behavioural symptoms in AD. 
For example, the Present Behavioural Examination (Hope and Fairburn 1992), the 
Columbia University Scale for Psychopathology in AD (Devanand et al. 1992a), the 
Manchester and Oxford University Scale for the Psychopathological Assessment of 
Dementia (Allen et al. 1996), the Neurobehavioural Rating Scale (Levin et al.
1987), Behave-AD (Reisberg et al. 1987b), the Brief Psychiatric Rating Scale
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(Overall and Gorham 1962) and the Neuropsychiatric Inventory (NPI) (Cummings 
1994). The NPI is probably the most widely used and regarded of these 
classification systems for both research and clinical settings (Cummings 1997) and 
was the system of choice for this study. Classification criteria were determined 
following extensive literature searches of previously employed thresholds for both 
linkage and association studies of AD+P (Bacanu et al. 2002; Sweet et al. 1998). 
The classification procedures used in non-genetic longitudinal studies (Ballard et 
al. 1995; Lyketsos et al. 2001; Mintzer and Targum 2003) were also evaluated 
before the threshold for AD+P and AD-P classification were decided upon. The NPI 
and the threshold criteria utilised for sample classification are fully described in 
chapters 2.2.1, 2.2.3 and 5.2.1.
1.3. Environmental Risk Factors for Alzheimer’s disease with Psychosis
Non-genetic risk factors for AD+P have not been studied to any great extent, 
and those studies that have been conducted show conflicting results.
Psychosis in AD has been reported to associate with many clinical and biological 
factors, such as age (Binetti et al. 1995; Forstl et al. 1993; Gilley et al. 1991; Hirono 
et al. 1998b; Kotrla et al. 1995b; Swearer et al. 1988), sex (Burns et al. 1990a; 
Devanand et al. 1992b; Hirono et al. 1998b; Reisberg et al. 1987a), and education 
(Devanand et al. 1992b). For example, one of the larger studies of over 110 cases 
with psychosis, conducted by Hirono and colleagues (Hirono et al. 1998b), found 
that sex and age were each significantly and independently associated with 
psychosis, and that the level of education was not a significant predictor of the 
presence of psychosis. Despite general consensus as to the environmental risk 
factors for AD+P, there is contradiction in the direction of effect across a number of 
studies. For example older age was shown to be a significant risk factor for the 
development of psychosis by several investigators (Binetti et al. 1995; Forstl et al. 
1993; Hirono et al. 1998b; Kotrla et al. 1995b; Swearer et al. 1988), whereas Gilley 
and colleagues (Gilley et al. 1991) reported that early onset was significantly 
associated with psychosis. Devanand and colleagues (Devanand et al. 1992b) 
maintained that age at examination was associated with paranoid delusions and 
inversely correlated with hallucinations. While, many studies failed to show a
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significant relationship between age and psychosis (Binetti et al. 1993; Doody et al. 
1995; Jeste et al. 1992; Lehtovirta et al. 1996; Migliorelli et al. 1995; Patterson et 
al. 1990; Reisberg et al. 1987a; Rosen and Zubenko 1991; Rubin et al. 1993; 
Starkstein et al. 1994; Teri et al. 1988).Fe male sex has been suggested as a risk 
factor for Alzheimer’s disease (Hirono et al. 1998b). However, few studies have 
considered whether sex specifically predisposes patients to the development of 
psychotic symptoms in Alzheimer’s disease. Reisberg and colleagues (Reisberg et 
al. 1987a) found that women tended to exhibit behavioural symptoms more often 
than men and Devanand and colleagues (Devanand et al. 1992b) reported that 
women’s scores of delusion were significantly higher than those of men. On the 
other hand, Burns and colleagues (Bums et al. 1990a) reported a higher 
prevalence of delusions of theft in men. Other studies have failed to show an 
association of psychosis with sex (Becker et al. 1994; Binetti et al. 1993; Binetti et 
al. 1995; Doody et al. 1995; Migliorelli et al. 1995; Rosen and Zubenko 1991; 
Starkstein et al. 1994) A 2005 study by Ropacki and Jeste (Ropacki and Jeste 
2005), which reviewed data from 55 studies investigating risk factors associated 
with psychosis in AD, found positive association with African American ethnicity in 
5 studies, with negative findings reported in 2 studies (Ropacki and Jeste 2005). 
Education, sex, and family history of dementia or psychiatric disorder were weakly 
associated with increased risk for psychosis in the majority of reviewed studies. 
While the relationships between psychosis and patients’ age and age at onset of 
Alzheimer’s disease were generally equivocal (Ropacki and Jeste 2005). From this 
data it is clear that further studies are needed to convincingly test the myriad of 
potential environmental risk factors for AD+P and elicit their role in disease 
aetiology.
1.4. Mapping Complex Traits
1.4.1. Familialitv
Measures of familiality compare the rate of a disorder in relatives of an 
affected person to a baseline rate found in the general population (Falconer and 
Mackay 1996). Quantifying familiality is the initial step in determining whether a 
disorder has a genetic aetiology. However, familiality alone is not sufficient to
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confirm that genes are important in the development of a disorder since families 
also share common environments.
1.4.2. Heritability
The heritability of a trait or disease is defined as the proportion of the total 
variance which is genetic (Strachen and Read 2003).Heritability may be estimated 
by the use of twin studies which offer a unique design for teasing apart the relative 
importance of genetic and environmental influences. Monozygotic (MZ) twins are 
genetically identical clones and will be concordant for any genetically determined 
character (Strachen and Read 2003). This is true regardless of the mode of 
inheritance or number of genes involved; the only exceptions are for characters 
dependent on postzygotic somatic genetic changes (Strachen and Read 2003). 
Dizygotic (DZ) twins share half their genes on average, the same as any full 
siblings (Strachen and Read 1999). Genetic characters should therefore show a 
higher concordance in MZ than DZ twins (Strachen and Read 2003). However, 
higher concordance in MZ twins compared to DZ twins may also be affected by 
sex, which can be discordant in DZ twins, and environmental factors (Strachen and 
Read 2003).
1.4.3. Linkage Analysis
Historically the starting point in determining the genetic aetiology of both 
simple and complex disease has been linkage analysis. It can be used to identify 
broad genomic regions that might contain a disease gene, in the absence of 
previous biologically driven hypotheses (Teare and Barrett 2005). Linkage analysis 
detects departure from independent inheritance (Teare and Barrett 2005) by 
testing co-segregation of a genetic marker and disease phenotype within many 
independent families or over many generations in an extended pedigree.
Parametric linkage analysis analyses the co-segregation of genetic loci in 
pedigrees. This requires specification of a genetic model, making this analysis a 
powerful method for detecting loci segregating in Mendelian (simple) diseases 
(Teare and Barrett 2005). For multifactorial traits, such as AD+P, there is no clear 
mode of inheritance. Therefore, non-parametric linkage analyses are used. These
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methods examine allele sharing identity by descent (IBD) in affected relatives.
Allele sharing IBD increases above the level expected by chance when a marker is 
linked to a variant influencing susceptibility to the phenotype, irrespective of the 
mode of inheritance (Teare and Barrett 2005). In practice, IBD sharing between 
relative pairs is rarely known with complete certainty (Teare and Barrett 2005), 
meaning that non-parametric analysis is less powerful than conventional 
parametric analysis.
To allow for imperfect informity the genome is scanned with a dense 
collection of genetic markers, typically 300-600 microsatellite markers, 
corresponding to marker-marker intervals of 10-5 centimorgans (cM) respectively 
(Lander and Kruglyak 1995). Linkage analysis results are generally shown as a 
logarithm of the odds (to the base 10) (LOD) score function, that is the logarithm of 
the odds that the locus is linked to the trait compared to the odds that the locus is 
not linked to the trait. It is a function of the recombination fraction (0) (the 
probability of recombination between two loci at meiosis) or chromosomal position 
measured in cM (Teare and Barrett 2005). The best (maximum likelihood) estimate 
of 0 or position which maximises the lod score function is named the maximum 
LOD score (MLS) (Teare and Barrett 2005). Interpretation of the statistical data 
produced by these analyses is contentious (Teare and Barrett 2005). In general, 
the higher the LOD score, the greater the evidence for linkage. The level of 
significance can be assessed according to standards devised by Lander and 
Kruglyak (Lander and Kruglyak 1995). Classification is based on the number of 
times that one would expect to see a result at random in a dense, complete 
genome scan (Table 1.4). It is important to note that prohibitively large samples are 
required to detect effects of a low magnitude in linkage analyses. Therefore, most 
linkage studies are only capable of detecting loci with moderate to large effects 
(Feingold 2001).
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Table 1.4. Linkage analysis criteria and classification as defined by Lander and Kruglyak 
(Lander and Kruglyak 1995). LOD scores quoted refer to those for an affected sibling pair 
(ASP) study.
Classification Criteria (LOD>)
Suggestive 2.2; statistical evidence that would be expected to occur one 
time at random in a genome scan
Significant 3.6; statistical evidence expected to occur 0.05 times in a 
genome scan (that is, with probability 5%)
Highly significant 5.4; evidence expected to occur 0.001 times in a genome scan
Confirmed significant linkage from one or a combination of initial studies 
that has been confirmed in a further sample, preferably by an 
independent group of investigators (a nominal P  value of 0.01 is 
required)
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1.4.4. Association Analysis
Association is a statistical statement referring to the co-occurrence of a 
particular allele(s) and a phenotype above a level expected by chance (Strachen 
and Read 2003). Both linkage and association rely on co-inheritance of DNA 
variants adjacent to each other. However, linkage looks at the information by 
identifying haplotypes that are inherited intact over only a few generations (where 
little recombination has occurred) and association looks at the retention of adjacent 
variants over many generations (where much recombination may have occurred). 
Association analyses are less sensitive to misdiagnosis, decreased penetrance 
and genetic heterogeneity than linkage analyses (Hodge 1993) and have been 
able to detect loci that linkage has failed to identify. Association studies can be 
subdivided into direct or indirect models. Direct association studies assume that if 
they exist in a gene, susceptibility or casual alleles themselves are evaluated. 
Indirect association studies assume that the actual susceptibility allele may not be 
genotyped, but that it is located near to a genotyped marker so any association 
detected is due to linkage disequilibrium (LD). Recent technological advances have 
significantly advanced the through-put of association analyses and have brought 
about the era of genome-wide association studies. A genome-wide association 
study (GWAS) involves rapidly scanning markers across the complete genomes of 
many people to find genetic variations associated with a particular disease. Such 
studies are particularly useful in finding genetic variations that contribute to 
common, complex diseases, and have proved successful in investigating 
numerous conditions including type II diabetes (Zeggini et al. 2008) and 
Alzheimer’s disease (Harold et al. 2009).
1.4.5. Replication of Association Studies
The majority of associations reported do not replicate in secondary samples 
and contradictory findings are common in complex diseases. For replication studies 
it should only be necessary to genotype the marker or markers that have been 
reported to be associated with the disease. However, it is important when 
designing a replication study to ensure numerous variables are controlled; 1) 
population differences are common and may be the result of real biological 
differences or differences in allele frequencies and varying LD in differing
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populations. Testing for genetic heterogeneity between sample groups and 
stratifying by ancestry and demographic location can help control type I (false 
positive) and type II (false negative) errors. 2) Complex diseases can vary in 
severity and type of symptoms resulting in difficulties defining the global 
phenotype. The genetic aetiology of each subtype of a complex phenotype may 
differ, therefore, using distinct phenotypes, even those highly correlated, to study 
the same gene can result in different observations (Recker and Deng 2002). This 
problem is compacted by the frequency of differing measures being used to 
phenotype samples. 3) Differences in gene-gene and gene-environment 
interactions within samples could also account for non-replication of associations.
It is vital to replicate a positive finding before accepting an association as 
definitive. It is possible that the initial association finding may be a type I error, as 
there is a 1 in 20 chance of rejecting the null hypothesis when it is in fact true given 
a significance level of a=0.05. To avoid inflation of these chance findings 
significance thresholds should be adjusted appropriately whenever multiple 
statistical tests are performed on the same dataset. The degree to which data 
should be corrected for multiple testing is a source of much debate. The Bonferroni 
correction (which approximates by dividing the required significance level by the 
number of independent null hypotheses being tested) is highly regarded to be 
overly conservative (Sha et al. 2006). Throughout this thesis multiple testing was 
corrected for by a permutation calculation which is discussed more fully in chapter 
2.9. There are other methods of multiple testing correction in genetic association 
analyses most of which, like the Bonferroni correction and permutation analysis, 
control the overall error rate. Alternative forms of multiple testing correction include 
the false discovery rate (FDR), which is defined as the expected number of false 
rejections divided by the number of rejections (Benjamini et al. 2001). Controlling 
the FDR automatically controls the overall error rate in the special case that all the 
null hypotheses are true. (Devlin et al. 2003).
Type II errors are inflated when type I errors are decreased, increasing the 
likelihood of a false negative association can be as erroneous as a false positive. A 
replication study may fail to detect association when variation at that locus does in 
fact cause susceptibility to the disease. A likely reason is that the replication study 
is insufficiently powered to detect the effect size. Many studies are underpowered 
to detect even moderate odds ratios. Especially, as power calculations assume that
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either the susceptibility allele itself or a marker in complete LD with the 
susceptibility allele is being tested. Therefore, a well designed study needs to 
utilise both a suitably sized sample and appropriately informative markers.
1.4.6. Linkage Disequilibrium
If loci do not segregate independently, more often than can be accounted for 
by chance, they are said to be in linkage disequilibrium (LD). Any new mutation 
arising on a chromosome will be in complete LD with all the other polymorphisms 
carried by that chromosome at that time. LD varies across the genome, therefore it 
must be considered locally for informative studies to be undertaken. The extent of 
LD is affected by numerous factors. The primary drive in the breakdown of LD is 
meiotic recombination (Tsunoda et al. 2004). As recombination occurs the LD 
between variations decays. The closer two loci are on a chromosome the less likely 
it is that crossover will separate them (Strachen and Read 2003). Thus, the 
recombination fraction is a measure of the distance between two loci, this equates 
to genetic distance which is measured in cM. The recombination rate may vary 
from 0 to as high as 5 cM/Mb (5% chance of recombination at each meiosis per 
megabase) (Kong et al. 2002). Nonreciprocal exchange of short tracts of DNA 
between homologous chromosomes can result in the breakdown of LD, as can 
recurrent mutation and gene conversion (Hallast et al. 2005). Conversion rates in 
humans are high and become relatively important for very tightly linked markers 
(Collins 1999; Frisse et al. 2001; Quintana et al. 2001), as gene conversions 
disrupt LD between closely linked markers faster than may be predicted by the 
recombination rate.
Several factors add to the accumulation of LD. Inversion polymorphisms 
suppress recombination (Martin et al. 2000; Pritchard and Przeworski 2001), and 
slow LD breakdown. Assortative mating violates the assumption that two genes 
segregate independently by increasing the likelihood of offspring being 
homozygous (Hasstedt 1995). A reduction in population size (i.e. a population 
bottleneck) reduces the number of haplotypes in a population. Therefore, if a 
bottleneck has occurred recently (in terms of generations) there may be extensive 
LD (Reich et al. 2001).Gen etic drift is relevant in small populations; rapid changes 
in gene frequencies result in one allele at a locus becoming fixed inflating LD in this
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region. Natural selection can also lead to gene fixation (Wang and Rannala 2004). 
Greater levels of LD are seen in populations where there has not been a recent 
demographic expansion i.e. founder populations, than in exponentially expanded 
populations (Terwilliger et al. 1998; Terwilliger and Weiss 1998). The introduction 
of genes from one distinct population into another can create LD. The resulting 
offspring will have linked and unlinked pairs of loci. Over time LD decays, but much 
more rapidly for the unlinked loci than the linked pairs.
Under a uniform recombination rate of 1 cM/Mb and a simple model of 
human demography, LD in the human genome is unlikely to extend further than 3 
kilobases (kb) (Kruglyak 1999). However, LD may extend further if the assumptions 
of the model are relaxed, and the average extent of ‘useful’ LD for disease marker 
association has been estimated to be 11 kb in African populations and 22 kb in 
other populations (Gabriel 2002). Measures of linkage disequilibrium quantify how 
frequently two alleles are found on the same chromosome in a certain population. 
The statistical measures D’ and r2 commonly summarise the LD between two 
markers. Both measures are based on the basic pairwise-disequilibrium coefficient 
D, the difference between the probability of observing two markers alleles on the 
same haplotype and observing them independently in the population. D has the 
disadvantage of depending on the frequency of the alleles. D’ is the normalisation 
of D by dividing it with the theoretical maximum for the observed allele frequencies 
(Hedrick and Kumar 2001). Thus,
D'=
j r \  when D>0
max
JT) when D<0
mm
When D’ is 0 the two loci are deemed to be independent. A value of 1 
implies all copies at one locus occur exclusively with one of the two possible alleles 
at the second marker, r2 is the square of the correlation coefficient, r, that 
measures the association between alleles (Hedrick and Kumar 2001);
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where; p \=  frequency of allele 1 at locus 1, p 2 = frequency of allele 2 at locus 1, 
q\ = frequency of allele 1 at locus 2, qi = frequency of allele 2 at locus 2
r is commonly squared to remove the arbitrary sign (Hedrick and Kumar 2001). If r2 
equals 0, independence is implied, r2 equals 1 when the occurrence of an allele at 
one marker perfectly predicts which allele will be present at a second locus.
1.5. Genetics of Alzheimer’s disease with Psychosis
1.5.1. Familiality of Alzheimer’s disease with Psychosis
There is evidence that familial factors play an important role in the aetiology 
of AD with psychosis (AD+P). Analysis of 280 siblings of AD+P probands versus 91 
siblings of AD probands without psychosis (AD-P) showed an increase in familial 
risk when AD+P was defined by multiple symptoms (P < 0.0001; OR = 3.2, Cl 95%; 
2.2-4.7J compared to AD+P defined by a single symptom (P = 0.0006, OR = 2.4, Cl 
95%; 1.5-4.0) (Sweet et al. 2002b). This finding was replicated in two additional 
studies (Eror et al. 2005; Hollingworth et al. 2007), meaning that there is strong 
support for a genetic element to AD+P.
1.5.2. Heritability of Alzheimer’s disease with Psychosis
Using a pedigree of 826 subjects Bacanu and colleagues (Bacanu et al. 
2005) employed affected sibling pair (ASP) analysis to estimate heritability of 
AD+P. The heritability estimate assumes uncorrelated environmental effects and 
that occurrence of psychosis is independent of ascertainment on AD (Bacanu et al.
2005). Heritability of AD+P defined by multiple psychotic symptoms was estimated 
at 61% (P = 0.02; halfX2  ^= 5.18); and 30% for AD+P defined by any occurrence of 
psychosis (P = 0.04; halfX2<\ = 3.25) (Bacanu et al. 2005). The former estimate
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compares favourably with generally accepted heritability estimate of 58-79% for 
LOAD (Gatz et al. 2006), and approximately 80% for schizophrenia (Owen 2005).
1.5.3. Linkage Analyses of Alzheimer’s disease with Psychosis
The AD with psychosis phenotype demonstrates linkage to specific 
chromosomal regions (Avramopoulos et al. 2005; Bacanu et al. 2002, Hollingworth 
et al. 2007). The first AD+P linkage study was conducted by Bacanu and 
colleagues (Bacanu et al. 2002). They selected a subset of 65 pedigrees 
containing at least two siblings diagnosed as having AD+P from those collected as 
part of the National Institute for Mental Health (NIMH) AD genetics initiative. Data 
from 237 markers previously genotyped by Kehoe and colleagues (Kehoe et al. 
1999) was analysed. A secondary analysis was performed restricted to the 42 
families in which both siblings also possessed at least one APOE e4 allele 
(LOAD+P+e4). This secondary analysis produced significant linkage on 
chromosome 2p at approximately 64.3 cM (MLS = 3.52) (Figure 1.5a). Some 
support for the region can be gathered from schizophrenia literature (Coon et al. 
1998). However, the increase in MLS to reach statistical significance appears to be 
solely due to the influence of the APOE e4 allele. Under both models suggestive 
linkage on chromosome 6 at approximately 112cM was identified (AD+P; MLS = 
2.51 and AD+P+e4; MLS = 2.01) (Figure1.5b) (Bacanu et al. 2002). Chromosome 6 
is an interesting candidate region for psychosis as numerous schizophrenia (Cao et 
al. 1997; Levinson et al. 2000; Martinez et al. 1999) and bipolar disorder (Dick et 
al. 2003; Lambert et al. 2005; Pato et al. 2004) studies have identified evidence for 
linkage in this region. Thus, suggesting that this region harbours a locus (or loci) 
that influences susceptibility to a broad psychosis phenotype. Bacanu and 
colleagues (Bacanu et al. 2002) have also reported suggestive linkage on 
chromosome 21 under a AD+P+e4 model (36.8 cM; MLS = 1.94) (Figure 1.5c) 
(Bacanu et al. 2002).L inkage of chromosome 21 q to AD was reported in the 
original Kehoe study (Kehoe et al. 1999), although this evidence comes from the 
e4-negative families, making the finding of linkage to LOAD+P+e4 at this region 
questionable.
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Figure 1.5a. Chromosome 2. Multipoint MLS for families with AD+P (solid, thin line) and 
AD+P with A P O E  e4 allele (Solid, thick line). Map distance on x-axis (in centimorgans) as 
given by NIMH. Reference lines on y-axis indicate critical values for genome-wide 
significant (solid) and suggestive (dashed) linkage. [Source Bacanu et al. (2002).]
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Figure 1.5b. Chromosome 6. Multipoint MLS for families with AD+P (solid, thin line) and 
AD+P with A P O E  e4 allele (Solid, thick line). Map distance on x-axis (in centimorgans) as 
given by NIMH. Reference lines on y-axis indicate critical values for genome-wide 
significant (solid) and suggestive (dashed) linkage. [Source Bacanu et al. (2002).]
27
Chapter 1. General Introduction: Psychosis in A lzheim er’s disease
cor^
to
CO5
co
o
60 8020 4 0
Figure 1.5c. Chromosome 21. Multipoint MLS for families with AD+P (solid, thin line) 
and AD+P with A P O E  e4 allele (Solid, thick line). Map distance on x-axis (in 
centimorgans) as given by NIMH. Reference lines on y-axis indicate critical values for 
genome-wide significant (solid) and suggestive (dashed) linkage. [Source Bacanu et al. 
(2002).]
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Avramopolous and colleagues (Avramopolous et al. 2005) performed a 
regression based covariate analysis (Goddard et al. 2001; Olson 1999) using 
genotypes from the AD genome screen reported by Bassett and colleagues 
(Bassett et al. 2002). Analysis was based on the presence or absence of 
hallucinations and delusions using data from 381 markers (average spacing 9 cM) 
through 148 NIMH families having at least two affected siblings (ages of onset 
more than 50 years). Their most significant evidence for linkage was on 
chromosome 14q24.3 (LOD = 3.91; genome-wide empirical P  = 0.052 at 
D14S540), near PSEN1. This effect was derived from individuals that did not have 
co-morbid hallucinations, a lower LOD score was observed for individuals without 
delusions. Linkage appeared to be stronger in families containing individuals with 
an age at onset < 65 years, with a LOD score empirically shown to approach 
genome-wide significance (LOD = 5.74; genome-wide empirical P = 0.048) 
(Avramopoulos et al. 2005). Evidence for linkage was observed on chromosome 1 
for the hallucinations covariate in discordant siblings (LOD = 2.26) and 
approximately the same region showed linkage for the delusions covariate 
(Avramopolous et al. 2005). Moderate evidence for linkage on chromosome 3 was 
observed, with a LOD score of 2.75 detected at marker D3S4523 for delusions, 
compared to a LOD score of 2.1 for hallucinations (Avramopolous et al. 2005). 
Avramopolous and colleagues (Avramopolous et al. 2005) showed linkage to a 
region of chromosome 7 in sibling pairs discordant for hallucinations (LOD = 2.14). 
There is also evidence for linkage to delusional symptomatology at approximately 
the same position.
The final study by Hollingworth and colleagues (Hollingworth et al. 2007) 
combined microsatellite marker genotypes from three LOAD genome screens 
(Blacker et al. 2003; Kehoe et al. 1999; Myers et al. 2002) utilising data from 321 
affected relative pairs (ARPs) from the USA and UK. This provided data from 610 
markers with an average between marker spacing of 6cM. Logistic regression was 
employed to model the probability of allele sharing, which then allowed psychosis 
to be incorporated into the model as a categorical variable (Hamshere et al. 2005a; 
Risch 1990). This methodology also incorporates information from affected 
relatives who have not displayed psychotic symptoms. A MLS of 2.84 
(chromosome-wide p-value = 0.012, genome-wide p-value = 0.242) was identified 
on chromosome 7, at 91 cM (nearest marker: D7S2204 at 78.0 Mb) for ARPs who
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were concordant for the absence of psychotic symptoms (Hollingworth et al. 2007). 
This region of chromosome 7 is approximately that identified by Avramopolous and 
colleagues (Avramopolous et al. 2005), who saw evidence for linkage in AD cases 
discordant for psychosis. APOE z4 status had a minimal effect on linkage evidence 
on chromosome 7 with a MLS increase of 0.06 after its inclusion as a covariate 
(Figure 1.5d) (Hollingworth et al. 2007). Hollingworth and colleagues (Hollingworth 
et al. 2007) observed their most significant increase in LOD score on chromosome 
15 (MLS = 3.16, chromosome-wide P -  0.001, genome-wide P  = 0.039) 
(Hollingworth et al. 2007). ARPs who were concordant for the absence of psychotic 
symptoms provided the most evidence for linkage, and APOE z4 status had a 
minimal effect (Figure 1.5e). A MLS of 1.07 was observed close to the linkage 
region on chromosome 6 reported by Bacanu and colleagues (Bacanu et al. 2002) 
(Figure 1.5f). A secondary analysis was performed adding APOE z4 status to the 
logistic regression model, this increased the observed LOD score to 2.98 (Figure 
1.5f). Evidence for a potential locus at 35 to 36 Mb on chromosome 21 was 
observed when psychosis and APOE z4 status were included in the analysis 
(Figure 1.5g) (Hollingworth et al. 2007). However, this locus was not in the same 
region as that identified by Bacanu and colleagues (Bacanu et al. 2002) and the 
majority of the increase in the maximum LOD score was accounted for by APOE z4 
status, agreeing with previous findings in studies using part of this sample (Kehoe 
et al. 1999; Olson et al. 2001).
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Figure 1.5d. Covariant linkage analysis of LOAD-P and LOAD-P+e4 on chromosome 7q. 
LOD score for ARPs with LOAD (solid, thin line), LOAD-P (dashed line) and LOAD-P 
WxihAPOE e4 allele (solid, thick line). [Source Hollingworth et al. (2007).]
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Figure 1.5e. Covariant linkage analysis of LOAD-P and LOAD-P+e4 on chromosome 15q. 
LOD score for ARPs with LOAD (solid, thin line), LOAD-P (dashed line) and LOAD-P 
with A PO E  s4 allele (solid, thick line). [Source Hollingworth et al. (2007).]
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Figure 1.5f. Covariant linkage analysis of LOAD+P and LOAD+P+e4 on chromosome 6q. 
LOD score for ARPs with LOAD (solid, thin line), LOAD+P (dashed line) and LOAD+P 
vn ihA P O E  e4 allele (solid, thick line). [Source Hollingworth et al. (2007).]
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Figure 1.5g. Covariant linkage analysis of LOAD+P and LOAD+P+e4 on chromosome 21. 
LOD score for ARPs with LOAD (solid, thin line), LOAD+P (dashed line) and LOAD+P 
vn ihA P O E  e4 allele (solid, thick line). [Source Hollingworth et al. (2007).]
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None of the AD+P linkage analyses are conclusive, as none show 
significant, replicable evidence for linkage. However, there is overlap in the 
identified linkage regions between studies suggesting that susceptibility loci for 
psychosis in AD may reside at these locations, and that loci within these regions 
should be prioritised for future investigations. The sample used in the study of 
Bacanu and colleagues (Bacanu et al. 2002) was small in comparison to the other 
linkage analyses, with the study of Hollingworth and colleagues (Hollingworth et al.
2007) by far the largest of the 3 published analyses. The Avramopolous study 
(Avramopolous et al. 2005) utilised a design with a broad age range which is not 
conducive to the identification of linkage regions for LOAD. Indeed, the linkage 
observed on chromosome 14 in early onset patients without psychosis is within 40 
Mb of the PSEN1 gene, mutations of which are known to cause EOAD. The 
evidence for linkage identified by analysis of AD+P ARPs (chromosomes 2, 6 and 
21) appears to be largely due to APOE z4 status. Bacanu and colleagues (Bacanu 
et al. 2002) showed significant linkage on chromosome 2p at approximately 64.3 
cM as a result of inclusion of APOE z4 status into the analysis. Hollingworth and 
colleagues (Hollingworth et al. 2007) saw a small increase in linkage evidence for 
LOAD+P on chromosome 2p but this failed to reach chromosome-wide 
significance. Bacanu and colleagues (Bacanu et al. 2002) detected evidence for 
suggestive linkage on chromosome 6 at approximately 112cM (Bacanu et al.
2002). A region close to this showed evidence for linkage in the study by 
Hollingworth and colleagues (Hollingworth et al. 2007). Although, the LOD score 
increase attributable to psychosis, after controlling for APOE e4 status did not meet 
criteria for chromosome-wide significance in either study. This region of 
chromosome 6 remains an interesting candidate region for psychosis as numerous 
schizophrenia (Cao et al. 1997; Levinson et al. 2000; Martinez et al. 1999) and 
bipolar disorder (Dick et al. 2003; Lambert et al. 2005; Pato et al. 2004) studies 
have identified evidence for linkage in this region. The overlap of linkage in AD+P, 
schizophrenia and bipolar disorder suggests that this region harbours a locus that 
influences susceptibility to psychotic symptoms across disorders. Both Bacanu and 
colleagues (Bacanu et al. 2002) and Hollingworth and colleagues (Hollingworth et 
al. 2007) have reported suggestive linkage on chromosome 21 under a AD+P+e4 
model, with the increase in MLS attributable to psychosis not meeting criteria for 
suggestive linkage. Thus, suggesting that a gene residing on chromosome 21 may
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have a role in the aetiology of LOAD+P dependent on APOE. However, the linked 
regions identified differ between studies and replication is warranted. Linkage 
regions identified by analysis of LOAD+P and LOAD without psychosis (LOAD-P) 
ARPs (chromosomes 1, 3, 7, 14 and 15) largely show evidence of linkage in AD 
patients without psychosis irrespective of APOE 84 status. Chromosomes 1 and 3 
provide poor evidence of linkage (Avramopoulos et al. 2005), with no replication of 
these regions (Hollingworth et al. 2007). Hollingworth and colleagues (Hollingworth 
et al. 2007) showed suggestive evidence for linkage of LOAD+P to chromosome 7 
as do Avramopoulos and colleagues (Avramopoulos et al. 2005) at a similar 
position, although under a different psychosis model; Avramopolous and 
colleagues in discordant sibling pairs (Avramopolous et al. 2005) and Hollingworth 
and colleagues in pairs concordant for the absence of psychosis (Hollingworth et 
al. 2007). Despite this, the concurrence across studies as to the linked region 
suggests that this region of chromosome 7 harbours variant(s) associated with 
psychotic symptomology in AD. Additional chromosomal regions identified as 
showing linkage to AD patients without psychosis are chromosome 14 
(Avramopolous et al. 2005) and chromosome 15 (Hollingworth et al. 2007), 
indicating that these regions may harbour gene(s) protecting against the psychotic 
phenotype of AD, independent of APOE status. A notable limitation of the linkage 
analyses of AD+P is that all studies have used overlapping subsets of the NIMH 
sample; therefore no finding in any study has been independently replicated. The 
study by Hollingworth and colleagues (Hollingworth et al. 2007) in particular 
incorporates a substantial number of additional pedigrees and marker genotypes. 
Thus, suggesting that while independent replication is essential, the evidence for 
linkage at chromosomes 6 and 7 is probably robust. The convergence of linkage 
findings on chromosomes 2p in schizophrenia and AD+P, and 6q in schizophrenia, 
bipolar disorder and AD+P is consistent with the hypothesis that multiple genes, no 
single one of which is a major locus for idiopathic psychoses, could increase the 
risk for psychosis onset in the context of neurodegenerative and 
neurodevelopmental conditions (Bacanu et al. 2002). However, this interpretation 
should be made cautiously as despite the common psychosis phenotype, there are 
substantial clinical and neurobiological differences between the disorders, and the 
chromosomal region in which linkage has been detected in these conditions is 
broad. Moreover, alternative models are possible. For example, variants in genes
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may contribute major risk for idiopathic psychoses such as schizophrenia, and may 
also increases risk for AD+P. Or variants in genes that increase the liability to onset 
of AD could also increase risk for psychosis.
1.5.4. Association Analyses of Alzheimer’s disease with Psychosis
Relatively few association studies have been performed in AD+P. Of those 
that have, none provide consistent or compelling evidence for association with any 
gene. Studies investigating the association between APOE genotype and psychotic 
symptom in AD have reported contradictory results. At least 20 studies have 
examined APOE  genotype in respect to psychosis in AD. Eight have reported that 
the e4 allele increases the risk for psychosis (Ballard et al. 1997; Chang et al.
2004; Harwood et al. 1999; Ramachandran et al. 1996; Scarmeas et al. 2002; 
Spalletta et al. 2006; Weiner et al. 1999; Zdanys et al. 2007).For example, APOE 
£4 was significantly associated with psychotic symptoms (P  = 0.029, OR = 1.87) in 
the study by Zdanys and colleagues (Zdanys et al. 2007). The effect seemed to be 
specific to patients with severe-stage AD and primarily from an association 
between £4 and delusions (Zdanys et al. 2007). In a longitudinal study of 171 AD 
patients APOE z4 allele possession was associated with increased levels of 
delusions (P < 0.05, OR = 1.23) (Spalletta et al. 2006). Both hallucinations and 
delusions showed association to APOE £4 in the 2004 study by Chang and 
colleagues (Chang et al. 2004). Fifty six patients without psychotic symptoms were 
followed to identify incident psychotic symptoms. The presence of the APOE £4 
allele carried a 19-fold risk for developing hallucinations and a 3.4-fold risk for 
delusions (Chang et al. 2004). The studies which have identified a positive 
association between psychosis in AD and APOE z4 possession do not show 
association to the same phenotype of AD+P. For example 2 longitudinal studies 
show association to delusions only (Scarmeas et al. 2002; Spalletta et al. 2006) 
while Chang and colleagues show an association to both delusions and 
hallucinations, with the strongest effect seen with hallucinations (Chang et al.
2004). Eleven studies have found no effect of £4 on AD+P risk (Borroni et al. 2006; 
Cacabelos et al. 1997; Gabrvelewicz et al. 2002; Hirono et al. 1998a; Hirono et al. 
1999; Hollingworth et al. 2006; Lehtovirta et al. 1996; Levy et al. 1999; Lopez et al. 
1997; Lyketsos et al. 1997; Quaranta et al. 2009; Sweet et al. 2002c), including a
37
Chapter I. General Introduction: Psychosis in Alzheimer's disease
study of APOE genotype in the MRC LOAD sample (Hollingworth et al. 2006). The 
MRC genetic resource for LOAD is the largest of the sample-sets used to study the 
potential APOE z4 association with AD+P. The study included 1120 subjects, 879 
of which were genotyped for APOE e4 (Hollingworth et al. 2006). The number of 
APOE 64 alleles was not associated with any behavioural component (Hollingworth 
et al. 2006). Therefore, despite a number of studies reporting a relationship 
between APOE genotype and psychosis in AD, the majority have found no 
relationship. The results of the studies which do identify association of e4 with 
AD+P should be received with caution. All of these studies are based on small 
sample sets, of less than 300 AD cases (40% to 60% of which will experience 
psychosis), and different populations and statistical methods have been used 
across studies to detect association. It therefore seems unlikely that APOE is 
implicated in the prevalence or severity of psychosis in AD.
The catechol-O-methyltransferase (COMT) gene is a putative susceptibility 
candidate for schizophrenia owing to its role in dopamine metabolism, and location 
within the deleted region in Velocardiofacial Syndrome (VCFS), a disorder 
associated with high rates of schizophrenia (Craddock et al. 2006). Numerous 
studies have found a highly significant association between schizophrenia and 
COMT (Lee et al. 2005; Palmatier et al. 2004; Shifman et al. 2002), and also an 
association with lower COMT mRNA expression (Bray et al. 2003a). Genetic 
variation at multiple COMT  polymorphisms has been investigated in AD+P. A 
significant association with the val/met variant rs4680 has been observed (Borroni 
et al. 2004) and replicated (Borroni et al. 2006; Borroni et al. 2007; Sweet et al.
2005); this association was found to be specific to hallucinations (Borroni et al.
2006). Haplotype analysis of COMT markers revealed a highly significantly 
associated 4-locus haplotype in two studies of AD+P (Borroni et al. 2006; Borroni 
et al. 2007; Sweet et al. 2005). The association with COMT and AD+P appears 
robust although only nominally significant; the studies have been well constructed 
despite small sample sizes. The identification of association with AD+P to the 
val/met variant and haplotypes at the COMT locus by 2 independent groups 
suggests these findings are not false positives. Although, it would be interesting to 
determine if the associations seen would replicate in a suitably powered sample- 
set.
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Polymorphisms of the serotonin receptor 5HT-2A have been shown to 
associate with hallucinatory symptoms and delusions in demented and non­
demented cohorts (Holmes et al. 1998). In schizophrenic cohorts the most clearly 
linked serotonergic genotypic variant is the 5HT-2A T/C 102 polymorphism 
(Williams et al. 1997; Prasad et al. 2002). Numerous groups have reported the 
influence of the C variant in producing psychotic symptomatology in AD (Holmes et 
al. 1998; Nacmias et al. 2001; Rocchi et al. 2003), other groups have reported 
significant under representation of 5HT-2A 102C homozygotes in AD+P (Lam et al. 
2004; Assal et al. 2004). One study of this polymorphism in AD+P found no 
significant genotypic or allelic association (Craig et al. 2007). However, a recent 
meta-analysis of the 5HT-2A T/C 102 polymorphism in AD+P showed a significant 
effect of both the C allele (OR = 2.19) and the CC genotype (OR = 5.14) 
(Ramanathan and Glatt 2009), strongly supporting the action of this variant in the 
aetiology of AD+P. Borroni and colleagues (Borroni et al. 2006) found that AD+P 
patients carrying the serotonin gene-linked promoter region (5-HTTLPR) long 
variant experienced fewer delusions (OR = 0.38, Cl 95%; 0.01-0.90). An 
independent study of 148 AD patients found significant association of the long 
variant of 5-HTTLPR with psychosis in AD (Quaranta et al. 2009). However, the 
association was in the opposite direction to the study of Borroni and colleagues 
(Borroni et al. 2006), with the percentage of AD+P increasing with the number of 
copies of the long-allele: 13% among short allele homozygotes; 36% among 
heterozygotes (P = 0.018, OR = 3.91); 51% among long allele homozygotes (P = 
0.003, OR = 7.25) (Quaranta et al. 2009). Thus, providing strong support for the 
action of this variant in the aetiology of AD+P. The long variant of the 
polymorphism increases the transcriptional efficiency of the 5-HTT gene promoter 
resulting in enhanced 5-HTT expression and 5-HT uptake in lymphoblasts (Lesch 
et al. 1996). The cumulative effect of COMT and 5-HTTLPR polymorphisms was 
investigated in AD+P using previously reported data (Borroni et al. 2004; Borroni et 
al. 2006). The findings claim a synergic effect of C O M TG  and 5-HTTLPR__short 
variant polymorphisms on the risk of psychosis in AD. Carriers of one 
polymorphism showed a 2-fold increase in risk, and carriers of both polymorphisms 
showed a 5-fold increased risk for psychosis, compared with patients bearing no 
polymorphisms (Borroni et al. 2006). This cumulative association has not been
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tested in independent populations, but due to the reported associations of both 
polymorphisms independently, warrants investigation.
Neuregulin-1 (NRG1) is a strong functional candidate for psychosis with 
isoforms involved in generation of neurons and development of Schwann cells 
(Falls 2003). Numerous studies in schizophrenia (Li et al. 2004b; Stefansson et al. 
2003; Williams et al. 2003a; Zhao et al. 2004) and bipolar disorder (Green et al. 
2005; Thomson et al. 2007) have shown positive association of the gene with 
disease. Following linkage analyses of 65 families enriched for AD+P, Go and 
colleagues (Go et al. 2005) demonstrated a significant association with a NRG1 
SNP (rs3924999) and AD+P (P = 0.008). Despite requiring replication, the linkage 
and association findings at first appear convincing. However, it is unclear whether 
the 65 families used to identify linkage contained both early-onset and late-onset 
AD pedigrees. The group had at their disposal 437 pedigrees, of which 65 were 
enriched for psychosis and 320 of the families were late-onset AD, it is unclear 
which of these sample sets was used for the association analysis.
Dopamine receptors are a class of metabotropic G protein-coupled 
receptors that are prominent in the central nervous system (CNS). They have key 
roles in many processes including the control of motivation, learning, and fine 
motor movement, as well as modulation of neuroendocrine signaling. Abnormal 
dopamine receptor signaling and dopaminergic nerve function is implicated in 
several neuropsychiatric disorders (Girault and Greengard 2004). The dopamine 
receptor D2 (DRD2) has shown association with schizophrenia in a Japanese 
population (Arinami et al. 1994), but not in a European population (Sobell et al.
1994). In contrast, a persistent association of the dopamine receptor D3 (DRD3) 
8a/l polymorphism with schizophrenia has been reported (Jonsson et al. 2003; 
Nimgaonkar et al. 1996). Polymorphisms in the dopamine receptors DRD1, DRD2, 
DRD3, and DRD4 have been investigated for association with AD+P (Sweet et al. 
1998). Among Caucasian patients psychosis was significantly more frequent in 
DRD1 B2/B2 homozygotes (P < 0.02) and DRD3 Ba/I 1/1 or 2/2 homozygotes (P < 
0.05) (Sweet et al. 1998). The joint risk for psychosis due to the DRD1 and DRD3 
polymorphisms exceeded the risk due to either locus alone, suggesting an 
interaction (Sweet et al. 1998). Neither the DRD2 S311C polymorphism nor the 
presence of long alleles for the DRD4 exon III repeat sequence were associated 
with presence of psychosis (Sweet et al. 1998). The associations between the
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variation in the DRD1 and DPD3 receptor genes and psychosis in Alzheimer's 
disease have replicated (Holmes et al. 2001). Although, the replication study was 
performed by the authors of the original finding, and a negative finding of the DRD3 
Bal\ polymorphism and the presence or absence of psychotic symptoms in AD has 
been reported (Craig et al. 2004a).
Glutamate is an excitatory neurotransmitter in the central nervous system 
(CNS). The D-amino acid oxidase activator (DAOA) gene, plays a key role in the 
glutamate pathway regulated through the NMDA receptors. Hypofunction of the 
NMDA glutamate receptor is a well regarded model in the aetiology of psychosis 
and polymorphisms in this gene have been implicated in susceptibility to 
schizophrenia and bipolar affective disorder, (Farber 2003). A recent study 
genotyped a panel of DAOA SNPs in a cohort of 185 Alzheimer's disease patients, 
investigating these variants with respect to the occurrence of delusions and 
hallucinations in AD (Di Maria et al. 2009). The analysis demonstrated a nominally 
significant association with the delusion phenotype (P < 0.05) with one SNP 
(rs2153674). Multivariate regression showed that the rs2153674 genotype 
accounts for up to 15% of the variance in delusions severity, as assessed by using 
the Neuropsychiatric Inventory (Di Maria et al. 2009). This study seems well 
constructed and if replicated, the glutamate hypothesis could be invoked to explain 
the occurrence of psychosis in neurodegenerative. However, the association 
identified is not striking and the sample utilised is small.
Regulation disturbances of cytokines, such as interleukins, have been noted 
in schizophrenia (Gaughran 2002) and AD (Tarkowski et al. 2003) and the low 
expression variant (C) of interleukin-1 p (IL-ip) has been implicated in producing an 
increased risk for schizophrenia (Katila et al. 1999). Craig and colleagues (Craig et 
al. 2004b) investigated the -511 promoter polymorphism of IL-1 p in 424 LOAD 
patients. The CC genotype and C allele was significantly over represented in those 
LOAD patients experiencing delusions (P = 0.002; OR = 1.49), hallucinations (P = 
0.014; OR = 1.6), and the combined phenotype (P = 0.048; OR = 1.62) (Craig et al. 
2004b). This study seems to be well executed and the findings warrant replication 
in independent samples.
Finally, the alpha 7 nicotinic acetylcholine receptor gene (CHRNA7) which 
has been associated with schizophrenia in linkage and association studies 
(Stephens et al. 2009; Xu et al. 2001), has shown association with AD+P in a
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Northern Ireland population. The most significant association was seen between 
delusions and the T allele of rs6494223 (P = 0.014, OR = 1.63) (Carson et al.
2008). This study appears robust with the utilisation of a more adequately sized 
cohort of over 900 individuals. This novel finding requires independent replication.
To date, variants in 11 genes have been tested for association with AD+P. A 
number of studies have reported a relationship between APOE genotype and 
psychosis in AD, however the results of the studies should be received with 
caution. The majority of comprehensive studies have found no relationship with 
APOE e4 and AD+P. It therefore seems unlikely that APOE is involved in the 
manifestation of psychosis in AD. Polymorphism rs4680 and a 4-marker haplotype 
of COMT have both shown association with AD+P which replicates in independent 
samples (Borroni et al. 2004; Borroni et al. 2006; Sweet et al. 2005). However, the 
significance levels seen are underwhelming and the sample sets utilised are 
underpowered to identify such an association. Further analysis of these variants 
would eliminate the possibility that these findings are false positive associations. 
Studies of serotonin genes have given conflicting results (Craig et al. 2007; Holmes 
et al. 1998; Nacmias et al. 2001; Rocchi et al. 2003). The most consistent findings 
appear to be with the 5-HTTLPR long variant (Borroni et al. 2006; Quaranta et al.
2009), which has also shown significant association to LOAD+P in conjunction with 
COMT (Borroni et al. 2006). The NRG1 marker rs3924999 has shown significant 
association with AD+P, but it is unclear whether this finding is exclusive to late- 
onset AD+P (Go et al. 2005) and requires replication. The DRD1 and DRD3 genes 
show association to AD+P which replicate, but the discovery and replication 
studies have been performed by the same group (Holmes et al. 2001; Sweet et al. 
1998), and a negative association of DRD3 with AD+P has also been published 
(Craig et al. 2004a). Nominal associations of AD+P to IL-113 (Craig et al. 2004b) 
and CHRNA7 (Carson et al. 2008) have been identified but not replicated. Most, of 
these association studies have only utilised a small number of samples, meaning 
that they are underpowered to confidently accept or decline a putative variant as 
being associated to disease. An excellent and comprehensive examination of 
practical sample size requirements is provided by Wang and colleagues (Wang et 
al. 2005). The positive associations that are seen are generally only nominally 
significant and most have not replicated. It is also of note that comparison of AD+P 
studies is confounded by a number of factors including; variability in the definitions
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of delusions and hallucinations (Scarmeas et al. 2002), analysis of hallucinations 
and delusions separately in some studies but jointly in others, and use of differing 
classification systems and threshold criteria to quantify psychosis. However, these 
analyses have prioritised interesting candidate genes and variants for future 
investigations and highlighted the need for a uniform classification system to 
accurately assess and define AD+P.
1.6. Study Design
This thesis is based on the wealth of evidence that psychosis in AD is a 
distinct form of AD showing a more severe phenotype (Sweet et al. 2002b). The 
AD+P phenotype displays familiality (Eror et al. 2005; Hollingworth et al. 2007; 
Sweet et al. 2002b), heritability (Bacanu et al. 2005), linkage (Avramopoulos et al. 
2005; Bacanu et al. 2002; Hollingworth et al. 2007), and association (Borroni et al. 
2004; Borroni et al. 2006; Borroni et al. 2007; Go et al. 2005; Holmes et al. 2001; 
Sweet et al. 1998; Sweet et al. 2005), making the phenotype an excellent 
candidate for gene mapping efforts. The findings from previous linkage and 
association studies predominantly highlight putative psychosis susceptibility 
regions and genes in the aetiology of LOAD+P, supporting the theory that 
psychosis modifier genes act across schizophrenia, bipolar disorder and AD+P. 
There are clinical differences in the manifestation of psychosis observed across 
neurodegenerative and neurodevelopmental disease. Psychosis in AD develops 
within a few years of dementia onset and usually persists only a matter of months 
before ceasing (Chen et al. 1991; Paulsen et al. 2000b; Ropacki and Jeste 2005). 
Psychosis in Parkinson’s disease (PD), vascular dementia and Huntington’s 
disease (HD) also develops post disease onset, while in dementia with lewy bodies 
(DLB) psychosis is one of the first symptoms of disease. The prevalence of 
psychosis is increased in DLB subjects (McKeith et al. 2005) and decreased in 
vascular dementia (Ballard et al. 2000) and HD patients compared to those 
suffering with AD (Paulsen 2001). Delusions are the most common psychotic 
symptom in AD (Jeste and Finkel 2000), with visual hallucinations occurring less 
frequently, and often co-occurring with delusions (Cook et al. 2003). The presence
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of psychosis in vascular dementia follows a similar pattern to that seen in AD. In 
DLB (McKeith et al. 2005) and PD (Goetz et al. 2005) visual hallucinations are the 
most common form of psychosis. Whereas, auditory hallucinations are the most 
predominant psychotic symptom in HD (Correa et al. 2006). Psychotic symptoms in 
neurodevelopmental conditions have a more common clinical presentation. 
Hallucinations are the most common psychotic symptom which are predominantly 
auditory in nature (Bocker et al. 2000). Delusions of persecution, grandiosity and 
paranoid or bizarre delusions are frequent (Corner 2004; Tasman 1997). 
Schizophrenia is a psychosis, a disorder of thought and sense of self (Andreasen
1995). Although it affects emotions, it is distinguished from mood disorders in 
which changes in emotion are primary. Psychosis in bipolar disorder usually occurs 
during a manic or depressed episode (Goodwin and Jamison 1990) and tends to 
reflect the extreme mood state at the time (Tasman 1997). While, psychosis in 
schizoaffective disorder commonly occurs after depressive, mixed and/or manic 
episodes (Blacker and Tsuang 1992). However, in neurodevelopmental and 
neurodegenerative disease the core symptoms of psychosis, delusions and 
hallucinations are observed. Therefore, the prioritisation of putative schizophrenia 
and bipolar disorder susceptibility polymorphisms and genes for investigation in 
LOAD+P seems a logical starting point on the quest to identify genetic variants 
involved in the aetiology of this form of LOAD.
1.7. General Aims
The aim of the research presented within this thesis is to detect a novel 
locus or loci conferring susceptibility to LOAD+P. Using aspects of clinical variation 
to identify sub-phenotypes has proved successful in identifying genes for other 
complex disorders such as Crohn’s disease (Rioux et al. 2001), and asthma (Van 
Eerdewegh et al. 2002). In the analysis of complex genetic traits there are a 
number of sample designs. Cross-sectional studies utilise a specific population, 
cohort studies study outcome and exposure in a longitudinal fashion, family based 
studies investigate disease in selected pedigrees, and case-control studies define 
the outcome before measuring the exposure. This study utilises a case-control
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sample design. A number of affected individuals (cases) and unaffected individuals 
(controls) are genotyped. Controls are carefully selected to avoid population 
stratification, by matching with cases for age, sex and ethnicity. Thus, preventing 
false representation of the population the sample group is estimating and reducing 
the probability of false findings. Implicit in a case-control approach is the concept 
that the phenotype studied is clinically homogeneous and can be defined 
categorically as either present or absent. However, LOAD is a clinically 
heterogeneous illness and increasing attention is now being paid to utilizing 
defined subgroups in the hope of unpicking the complex aetiology of the illness 
(Olson et al. 2001; Pericak-Vance et al. 2000; Sweet et al. 2003). Currently, little is 
known about the underlying causes of the clinical differences observed in AD. 
Gaining a more comprehensive understanding of LOAD+P may aid both the study 
of this form of clinical heterogeneity and AD as a whole, providing a strong platform 
for the development of future preventative and therapeutic strategies.
1.8. Thesis Outline
This thesis aims to investigate the underlying genetic aetiology of psychosis 
observed among AD sufferers. Psychotic variation will be considered from two 
distinct standpoints. First, psychosis could identify a distinct ‘sub-phenotype’, or 
more homogeneous form of the disease. Under such a model, genetic variation 
would increase disease risk but only within those sufferers experiencing AD with 
psychosis. Alternatively, genetic variants may act as ‘disease modifiers’. Under 
such a model, genetic variation would not increase the risk of developing AD, but 
could influence the presentation of psychosis in the presence of 
neurodegeneration. In this thesis both theories as to the development of psychosis 
in AD will be explored. Initial work focuses on exploration of the current literature to 
determine the criteria used to classify psychosis presence or absence in AD. 
Following extensive literature searches a threshold criterion is determined. This is 
comprehensively described in chapter 2.2.3. A 2 stage approach to identify genes 
implicated in the aetiology of AD+P is then undertaken. As discussed the region of 
chromosome 6q previously identified by linkage analyses of LOAD+P (Bacanu et 
al. 2002; Hollingworth et al. 2007) overlaps with linkage regions identified for
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schizophrenia (Cao et al. 1997; Levinson et al. 2000; Martinez et al. 1999) and 
bipolar disorder (Dick et al. 2003; Lambert et al. 2005; Pato et al. 2004). Also 
association analyses in LOAD+P have identified positive associations to putative 
schizophrenia and bipolar disorder candidate genes. In chapter 3 of this thesis 73 
variants from 11 psychosis candidate genes are tested for association with 
LOAD+P in the large MRC genetic resource for LOAD sample which comprises a 
cohort of 1205 AD sufferers. The aim of this study is to test if any ‘historical’ 
putative psychosis candidate genes or variants highlighted by studies of psychotic 
disorders such as schizophrenia and bipolar disorder, contribute to the aetiology of 
LOAD+P. This analysis is based on the hypothesis that these genes may affect 
psychosis across disorders through a common underlying neuropathology. The 
same design approach is used in chapter 4. In this chapter ‘novel’ variants and 
genes identified by a recent genome-wide association study of schizophrenia 
(O’Donovan et al. 2008) are investigated for association with LOAD+P in the MRC 
genetic resource for LOAD sample. In chapter 5 the second method of identifying 
susceptibility loci for LOAD+P is employed. In this chapter a hypothesis free 
approach is utilised by analysis of genome-wide association data for AD 
conditioning on the presence or absence of psychosis. This data consists of 
genotypes for over 500,000 markers. This study examines 4957 LOAD cases,
1671 with information on their experience of psychosis during disease, and 9682 
controls, including 2486 elderly controls matched for age, sex and ethnicity. The 
prevalence of psychotic symptoms in the combined sample is 39.9%. This is the 
first genome-wide association study of LOAD+P. The identification of loci which 
increase susceptibility to LOAD+P will be the first step in understanding the causes 
and pathogenesis of a distinct sub-phenotype of AD.
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2. Materials and Methods
2.1. Sample Ascertainment
2.1.1. MRC Genetic Resource for LOAD Sample
Clinical data and DNA samples were collected by members of the 
Alzheimer’s field team from 1,205 individuals (71% females) with late onset 
Alzheimer’s disease (LOAD) and 1,361 control subjects (62% females). Age at 
onset (AAO) ranged from 60 to 95 years (mean = 75.84 years, SD = 6.79). Controls 
were matched for age (mean = 76.53 years, SD = 6.33), sex and ethnicity. The 
sample consisted of individuals ascertained from both community and hospital 
settings in the UK collected as part of the Medical Research Council (MRC) genetic 
resource for LOAD. AD cases and controls described here were ascertained by 
three collaborating centres. Department of Psychological Medicine, Cardiff 
University, Cardiff (co-ordinating centre); Institute of Psychiatry, London; and 
Cambridge University, Cambridge, as previously described (Morgan et al. 2007). 
Ethical permission was obtained from the Multi-centre Research Ethics Committee, 
relevant local ethics committees and NHS trusts.
All cases were Caucasian, of UK origin (parents born in the UK) and 
diagnosed with probable AD in accordance with the National Institute of 
Neurological and Communication Disorders and Stroke and the Alzheimer's 
disease and Related Disorders Associations (NINCDS-ADRDA) clinical diagnostic 
criteria for AD (McKhann et al. 1984). All diagnoses were made based on a semi­
structured interview with known validity for AD pathology (i.e. positive predictive 
value of 92-95% (Foy et al. 2007; Holmes et al. 1999)), which included: (1) The 
Mini Mental State Examination (MMSE) (Folstein et al. 1975); (2) The Cambridge 
Mental Disorders of the Elderly Examination (CAMDEX; informant interview) (Roth 
et al. 1986); (3) The Blessed Dementia Scale (Blessed et al. 1968); (4) The Bristol 
Activities of Daily Living Scale (Bucks et al. 1996); (5) Webster Rating Scale 
(Webster 1968); (6) Global Deterioration Scale (GDS) (Reisberg et al. 1988); (7) 
Cornell Scale for Depression in Dementia (Alexopoulos et al. 1988); (8)
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Neuropsychiatric Inventory (NPI) (12 Item version) (Cummings 1997). Interviews 
were primarily conducted with the AD sufferer's next of kin by members of the 
Alzheimer’s field team.
MRC control subjects were either spouses of AD patients or selected from 
primary-care practices situated in the same geographical areas as AD patients. All 
controls were 60 years or above and of UK origin. Control individuals were 
screened for cognitive decline using the MMSE, and a cut-off score of 28 or above 
was adopted. Assessment also included a section of the Cambridge Mental 
Disorders of the Elderly Examination and the Geriatric Depression Scale (Sheikh 
and Yesavage 1985). Exclusion criteria included the presence of dementia, 
depression, delirium or other illnesses likely to significantly reduce cognitive 
function.
2.2. Behavioural Assessment
2.2.1. The Neuropsvchiatric Inventory
The Neuropsychiatric Inventory (NPI) (Cummings 1997) was used to assess 
the prevalence and severity of behavioural and psychological symptoms in all 
participants. The NPI is an informant-based rating scale which evaluates 12 
common behavioural and psychological symptoms in AD including delusions, 
hallucinations, agitation, depression/dysphoria, anxiety, euphoria, apathy, 
disinhibition, irritability, aberrant motor behaviour, night-time behaviour 
disturbances, and appetite/eating abnormalities. The severity of each symptom is 
rated categorically from 0-3, with anchor points for ‘does not occur’ (0), ‘mild’ (1), 
‘moderate’ (2) and ‘severe’ (3). The frequency with which the symptom occurs is 
rated categorically from 0-4, with points for ‘never’ (0), ‘less than once per week’
(1), ‘about once per week’ (2), ‘several times per week’ (3) and ‘once or more per 
day’ (4). Frequency and severity scores are then multiplied to give an overall 
domain score for each symptom ranging from 0 to 12. Content validity, concurrent 
validity, inter-rater reliability, and test-retest reliability of the NPI are well
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established and it is commonly used in both research and clinical settings 
(Cummings 1997).
2.2.2. Principle Components Analysis
Behavioural and psychological symptoms in AD had been previously 
assessed under the hypothesis that these symptoms represent fewer underlying 
components, and that symptoms of the same component are more likely to co­
occur (Hollingworth et al. 2006). The identification of behavioural and psychological 
components in complex diseases may allow identification of more homogeneous 
samples with sufficient power (through relatively large sample sizes) to detect 
susceptibility variants for disease. The assessment used NPI data from a total of 
1,120 individuals collected as part of the MRC genetic resource for LOAD 
(Hollingworth et al. 2006). Domain scores for each section of the NPI were used to 
test the component structure of the NPI and determine clusters of symptoms which 
occur together, the resulting correlation matrix was submitted to principal 
components analysis. Four interpretable components were identified: behavioural 
dyscontrol (euphoria, disinhibition, aberrant motor behaviour sleep, and appetite 
disturbances), psychosis (delusions and hallucinations), mood (depression, 
anxiety, and apathy), and agitation (aggression and irritability) (Hollingworth et al. 
2006).
2.2.3. Sample Classification Criteria
Samples were classified based on the scores of the NPI, rated to reflect the 
worst episode of each symptom over the lifetime of the illness. Individuals classified 
as having late-onset Alzheimer’s disease with psychosis (LOAD+P) first had to 
meet a frequency threshold for presence of symptom(s) £ 2, this minimum criterion 
aimed to exclude those patients experiencing very few psychotic episodes which 
maybe attributable to another cause.I ndividuals classified as LOAD+P had to 
experience both hallucinations and delusions or experience hallucinations or 
delusions singly with a NPI domain score > 3. These criteria were designed after
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extensive literature searches and were based on similar classification definitions of 
NPI data being implicated in AD (Cummings et al. 2005). Three hundred and 
seventy nine individuals were categorised as LOAD+P (78% females, mean AAO 
= 76.07 years). AD cases who had not displayed any hallucinations or delusions 
were coded as having late-onset Alzheimer's disease without psychosis (LOAD-P). 
The prevalence and severity of psychosis in AD has been shown to increase with 
advancing disease progression (Paulsen et al. 2000b; Ropacki and Jeste 2005). 
Therefore, individuals with mild-moderate AD (GDS < 5) were considered at 
unknown risk of developing psychosis and excluded from the LOAD-P subgroup. 
Two hundred and sixty nine individuals were categorised as having late-onset 
Alzheimer’s disease without psychosis (LOAD-P) (70% females, mean AAO 
= 75.97 years).
2.3. Marker Selection
Three approaches to gene investigation were undertaken in this study. The 
first was to genotype specific markers and haplotypes previously shown to be 
associated with some form of psychosis. Where no individual marker or haplotype 
was specifically associated with disease state, the locus was “tagged”. Functional 
variants were analysed at those loci that were practically and financially too large to 
be “tagged” to a satisfactory standard. Following extensive literature searches 
using PubMed (see section 2.9.1.) and consultation with senior members of the 
department (Professor’s Michael Owen. Michael O’Donovan, Nick Craddock and Dr 
Nigel Williams), who are experts in the genetics of schizophrenia and bipolar 
disorder, markers and haplotypes were chosen that were deemed to be putatively 
associated with psychosis. Polymorphisms chosen to tag a specific gene were 
identified using the tagger tab within the HAPLOVIEW software version 4.0 (Barrett 
et al. 2005) with input data from the HapMap project (www.hapmap.org) (see 
sections 2.9.2 and 2.10.3 respectively), or in house CEPH genotypes. SNPs were 
chosen to tag the gene of interest plus an additional 40 kb (20 kb of flanking 
sequence either side of the gene of interest) using the pairwise tagging algorithm, 
meaning that all tag SNPs act as direct proxies to all other untyped SNPs, with a r2 
threshold of 0.8, the minimal coefficient of determination r2 at which all alleles are
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to be captured. Functional variants included SNPs within coding regions (exons), 
un-translated regions, putative promoter regions, evolutionary conserved regions 
and transcription factor binding sites. These markers were identified using the 
UCSC genome browser (see section 2.10.2) and their surrounding sequences 
downloaded from the database.
2.4. DNA Extraction, Quantification, Storage and Sample Preparation
2.4.1. DNA Extraction
All MRC DNA samples were obtained from venous blood taken by members 
of the Alzheimer’s field team from participants willing to give blood. DNA was 
extracted as high molecular weight fractions from lymphocytes using standard 
phenol-chloroform procedures followed by ethanol precipitation.
2.4.2. DNA Quantification
Following DNA extraction DNA concentration was calculated. Firstly, by 
ultraviolet (UV) absorbance using an uQuant spectrophotometer (Biotek® 
Instruments Inc, Winooski, Vermont, USA). An aliquot of extracted DNA was diluted 
to 5% its original concentration. UV light absorbance (A) at 260 nm and 280 nm 
wavelength (A) were measured and the ratio between A260 nm and A280 nm calculated. 
Assuming that an A26o nm of 1 is equivalent to 50 pg of DNA, a ratio above 1.8 
indicated a suitable level of clean DNA and the absence of contaminating RNA or 
protein. An aliquot of extracted DNA was diluted to approximately 20 ng/pl in sterile 
water (Fresenius Kabi, Paris, France) based on the concentration calculated by 
spectrometry.
The Quant-iT™ PicoGreen® double-stranded (ds) DNA Quantification kit 
(Molecular Probes®, Carlsbad, California, USA) and a Fluoroskan Ascent® 
fluorometer (LifeSciences International Ltd, Singapore) with Ascent® Software 
(Thermo Labsystems, Altrincham, UK) were used to calculate more accurately the 
concentration of DNA. The Quant-iT™ PicoGreen® reagent specifically interacts 
with dsDNA and is therefore a more accurate method of quantification than
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spectrometry. The 20 ng/pl DNA aliquot was further diluted to 1% concentration in 
1x TE buffer in a 96 well labsystems cliniplate (Thermo Labsystems, Altrincham, 
UK). A working concentration of Quant-iT™ PicoGreen® reagent was produced by 
adding 5 pi Quant-iT™ PicoGreen® at 200x to 995 pi of 1x TE buffer. One hundred 
microlitres of Quant-iT™ PicoGreen® working concentration was dispensed into 
each sample by the fluorimeter and the DNA concentration measured using a UV 
excitation wavelength of 485 nm and an emission wavelength of 538 nm. DNA was 
quantified by comparison to the gradient of a standard curve produced by using the 
calibrant standard provided. Using this accurate measure of dsDNA concentration, 
working concentrations of 5 ng/pl genomic DNA were prepared by sterile water 
dilutions in 96-shallow-well boxes (ABgene, Epsom, UK) using a liquid handling 
system (Biomek® FXP Laboratory Automation Workstation, Beckman Coulter Inc, 
Fullerton, California, USA).
2.4.3. Liquid Handling
All large scale liquid processing was undertaken using semi-automated 
robotic liquid handling systems. DNA samples and pre-PCR reagents were 
aliquoted using a Biomek® FXP Laboratory Automation Workstation (Beckman 
Coulter Inc, Fullerton, California, USA). Post polymerase chain reaction (PCR) 
reagents were aliquoted using a Biomek® NXP Laboratory Automation Workstation 
(Beckman Coulter Inc, Fullerton, California, USA). All liquid handling programs 
utilised during this study were written by other members of the department.
2.4.4. DNA Storage
All DNA stocks were kept at -20°C in water in individual microcentrifuge 
tubes. All DNA dilutions were prepared in 96-shallow-well boxes (ABgene, Epsom, 
UK) and stored at -20°C.
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2.4.5. Sample Preparation
3 pi of 5 ng/pl genomic DNA was aliquoted into 384-well PCR plates using a 
Biomek® FXP Laboratory Automation Workstation. Sample plates were dried on 
384 well tetrad thermocyclers (MJ Research Genetic Research Instrumentation, 
Rayne, UK) at 55°C for 30 min in preparation for PCR amplification.
2.5. Polymerase Chain Reaction
Polymerase chain reaction (PCR) is a well established method of amplifying 
a specific DNA sequence that lies between two regions of known sequence. The 
technique is dependent upon the thermostable enzyme Thermus Aquatics (Taq). 
Taq polymerase performs the synthesis of the complementary DNA strand from a 
denatured DNA template in the presence of a suitable buffer containing MgCI2, 
deoxy-nucleotide triphosphates (dNTPs), and forward and reverse oligonucleotide 
primers. The oligonucleotide primers are designed to anneal to the known 
sequence and flank the region to be amplified. The Taq polymerase uses these 
primers as a double stranded initiation point for 5’ to 3’ synthesis of DNA. The PCR 
reaction involves the denaturation of the double stranded DNA at a high 
temperature to produce a single stranded DNA template, the annealing of the 
oligonucleotide primers to their complementary sequence, and the enzymatic 
extension of the DNA product. Each stage of the PCR reaction, denaturation, 
annealing and extension is repeated in a cyclic manner by alteration of reaction 
temperature using a MJ Tetrad thermocycler (MJ Research, Rayne, UK) (see 
Figure 2.5), the template and synthesised product is sequentially amplified for 
approximately 35 cycles.
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Figure 2.5. Schematic outline of DNA amplification by Polymerase Chain Reaction. 
Extended primers are complementary to their template.
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2.5.1. Oligonucleotide Primer Design
Oligonucleotide primers for PCR reactions used in this study were designed 
using the online Primer3 (v4.0) software (Rozen and Skaletky 2000) 
(http://frodo.wi.mit.edu/cqi-bin/primer3/prirner3 www.cqi). the Amplifluor™ 
AssayArchitect™ software (https://apps.seroloqicals.com/AAA/) and the 
Sequenom™ MassARRAY™ Assay Design software. Flanking sequences were 
obtained from the ‘get DNA’ function of the UCSC genome browser 
(http://qenome.ucsc.edu/) with surrounding polymorphisms highlighted. Primer 
sequences were designed to not overlap with any polymorphism to ensure 
optimum primer binding and subsequent product amplification. Oligonucleotides 
used in this thesis were synthesised by Eurogentec (Eurogentec Ltd, Southampton, 
UK) (www.euroqentec.com). Invitrogen™ (Invitrogen Ltd, Paisley, UK)
(www.invitroqen.com). Metabion (Metabion International AG, Martinsried,
Germany) (www. metabion .com). or Sigma-Aldrich® (Sigma-Aldrich Company Ltd, 
Dorset, UK) (www.siqmaaldrich.com).
2.5.2. PCR Reagents
Two types of Taq polymerase were used for PCR; HotStar Taq (Qiagen, 
Valencia, California, USA) and Titanium Taq (BD Biosciences) the latter of which 
was used exclusively for Amplifluor genotyping (see section 2.7.2). HotStar Taq is 
chemically modified to prevent enzymic activation before heating at 95°C for 15 
minutes preventing non-specific elongation. HotStar Taq based PCR was 
performed in a 5 pi volume containing 5 pmol of each primer, 20 pM dNTPs 
(Amersham Biosciences, UK Ltd), 1 x PCR buffer (Qiagen, Valencia, California, 
USA) and 0.5 units Hotstar taq Polymerase (Qiagen, Valencia, California,
USA)(see Table 2.5a), which was aliquoted into sample plates containing pre-dried 
DNA.
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Table 2.5a. Reagents used for PCR reactions (note: volume quoted per single PCR 
reaction).
Reagent Company Volume
Buffer (10x containing 15 mM MgCI2) Qiagen, USA 0.5 pi
dNTPs (2.5 mM) Amersham, UK 0.1 pi
Primer (10 pmol/pl)-Forward Eurogentec, UK 0.2 pi
Primer (10 pmol/pl)- Reverse Eurogentec, UK 0.2 pi
ddH20 UHW, UK 3.9 pi
Hot Start Taq Polymerase (5 Units/pl) Qiagen, USA 0.1 pi
2.5.3. PCR Condition Optimisation
Where possible the PCR cycling conditions followed a standard three step 
method. Assays that failed to optimise under such conditions were optimised using 
a “touch-down” PCR. To find the optimum temperature (Tm) for primer annealing 
optimisation reactions were undertaken for each primer pair on control DNA using a 
temperature gradient (52°C, 53°C, 56°C, 60°C, 64°C and 66°C) on MJ Tetrad 
thermocyclers (MJ Research, Rayne, UK).
Standard Three-step Cycling Conditions;
1. 94°C - 96°C for 15 minutes
2. 94°C - 96°C for 20 - 30 seconds
3. Tm°C for 20 - 30 seconds
4. 72°C for 30 - 45 seconds
5. Repeat steps 2 -  4 for 34 - 36 cycles
6. 72°C for 10 minutes
7. 15°C for 10 minutes
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Touch-down PCR Conditions;
1. 94°C - 96°C for 15 minutes
2. 94°C - 96°C for 5 seconds
3. Tm°C + 6°C for 5 seconds (-0.5 °C per cycle)
4. 72°C for 10 seconds
5. Repeat steps 2 - 4 for 1 1 - 1 5  cycles
6. 94°C for 5 seconds
7. Tm°C for 5 seconds
8. 72°C for 10 seconds
9. Repeat steps 6 -  8 for 19 - 25 cycles
10 72°C for 10 minutes
11 . 15°C for 10 minutes
2.6. Agarose Gel Electrophoresis
Agarose gel electrophoresis was undertaken to check PCR product 
production. DNA fragments are fractionated according to their size and 
conformation when an electrical potential difference is applied through a porous 
substance such as an agarose gel. The negatively charged phosphate group of 
DNA allows the migration of the fragment towards the positive anode. Hence, 
allowing fragments of differing sizes and shapes to be separated. Analysis of post 
PCR samples was performed using 2% agarose gels. The reagents to construct a 
2% agarose gel are listed in Table 2.6a. The agarose -  TBE mixture was heated to 
ensure complete liquefaction and mixing. The solution was allowed to cool before 
the Ethidium Bromide solution was added. The molten gel was poured into a gel 
casting tray and appropriate well former combs were added before the gel was 
allowed to set at room temperature for approximately 30 minutes.
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Table 2.6a. Reagents to prepare a 2% Agarose Gel.
Reagent Supplier Quantity
ddH20 UHW, UK 95 ml
TBE (x10) National Diagnostics, USA 5 ml
Agarose AGTC Bioprod Ltd, UK 2 g
Ethidium Bromide (10 mg/ml) Fischer Scientific, UK 1 pi
After PCR, 2 pi of PCR product was mixed with 2 pi of loading buffer (see 
Table 2.6b). Loading buffer allows the PCR product to “fall” into the wells and also 
enables tracking of DNA migration through the agarose gel. The resulting mix was 
aliquoted into the formed wells of the solidified gel, along with a 4 pi aliquot of size 
standard (1 kb plus DNA ladder, see Table 2.6c). This ladder constitutes DNA 
fragments of known size and was used to assess the size of PCR amplified 
fragments. The gel was immersed in an electrophoresis tank (Thermo Scientific, 
Northumberland, UK) containing 0.5 x TBE buffer. Gel electrophoresis was 
performed at 120 volts for 45 minutes. DNA products assayed by agarose gel 
electrophoresis were visualised using an UV transilluminator (UVP, Upland, 
California, USA) and photographs taken using an attached Kodak Electrophoresis 
Gel documentation and analysis system (Eastman Kodak Company, Rochester, 
New York, USA).
Table 2.6b. Reagents for Loading Buffer.
Reagent Supplier Quantity
ddH20 UHW, UK 20 ml
EDTA (0.5 M) Sigma, UK 4 ml
Ficoll BDH, USA 3g
Orange G/Bromophenol Blue Sigma, UK 0.01 g
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Table 2.6c. Reagents for 1 kb+ ladder.
Reagent Supplier Quantity
ddH20 
1 kb+ Ladder 
Loading Buffer
UHW, UK 
New England Biolabs, USA 
Prepared Above
140 pi 
30 Ml 
30 Ml
2.7. Genotyping Methods
Individual SNP genotyping was performed using either MassARRAY™ 
(Sequenom™, San Diego, California, USA) or Amplifluor™ (Millipore, Billerica, 
Massachusetts, USA) platforms. The iPlexGOLD™ assay for the MassARRAY™ 
system allows multiplexing of SNP assays up to the 39-plex level (Oeth et al. 2005) 
and is explained in detail in section 2.7.3. Microsatellite markers and repeat 
elements were also investigated in this study and were genotyped by the genescan 
fluorescent PCR method.
2.7.1. Genescan Fluorescent PCR
The genescan fluorescent PCR method is often used to genotype 
insertions/deletions and repeat elements. The methodology is based on 5’ fluor- 
labelled oligonucleotide PCR primers (the 5’ primer is labelled and the 3’ primer is 
unlabelled). The fluorescent labels used were FAM and HEX which fluoresce at 
different wavelengths. A panel of markers was designed so that the size of 
amplimer for each marker (and all allelic variants) did not overlap with the size of 
any other marker amplimer (and that markers alleles) labelled with the same 
fluorophore. All marker PCRs used in this study had a size greater than 100 bp and 
smaller than 400 bp.E ach fluorescent PCR was performed and purified separately. 
Unincorporated dNTPs and unextended primers were disabled using;
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0.5 pi Shrimp Alkaline Phosphatase (SAP) (GE Biosci, Bucks, UK)
0.1 pi Exonuclease I (exo I) (GE Biosci, Bucks, UK)
4.4 pi ddH20
Incubated at;
1. 37°C for 1 hr
2. 80°Cfor15min
The independent products were pooled at an appropriate ratio to allow 
genotyping to be performed (as determined by a pre-test on optimisation DNA). For 
analysis 4 pi clean multiplexed PCR product was added to 9 pi HiDi formamide 
(Applied Biosystems, Foster City, California, USA) and 0.5 pi fluorescent size 
standard. The size standard used was Genescan™ -500 ROX™ (Applied 
Biosystems, Foster City, California, USA) which is designed for sizing DNA 
fragments in the 35-500 bp range, and provides 16 single-stranded fragments of 
35, 50, 75, 100, 139, 150, 160, 200, 250, 300, 340, 350, 400, 450, 490, and 500 
bases.
The fluorescent labelled products were analysed using an automated ABI3100 
PRISM Genetic Analyser (Applied Biosystems, Foster City, California, USA). The 
ABI3100 PRISM Genetic Analyser (Applied Biosystems, Foster City, California, 
USA) loads the samples by electrokinetic injection, the samples are then 
electrophoretically moved through a polyacrylamide filled capillary where the 
fluorophore is excited by a laser; the resultant fluorescence is measured by a 
Photo-Multiplier-Tube. The PCR samples were run through a 36 cm long capillary 
using POP4 polyacrylamide (Applied Biosystems, Foster City, California, USA). 
Analysis of the fluorescent fragments was performed automatically using Genescan 
Analysis version 3.7 software (Applied Biosystems, Foster City, California, USA). 
These data were then analysed using Genotyper software (Applied Biosystems, 
Foster City, California, USA), which allows the user to delineate the size of the 
fluorescently labelled product and judge whether alleles are present for size- 
polymorphic markers. Genotype results were exported to a Microsoft excel file for 
further analysis. If alleles were genotyped in samples that contained water instead 
of DNA then a PCR contamination had occurred and the experiment was re­
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performed. Experiments were also re-performed for markers where more than two 
alleles were present.
2.7.2. Amplifluor™ UniPrimer Chemistry
Amplifluor™ UniPrimer Chemistry is based on PCR amplification of genomic 
DNA using two allele-specific tailed primers that introduce priming sites for 
universal energy transfer labelled primers. The reaction requires no post-PCR 
handling (Myakishev et al. 2001). The assays were designed by the Amplifluor™ 
AssayArchitect™ software freely available online at the Amplifluor™ website 
(https://apps.seroloqicals.com/AAA/). The design process entails the input of the 
SNP details and the flanking DNA sequence into the design software. The 
technique utilises five primers: two forward allele-specific tailed primers, a single 
universal anti-sense reverse primer and two “universal” energy-transfer labelled 
primers (UniPrimers). Each UniPrimer contains a 3’ sequence of approximately 15- 
20 bp, which is complimentary to the 5’ end of one of the allele specific tailed 
primers and is labelled with either a green dye (fluorescein, FAM) or a red dye 
(sulforhodamine, SR) as well as a quencher (Dabsyl) at the 5’ hairpin structured 
end. In this hairpin state the primers emit very low levels of fluorescence because 
the energy from the fluorophore is transferred to the nearby quencher.
The allele-specific primers initiate a competitive allele-specific PCR and 
these amplimers serve as templates for the binding of the UniPrimers. The 
incorporation of the UniPrimer into the allele-specific amplimer linearises the 
hairpin structure of the UniPrimer, separating the fluorophore from its quencher and 
enhancing the level of fluorescence. The resultant levels of red or green 
fluorescence can distinguish the levels of each allele. The aim of the assay is to 
have one homozygote yield green fluorescence only, the other homozygote red 
only, and the heterozygote a mix of red and green fluorescence. The step by step 
reaction is displayed in Figure 2.7a.
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Allele 1 Allele 2
Allele 1-specific primer
Common Primer
Allele2-specific primer
Common Primer
Quencher Quencher
Green Amplifluor primer Red Amplifluor primer
Allele 1 fluorescent product Allele 2 fluorescent product
Figure 2.7a. Schematic of the step-by-step Amplifluor™ reaction.
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The primer specific PCR primer mix for the reaction (primers were obtained at 100
pmol/pl);
Forward primer (Allele 1) 2.5 pi
Forward primer (Allele 2) 2.5 pi
Reverse primer 25 pi
ddH20  470 pi
The reagent mix for the Amplifluor™ reaction;
10x Titanium Taq Buffer (BD Biosciences, NJ, USA) 0.5 pi
dNTPs (2.5 mM each) (Amersham Biosciences, UK) 0.4 pi
Primer mix (as prepared above) 0.07 pi
SR labelled primer (BD Biosciences, NJ, USA) 0.07 pi
FAM labelled primer (BD Bioscience, NJ, USA) 0.07 pi
Titanium Taq Polymerase (BD Biosciences, NJ, USA) 0.05 pi
Reaction Mix S (BD Biosciences, NJ, USA)* 0.0625 pi
ddH20  3.84 pi (3.2 pi*)
* Reaction Mix S is an optional additive which may improve assay clusters.
The total volume of the reaction mix is 5 pi. The mix was added to 15 ng of 
dried sample DNA in a black 384 well microtitre plate (ABgene, Epsom, UK). For 
large scale genotyping the reaction mix was added using a Biomek® FXP 
Laboratory Automation Workstation (Beckman Coulter Inc, Fullerton, California, 
USA). The cycling conditions for the reaction on a MJ thermocycler (MJ Research, 
Rayne, UK) are as follows;
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1. 96°C for 4 minutes
2. 96°C for 10 seconds
3. 58°C for 5 seconds*
4. 72°C for 10 seconds
5. Repeat steps 2 -  4 for 20 cycles
6. 96°C for 10 seconds
7. 55°C for 20 seconds
8. 72°C for 40 seconds
9. Repeat steps 6 -  8 for 15 - 22 cycles*
10.68°C for 7 minutes
11.15°C for 10 minutes
*These steps require optimisation for each specific polymorphism reaction.
The Amplifluor™ reaction takes place in two stages. The first stage (steps 1- 
5) involves the denaturation of the DNA sample, the annealing of the allele specific 
primers to the DNA template and the elongation of the fragments which include the 
complimentary tails for the universal UniPrimer. In the second stage (steps 6-11) 
the PCR product is denatured and the UniPrimers anneal to their complimentary 
sequence and then subsequently extend to unfold their hairpin structures and allow 
a fluorescent signal to be generated. The fluorescence of each sample was 
analysed using an Analyst HTS Assay Detection Platform (LJL Biosystems, 
Sunnyvale, California, USA) at the wavelengths shown in Table 2.7a.
Table 2.7a. Excitation and Emission wavelengths for the each fluorophore (FAM and SR) 
used in this study.
Excitation Emission
FAM 485 nm 520 nm
SR 580 nm 620 nm
64
Chapter 2. Materials and Methods
The results are given as signal intensities for the two fluorophores which 
were plotted on a graph program (http://apps.seroloqicals.com). The clusters of 
sample fluorescent points correspond to the three genotype classes. The output of 
the program is in the form of 11, 12 or 22 where 1 corresponds to the FAM allele 
and 2 the SR allele.
2.7.3. Sequenom™ iPlexGOLD™ MassARRAY™
The Sequenom™ MassArray™ genotyping system allows the highly 
accurate genotyping of simple polymorphisms by combining primer extension 
chemistry with MALDI-ToF (Matrix Assisted Laser Desorption Ionisation -  Time of 
Flight) Mass Spectrometry (MS). Sequenom™ iPlexGOLD™ MassARRAY™ 
genotyping involves primer extension over the polymorphism of interest and the 
examination of the mass of the extended product to discern the genotype of a 
sample. The main advantages of the MassARRAY™ genotyping system is its 
accuracy and high assay multiplexing level (up to 39-plex) which increases 
throughput and minimises cost.
2.7.3.1. Multiplex Assay Design
The initial step of MassARRAY™ genotyping involves the design of the 
multiplex assay. For each polymorphism the flanking DNA sequence was obtained, 
from the UCSC browser ‘get DNA’ feature, with any DNA sequences or variants 
that may confound PCR amplification (e.g. known SNPs and repetitive sequence) 
highlighted to prevent assay design over these regions. The highest multiplex 
assay possible was then designed using the Sequenom™ MassARRAY™ Assay 
Design 3.1 software, which analyses the flanking sequences, primer parameters 
and secondary structures for each polymorphism to create an optimum set of 
multiplex reactions. Details of the PCR primers and an appropriate 
MassEXTEND™ extension primer for each polymorphism are provided in an output 
file (.trs) on design completion. Where necessary the design software adds a 10 bp 
non-specific “tag” sequence to the 5’ end of PCR primers, to ensure they are 
detected later in the MALDI-ToF mass spectrum. The software designs the PCR 
oligonucleotides to create the shortest amplimer possible to allow efficient PCR,
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and an annealing temperature as close to 56°C as possible to match the universal 
PCR conditions detailed below. The extension is terminated after a single base 
during the iPlex™ reaction. The mass is resolved either by the extended primer or 
by the addition of a non-specific sequence to the extension primer by the 
MassARRAY™ Assay Design software, allowing for better size discrimination 
between allele masses of different assays.
2.7.3.2. Multiplex Assay PCR
The forward and reverse PCR primers for all SNPs were combined into a 
primer mix with a final concentration of 1 pmol/pl for each of the separate primers. 
The PCR was performed on 15 ng of each sample aliquoted into a 384 well PCR 
plate and dried down by incubating at 55°C for 30 minutes. The PCR mastermix 
was made and 5 pi added to each of the 384 samples.
Multiplex PCR Reaction Mix;
ddH20  3.39 pi
PCR Buffer 10x (Qiagen, USA) 0.625 pi
MgCI2 (25mM) (Qiagen, USA) 0.325 pi
dNTPs (25mM) (Amersham Biosciences, UK) 0.1 pi 
HotstarTaq (Qiagen, USA) 0.06 pi
F and R PCR primers (1 pmol/pl) 0.5 pi
The PCR reaction was then performed on a MJ thermocycler (MJ Research, 
Rayne, UK) using the listed conditions:
1. 95°C for 15 minutes
2. 94°C for 20 seconds
3. 56°C for 30 seconds
4. 72°C for 1 minute
5. Repeat steps 2-4 for 44 cycles
6. 72°C for 3 minutes
66
Chapter 2. Materials and Methods
The PCR products were examined by electrophoresis on an agarose gel (as
described in section 2.6) to check that the correct sized products had been
generated and there was no contamination present. Two genomic DNA positive 
samples and two negative water samples per 384-well PCR plate plus two reaction 
mix blanks were electrophoresed. Due to the large amount of primers being added 
to the reaction it was important to recognise any primer dimers that were present in 
either the DNA samples or the negative controls and not mistake them for either 
PCR product or contamination.
2.7.3 3. PCR Purification
If no PCR contamination was identified by the agarose gel electrophoresis, 
the PCR product was cleaned using the shrimp alkaline phosphatase enzyme 
(SAP) to remove any unincorporated dNTPs and unused primers from the reaction. 
A 2 pi mix was added to each PCR product. The mix contained;
Shrimp alkaline phosphatase (SAP) 0.3 pi
SAP buffer 0.17 pi
ddH20  1.53 pi
The samples were then incubated to allow PCR clean up, before the enzyme is 
denatured. The thermocycler conditions for this reaction are as follows;
1. 37°C for 30 minutes
2. 85°C for 15 minutes
3. 95°C for 5 minutes
2.7.3.4. iPlexGOLD™ Primer Extension
The iPlex™ extension primers are designed to extend over the polymorphic 
base to one base past the SNP before termination. This allows un-extended and 
extended primer to be separated by sufficient mass for accurate genotyping of 
alleles. The MALDI-ToF system can resolve masses that differ by as little as 3 
Daltons. Regardless of the number of assays, the reaction conditions are universal 
for all stages, the only optimisation required is the adjustment of extension primer 
concentration. This optimisation was achieved by amplification of 18 control DNA
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samples and 6 negative controls. The procedure split the extension primers into 
four groups dependent on their masses, which were initially diluted to final 
concentrations of 0.9375 pM, 1.17 pM, 1.425 pM and 1.875 pM (lowest mass to 
highest mass). Extension primers are divided into mass groups because lower 
mass products generate a lower signal-to-noise ratio when detected by MALDI-ToF 
MS. After the initial test run extension primers were diluted according to the 
following equation:
„  OptimalPeakHeightDilutionFactor  ----- -------------------------------
(ActualPeakHeight /10)
The optimum peak height (user detected -  30-50) and actual peak height are 
obtained from the raw MassARRAY spectra. At the optimisation stage, failed or 
anomalous assays (e.g. self-priming) are removed.
Once the multiplex PCR has been SAP treated the optimised iPlex 
extension reaction can be performed. The extension reaction involves the addition 
of the unextended iPlex™ primer, the specific 3 base termination mix (two ddNTPs 
and one dNTP corresponding to the polymorphic base plus the extra non- 
polymorphic base) and thermosequenase in the following mix; 
iPlexGOLD™ Buffer Plus 0.2 pi
iPlexGOLD™ Termination Mix 0.2 pi
Extension Primer Mix 1.559 pi
iPlex™ Enzyme 0.041 pi
2 pi of the iPlex™ extension reaction mix was added to each 7 pi of clean PCR 
product and thermocycled following the conditions detailed below;
1. 94°C for 30 seconds
2. 94°C for 5 seconds
3. 52°C for 5 seconds
4. 80°C for 5 seconds
5. Repeat steps 3-4 for 4 cycles
6. Repeat steps 2-5 for 39 cyles
7. 72°C for 3 minutes
8. 4°C for 10 minutes
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Figure 2.7b. Schematic of the Sequenom™ iPlex™ Assay (The scheme depicts a single 
assay).
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2.7.4. Quality Control
With all genotyping methods it is vital that standard quality control 
procedures are adopted to ensure accurate genotype calls. On all genotyping 
plates a number of wells were “blank” meaning that they were empty of DNA. An 
aliquot of reaction mix was added to these wells, and post-PCR an aliquot from at 
least two blank wells was run on agarose gel electrophoresis. This procedure 
checks for assay contamination. A number of case and control samples were 
duplicated across sample plates as one method of calculating genotype accuracy 
and correlation. Assays were optimized in the Centre d’Etude du Polymorphisme 
Humain (CEPH) sample and where possible, the in house genotype calls were 
compared to those freely available from the HapMap database (www.hapmap.org). 
CEPH samples were also included on every sample plate. In house CEPH 
genotypes and HapMap CEPH genotypes were compared using a command script 
operated program written by Dobril Ivanov. Markers were assessed to ensure they 
followed the law of Hardy-Weinberg Equilibrium (HWE). This states; ‘If an infinitely 
large, randomly mating population is free from outside evolutionary forces (i.e. 
mutation, migration and natural selection), then the gene frequencies will not 
change over time’. Using a chi squared distribution the observed genotype 
frequencies obtained from the data were compared for deviation from the expected 
genotype frequencies as defined by the law of HWE.
2.8 Data Storage
Following genotyping and QC checks, raw data were formatted so that it 
could be uploaded into in-house PsychMed database (created by Dr. Ivan Nikolov). 
Numerous formats are acceptable for upload, dependent on the genotyping 
system. Sequenom™ data is acceptable in its output format. The PsychMed 
database contains all the phenotypic data for all the samples in the study. Once all 
the genotypic data had been imported, the database was used to store data and 
construct the PLINK ready files for statistical analysis.
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2.9. Statistical Analysis
Following genotyping and providing markers passed QC, the numbers of 
individuals homozygous for allele 1, heterozygous, and homozygous for allele 2 
was determined; from these figures 2><3 Chi-square tables were constructed to 
calculate genotypic chi square (%2) and p-values for differences between groups. 
Allele frequencies in each comparison group, relative allelic %2 using 2 x 2  tables, p- 
value and odds ratio were calculated using the PLINK software (section 2.9.1). 
Polymorphisms with allele or genotype frequency differences at P £ 0.05 were 
considered as significantly associated with disease after permutation correction for 
multiple testing. Permutation correction was performed using 10,000 permutations 
via the PLINK software. This corrects for multiple testing but accounts for 
correlation between markers and so is less conservative than a Bonferroni 
correction, which is appropriate for independent tests. To perform the permutation 
test, the case and control status are reassigned. In each replicate, all the selected 
markers are analysed and the most significant p-value stored, so that the 
permutation procedure gives a significance level corrected for the multiple markers 
tested. The D’ and r2 estimates of linkage disequilibrium (LD) were calculated using 
various versions of HAPLOVIEW
(http://www.broad.mit.edu/personal/icbarret/HAPLOVIEW/index.php) (section 
2.9.2).Most haplotype frequency analysis was performed using PLINK with a 
permutation test. Some early haplotype analyses were performed using 
UNPHASED (v3.0) (Dudbridge 2003). All polymorphisms typed individually were 
tested for deviation from Hardy-Weinberg equilibrium (HWE) using a goodness of 
fit test using the PLINK software (Purcell et al. 2007).
2.9.1. PLINK
PLINK (v1.05 and v1.06) is freely available for online download 
(http://pnau.mQh.harvard.edu/purcell/plink/). The software is a whole genome 
association analysis toolset, designed to perform a range of basic, large-scale 
analyses in a computationally efficient manner (Purcell et al. 2007). There are five 
main functional domains to PLINK; Data management, which allows data recoding 
and reformatting, file merging and compressing and subset extraction amongst
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other operations; Summary statistics for quality control, which include functions 
such as HWE calculations, missing call rates, inbreeding and non-Mendelian 
transmission; Population stratification detection; Association analysis, in both 
case/control and familial samples using multiple methods and including multiple 
testing correction by permutation analysis; and Identity-by-descent estimation. 
Other functions include haplotypic tests and imputation methods, copy number 
variant analysis and epidemiologic analyses. PLINK data can be integrated into 
HAPLOVIEW using the gPLINK function. gPLINK is a freely-available, Java-based 
software package that is a graphical user interface (GUI) allowing construction of 
many common PLINK operations. In this thesis, the summary statistics; association 
analysis, haplotype testing, logistic regression, multidimensional scaling, identical 
by state calculation and set-based analysis functions of PLINK were utilised. These 
were run using cygwin, a Linux-like environment for Windows freely available at 
http://www.cvawin.com/.
2.9.2. HAPLOVIEW
HAPLOVIEW is designed to simplify and expedite the process of haplotype 
analysis by providing a common interface to several tasks relating to such analyses 
(Barrett et al. 2005). HAPLOVIEW supports LD & haplotype block analysis, 
haplotype population frequency estimation, single SNP and haplotype association 
tests and permutation testing for association significance. HAPLOVIEW accepts 
input in a variety of formats. Pedigree data can be loaded as partially or fully 
phased chromosomes or as unphased diplotypes in a standard linkage/PLINK 
format. These formats allow the user to specify family structure information as well 
as disease affection or case/control status. Marker information, including name and 
location is loaded separately. HAPLOVIEW directly accepts genotype data 
‘dumped’ from the Human HapMap website (http://www.hapmap.org) detailed in 
section 2.10.3 or can retrieve data directly from the HapMap website providing an 
internet connection is in place. The software presents a series of marker 
genotyping quality control measures which include a check for conformance with 
HWE, a tally of Mendelian inheritance errors and the genotyping success rate for 
each marker. The program filters out markers which fall below a preset threshold 
for these tests which can be defined by the user, who can also add or remove
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markers from the analysis. The HAPLOVIEW program calculates several pairwise 
measures of LD, which it uses to create a graphical representation, examples of 
which are presented throughout the thesis. A number of different colour schemes 
are available to represent the LD relationships in either D’ or r2. HAPLOVIEW uses 
a two marker expectation-maximization (EM) algorithm (ignoring missing data) to 
estimate the maximum-likelihood values of the four gamete frequencies, from which 
the D \ LOD and r 2 calculations are derived (Barrett et al. 2005). Hedrick's 
multiallelic D', is also used, which represents the degree of LD between two blocks, 
treating each haplotype within a block as an ‘allele’ of that region (Barrett et al. 
2005). Several block definitions are available to partition the region into segments 
of strong LD; alternatively manual selection of groups of markers for haplotype 
analysis is possible. If affection status is included in the input file, HAPLOVIEW 
calculates the standard transmission disequilibrium test (TDT) statistic (for trio 
data) or simple \ 2 (for case/control data) for each marker that can be used for 
association studies. Haplotype and pairwise-tag SNP selection methods are 
included in the software, as well as haplotype-based association testing and 
evaluation of significance using permutation testing. The information produced by 
HAPLOVIEW may be exported to a portable network graphics for use in 
presentations or publications or dumped to a text file. Through-out this project 
HAPLOVIEW was frequently used to calculate the LD between variants and create 
graphical representations of these LD measures. The software was also used to 
choose tag SNPs for a locus using the pair-wise tagging approach (r2 > 0.8; MAF > 
0.05) and to estimate the coverage of a locus by previously genotyped markers.
2.9.3 UNPHASED
UNPHASED (v3.0) is a versatile application for performing genetic 
association analysis. Its features include; analysis of nuclear families and unrelated 
subjects, and combinations of the two, analysis of discrete or quantitative traits, 
maximum likelihood treatment of missing genotype data and uncertain haplotypes, 
global association tests and tests of individual haplotypes, conditioning tests that 
allow for previous associations of linked loci, inclusion of information from 
additional tag markers, support for non-genetic covariates including parent-of-
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origin, and permutation tests. For this thesis, the association tests of haplotypes 
function were used for some of the haplotypes investigated in chapter 3.
2.9.4. R
R (v2.9.1) is a language and environment for statistical computing and 
graphics. It is available as free Software (http://www.R-proiect.org) and runs on a 
wide variety of UNIX platforms, Windows and MacOS. R includes; a data handling 
and storage facility, a suite of operators for calculations on arrays, a large 
integrated collection of intermediate tools for data analysis, graphical facilities for 
data analysis and display either on-screen or on hardcopy, and simple and 
effective programming language which includes conditionals, loops, user-defined 
recursive functions and input and output facilities (R Development Team 2008). In 
this thesis, R was used to create the quantile-quantile plots for the LOAD+P GWAS 
in chapter 5.
2.9.5. WGAViewer
WGAViewer (v1.26A) is a free software tool 
(http://people.genome.duke.edu/-dg48/WGAViewer/download.php) developed in 
JAVA language that is designed to annotate, visualize, and help interpret the full 
set of p-values indicating evidence of association resulting from a Whole Genome 
Association (WGA) study (Ge et al. 2008). The software includes; chromosome 
view of WGA results, genetic annotation of WGA results, SNP annotation, 
gene/SNP finding, comparison of multiple genome scans, and uploading of 
supporting/QC data. The WGAViewer was extensively used in chapter 5 of this 
thesis to visualise the LOAD+P GWAS data. Specifically to annotate top hits, find 
SNPs of interest or relevant proxies using the WGAViewer’s link to the HapMap 
database, find genes of interest, create a gene SNP list, and to use the databases 
external links to define SNP and gene functions.
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2.9.6. Power Calculations
Power estimations and sample size requirements for case-control samples 
were calculated using the downloadable Power and Sample Size Calculation (PS) 
(v3.0) program provided by the Department of Biostatistics, Vanderbilt University 
(http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize). PS is an 
interactive program for performing power and sample size calculations. The 
program can determine the sample size needed to detect a specified alternative 
hypothesis with the required power, the power with which a specific alternative 
hypothesis can be detected with a given sample size, or the specific alternative 
hypotheses that can be detected with a given power and sample size (Dupont and 
Plummer 1998). The PS program can evaluate multiple study designs as listed in 
Table 2.9a. For this study the Dichotomous tab was used to compare case-control 
sample designs analyzed by chi-squared or Fisher's exact-test. The PS program 
can produce graphs to explore the relationships between power, sample size and 
detectable alternative hypotheses and multiple curves can be plotted on a single 
graphic allowing easy comparison. PS graphics may be saved as Windows 
Metafiles, printed, or copied and pasted into other programs. A useful introduction 
to the program and instruction on its use is provided within the software.
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Table 2.9a. The PS program tab labels and the study designs provided by each tab. The 
program provides an additional tab which summarises the users’ calculations and graphics.
Program Tab Study Design
Dichotomous Comparing matched or independent dichotomous outcomes
Manten-Haenszel Test for common odds ratio within multiple 2 x 2  tables
Regression 1 Testing the slope of a simple linear regression line
Regression 2 Comparing two linear regression lines
Survival Comparing survival data for two groups
t-test Comparing matched or independent continuous outcomes
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2.10. Bioinformatics
Numerous web-based resources allow the user to search for and retrieve 
desired information from the wealth of available data on the human genome and 
the research that has been conducted in the field of genetics/genomics. These 
resources database and correlate this information behind user-friendly interfaces 
for quick and easy access. Details of the bioinformatics resources predominantly 
used during this study are provided in this section.
2.10.1. National Center for Biotechnology Information
The National Center for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov/) was established in the USA in 1988 as a resource for 
molecular biology information; NCBI creates public databases, conducts research 
in computational biology, develops software tools for analyzing genome data, and 
disseminates biomedical information to improve understanding of molecular 
processes affecting human health and disease. For this thesis, the public 
databases of the NCBI were utilised, primarily the PubMed database. PubMed is a 
service of the US National Library of Medicine (http://www.nlm.nih.gov/). it includes 
over 18 million citations from the MEDLINE database (http://medline.cos.com/) and 
other life science journals for biomedical articles back to 1948. PubMed provides 
an advanced search facility to link to full text articles and other related resources. 
Other databases utilised include; 1) The Online Mendelian Inheritance in Man® 
(OMIM®) database which is a comprehensive compendium of human genes and 
genetic phenotypes. The full-text, referenced overviews in OMIM® contain 
information on all known Mendelian disorders and over 12,000 genes. OMIM® 
focuses on the relationship between phenotype and genotype, it is updated daily, 
and the entries contain links to other genetics resources. 2) The Entrez Single 
Nucleotide Polymorphism (SNP) database catalogues all known genetic variants 
allowing one to search for a polymorphism/groups of polymorphisms across the 
genomes of numerous organisms. The SNP record contains substantial information 
for each marker, including; the allelic variation seen, chromosomal position, base 
position, gene name (if intragenic), polymorphism function, assay method used to
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detect polymorphism and genotyping success rate, heterozygosity in genotyped 
samples, date of publication, all polymorphism IDs used, validation status, and 
polymorphism class (e.g. SNP, microsatellite). The SNP database is regularly 
updated and provides links to other useful resources, both internal and external to 
NCBI. 3) The Entrez Gene database which is a searchable database of genes; 
from Reference Sequence (RefSeq) genomes
(http://www.ncbi.nlm.nih.gov/RefSea/) defined by sequence and/or located in the 
NCBI Map Viewer (http://www.ncbi.nlm.nih.gov/mapview/). The RefSeq collection 
aims to provide a comprehensive, integrated, non-redundant, well-annotated set of 
sequences, including genomic DNA, transcripts, and proteins. It provides a stable 
reference for genome annotation, gene identification and characterisation, mutation 
and polymorphism analysis, expression studies, and comparative analyses. Entrez 
Gene aims to supply key connections in the nexus of map, sequence, expression, 
structure, function, citation, and homology data. Unique identifiers are assigned to 
genes with defining sequences, genes with known map positions, and genes 
inferred from phenotypic information. These gene identifiers are used throughout 
NCBI's databases and tracked through updates of annotation and related 
information.
2.10.2. University of California Santa Cruz Genome Browser
The University of California Santa Cruz (UCSC) Genome Browser website 
(Kent et al. 2002; Karolchik et al. 2008) (http://genome.ucsc.edu/) contains the 
reference sequence and working draft assemblies for a large collection of 
genomes. It also provides a portal to the ENCyclopedia Of DNA Elements 
(ENCODE) project (Kent 2007) (http://www.qenome.qov/10005107). The website 
provides a number of applications. The Genome Browser was intensively used 
during this project. This allows the user to zoom and scroll over chromosomes, 
showing the work of annotators worldwide and providing detailed information of 
each known or hypothesised element (e.g. gene, polymorphism, repeat element). 
The Table Browser (Karolchik et al. 2004) provides convenient access to the 
underlying database, this function of the UCSC Genome Browser was also heavily 
used, specifically to identify conserved regions and is detailed further in section
79
Chapter 2. Materials and Methods
2.11.2. The basic local alignment tool (blat) (Kent 2002) maps your sequence to the 
genome, while In-Silico PCR searches a sequence database with a pair of PCR 
primers, using an indexing strategy for fast performance. Both these functions were 
utilised during this project to ensure amplimers and PCR primers utilised were 
region specific. The Gene Sorter shows expression, homology and other 
information on groups of genes that can be related in many ways. VisiGene lets 
you browse through a large collection of in situ mouse and frog images to examine 
expression patterns. While, Genome Graphs allows you to upload and display 
genome-wide data sets.
2.10.3. The International HapMap Project
The International HapMap Project (The International HapMap Consortium 
2003; The International HapMap Consortium 2004; The International HapMap 
Consortium 2005; Frazer et al. 2007; Thorisson et al. 2005) aims to develop a 
haplotype map of the human genome. The Project is a collaboration among 
scientists in Japan, the UK, Canada, China, Nigeria, and the US. Due to haplotype 
frequency differences between populations several populations (30 trios of Yoruba 
people in Ibadan, Nigeria; 45 unrelated Japanese individuals from Tokyo; 45 
unrelated Han Chinese individuals from Beijing and 30 trios from the US with 
ancestry from Northern and Western Europe which were collected in 1980 by the 
Centre d'Etude du Polymorphisme Humain (CEPH)) are being genotyped by the 
HapMap project. Phase I and II of the HapMap data were used in this thesis which 
contains data on approximately 3.4 million SNPs the majority of which were 
identified by the project. Aliquots of the CEPH DNA samples were used to optimise 
assays and as a quality control measure on each sample plate. The HapMap 
project data can be directly downloaded or ’dumped’ from the website providing 
genotype data of all genotyped SNPs in a particular gene or region. These data 
were used to choose tag SNPs for genes/regions and to define the degree of LD 
between linked variants using the HAPLOVIEW software (section 2.9.2).
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2.10.4. Ensembl Genome Browser
Ensembl began in 2000 as a browser for the human genome, but has 
expanded to host the genomes and associated information for more than 40 
species of vertebrates and other eukaryotic species (Flicek et al. 2008). Ensembl 
(v52) automatically annotates the genome, integrates this annotation with other 
available biological data and makes this data publicly available via the web 
(http://www.ensembl.org/index.html). The range of available data has expanded to 
include comparative genomics, variation and regulatory data, in addition to the long 
established location, gene, transcript and variation views previously available. The 
Ensembl database allows the user to add and remove tracks, configure graphical 
displays and upload and manage your own data. The database also provides links 
to other useful web-based resources. The BioMart function of Ensembl is a search 
engine that can find multiple terms and put them into a table format. For example, 
human gene IDs, chromosome and base pair position.
2.10.5. SchizophreniaGene
The SchizophreniaGene (szgene) database 
(http://www.schizophreniaforum.org/res/sczaene/default.asp) is a comprehensive, 
unbiased, publicly available and regularly updated collection of published genetic 
association studies performed on schizophrenia (Allen et al. 2008). Eligible 
publications are identified following systematic searches of scientific literature 
databases, as well as the table of contents of journals in genetics and psychiatry 
(Allen et al. 2008). This database calculates crude odds ratios (ORs) from the 
reported allele distributions of SNPs in four or more independent samples. The 
most promising meta-analysis results indicate the most strongly associated genes 
(Top Results’), which are ranked by effect size. In this thesis, the szgene 
database’s Top Results’ list was used to define genes investigated in secondary 
analyses in chapter 5. The SNPs which led these genes to be considered as Top 
Results’ were also investigated in the LOAD+P GWAS data.
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2.10.6. SNP Annotation and Proxy Search
The SNP Annotation and Proxy Search (SNAP) (v2.1), provided by the 
Broad Institute (http://www.broadinstitute.org/mpg/snap/) , finds proxy SNPs based 
on linkage disequilibrium, physical distance and/or membership in selected 
commercial genotyping arrays (Johnson et al. 2008). Pair-wise linkage 
disequilibrium is pre-calculated based on phased genotype data from the HapMap 
(Johnson et al. 2008). The software can also generate linkage disequilibrium plots 
and allows the user to map SNP IDs. For this thesis the proxy search facility was 
used to identify SNPs present on the Affymetrix 5.0 array which act as proxies for 
SNPs present on the lllumina HumanHap 610quad array. The proxy search 
application allows batch upload of SNPs of interest and filtering of the proxy search 
by either Affymetrix or lllumina arrays.
2.11. Conservation and Transcription Factor Binding Site Prediction
Programs to identify evolutionary conserved regions (ECRs) such as 
transcription factor binding sites, or putative binding motifs are a useful tool to 
decipher the functionality of an association. ECRs correspond to protein coding 
exons which are generally under strong selection pressure to stay unchanged. 
Other ECRs can be identified, including promoter and enhancer elements which 
are usually located upstream of a gene; functional elements that lie far away from 
genes and regulate the spatial and temporal transcription patterns of neighbouring 
genes, and active regulatory elements that can be located hundreds of kb away 
from the genes that they control, especially in regions of low gene density. Three 
software packages were used in this study to identify such regions.
2.11.1. Cluster Buster
Cluster Buster (Frith et al. 2003) is a program for finding clusters of pre­
specified motifs in nucleotide sequences. The program is freely available and may 
be used via a web server (http://zlab.bu.edu/cluster-buster/cbust.html) or 
downloaded for use on a local computer. Genomic sequences greater than
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100,000 kb can only be analysed via the downloaded program. The main 
application of Cluster Buster is detection of sequences that regulate gene 
transcription, such as enhancers and silencers, but other types of biological 
regulation may be mediated by motif clusters. The Cluster Buster program provides 
numerous motifs for the user to select and identify within their. These motifs are; 
TATA boxes (bound by TATA binding protein, a component of the transcription 
factor binding complex TFIID), CCAAT boxes (found in gene promoters and bound 
by the transcription factor NF-Y), Sp1 (found in gene promoters and bound by 
transcription factors), AP-1 (Activator Protein 1), CRE (cAMP Response Element), 
Ets, ERE (Estrogen Response Element), Myc, NF1, GATA, E2F, LSF, Mef-2 
(Myocyte Enhancer Factor 2), SRF (Serum Response Factor), Myf (Myogenin / 
MyoD family) and Tef (Transcription Enhancer Factor) sequences. It is also 
possible to enter your own motifs or upload predicted or verified motifs from other 
genetic resources into the Cluster Buster program. The software parameters can 
be set by the user and include; gap parameter, cluster score threshold, motif score 
threshold, residue abundance range, and pseudocount, details of which can be 
found at the webpage listed above. All analyses reported in this thesis utilised the 
default parameter settings and selection to search for all motifs provided by the 
program. The Cluster Buster output provides a diagram of motif cluster locations 
within the input sequence, along with protein-coding regions (CDS) annotated on 
the GenBank record. Detailed information for each cluster is also supplied. This 
includes a comprehensive cluster diagram and the sequence position, DNA strand, 
log likelihood ratio and nucleotide bases of each motif identified within the cluster. 
The position of the identified clusters and the motifs within can then be compared 
to the position of known polymorphisms within the nucleotide sequence of interest.
2.11.2. University of California Santa Cruz Most Conserved Track
The University of California Santa Cruz (UCSC) Most Conserved Track is a 
facility within the Table Browser (Karolchik et al. 2004) option of the UCSC web 
based database (http://qenome.ucsc.edu/) . The Table Browser provides convenient 
access to the underlying database and enables the user to retrieve the data 
associated with a track in text format. The Most Conserved Track is part of the
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Comparative Genomics group within the Table Browser. For this thesis the clade 
Vertebrate, genome Human, assembly Mar. 2006 and table Mammal 
(phastConsElements28wayPlacMammal) were utilised on a specified chromosomal 
position with output format all fields from the selected table. The data output of the 
chromosomal positions of the most conserved regions corresponds to those 
depicted on the genome browser track. Using this output it is possible to accurately 
align polymorphisms within your nucleotide sequence of interest to the most 
conserved mammalian regions according to the UCSC genome browser.
2.11.3. Evolutionary Conserved Region Browser
The Evolutionary Conserved Region (ECR) browser is a web based 
software package that allows comparison of Human, Mouse, Chimpanzee, Dog, 
Opossum, Rat, Cow, Chicken, Frog, Blowfish, Zebrafish and Pufferfish genomes 
(Ovcharenko et al. 2004) (http://ecrbrowser.dcode.org/). The conservation profile is 
created by aligning one “base” sequence with all others in a pair-wise fashion, 
utilizing the Basic Local Alignment Tool (BLAT) (http://genome.brc.mcw.edu/cqi- 
bin/hqBlat) and Basic Local Alignment Search Tool (BLAST) 
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). Finally a pair of sequences from every 
homology block is aligned to establish nucleotide level match-mismatch similarity 
profiles using BLASTZ (Schwartz et al. 2003). ECRs are identified as regions of 
high sequence identity against a neutrally evolving background. By scanning an 
alignment the browser detects and highlights sequence elements of significant 
length that are conserved above a specified level of sequence identity between the 
two genomes (user-defined parameter). Visually ECRs are represented as 
coloured peaks on a graph, with the x-axis representing positions in the base 
genome and the y-axis representing percentage identity between the base and 
aligned genomes at that specified position. The quickest way to navigate the ECR 
browser is to type in the gene name or the chromosomal position into the ECR 
interface. However, for absolute accuracy it is advisable to submit a nucleotide 
sequence into the software to which the program will align. In this thesis the Human 
genome (freeze 18) was used as the base sequence which was aligned with the 
Dog and Mouse genomes. In certain regions Human-Mouse conservation is too 
high for alignments to usefully single-out specific conserved elements for further
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study (Nobrega et al. 2003). Therefore, Human-Dog conservation was also 
analysed. The Dog genome is evolutionary more distant to the Human genome 
than Mouse, Rat and Chimpanzee genomes and therefore comparing Human, 
Mouse and Dog genomes should highlight only those regions that have been 
selectively conserved in Mammals. Only regions conserved between all three 
genomes were classed as ECRs. The sequence identity threshold for an alignment 
to be called an ECR was set at default (minimum sequence length 100 bp, 
minimum sequence identity 70%), thus detecting only very long or highly conserved 
ECRs. Through the conserved SNP tab the ECR browser also allows easy access 
to and data output of database SNPs residing within the reference sequence that 
lie within conserved regions in each species. This list of conserved SNPs can then 
be compared between species to highlight any SNPs that overlap species.
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3. Psychosis Candidate Gene Association Study
3.1. Introduction
In this chapter, specific markers which have previously been directly or 
indirectly associated with psychosis, have been tested for association with 
LOAD+P. This experimental methodology is predominantly based on the 
hypothesis that psychosis susceptibly genes may act across disease divides, thus 
modifying psychotic symptoms in multiple distinct disorders. The hypothesis that 
psychosis susceptibility genes may affect psychosis in Alzheimer’s disease is 
borne from the findings of recent studies which have shown overlap in the genetic 
susceptibility variants for distinct complex psychotic disorders such as bipolar 
disorder and schizophrenia (Craddock et al. 2009). The majority of the genes 
chosen for investigation in this study have long been considered to show 
association to either schizophrenia, bipolar disorder, or both disorders. The 
additional genes were chosen for investigation due to the recent (at the date of 
study commencement) identification of novel variants showing significant 
association to schizophrenia. The genes and where applicable, the specific 
variants studied were identified from literature searches, using the NCBI PubMed 
database using search terms; ‘schizophrenia AND genetic AND association’, 
‘bipolar AND genetic AND association’ and ‘psychosis AND genetic AND 
association’. The szgene website was used to identify and prioritise genes. Finally 
the list of genes identified was refined by a number of world renowned experts in 
the field of psychiatric genetics, including Professor’s Michael Owen, Michael 
O’Donovan, Nick Craddock and Dr. Nigel Williams. Genes were also prioritised if 
they had previously shown a genetic association to a neurodegenerative disorder 
(Rubinsztein et al. 1997), or if they resided in a region of the genome identified as 
showing linkage to LOAD+P (Hollingworth et al. 2007). In this chapter the general 
experimental design of the study is discussed, before a literature review, the 
experimental design strategy, and the results of the studied genes are reported. 
Conclusions include a discussion of the study, its limitations and implications.
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3.2. Genotyping Strategy
This study is based on the hypothesis that the genes investigated may 
modify psychotic symptoms across disease. Thus, in LOAD these genes are 
assumed to work independently of LOAD susceptibility genes. Therefore, the most 
appropriate and conservative study design is to compare allele and genotype 
frequencies between LOAD cases with psychosis (LOAD+P) with LOAD cases 
without psychosis (LOAD-P) in a case-control design. Using the diagnostic criteria 
described in chapter 2 2.3, there are 379 LOAD+P cases and 269 LOAD-P cases 
available for genotyping from the MRC genetic resource for LOAD sample. This 
dataset provides a limited power of 0.34 to detect an association with an effect size 
of 1.3 and a risk variant frequency of 30%. An alternative hypothesis is that these 
putative psychosis susceptibility genes may be involved in the aetiology of AD+P, 
as a sub-form of the disease. This hypothesis is tested by comparing allele and 
genotype frequencies of LOAD+P cases with control subjects (n=1,361) screened 
for both dementia and psychosis, and carefully matched with cases for age, sex, 
sex and ethnicity. This analysis provides a power of 0.57 to detect the association 
detailed above. As the latter analysis may identify variants associated with LOAD 
alone rather than the LOAD+P sub-form of disease, allele and genotype 
frequencies of LOAD cases (n=1,205) against control subjects have also been 
compared. This analysis has a power of 0.88 to detect the afore mentioned 
association. At loci where sex differences had previously been identified, data were 
re-analysed according to sex. For the association detailed above; male analyses 
had power of 0.11, 0.18, and 0.25 for LOAD+P (n=74) versus LOAD-P (n=67), 
LOAD+P versus control (n=423), and LOAD (n=282) versus control data 
respectively, female analyses had power of 0.23, 0.41, and 0.63 for LOAD+P 
(n=271) versus LOAD-P (n=164), LOAD+P versus control (n=695), and LOAD 
(n=693) versus control data respectively.
Markers were selected for each gene dependent on gene size. Where 
possible, variants were chosen to ‘tag’ the gene of interest ± 20 kb at an r2 't 0.8 
and a MAF > 5% using Centre d’Etude du Polymorphisme Humain (CEPH) 
genotype data from the HapMap website or in house CEPH data from previous 
studies. However, where the gene size was large, requiring an excessive number
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of markers to sufficiently ‘tag’ the region of interest, variants which have previously 
shown published association to psychosis were chosen for investigation. All SNPS 
were designed for genotyping using the Sequenom™ MassArray™ platform 
(Sequenom, San Diego, CA) extensively described in chapter 2. 7.3. The 4 bp 
DISC1 variant was also genotyped using the Sequenom™ MassArray™ platform 
(Sequenom, San Diego, CA). The validity of this platform to genotype deletions has 
previously been confirmed (Green et al. 2006b). Where markers failed the assay 
design process or failed the genotyping quality control measures, they were 
instead genotyped using the Amplifluor™ UniPrimer Chemistry (chapter 2 .7.2).
The two microsatellites and one TAA repeat studied were genotyped using the 
genescan fluorescent PCR methodology. The respective PCR and extension 
primers utilised are provided in Appendix 3. Example schematics for each 
genotyping method are provided in Appendix Figures 3.1, 3.2 and 3.3.
All assays were optimised, and deviation from Hardy-Weinberg equilibrium 
(HWE) was tested as described in chapter 2.7.4. The minimum genotyping success 
rate was set at 90% of the full sample set (n = 2,566). The percentage genotype for 
each variant in the full sample, and the HWE p-values for each SNP in each 
dataset (i.e. LOAD+P, LOAD-P, LOAD and control) are provided in Table 3.1. Ten 
SNPs show deviation from HWE in at least one dataset. The DTNBP1 SNP 
rs2619539 shows deviation from HWE in both the LOAD-P and LOAD datasets (P 
= 0.001 and P  = 0.04 respectively). The GRM3 SNP rs2282966 shows a significant 
deviation from HWE in the control dataset (P =  0.001). The remaining 8 SNPs 
show nominally significant deviation from HWE (p-values 0.01 -  0.04) in 1 of the 4 
datasets, with no over-representation in any 1 dataset.
For SNPs and haplotypes, statistically significant differences between 
genotype and allele frequencies were analysed as described in chapter 2.9. 
Microsatellite and TAA repeat genotype frequencies were estimated by direct 
counting. The significance of the distribution of alleles between comparison 
datasets were tested by the chi-square method, comparison between two groups 
was made with 95% confidence interval to estimate statistical significance. Power 
calculations are as described in chapter 2.9.6.
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Table 3.1. All genotyped variants. Table provides chromosome, gene, marker name, base position, ancestral allele, marker function, CEU MAF, 
percentage genotyped in full sample, and HWE p-values in each comparison dataset.
Chr Gene Marker bp Allele Function
CEU
MAF
%
Geno
HWE
LOAD+P LOAD-P LOAD Controls
1 DISC1 rs3738401 228137030 G Non-Syn 0.36 96.4 0.33 0.66 0.56 0.35
1 DISC1 rs6675281 228260836 C Non-Syn 0.16 99.1 0.22 0.16 0.9 0.47
1 DISC1 rs821616 228451333 A Non-Syn 0.31 97.2 0.89 1 0.28 0.57
1 DISC1 4bp deletion n/a n/a Exonic n/a 96.7 n/a n/a n/a n/a
6 DTNBP1 rs12525702 15735750 C Intronic 0.1 97.8 1 0.36 0.5 0.77
6 DTNBP1 rs17470454 15631427 G Non-Syn 0.06 98.5 0.21 1 1 0.61
6 DTNBP1 rs2619538 15773188 T 5 prime 0.39 98.1 0.45 0.13 0.12 0.86
6 DTNBP1 rs2619539 15728834 C Intronic 0.47 97 0.29 0.001 0.04 0.22
6 DTNBP1 rs3213207 15736081 A Intronic 0.11 98.4 0.37 0.75 0.65 1
6 GRIK2 rs6922753 102354366 C Intronic 0.1 92 0.65 0.46 0.8 0.9
6 GRIK2 TAA repeat n/a n/a 3’UTR n/a 90.2 n/a n/a n/a n/a
7 GRM3 rs13242038 86152356 C Intronic 0.23 99.2 0.03 1 0.24 0.85
7 GRM3 rs1468412 86271387 A Intronic 0.28 98.6 0.79 0.87 0.58 0.1
7 GRM3 rs187993 86101616 G 5 prime 0.34 99.9 0.3 0.06 0.5 0.7
7 GRM3 rs2228595 86253923 C Synon 0.06 99.3 0.01 0.61 0.09 0.13
7 GRM3 rs2282966 86313603 G Intronic 0.28 97.8 0.38 0.11 0.87 0.001
7 GRM3 rs6465084 86241411 A Intronic n/a 94 0.67 0.6 0.8 0.04
7 GRM3 rs917071 86191717 C Intronic 0.28 95.5 0.51 0.88 0.53 1
8 NRG1 rs12681411 31582591 C 5 prime 0.35 97.8 0.5 0.5 0.05 0.15
8 NRG1 rs3924999 32572900 G Non-Syn 0.43 96.2 0.82 1 0.39 1
89
8 NRG1 SNP8NRG221533 31593683 T 5 prime
8 NRG1 420M9-1395 n/a n/a 5 prime
8 NRG1 478B14-848 n/a n/a 5 prime
11 BDNF rs6265 27636492 C Non-Syn
13 DAOA 3* UTR 104927538 C 3' UTR
13 DAOA rs1341402 104913510 T 5 prime
13 DAOA rs1421292 104996236 T 3 prime
13 DAOA rs2391191 104917447 C Non-Syn
13 DAOA rs3916965 104901361 G 5 prime
13 DAOA rs3918342 104983750 C 3 prime
13 DAOA rs778293 104967200 G 3 prime
13 DAOA rs778294 104940236 G Intronic
13 DAOA rs954581 104950267 T 3 prime
17 CNP rs55955100 37375664 A Intronic
17 CNP rs35967904 37379713 G 3' UTR
17 CNP rs10540926 37371281 G 3 prime
17 CNP rs11079028 37379659 G 3’ UTR
17 CNP rs 11296 37380586 T 3' UTR
17 CNP rs12602950 37377355 A Intronic
17 CNP rs12952915 37372078 G 5 prime
17 CNP rs2070106 37379390 G Synon
17 CNP rs4796750 37368070 G Intronic
17 CNP rs4796751 37381063 C 3' UTR
21 OLIG2 rs62216115 33324327 G Intronic
21 OLIG2 rs1005573 33320586 T Intronic
21 OLIG2 rs1059004 33322333 A 3' UTR
21 OLIG2 rs11701698 33315815 T Intronic
n/a 95.6
n/a 90.3
n/a 90.5
0.2 99.8
n/a 97.1
0.36 98.1
0.49 96.8
0.37 94.9
n/a 95.7
0.48 98.5
0.39 97.7
0.31 98.2
0.12 97.7
n/a 97.7
n/a 98.8
n/a 98.1
0.23 97.9
0.06 97.4
0.25 97.7
n/a 93.8
0.4 96.7
0.25 96.6
0.12 98.8
n/a 97.4
0.3 96.6
n/a 95.4
0.2 98.4
0.76 0.54
n/a n/a
n/a n/a
1 0.17
0.82 0.02
1 0.73
0.46 0.45
0.37 0.57
0.58 0.68
0.25 0.71
0.59 0.11
0.33 0.04
0.38 0.01
0.89 1
0.12 0.9
0.71 0.36
0.87 0.18
1 0.42
0.08 0.88
0.4 0.13
0.73 0.42
0.02 0.82
0.66 1
1 0.36
0.45 0.54
0.33 1
0.1 0.29
0.49 0.96
n/a n/a
n/a n/a
0.03 0.24
0.69 0.74
0.5 0.93
0.38 0.73
0.89 0.95
0.89 0.85
0.35 1
0.4 0.33
0.1 0.53
0.22 0.27
0.47 0.7
0.12 0.9
0.44 0.75
0.51 0.18
0.35 0.42
0.64 0.88
0.19 0.13
0.49 0.42
0.2 0.82
0.45 1
0.92 0.71
0.66 0.53
0.9 0.51
0.37 0.63
21 OLIG2 rs11701762 33325096 G Intronic n/a 96.6 0.4 0.15 0.87 0.11
21 OLIG2 rs13046814 33323247 T 3' UTR n/a 96.2 0.26 0.77 0.58 0.41
21 OLIG2 rs2834070 33309322 G Intronic 0.34 96.8 0.55 0.24 0.43 0.55
21 OLIG2 rs2834072 33332334 G Intronic 0.48 96.8 1 0.16 0.9 0.6
21 OL1G2 rs762178 33321271 G Synon 0.39 94.6 1 0.79 0.7 0.39
21 OLIG2 rs881666 33327136 G Intronic 0.39 97.8 0.6 0.9 0.37 0.29
21 OLIG2 rs762237 33330047 C Intronic 0.36 98.7 1 0.1 0.95 0.57
22 COMT rs2020917 18303438 C 5 prime 0.33 97.7 1 0.05 0.4 0.19
22 COMT rs737865 18304675 T Intronic 0.33 99.1 0.52 0.08 0.29 0.1
22 COMT rs4680 18325825 A Non-Syn 0.48 95.2 0.16 0.7 0.05 0.48
22 COMT rs165599 18331335 A 3' UTR n/a 96.1 1 0.01 0.38 0.16
Note; SNP rs55955100 previously known as marker 3235AG, SNP rs35967904 previously known as marker 7284GA and SNP rs62216115 
previously known as marker F16GA.
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3.3. Disrupted in Schizophrenia 1
The disrupted in schizophrenia 1 (D/SCf) locus was originally identified in a 
large Scottish pedigree, in which numerous members carried a balanced (1,11) 
(q42.1;q14.3) translocation that segregated with major psychiatric disorders, 
including schizophrenia, bipolar disorder and recurrent major depression (St Clair 
et al. 1990). The (1,11) (q42.1;q14.3) translocation lies in a gene desert on 
chromosome 11 and directly disrupts two genes, DISC1 and Disrupted in 
schizophrenia 2 (DISC2) at 1q42 (Millar et al. 2000). Seven studies have reported 
linkage to the DISC1 region (1q42) and neighbouring chromosomal bands in 
schizophrenia (Ekelund et al. 2001; Ekelund et al. 2004; Hovatta et al. 1999; Hwu 
et al. 2003) and bipolar disorder (Curtis et al. 2003; Detera-Wadleigh et al. 1999; 
Macgregor et al. 2004). However, these analyses have not consistently replicated, 
probably due to the employment of a more conservative phenotype (Macgregor et 
al. 2004; Segurado et al. 2003; Lewis et al. 2003). The strongest evidence for 
linkage in the region comes from analyses using a broad phenotype including 
schizophrenia, bipolar disorder, schizoaffective disorder and other non-affective 
psychotic disorders (Hamshere et al. 2005b; Hwu et al. 2003), suggesting the 
presence of one or more loci influencing susceptibility to a spectrum of psychotic 
disorders.
The first association study of DISC1 produced negative results, with no 
association to schizophrenia or bipolar disorder (Devon et al. 2001). A positive 
association of multiple haplotypes across DISC1 with a broad psychosis phenotype 
(schizophrenia, schizoaffective disorder, schizophrenia spectrum disorder and 
bipolar disorder or major depressive disorder) was reported in 2003 in a population 
of Finnish families (Hennah et al. 2003). The most significant association (P =
3.1x1 O'3) was seen with a common two SNP haplotype (rs751229 and rs3738401) 
(HEP3), spanning from intron 1 to exon 2, which also displayed sex differences (P= 
2.4x1 O'4) (Hennah et al. 2003). Additional positive (Hodgkinson et al. 2004; Palo et 
al. 2007; Zhang et al. 2006) and negative (Thomson et al. 2005) associations of 
this haplotype have been documented in Caucasian samples, across a broad 
spectrum of diagnoses, with inconsistent findings of sex differences (Palo et al. 
2007; Zhang et al. 2006). Independent association of DISC1 to schizophrenia and
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schizoaffective disorder has been provided by the non-synonymous SNP of the 
HEP3 haplotype in a UK sample (Zhang et al. 2006). However, this association has 
not replicated in multiple populations (Kim et al. 2007; Thomson et al. 2005) 
suggesting that variants in the HEP3 locality of DISC1 influence risk for a broad 
range of psychotic disorders, specifically schizoaffective disorder and 
schizophrenia spectrum disorder. A two SNP haplotype (rs821616 and rs1411771) 
at the 3’ end of DISC1 has shown under-transmission to individuals with bipolar 
disorder (P = 0.0002) (Palo et al. 2007), with the non-synonymous variant of the 
haplotype rs821616 (Ser704Cys) showing reproducible independent association 
with schizophrenia in Caucasian and African American samples (Callicott et al. 
2005; DeRosse et al. 2007; Qu et al. 2007). However, negative findings with 
rs821616 have also been reported (Hennah et al. 2008; Zhang et al. 2005), which 
are likely to be explained by ethnic and phenotypic differences between study 
groups. Among other positive associations of the DISC1 locus to both 
schizophrenia (Cannon et al. 2005; Hwu et al. 2003; Qu et al. 2007) and bipolar 
disorder (Maeda et al. 2006; Thomson et al. 2005) is the DISC1 mis-sense variant 
rs6675281 (allelic P = 2.3 x 10"6, Relative Risk = 2.42) (Hodgkinson et al. 2004). 
However, no study has replicated this association. A 4 bp deletion at the extreme 3' 
end of DISC1 (exon 12) was identified in an American pedigree with schizophrenia 
but not found in 424 control individuals (Sachs et al. 2005). The mutation produces 
a truncated transcript that is detectable at a reduced level protein, and a mutant 
protein. A UK study failed to replicate this association with control subjects also 
carrying the mutation (Green et al. 2006b). Numerous negative associations of 
DISC1 and psychosis have been documented, specifically in Asian samples (Chen 
et al. 2007; Kim et al. 2007; Zhang et al. 2005). Expression analysis of bipolar 
disorder patients, stratified by genomic risk variants, identified a significant 
decrease in DISC1 mRNA in bipolar disorder patients compared to unaffected 
subjects (P = 0.006) (Maeda et al. 2006), with the prevalence of manic symptoms 
correlating with lower levels of DISC1 expression (P = 0.008) (Maeda et al. 2006).
The DISC1 gene is relatively large, spanning over 410 kb (Figure 3.3.). It is 
ubiquitously expressed with high expression in the central nervous system. The 
gene encodes an 854-amino acid wild-type protein which is functional in the 
nucleus, cytoplasm and mitochondria (James et al. 2004; Ozeki et al. 2003;
Miyoshi et al. 2003; Sawamura et al. 2005). DISC1 appears to be an important
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multi-functional protein active in intracellular transport, neuronal migration and 
architecture, neuronal cell signalling and gene expression (Hodgkinson et al.
2004), eliciting its roles through protein interactions, including proteins that 
transduce signals from membrane receptors (Morris et al. 2003a). Functional 
studies of DISC1 isoforms provide clear evidence that loss of normal DISC1 protein 
has detrimental effects on neurodevelopment, specifically neurite outgrowth 
(Kamiya et al. 2005) and positioning (Duan et al. 2007), which can result in 
schizophrenia-like phenotypes (Li et al. 2007; Pletnikov et al. 2007). DISC1 has 
shown interactions with other proteins implicated in susceptibility to schizophrenia, 
specifically phosphodiesterase 4B (PDE4B) (Pickard et al 2007; Millar et al. 2005). 
The reduced expression of DISC1 seen in psychosis (Maeda et al. 2006) may 
minimise or eradicate these important protein interactions, resulting in a psychosis 
phenotype. Sub-cellular distribution of the wild-type DISC1 isoform is known to be 
significantly different in schizophrenia brains when compared with controls 
(Sawamura et al. 2005), suggesting the redistribution of this isoform by a mutant 
DISC1 isoform. This action further reduces the availability of wild-type DISC1 to 
perform its usual biological roles. In animal models mutant Disci fails to interact 
with an array of proteins and shows perturbed localisation (Morris et al. 2003a). 
Mutant Disci interacts with and redistributes wild-type Disci and disassociates the 
Disci-dynein complex from the centrosome. Thus, impairing neurite outgrowth in 
vitro, and leading to impaired cerebral cortex development in embryonic mice 
(Kamiya et al. 2005).
94
228100k 228200k 228300k 228400k 228500k
c
_  Translocation .2
Breakpoint
DISC1
DISC2
Figure 3.3. The DISC 1 locus. Schematic shows chromosomal position (bp), the SNPs and 4 bp deletion genotyped in this study, 
with their position within the gene indicated by an arrow, the direction of transcription indicated by black horizontal arrow, the 
DISCI gene with exons/UTR indicated by black bars. The balanced (1,11) (q42.1 ;q 14.3) translocation breakpoint. The D1SC2 
loci and its direction of transcription is indicated in red. The LD plot of the region (r2) is provided at the bottom of the schematic.
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3.3.1. Literature Summary
Convergent linkage data strongly suggest that variation in the 1q42 region 
influences susceptibility to mood-psychosis phenotypes that cut across the 
traditional Kraepelinian divide (Owen et al. 2007). Preliminary association studies 
within and around the DISC1 gene have not produced compelling or consistent 
results, although the locus is large and no study has thoroughly covered the region. 
Numerous associations have been identified, generally with a broad spectrum of 
psychosis (Callicott et al. 2005; Hennah et al. 2003; Hodgkinson et al. 2004), some 
of which have replicated (Callicott et al. 2005). The 5’ end of the gene shows most 
promise for association to psychosis (Hennah et al. 2003; Palo et al. 2007; Zhang 
et al. 2006), while the 3’ end has displayed association to mood disorders (Palo et 
al. 2007). Other than the familial disruptions identified (St Clair et al. 1990; Sachs 
et al. 2005) there is no direct link between the risk haplotypes or genotypes 
identified and a specific biological or developmental dysfunction. However, DISC1 
remains an interesting functional and positional putative susceptibility gene for a 
wide spectrum of non-familial psychotic disorders. Functional studies provide clear 
evidence that loss of normal DISC1 protein has detrimental effects on 
neurodevelopment (Duan et al. 2007; Kamiya et al. 2005) which can result in 
schizophrenia-like phenotypes (Li et al. 2007; Pletnikov et al. 2007), which is 
consistent with the reduced expression of DISC1 demonstrated in schizophrenia 
(Maeda et al. 2006).
3.3.2. Study Design
There are no compelling associations to specific DISC1 markers or 
haplotypes documented in the literature. Therefore, three validated non- 
synonymous SNPs (rs3738401: Arg264Gln, rs6675281: Leu607Phe, and 
rs821616: Ser704Cys) within the DISC1 gene were genotyped, in addition to the 4 
bp deletion that has shown association to schizophrenia (Sachs et al. 2005).
Variant rs821616 has shown the most consistent association to schizophrenia and 
bipolar disorder of any tested variant, and also shows association across numerous 
ethnic populations (Callicott et al. 2005; Thomson et al. 2005b; Kim et al. 2007; Qu
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et al. 2007; Palo et al. 2007). Marker rs3738401 has shown independent 
association to schizophrenia (Zhang et al. 2006), while variant rs6675281 shows 
association to schizoaffective disorder (Hodgkinson et al. 2004). All markers were 
genotyped using the Sequenom™ MassARRAY™ system (Sequenom, San Diego, 
California, USA) as described in chapter 2.7.3. The validity of this platform to 
genotype deletions has previously been confirmed (Green et al. 2006b). The LD 
structure across the DISC1 locus and surrounding region according to the HapMap 
CEPH genotypes can be seen in Figure 3.3, along with the positions of the variants 
tested in this study. The relative marker PCR and extension primers are shown in 
Appendix Table 3.1.
3.3.3. Results
No LOAD individual with psychosis, but 1 LOAD individual without 
psychosis, 1 LOAD individual that did not meet criteria for LOAD+P or LOAD-P, 
and 1 control individual were identified to carry the 4 bp deletion in the 
heterozygous form. No difference in allele or genotype frequencies for any SNP 
was observed when comparing within cases, LOAD+P versus LOAD-P nor when 
comparing LOAD+P cases to controls. No allele or genotype differences were 
observed between the full sample of cases (n = 1,205) and controls (n = 1,361) 
denoting no association of the tested SNPs with LOAD (Tables 3.3a and 3.3b).
Due to sex transmission differences previously seen at the locus (Chen et al. 2007; 
Hennah et al. 2003; Maeda et al. 2006), genotyped SNPs were analysed in 
females and males separately. No SNP showed a sex specific association with 
LOAD+P (Appendix Tables 3.2 - 3.5). The lack of association in these analyses is 
not surprising due to a further reduction in study power by sample size reduction. 
Analysis in female cases and controls produced no significant association with 
LOAD for any SNP. Conversely analysis in male LOAD cases and controls 
produced a significant association with marker rs3738401 (P =  0.03), however this 
association does not survive correction for multiple testing (permuted P = 0.15).
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3.3.4. Discussion
The findings provide no evidence for the involvement of the DISC1 locus in 
LOAD+P or LOAD. After allowing for sex effects a significant association with 
LOAD was seen in male subjects, but this association does not withstand 
correction for multiple testing. Only the non-synonymous variants within the gene 
and a familialy associated 4 bp deletion have been tested. Therefore, the locus can 
not be excluded as a potential susceptibility locus for psychosis in LOAD. The 
extensive size of the locus makes it difficult to investigate the region with a 
satisfactory number of markers at the present time. Future work at the DISC1 locus 
will be to investigate variants within the gene region ± 20 kb in the LOAD+P 
genome-wide association study (GWAS) described in chapter 5.
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Table 3.3a. MAF and genotype counts of tested D IS C I SNPs. Table shows; SNP ID, minor allele, MAF and genotype counts in LOAD+P,
LOAD-P, LOAD and control samples.
SNP ID MA
MAF Genotype Counts
LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs3738401 A 0.32 0.31 0.31 0.33 40/148/172 22/108/112 96/448/474 133/501/534
rs6675281 T 0.15 0.13 0.15 0.14 5/102/260 7/53/197 23/262/767 20/294/882
rs821616 T 0.27 0.3 0.28 0.28 24/141/190 23/105/123 72/426/528 90/485/597
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Table 3.3b. Individual genotyping of D IS C I SNPs through LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
LOAD+P vs. LOAD- 3 LOAD+P vs. Control LOAD vs. Control
Alleles Genotype Alleles Genotype Alleles Genotype
SNP ID x2 p OR X2 P x2 p OR X2 P x2 p OR Q.
CMX
rs3738401 0.009 0.92 1.01 (0.79-1.3) 1.06 0.59 0.34 0.56 0.95(0.79-1.13) 0.48 0.79 0.98 0.32 0.94(0.83-1.07) 2.23 0.33
rs6675281 1.22 0.27 1.2(0.87-1.67) 5.3 0.07 0.77 0.38 1.11 (0.88-1.4) 1.64 0.44 0.42 0.52 1.06(0.89-1.25) 0.85 0.65
rs821616 1.74 0.19 0.84(0.65-1.09) 1.84 0.4 0.83 0.36 0.92(0.76-1.11) 0.85 0.66 0.19 0.66 0.97(0.85-1.11) 0.36 0.84
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3.4. Dystrobrevin Binding Protein 1
The gene encoding Dystrobrevin binding protein 1 (DTNBP1), also known 
as Dysbindin-1, is a 140 kb gene located on 6p22.3 (Figure 3.4), one of the best 
supported regions that have emerged from linkage studies of schizophrenia 
(Raybould et al. 2005). Consequently DTNBP1 has been extensively studied in 
psychiatric disorders (Norton et al. 2006; Wray et al. 2008). Evidence of significant 
linkage to chromosomal region 6p24-22 in schizophrenia was identified in Irish 
pedigrees (LOD = 3.51, P = 0.0002) (Straub et al. 1995), with maximal linkage 
under an intermediate phenotype (Straub et al. 1995). There is support for 
schizophrenia linkage on chromosome 6p by independent groups, including 2 
studies by Schwab and colleagues (Schwab et al. 1995; Schwab et al. 2000) and a 
collaborative study of 559-758 pedigrees (MLS = 2.68) (Schizophrenia 
collaborative group 1996). Several SNPs and 3 marker haplotypes between exon 5 
and exon 1 of the DTNBP1 gene have demonstrated a high degree of statistical 
significant association with schizophrenia (P = 0.008-0.0001) (Straub et al. 2002). 
Association at this gene, albeit with different haplotypes, has been identified in 
parent-offspring trio samples of German, Hungarian, Israeli and Bulgarian origin 
(Kirov et al. 2004; Schwab et al. 2003), in a case-control study of Swedish (Van 
Den Bogaert et al. 2003) and Hispanic (Funke et al. 2004) origin, but not in a case 
control study of Caucasian Irish Individuals (Morris et al. 2003b). Schwab and 
colleagues (Schwab et al. 2003) tested six of the most positively associated 
polymorphisms using their original linkage sample and a sib-pair sample. Evidence 
for association was observed for one SNP (P = 0.0068) and a multivariant 
haplotype (P = 1x1 O'5). A study of dysbindin in a UK sample of 708 schizophrenia 
cases and 711 controls found strong evidence for association (P < 0.0006) with 
multiple novel 3-marker haplotypes, but these associations did not replicate 
(Williams et al. 2004). The evidence for DTNBP1 as a susceptibility gene for 
schizophrenia extends to samples of non-European origin, with significant 
haplotypic association reported in a Chinese sample (P = 0.0007) (Tang et al.
2003) and a Japanese case-control sample (P =  0.001) (Numakawa et al. 2004). 
The absence of functional schizophrenia associated polymorphisms in DTNBP1 
strongly suggests that susceptibility is conferred by variation affecting mRNA 
expression. Such c/s-acting variants have been shown to exist in DTNBP1, and to
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operate in human brain (Bray et al. 2003b). Moreover, there is direct evidence 
linking schizophrenia risk haplotypes at the 3’ end of the DTNBP1 locus with 
reduced allelic expression of DTNBP1 (Bray et al. 2005). This region of 
chromosome 6p22.3 also receives genome-wide significant support in bipolar 
disorder (Ewald et al. 2002). Some small studies show association of DTNPB1 
polymorphisms with bipolar disorder in Korean (Joo et al. 2007; Pae et al. 2007) 
and UK samples (Breen et al. 2006; Gaysina et al. 2008). Another UK study found 
modestly significant evidence for association of DTNBP1 with a subset of cases 
with predominantly psychotic episodes of mood disturbance (Raybould et al. 2005). 
A trio based Ashkenazi Jew sample showed evidence that DTNBP1 is associated 
with the development of both schizophrenia and bipolar disorder (Fallin et al.
2005).
The 352-amino acid 40 kDa DTNBP1 protein is ubiquitously expressed 
including a wide distribution in the brain. Dysbindin is part of the dystrophin- 
associated protein complex (DPC) (Benson et al. 2001), found in the sarcolemma 
of muscle but also in postsynaptic densities in a number of brain areas. In the brain 
dysbindin expression is thought to be confined to neurons, where it is pre- and 
postsynaptic (Benson et al. 2001). Of most relevance to this study, dysbindin is 
expressed in glutamatergic neurons and synapses of the hippocampus (Benson et 
al. 2001; Sillitoe et al. 2003). Dysbindin has emerged as a component of the 
biogenesis of lysosome-related organelles complex 1 (BLOC-1) (Li et al. 2003), 
which acts through a mechanism that may involve self-assembly and interaction 
with the actin cytoskeleton (Falcon-Perez et al. 2002). How dysbindin’s role in the 
DPC or BLOC-1 relates to the pathogenesis of psychosis is unknown. Initially it 
was speculated dysbindin may influence schizophrenia risk through postsynaptic 
mechanisms (Straub et al. 2002). Compatible with the DPC’s role in synaptic 
structure, maintenance and synaptic signalling, altered dysbindin/DPC function 
may lead to several of the structural and functional abnormalities that have been 
reported in schizophrenia, including altered function at glutamatergic and 
GABAergic synapses, and reduced synaptic density in frontal cortex and 
hippocampus (Straub et al. 2002). A presynaptic role has also been hypothesised 
following the documentation of a significant reduction in presynaptic dysbindin 
expression in several hippocampal regions and an inverse relationship between 
presynaptic dysbindin and the vesicular glutamate transporter suggests the
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possibility of a mechanism related to glutamate release (Talbot et al. 2004). This 
hypothesis is supported by the demonstration that knockdown of endogenous 
dysbindin protein results in reduction of glutamate release (Numakawa et al. 2004). 
Reduced expression of dysbindin may result in disturbances of BLOC-1 function, 
and this among other things, may affect intracellular trafficking of glutamate 
vesicles and reduce glutamate release (Williams et al. 2005b). However, whether 
this mechanism has any relevance to the pathophysiology of schizophrenia is 
uncertain. Post-mortem evidence suggests DTNBP1 is expressed in regions of the 
brain that are critical to cognitive function and that expression is reduced in 
hippocampus and prefrontal cortex in patients with schizophrenia (Weickert et al.
2004).
3.4.1. Literature Summary
There is a substantial body of support for association of the DTNBP1 gene 
with schizophrenia which is far beyond what can be attributed simply to chance. 
However, there is considerable disagreement between studies with respect to the 
specific markers and haplotypes that associate with disease. No coding variant has 
yet been identified, strongly suggesting that susceptibility is conferred by variation 
affecting mRNA expression. There is direct evidence for this hypothesis, with 
reduced allelic expression of DTNBP1 linked to schizophrenia (Bray et al. 2005). 
Some studies show association of DTNPB1 with bipolar disorder (Breen et al.
2006; Fallin et al. 2005; Gaysina et al. 2008; Joo et al. 2007; Pae et al. 2007; 
Raybould et al. 2005). How dysbindin’s function relates to the pathogenesis of 
psychosis is unknown, but both pre- (Numakawa et al. 2004; Talbot et al. 2004) 
and post-synaptic (Straub et al. 2002) hypotheses have been suggested and 
supported. The reduced expression of dysbindin seen in schizophrenia may affect 
intracellular trafficking of glutamate vesicles and reduce glutamate release 
(Williams et al. 2005b). However, whether this mechanism has any relevance to 
the pathophysiology of schizophrenia is uncertain.
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Figure 3.4. The DTNBP1 locus. Schematic shows chromosomal position (bp), the SNPs genotyped in this study, with their 
position within the gene indicated by an arrow, the direction o f transcription indicated by horizontal arrow, the DTNBP1 gene 
with exons/UTR indicated by black bars (long/short bars respectively), and finally the LD plot o f the region (r2).
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3.4.2. Study Design
Five markers which had previously shown evidence for association to 
schizophrenia (Carroll et al. 2009; Williams et al. 2005b) were tested for 
association with LOAD+P and LOAD. All markers were genotyped using the 
Sequenom™ MassARRAY™ system (Sequenom, San Diego, California, USA) as 
described in chapter 2.7.3. The relative PCR and extension primers can be found 
in Appendix Table 3.6.
3.4.3. Results
One SNP in DTNBP1 showed deviation from HWE. This variant, rs2619539, 
gave a HWE p-value of 0.001 in the without psychosis subset of LOAD and a HWE 
p-value of 0.04 in the full LOAD case sample. As this variant shows no association 
to LOAD+P or LOAD, and has a genotyping success rate of 97%, no explanation 
for the observed HWE deviation was sort. In the within case analysis (LOAD+P 
versus LOAD-P), one SNP rs12525702 showed a trend towards allelic association 
(P = 0.06; OR = 1.46), with the major C allele over-represented in cases with 
psychosis, 92% compared to 88% in cases without psychosis. The same SNP 
showed significant association to LOAD+P when this subset was compared to 
controls (allelic P  = 0.03; OR = 1.39). The major C allele was again over­
transmitted in cases with psychosis, 92% compared to 89% in controls. However, 
this association did not survive correction for multiple testing (Permuted P  = 0.1). In 
the full analysis no individual variant showed an allelic or genotypic association to 
LOAD (Tables 3.4a and 3.4b). No significant haplotypic associations were seen, 
with global p-values of 0.77 for the within cases analysis (LOAD+P versus LOAD- 
P); 0.17 for the LOAD+P versus control analysis; and 0.28 for the LOAD versus 
control analysis, see Appendix Table 3.7.
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Table 3.4a. MAF and genotype counts of tested D TN B P J  SNPs. Table shows; SNP ID, minor allele, MAF and genotype counts in LOAD+P,
LOAD-P, LOAD and control samples.
SNP ID MA
MAF Genotype Counts
LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs17470454 A 0.05 0.04 0.06 0.06 2/31/310 0/21/219 3/109/881 5/124/996
rs2619539 C 0.47 0.43 0.46 0.47 80/162/101 56/96/88 223/464/306 234/579/312
rs12525702 T 0.08 0.12 0.1 0.11 2/53/288 5/46/189 12/176/805 15/221/889
rs3213207 G 0.1 0.1 0.12 0.12 5/60/278 2/46/192 16/201/776 15/242/868
rs2619538 A 0.41 0.43 0.43 0.45 64/156/123 50/104/86 194/458/341 228/548/349
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Table 3.4b. Individual genotyping of DTNBPl SNPs through LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
LOAD+P vs. LOAD-P LOAD+P vs. Control LOAD vs. Control
Alleles Genotype Alleles Genotype Alleles Genotype
SNP ID X2 P OR x2 P x2 P OR x2 P x2 P OR X2 P
rs17470454 0.33 0.57 1.18(0.68-2.05) 1.42 0.49 0.71 0.4 1.18(0.8-1.73) 1.19 0.55 0.05 0.82 1.03 (0.8-1.33) 0.29 0.87
rs2619539 1.48 0.22 1.16(0.91-1.46) 3.94 0.14 0.03 0.85 1.02 (0.86-1.21) 1.99 0.37 0.22 0.64 1.03 (0.92-1.16) 4.8 0.09
rs12525702 3.64 0.06 1.46 (0.99-2.15) 4.26 0.12 4.54 0.03 1.39(1.03-1.87) 4.55 0.1 1.31 0.25 1.12(0.92-1.36) 1.38 0.5
rs3213207 0.01 0.91 1.02 (0.7-1.5) 0.7 0.71 1.82 0.18 1.21 (0.92-1.6) 2.6 0.27 0.13 0.72 1.03 (0.86-1.25) 0.75 0.69
rs2619538 0.14 0.71 1.05 (0.83-1.33) 0.49 0.78 2.22 0.14 1.14(0.96-1.36) 2.83 0.24 1.76 0.19 1.09 (0.96-1.23) 2.67 0.26
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3.4.4. Discussion
In a bid to decipher if DTNBP1 is a susceptibility gene for Alzheimer’s 
disease with psychosis, 5 polymorphisms were genotyped that have previously 
provided significant evidence for association to schizophrenia in Caucasian 
samples (Carroll et al. 2009; Williams et al. 2005b). This study provides moderate 
evidence that a variant in DTNBP1 has some role in the aetiology of LOAD+P, with 
the major allele of rs12525702 over-transmitted in LOAD cases with psychosis, but 
this significant association does not withstand correction for multiple testing. If the 
within case analysis had greater power, through an increase in sample size, variant 
rs12525702 may have shown a significant association in this analysis. This is 
based on the observation that the effect size for rs12525702 is greater in the within 
case analysis (OR = 1.46) than the LOAD+P versus control analysis (OR = 1.39). 
The LOAD+P versus LOAD-P analysis has a power of 0.32, and the LOAD+P 
versus control analysis has power of 0.47 to detect an association with the MAF 
and OR seen with rs12525702. Future work will include analysis of the DTNBP1 
locus in the GWAS of LOAD with psychosis described in chapter 5, specifically 
variant rs12525702 or a proxy for this marker.
3.5. Glutamate Receptor lonotropic Kainate 2
This gene is located on chromosome 6q16.3-q21 in a region identified by 
two psychosis covariate analyses of AD linkage screens (Bacanu et al. 2002; 
Hollingworth et al. 2007). Multiple genome-wide scanning studies mapped a 
schizophrenia (Cao et al. 1997; Levinson et al. 2000; Martinez et al. 1999) and/or 
bipolar disorder (Dick et al. 2003; Lambert et al. 2005; Pato et al. 2004) 
susceptibility locus in the vicinity of GRIK2 (6q21-q22.3). There are relatively few 
genetic association studies of GRIK2 with psychosis. Previous studies have shown 
significant statistical association of the gene with obsessive compulsive disorder 
(OCD) (Delorme et al. 2004) and autism (Jamain et al. 2002), which has been 
linked to schizophrenia (Konstantareas and Hewitt 2001). Significant association 
between GRIK2 and schizophrenia has been reported (Bah et al. 2004), with the
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results similar to those previously reported for autism. Several studies report 
decreased kainate receptor expression (including GRIK2) in the brain of 
schizophrenic patients (Meador-Wood ruff et al. 2001a; Meador-Wood ruff et al. 
2001b; Porter et al. 1997). However, a Japanese case control study failed to find 
any association between GRIK2 and schizophrenia (Shibata et al. 2002). Of 
relevance to this study, genetic variation at the GRIK2 locus has shown significant 
association, in multiple studies, to the neurodegenerative disorder Huntington’s 
disease (Metzger et al. 2006; Zeng et al. 2006). A TAA repeat in the 3’ 
untranslated region has been shown to associate with age at onset of Huntington’s 
disease (AAO) (Rubinsztein et al. 1997).
The glutamate receptor GRIK2 is an excellent functional candidate for 
susceptibility to schizophrenia. Glutamate is an excitatory neurotransmitter in the 
central nervous system (CNS), which acts on two different groups of receptors: 
metabotropic and ionotropic receptors (Hollmann and Heinemann 1994). The 
ionotropic receptors are ionic channels separated into three different families: 
NMDA, AMPA and kainate receptors. GRIK2 is a member of the ionotropic kainate 
receptor family. It is expressed during brain development and post-transcriptionally 
modified by editing. The gene consists of 18 exons spanning over 700 kb (Figure 
3.5). The encoded protein is a 908 amino acid, 103 kDa subunit (GluR6) of a 
kainate glutamate receptor which assembles into a kainate-gated homomeric 
channel. Genetic variation at the GRIK2 locus alters the calcium permeability of 
this channel. The GRIK2 receptor plays an important role in synaptic plasticity and 
neural development (Nakanishi et al.1998), may be important for learning and 
memory (Shimizu et al. 2000}, and may have a role in neurodegeneration 
(Nakanishi et al.1998). Studies have reported abnormal kainate receptor 
expression and editing of GRIK2 in brains from schizophrenic patients (Meador- 
Woodruff et al. 2001b). The glutamatergic dysfunction hypothesis of schizophrenia 
suggests genes involved in glutamatergic transmission as strong candidates for 
schizophrenia-susceptibility genes (Shibata et al. 2002), based on the fact that an 
antagonist of a glutamate receptor induces phenotypes similar to schizophrenia in 
human and in animal models.
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3.5.1. Literature Summary
There is strong evidence for linkage to schizophrenia (Cao et al. 1997; 
Levinson et al. 2000; Martinez et al. 1999), bipolar disorder (Dick et al. 2003; 
Lambert et al. 2005; Pato et al. 2004) and AD+P (Bacanu et al. 2002; Hollingworth 
et al. 2007) on chromosome 6q. However there is little evidence from association 
studies to support these findings. Association with alternative psychotic disorders 
(autism and OCD) has been documented (Delorme et al. 2004; Jamain et al. 
2002), but there is no convincing data for the role of GRIK2 in the aetiology of 
schizophrenia from the 2 association studies (Bah et al. 2004; Shibata et al. 2002). 
The functional candidacy of GRIK2 as a susceptibility gene for psychosis is strong, 
due to the glutamatergic dysfunction hypothesis of schizophrenia and the report of 
abnormal kainate receptor expression and editing in the brains of schizophrenic 
patients (Meador-Woodruff et al. 2001b).
3.5.2. Study Design
GRIK2 has not been extensively studied in psychosis and the rationale for 
including it in this study is 1) It’s functional candidacy as a gene involved in 
glutamatergic transmission, 2) The gene’s chromosomal position in an overlapping 
linkage region for schizophrenia, bipolar disorder and AD+P, and 3) Its previous 
association with a neurodegenerative disease. The GRIK2 TAA repeat which has 
shown association to HD (Rubinsztein et al. 1997) was chosen for investigation in 
this study along with SNP rs6922753 which showed significant evidence for 
association with schizophrenia in the study of Bah and colleagues (Bah et al.
2004). The genomic position of the TAA repeat was identified from the paper of 
Rubinsztein and colleagues (Rubinsztein et al. 1997). This variant was genotyped 
using the genescan fluorescent PCR technology using a standard 57°C PCR 
program, see chapter 2.7.1. Polymorphism rs6922753 was genotyped using the 
Amplifluor™ Uniprimer Chemistry technique using a 58°C program with 22 cycles 
see chapter 2.7.2. The utilised PCR primer sequences are provided in Appendix 
Table 3.8.
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3.5.3. Results
The GRIK2 SNP (rs6922753) shows no association to LOAD+P in the within 
case analysis (allelic P  = 0.65, OR = 1.11, genotypic P  = 0.73) nor in the LOAD+P 
versus control analysis (allelic P = 0.97, OR = 1, genotypic P = 0.91). The variant 
also shows no association to LOAD alone (allelic P  = 0.31, OR = 1.09, genotypic P  
= 0.55) (Tables 3.5a and 3.5b). The TAA repeat had 15 observed genotypes, chi 
square statistics were used to determine if the number of genotypes differed 
significantly between ‘cases’ and ‘controls’ of each dataset analysed (Table 3.5c). 
There were no significant differences between the TAA genotypes in any analysis. 
The chi square statistic and p-value for each comparison dataset are shown in 
Table 3.5d.
3.5.4. Discussion
In this study the 3’UTR GRIK2 TAA repeat which has shown association to 
HD (Rubinsztein et al. 1997) and SNP rs6922753 which has shown significant 
evidence for association with schizophrenia were investigated (Bah et al. 2004). 
Neither of these variants show an association to LOAD+P or LOAD. However, due 
to the strategy of this study coverage of the GRIK2 locus is low meaning that 
variation at GRIK2 may prove to be a risk factor for psychosis in LOAD in future 
studies.
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Table 3.5a. MAF and genotype counts of tested G R IK 2  SNP. Table shows; SNP ID, minor allele, MAF and genotype counts in LOAD+P,
LOAD-P, LOAD and control samples.
MAF Genotype Counts
SNP ID MA LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs6922753 T 0.14 0.15 0.15 0.14 252/83/5 74/29/1 706/241/22 851/271/20
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Table 3.5b. Individual genotyping of G R IK 2  SNP through LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
LOAD+P vs. LOAD- 3 LOAD+P vs. Control LOAD vs. Control
Alleles Genotype Alleles Genotype Alleles Genotype
SNP ID X2 P OR x2 P x2 p OR X2 P X2 P OR X2 P
rs17470454 0.2 0.65 1.11 (0.71-1.72) 0.63 0.73 0.002 0.97 1 (0.78-1.29) 0.18 0.91 1.03 0.31 1.09(0.92-1.3) 1.19 0.55
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Table 3.5c. Observed genotypes and genotype counts for the G R IK 2  TAA repeat.
Genotype LOAD+P LOAD-P LOAD Controls
143 143 12 9 34 37
146 134 13 11 39 35
146 143 52 39 156 188
146 146 61 47 183 199
149 140 31 23 89 85
149 143 20 15 59 67
152 146 40 30 120 136
152 149 33 26 98 119
152 152 31 23 89 94
155 143 12 9 36 45
155 149 23 17 69 76
155 152 7 7 21 18
155 155 15 12 45 56
158 146 9 6 25 36
158 149 11 8 31 29
Table 3.5d. Chi-square statistic and p-value for each analysis of the G R IK 2  TAA repeat.
x2 P
LOAD+P v LOAD-P 0.4 0.98
LOAD+P v Control 2.5 0.64
LOAD v Control 2.49 0.63
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3.6. Glutamate Receptor Metabotropic 3
The glutamate receptor metabotropic 3 gene (GRM3) is one of the most 
hypothesised putative functional candidate genes for neurological disorders. 
Glutamate is the major excitatory neurotransmitter in the mammalian central 
nervous system and is involved in most aspects of normal brain function. The 220 
kb GRM3 gene (Figure 3.6) maps to locus 7q21.1-q21.2. This locus is on the edge 
of region 7q11.23-7q21.12 which provides significant evidence of linkage to 
psychosis in AD, making GRM3 a putative functional and positional candidate for 
AD with psychosis. Multiple groups have examined polymorphisms in the GRM3 
gene for association with schizophrenia and/or bipolar disorder. The results are 
conflicting with no study providing compelling evidence for genetic association with 
either disorder. Significant association of the synonymous polymorphism 
rs2228595, which is thought to modulate GRM3 splicing (Sartorius et al. 2008), 
was reported in German (P = 0.002) (Marti et al. 2002), European American (P = 
0.08) (Egan et al. 2004), and Han Chinese (P =  0.03) (Chen et al. 2005) 
schizophrenia samples. However, these associations were not all in the same 
direction and do not replicate in large case-control (Marti et al. 2002) or familial 
samples (Egan et al. 2004). The intron 2 SNP rs6465084 is thought to modulate 
synaptic glutamate, with AA homozygotes having lower mRNA levels of a glial 
glutamate transporter. This variant has shown significant evidence for association 
to schizophrenia in a Caucasian sample (Egan et al. 2004) which replicates in a 
sample of German Caucasian origin (Mossner et al. 2008). Negative associations 
of this marker with schizophrenia have also been reported (Egan et al. 2004). 
Nominally significant evidence for association with intronic marker rs1468412 has 
been reported in Japanese (P =  0.01) (Fujii et al. 2003) and African America (P = 
0.03) (Egan et al. 2004) schizophrenia samples, in addition to a number of 2 and 3 
marker haplotype combinations in the same sample sets (Egan et al. 2004; Fujii et 
al. 2003). Entirely negative results have been reported in population samples of 
Caucasian (Bishop et al. 2007; Fallin et al. 2005; Norton et al. 2005; Schwab et al. 
2008) and Asian ethnicity (Albalushi et al. 2008; Tochigi et al. 2006). There is no 
consistent pattern of diagnosis-related changes for GRM3 mRNA from studies of 
GRM3 expression in schizophrenia (Corti et al. 2007; Crook et al. 2002; Gupta et
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al. 2005; Ohnuma et al. 1998; Richardson-Burns et al. 2000; Sartorius et al. 2008). 
However, the study of Corti and colleagues (Corti et al. 2007) is of specific interest, 
as they found a marked decrease of the dimeric form of GRM3 in schizophrenia, 
which is though to denote a decrease in the functional activity of GRM3 in that 
disease (Harrison et al. 2008). Two of three studies have reported association of 
GRM3 with bipolar disorder (Fallin et al. 2005; Green et al. 2006a), suggesting that 
there may be a genetic association with a broader psychosis phenotype. Fallin and 
colleagues (Fallin et al. 2005) identified a four-marker haplotype that was 
associated with bipolar disorder in Ashkenazi Jew case-parent trios, but this 
association would not survive correction for multiple testing. Green and colleagues 
(Green et al. 2006a) found a significant association of the intron 2 SNP rs6465084 
in a case-control study from a UK-lrish population. While, Marti and colleagues 
provide the only negative study in a German case-control sample (Marti et al.
2002).
The postsynaptic actions of glutamate are mediated by two types of 
receptors. The ionotropic receptors are glutamate-gated ion channels, which cause 
neuronal depolarization. While the metabotropic glutamate receptors are a family of 
G protein-coupled receptors, that have been divided into 3 groups on the basis of 
sequence homology, putative signal transduction mechanisms and pharmacologic 
properties (Kuramoto et al. 1994). Group II includes GRM2 and GRM3 which have 
key roles in synaptic plasticity via inhibition of glutamate release (Johnson et al.
2005). Abnormal glutamatergic transmission has been proposed in schizophrenia, 
initially from the observation that exposure to ionotropic receptor antagonists can 
cause symptoms of schizophrenia and also relapse in patients with schizophrenia 
(Javitt and Zukin 1991; Kim et al. 1980). Interest in group II metabotropic glutamate 
receptors was stimulated when agonists of metabotropic glutamate receptors 2 and 
3 (GRM2 and GRM3) were shown to ameliorate the adverse behavioural effects 
induced by ionotropic receptor antagonists in the mouse (Moghaddam and Adams 
1998). This finding has been confirmed in subsequent rodent studies (Cartmell et 
al. 1999; Cartmell et al. 2000a; Cartmell et al. 2000b; Carter et al. 2004; Greco et 
al. 2005; Homayoun et al. 2005; Lorrain et al. 2003). The GRM3 gene has been 
specifically highlighted as a putative psychosis candidate gene for schizophrenia 
by three relatively recent developments. 1) Several studies have shown genetic 
association of GRM3 with schizophrenia (Chen et al. 2005; Egan et al. 2004; Fujii
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et al. 2003; Marti et al. 2002; Mossner et al. 2008; Schwab et al. 2006). 2) A clinical 
trial of a group II metabotropic glutamate receptor agonist has shown unequivocal 
antipsychotic efficacy (Patil et al. 2007). 3) A splice variant of GRM3 (GRM3A4) 
has been identified which encodes a truncated form of the receptor that is 
expressed in brain (Sartorius et al. 2008). Increased expression of GRM3A4 has 
been found to correlate with genetic risk factor for schizophrenia (Sartorius et al. 
2008).
3.6.1 Literature Summary
The existing studies do not provide compelling evidence for association of 
GRM3 with schizophrenia or bipolar disorder. Although, the majority of studies 
have been inadequately powered. For example, Fallin and colleagues noted that 
lack of power was a serious limitation of their study; with only 7% power to detect a 
susceptibility variant with an OR of 1.5, assuming a minimum MAF of 10% and that 
the tested variant is in a r2 of 1 with the functional variant (Fallin et al. 2005). Two 
SNPs (rs1468412 and rs6465084) within GRM3 have shown association to 
psychosis that replicates in independent samples (Egan et al. 2004; Fujii et al.
2003; Green et al. 2006a; Mossner et al. 2008). The positive associations of GRM3 
and psychosis are centred around exon 3 and adjoining introns, providing a degree 
of intragenic convergence that likely increases the chances that a true causal 
variant (or variants) is located in this region of the gene (Harrison 2008). Moreover, 
this localization leads to a prediction: if there is a pathophysiological consequence 
of allelic variation in the vicinity, it is likely mediated by effects on expression, and 
more specifically splicing, of the gene (Harrison and Weinberger 2005). The 
biological plausibility of GRM3 as a susceptibility gene for psychosis is more 
convincing, with a clinical trial of a group II metabotropic glutamate receptor agonist 
showing antipsychotic efficacy (Patil et al. 2007), and increased expression of a 
splice variant of GRM3 correlating with risk for schizophrenia (Sartorius et al.
2008).
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3.6.2. Study Design
Seven variants were tested for association with LOAD+P and LOAD. These 
were GRM3 markers which have previously shown significant evidence for 
association to schizophrenia in Caucasian samples. One SNP (rs2228595) showed 
significance in an early German sample (Marti et al. 2002), while the remaining 
SNPs were reported by Egan and colleagues in a large UK based case control 
sample (Egan et al. 2004). These SNPs and haplotypes have since been studied in 
an additional UK case control sample of comparable size to that of Egan and 
colleagues where they show no evidence of association to schizophrenia (Norton 
et al. 2005). All markers except rs187993 were genotyped using the Sequenom™ 
MassARRAY™ system (Sequenom, San Diego, CA) (see chapter 2.7.3). 
Polymorphism rs187993 was genotyped using the Amplifluor™ UniPrimer 
chemistry, comprehensively described in chapter 2.7.2. This SNP was genotyped 
on a 58°C program with 22 cycles. Marker PCR and extension primers are 
provided in Appendix Table 3.9.
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3.6.3. Results
Four SNPs showed deviation from HWE in one of the sample groups. 
Polymorphism rs13242038 shows deviation from HWE (P = 0.03) in the LOAD+P 
group as does variant rs2228595 (HWE P = 0.01). Marker rs6465084 has a 
nominally significant deviation from HWE in the control group (P= 0.04), while 
rs2282966 shows a greater deviation from HWE in this sample set (P = 0.001). No 
genotyping error was found, genotypes of HapMap samples included on the 
sample plates were checked and confirmed against HapMap data, and none of the 
SNPs were found to have a non-specific assay (where a primer shows high 
homology to multiple genomic regions) or a primer covering a known variant. 
Therefore, no reasons for the observed deviations from HWE were identified; 
hence the raw genotype data and the statistics calculated from these were 
received with caution (Martin et al. 2000; Wang et al. 2003). One of the GRM3 
SNPs (rs2228595) showed a nominal genotypic (P = 0.04) but no allelic difference 
between LOAD+P and LOAD-P cases. This genotypic association does not survive 
correction for multiple testing (permuted P = 0.28). The same SNP showed a 
significant association with both an allelic (P= 0.003, OR = 1.71, permutated P = 
0.01) and genotypic (P= 0.003, permutated P =  0.02) association to LOAD+P as a 
subtype of disease which survives correction for multiple testing. However, as 
discussed this variant shows deviation from HWE in the LOAD+P subgroup. Four 
SNPs (rs917071, rs6465084, rs2228595, rs1468412) showed a significant allelic 
association with LOAD. Two of these associations survived correction for multiple 
testing. Marker rs6465084 showed the most significant association with LOAD (P = 
0.002, OR = 1.27; permuted P = 0.009), but this variant shows slight deviation from 
HWE in the control dataset (P = 0.04). Polymorphism rs2228595 also showed a 
significant association with LOAD that survived correction for multiple testing (P = 
0.005, OR = 1.47, permuted P =  0.021). The minor T allele of this variant is over­
represented in cases with a MAF of 7% compared to a MAF of 5% in controls (see 
Tables 3.6a and 3.6b). Haplotype analyses revealed no stronger association than 
the allelic associations seen with LOAD+P, with global p-values of 0.93 and 0.2 
respectively, see Appendix Table 3.10. In the LOAD versus control dataset a global 
haplotypic p-value of 0.029 was detected, see Appendix Table 3.10. The most 
significant association was seen with a four marker haplotype (P = 0.0005)
121
Chapter 3. Psychosis Candidate Gene Association Study
including variants rs917071, rs2282966, rs1468412 and rs6465084. Two of these 
variants show deviation from HWE in the control dataset (rs282966, P  = 0.001; 
rs6465084, P  = 0.04)
3.6.4. Discussion
Association to LOAD+P was seen with the synonymous SNP rs2228595, 
this SNP shows deviation from HWE in the LOAD+P dataset and therefore the 
genotype data can not be relied upon. However, the association remains 
interesting and would be worthy of investigation in an independent dataset. Given 
the modest number of variants genotyped in this study it is possible that an 
alternate variant at the GRM3 locus is associated with LOAD+P. Four variants 
showed association to LOAD, two of which survived correction for multiple testing. 
The greatest association of GRM3 to LOAD was seen with a 4 SNP haplotype of 
these associated variants, however, variants rs2282966 and rs6465084 which are 
included in this haplotype show deviation from HWE. The association of GRM3 
with LOAD is interesting, but modest considering the ample size of our case-control 
sample. It warrants replication in an independent dataset and examination in a 
LOAD GWAS. Future work will include analysis of the GRM3 locus in a LOAD+P 
GWAS, specifically the rs2228595 variant or a proxy for this marker. This will be 
discussed further in chapter 5.
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Table 3.6a. MAF and genotype counts of tested G R M 3  SNPs. Table shows; SNP ID, minor allele, MAF and genotype counts in LOAD+P,
LOAD-P, LOAD and control samples.
SNP ID MA
MAF Genotype Counts
LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs187993 T 0.33 0.32 0.32 0.34 38/152/155 25/106/113 116/526/546 140/526/521
rs13242038 T 0.18 0.22 0.2 0.19 17/80/226 11/75/135 45/276/581 36/312/658
rs917071 T 0.28 0.3 0.28 0.24 29/122/172 20/91/110 77/345/480 62/ 66/578
rs6465084 G 0.25 0.25 0.25 0.21 19/126/178 15/79/127 62/332/508 53/317/636
rs2228595 T 0.08 0.06 0.07 0.05 6/39/278 0/26/195 8/108/786 3/90/913
rs1468412 T 0.27 0.27 0.27 0.24 25/122/176 17/85/119 72/340/490 68/346/592
rs2282966 A 0.23 0.27 0.25 0.25 20/106/197 12/94/115 59/337/506 82/332/592
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Table 3.6b. Individual genotyping of GRM3 SNPs through LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
LOAD+P vs. LOAD-P LOAD+P vs. Control LOAD vs. Control
Alleles Genotype Alleles Genotype Alleles Genotype
SNP ID x2 P OR x2 P x2 P OR x2 P x2 P OR x2 P
rs187993 0.15 0.7 1.05 (0.82-1.35) 0.15 0.93 0.2 0.66 1.04 (0.87-1.25) 0.21 0.9 2.26 0.13 1.1 (0.97-1.24) 2.84 0.24
rs13242038 3.1 0.1 1.31 (0.97-1.78) 5.45 0.07 0.66 0.42 1.1 (0.87-1.39) 5.74 0.06 0.87 0.35 1.08 (0.92-1.27) 2.33 0.31
rs917071 0.4 0.5 1.09 (0.84-1.42) 0.7 0.71 3.2 0.07 1.2 (0.98-1.47) 3.73 0.16 5.42 0.02 1.19(1.03-1.37) 5.67 0.06
rs6465084 0.07 0.8 1.04 (0.79-1.37) 0.67 0.71 5.41 0.02 1.28 (1.04-1.57) 6.92 0.03 9.71 0.002 1.27 (1.09-1.48) 9.73 0.01
rs2228595 1.14 0.2 1.37 (0.84-2.24) 6.62 0.04 9.13 0.003 1.71 (1.2-2.43) 11.8 0.003 7.74 0.005 1.47 (1.12-1.94) 7.76 0.02
rs1468412 0.01 0.9 1.02 (0.77-1.33) 0.03 0.99 1.88 0.17 1.15(0.94-1.41) 1.93 0.38 4.15 0.042 1.16(1.01-1.35) 4.13 0.13
rs2282966 2.4 0.1 1.25 (0.94-1.65) 5.33 0.07 1.12 0.29 1.12(0.91-1.38) 1.42 0.49 0.17 0.68 1.03 (0.89-1.19) 4.87 0.09
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3.7. Neuregulin 1
Neuregulin 1 (NRG1) (Figure 3.7) is genetically one of the most well 
supported susceptibility genes for schizophrenia (Craddock et al. 2005). 
Schizophrenia mapped to chromosome 8p21-22 in a genome-wide scan of 
Icelandic families (Stefansson et al. 2002), with the highest multipoint LOD score of 
3.06 at marker D8S532 (Stefansson et al. 2002). This region is 10-15 cM 
centromeric to the previously reported linkage to 8p (Brzustowicz et al. 1999;
Blouin et al. 1998; Gurling et al. 2001; Kaufmann et al. 1998; Kendler et al. 1996; 
Levinson et al. 1996; Pulver et al. 1995; Shaw et al. 1998). The localisation 
discrepancy is thought to be accounted for by low marker density, low resolution 
and uncertainty with maps in older studies (Stefansson et al. 2002). Extensive fine 
mapping of the locus revealed association between schizophrenia and a multi­
marker haplotype at the 5' end of NRG1 (Stefansson et al. 2002). Strong evidence 
for association with the same haplotype was subsequently found in a large sample 
from Scotland (P = 0.00031, RR = 1.8) (Stefansson et al. 2003) and a UK and 
Ireland sample (P < 0.04; RR = 1.25) (Williams et al. 2003a). The multi- marker 
haplotype can be identified using only 3 markers (SNP8NRG221533 and 
microsatellites 478B14-848 and 420M9-1395). Negative findings with this 
“Icelandic” haplotype have been reported in Caucasian populations (Bakker et al. 
2004; Corvin et al. 2004; Hall et al. 2004; Petryshen et al. 2005; Thiselton et al.
2004). However, association with individual variants of the Icelandic haplotype 
(Bakker et al. 2004) or alternative haplotypes (Corvin et al. 2004; Hall et al. 2004; 
Petryshen et al. 2005) have been reported in many of these studies. Summary 
analysis of the ‘Icelandic’ haplotype data from all Caucasian studies (n -  4,500) 
indicates a significant association with an odds ratio of approximately 1.5 (Tosato 
et al. 2005). In Asian populations, where the ‘Icelandic’ haplotype is not found, 
there is good evidence from several studies of association with other markers in the 
same region (Hong et al. 2004; Li et al. 2004b; Tang et al. 2004; Yang et al. 2003), 
although one negative study has been reported (Iwata et al. 2004). Two studies 
have investigated NRG1 in bipolar disorder, one of which found significant 
evidence for association of the ‘Icelandic’ risk haplotype with a similar effect size to
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that seen by the same group in schizophrenia (Green et al. 2005), the other found 
association with an alternative NRG1 variant (Georgieva et al. 2008). These 
findings suggest that NRG1 plays a role in influencing susceptibility to both bipolar 
disorder and schizophrenia, perhaps via alterations to gene expression or 
regulation due to the lack of genetic association with a coding variant. Go and 
colleagues (Go et al. 2005) performed linkage analysis on chromosome 8p in a 
NIMH Alzheimer disease sample. A specific linkage peak for Alzheimer disease 
with psychosis was demonstrated on 8p12, a region which encompasses the 
NRG1 gene. The authors subsequently demonstrated a significant association 
between an NRG1 SNP (rs3924999) and AD with psychosis (P = 0.008). This SNP 
is part of a 3-SNP haplotype preferentially transmitted to individuals with the 
phenotype suggesting that NRG1 plays a role in increasing the genetic risk for 
psychosis in a proportion of Alzheimer disease families (Go et al. 2005).
An extraordinary variety of different isoforms are produced from the NRG1 
gene by alternative splicing. These variants, which include glial growth factors and 
sensory and motor neuron-derived factors, show tissue-specific expression and 
differ significantly in their structure. In the brain, NRG1 is thought to encode around 
15 proteins with a diverse range of functions, including cell-cell signalling, receptor 
interactions, axon guidance, synaptogenesis, glial differentiation, myelination, and 
neurotransmission (Stefansson et al. 2004). A number of the proteins have a clear 
role in the expression and activation of neurotransmitter receptors, including the 
NMDA glutamate receptor (Stefansson et al. 2002) and are essential for neuronal 
development. NRG1 is a plausible susceptibility gene for schizophrenia because of 
its involvement in neurodevelopment, regulation of glutamate and other 
neurotransmitter receptor expression, and synaptic plasticity, any of which could 
potentially influence susceptibility to schizophrenia (Craddock et al. 2005). 
However, the pathophysiological mechanisms by which altered NRG1 function 
might lead to schizophrenia are unclear. The view that the association is related to 
altered NRG1 function or expression is supported by the observation of alteration 
in the ratios of NRG1 mRNA species in schizophrenic brain (Hashimoto et al.
2004). In animals, mutant NRG1 hypomorphic mice show a behavioural phenotype 
that overlaps with mouse models for schizophrenia, which can be partially reversed 
with clozapine, an atypical antipsychotic drug used to treat schizophrenia
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(Stefansson et al. 2002). Furthermore, NRG1 hypomorphic mice have fewer 
functional NMDA receptors than wildtype mice (Stefansson et al. 2002).
3.7.1. Literature Summary
There is strong evidence from several studies that genetic variation in NRG1 
confers risk to schizophrenia, but as yet, and in spite of extensive re-sequencing, 
specific susceptibility and protective variants have not been identified (Craddock et 
al. 2005). The most consistent association in Caucasian populations is with a multi­
marker haplotype, located at the 5 prime end of the gene. This “core” haplotype 
was originally identified in an Icelandic sample (Stefannson et al. 2002) and has 
replicated in Scottish (Stefannson et al. 2003) and UK (Williams et al. 2003a) 
samples. This Icelandic haplotype has also shown significant association with risk 
for bipolar disorder. The lack of identification of a coding NRG1 variant leads to the 
hypothesis that NRG1 contributes to schizophrenia aetiology via a reduction in 
protein function or expression (Hashimoto et al. 2004; Stefansson et al. 2002). 
NRG1 is thought to contribute to the aetiology of psychosis through one of its many 
roles in neurodevelopment, regulation of glutamate and other neurotransmitter 
receptor expression, and synaptic plasticity. Of particular interest to this study is 
that NRG1 SNP (rs3924999) has shown association to AD with psychosis (Go et 
al. 2005).
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3.7.2. Study Design
Three of the NRG1 variants investigated in this thesis were chosen due to 
their previous haplotypic association with schizophrenia (Stefansson et al. 2003). 
The relevant oligomeric primers given by the Stefansson et al. (2003) study were 
used to genotype the markers. The remaining variants (rs3924999 and 
rs12681411) were identified from two separate studies. Marker rs3924999 is 
associated with schizotypical personality (Lin et al. 2005a) and has shown 
association to AD+P (Go et al. 2005). Marker rs12681411 has shown evidence for 
correlation with gene expression (Davelos-Baines et al. 2008). All SNPs were 
genotyped using the Sequenom™ MassARRAY™ system (Sequenom, San Diego, 
CA) as described in chapter 2.7.3. Microsatellites 420M9-1395 and 478B14-848 
were genotyped by genescan fluorescent PCR (chapter 2.7.1) on 50°C 34 cycle 
touchdown, and 57°C standard PCR programs respectively. PCR and extension 
primer sequences are provided in Appendix Table 3.11.
3.7.3. Results
No SNP showed association to LOAD+P or LOAD (Tables 3.7a and 3.7b). 
Microsatellite 420M9-1395 had 21 observed genotypes, and microsatellite 478B14- 
848 had 22 observed genotypes (Tables 3.7c and 3.7e). Chi square statistics were 
used to determine if the number of microsatellite genotypes differed significantly 
between ‘cases’ and ‘controls’ (Tables 3.7d and 3.7f). There were no significant 
differences between the genotypes in any analysis. Haplotypic analysis of the 
Icelandic haplotype produced no significant results in any analysis (LOAD+P vs. 
LOAD-P global P = 0.59; LOAD+P vs. control global P  = 0.49; LOAD vs. control 
global P = 0.41 see Table 3.7g).
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Table 3.7a. MAF and genotype counts of tested N R G  I  SNPs. Table shows; SNP ID, minor allele, MAF and genotype counts in LOAD+P,
LOAD-P, LOAD and control samples.
MAF
SNP ID MA LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs12681411 G 0.38 0.35 0.37 0.37 52/156/135 27/119/98 146/437/411 146/549/448
SNP8NRG221533 C 0.31 0.29 0.32 0.3 49/165/138 31/121/93 132/448/445 139/560/541
rs3924999 A 0.4 0.42 0.4 0.39 56/163/124 42/119/83 166/463/365 173/546/424
Genotype Counts
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Table 3.7b. Individual genotyping of NRG1 SNPs through LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
LOAD+P vs. LOAD-P LOAD+P vs. Control LOAD vs. Contro
Alleles Genotype Alleles Genotype Alleles Genotype
SNP ID x2 P OR x2 P x2 P OR X2 P x2 p OR x2 P
rs12681411 0.74 0.39 1.11 (0.87-1.41) 2.13 0.34 0.28 0.6 1.05 (0.88-1.25) 1.49 0.47 0.01 0.94 1.01 (0.89-1.14) 3.95 0.14
SNP8NRG221533 0.69 0.47 1.24(0.83-1.52) 2.23 0.29 0.57 0.23 1.12(0.86-1.22) 1.52 0.53 0.36 0.41 1.08(0.91-1.21) 2.6 0.34
rs3924999 0.27 0.6 1.06(0.84-1.35) 0.3 0.86 0.25 0.62 1.05 (0.88-1.24) 0.31 0.86 0.42 0.52 1.04(0.92-1.18) 1 0.61
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Table 3.7c. Observed genotypes and genotype counts for microsatellite 420M19-1395.
Genotype LOAD+P LOAD-P LOAD Controls
181:181 1 0 3 4
181:183 2 1 6 8
181:185 7 6 3 4
183:183 9 6 27 36
183:185 11 8 33 44
183:187 17 14 51 62
183:189 25 18 75 95
185:185 20 15 60 77
185:187 35 26 105 113
185:189 28 23 84 102
185:193 12 9 3 4
187:187 44 33 132 155
187:189 54 47 162 189
187:193 27 15 81 91
189:189 14 12 42 51
189:193 8 4 24 32
193:193 7 3 21 24
196:187 5 1 15 18
196:189 2 0 6 8
196:193 0 0 2 0
196:196 0 0 2 0
Table. 3.7d. Chi-square statistic and p-value for each analysis of microsatellite 420M19- 
1395.
X2 P
LOAD+P v LOAD-P 1.34 0.86
LOAD+P v Control 0.16 0.99
LOAD v Control 0.33 0.98
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Table 3.7e. Observed genotypes and genotype counts for microsatellite 478B14-848.
Genotype LOAD+P LOAD-P LOAD Controls
215:215 0 0 0 2
215:217 1 0 1 0
215:219 6 7 17 19
217:217 9 6 28 34
217:219 8 6 24 25
217;221 15 14 46 53
217:223 27 19 85 95
219:219 61 43 177 198
219:221 45 38 143 162
219:223 27 16 72 81
219:225 12 11 41 46
219:227 33 23 105 118
221:221 34 22 97 107
221:223 18 13 54 65
221:225 25 19 84 100
221:227 12 7 31 38
223:223 1 0 2 7
223:225 1 1 3 0
223:227 3 2 9 8
225:225 1 0 1 0
225:227 0 0 1 0
227:227 0 0 0 1
Table 3.7f. Chi-square statistic and p-value for each analysis of microsatellite 478B14-848.
X2 P
LOAD+P v LOAD-P 1.97 0.74
LOAD+P v Control 4.31 0.37
LOAD v Control 1.83 0.77
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Table 3.7g. Results of haplotype analysis at the NRG1  locus. Table shows analysis dataset, 
number of markers analysed, chi square statistic and p-value.
 Dataset_________Number of Markers Analysed x2 Global P
LOAD+P v LOAD-P 3 0.3 0.59
LOAD+P v Control 3 0.54 0.49
LOAD v Control 3 0.67 0.41
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3.7.4. Discussion
This study investigated the ‘Icelandic/Stefansson’ haplotype, in addition to 
the functional variant rs3924999, which has previously shown association with 
schizotypical personality disorder (Lin et al. 2005a), and AD+P (Go et al. 2005), 
plus SNP rs12681411 which has been shown to correlate with gene expression. 
No individual variant showed an association to LOAD+P or LOAD in this study, 
meaning the association of rs3924999 to AD+P has not replicated. The original 
association was discovered in a familial sample of 65 pedigrees, suggesting the 
NRG1 variant rs3924999 is familialy associated with AD+P and may not be a risk 
variant in the general population. Haplotype analysis of the ‘Icelandic’ haplotype 
also revealed no significant associations with LOAD+P or LOAD. Despite the 
negative findings of this study NRG1 remains an interesting candidate gene for 
AD+P due to its previous associations with psychosis and its strong functional 
candidacy. This study only investigates 5 variants. Further investigation of this 
locus is warranted, and will be discussed in chapter 5 of this thesis where the 
NRG1 gene will be explored in a LOAD+P GWAS.
3.8. Brain-derived Neurotrophic Factor
The Brain Derived Neurotrophic Factor (BDNF) is a functional candidate 
gene that has attracted a great deal of interest in schizophrenia (Neves-Pereira et 
al. 2005) and bipolar disorder (Green et al. 2003). Only one frequent, non­
conservative polymorphism in the human BDNF gene has been identified, a SNP 
that causes a valine to methionine substitution at codon 66 (val66met) and may 
have a functionally relevant effect by modifying the processing and trafficking of 
BDNF (Egan et al. 2003).Su bjects with the met allele show abnormal hippocampal 
activity and poorer performance during episodic memory tasks, consistent with a 
reduced functional effect of BDNF (Egan et al. 2003). The variant has shown 
positive association to bipolar disorder in at least 3 family-based Caucasian 
samples (Geller et al. 2004; Neves-Pereira et al. 2002; Sklar et al. 2002), all 
showing over-representation of the common valine allele. There have been multiple 
case-control association studies of varying ethnicities which show no evidence for
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an allelic or genotypic association to bipolar disorder (Green et al. 2003; Hong et 
al. 2003; Nakata et al. 2003; Neves-Pereira et al. 2005; Oswald et al. 2004; 
Skibinska et al. 2004). However, one bipolar disorder case-control analysis in a 
European population showed a significant increase of the val allele in cases (P = 
0.028; OR of 1.22) (Lohoff et al. 2005). BDNF has attracted less interest in 
schizophrenia, but there are reports of positive association at val66met and a 2 
locus haplotype including this polymorphism in schizophrenia (Neves-Pereira et al.
2005) and schizophrenia-spectrum disorder (Rosa et al. 2006). This variant has 
shown association to AD in one Italian case-control analysis (Ventriglia et al. 2002) 
but not in multiple other studies (Bodner et al. 2005; He et al. 2007; Tsai et al.
2004; Tsai et al. 2006), and has also shown association with age at disease onset 
in Parkinson disease (Karamohamed et al. 2005). Expression of the BDNF gene is 
reduced in both Alzheimer's and Huntington disease patients (Pomponi et al. 2008; 
Zala et al. 2008).
The BDNF gene contains 11 exons and spans about 70 kb (Figure 3.8) 
(Pruunsild et al. 2007) of chromosome 11 p13 (Maisonpierre et al. 1991). It encodes 
a precursor peptide, which is cleaved proteolytically to form the mature protein 
(Seidah et al. 1996). The mature protein is a member of the nerve growth factor 
family. It is a pro-survival factor induced by cortical neurons, and is necessary for 
survival of striatal neurons in the brain (Zuccato et al. 2001). BDNF elicits long-term 
neuronal adaptations by controlling the responsiveness of its target neurons to the 
important neurotransmitter dopamine (Guillin et al. 2001). The biologic action is 
regulated by proteolytic cleavage, with profbrms preferentially activating apoptosis 
and mature forms activating receptors to promote survival (Lee et al. 2001). The 
mature form of BDNF is identical in all mammals examined, with conserved tissue 
distributions and neuronal specificities (Maisonpierre et al. 1991). Multiple 
transcript variants encoding distinct isoforms have been described for this gene but 
the full-length nature of only some have been determined. The transcripts differ in 
their use of alternative promoters, alternative splice donor and acceptor sites, and 
alternative polyadenlylation sites (Liu et al 2005; Pruunsild et al. 2007). In 
summary, the gene plays an important role in promoting and modifying growth, 
development, and survival of neuronal populations and, in the mature nervous 
system, is involved in activity-dependent neuronal plasticity (Duman et al. 1999).
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Of relevance to psychosis, mature BDNF has been shown to mediate long­
term potentiation in denate cells of mouse hippocampus (Kovalchuk et al. 2002; 
Pang et al. 2004), with induction of BDNF expression by selective activation of 
calcium influx (Tao et al. 2002). Indeed, calcium-responsive enhancer elements 
within the BDNF promoter have been identified (Tao et al. 2002). Also, BDNF has 
been shown to rapidly shift the neurotransmitter release properties of rat 
sympathetic neurons from excitatory to inhibitory cholinergic transmission in 
response to neural stimulation (Yang et al. 2002). Of interest to this study is that 
the BDNF gene has been implicated in Huntingdon’s disease (HD), with the 
Huntingtin protein upregulating transcription of BDNF (Zuccato et al. 2001), and 
enhancing vesicular transport (Gauthier et al. 2004). These events result in 
insufficient neurotrophic support and neuronal toxicity (Gauthier et al. 2004;
Zuccato et al. 2001) meaning that increasing BDNF production may be a 
therapeutic approach for treating HD. (Zuccato et al. 2001). Reduced expression of 
BDNF has also been noted in AD (Egan et al. 2003), which may have a result 
similar to that seen in HD. The oxidative stress hypothesis for the aetiology of AD 
lends support to this theory, as BDNF has been shown to attenuate neuronal 
damage induced by chemical hypoxia in vivo by a mechanism which may involve 
attenuation of oxidative stress (Kirschner et al. 1996).
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3.8.1. Literature Summary
The BDNF locus has not been extensively studied in psychotic illness or 
neurodegenerative disease. The val66met variant has shown positive association 
to bipolar disorder (Lohoff et al. 2005) and schizophrenia (Neves-Pereira et al.
2005), but with no consistency or certainty. The marker has also shown association 
to AD (Ventriglia et al. 2002) but only in one study which must be set against the 
numerous negative findings (Bodner et al. 2005; He et al. 2007; Tsai et al. 2004; 
Tsai et al. 2006). The protein is a good putative functional candidate for both 
psychosis and neurodegeneration with its involvement in the action of the 
neurotransmitter dopamine, and its actions as a pro-survival factor (Zuccato et al.
2001). BDNF has been shown to be induced by calcium influx (Tao et al. 2002), a 
pathway which has recently seen a wealth of interest from the field of psychiatric 
genetics (O’Donovan et al. 2009). The protein has also shown reduced expression 
in two neurodegenerative disorders, including AD (Egan et al. 2003).
3.8.2. Study Design
Brain derived neurotrophic factor (BDNF) is a good putative functional 
candidate gene for schizophrenia and neurodegeneration. The val66met 
polymorphism (rs6265) of BDNF is the only gene variant to show consistent 
association with schizophrenia (Neves-Pereira et al. 2005) and more broadly with 
psychosis (Rosa et al. 2006), as well as neurodegenerative disorders including AD 
(Ventriglia et al. 2002). This study investigates the val66met polymorphism 
(rs6265) with respect to psychosis in LOAD. Polymorphism rs6265 was genotyped 
using the Sequenom™ MassARRAY™ system (Sequenom, San Diego, CA) as 
described in chapter 2.7.3. The relative marker PCR and extension primers are 
shown in Appendix Table 3.12.
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3.8.3. Results
Marker rs6265 showed no evidence for association with LOAD+P under 
either analysis model (Table 3.8a and 3.8b). The minor T allele of the marker 
showed a frequency of 19% in the LOAD+P dataset and 17% in both LOAD-P and 
control datasets. Marker rs6265 did show a significant allelic association with 
LOAD (P = 0.01, OR = 1.2). The minor T allele of the marker is over-represented in 
cases, with a frequency of 19% compared to a frequency of 17% in controls. This 
difference in allele frequency is equal to that seen in both analyses of LOAD+P, but 
the LOAD sample has greater power to detect the association. Sex effects have 
previously been documented at the BDNF locus (Verhagen et al. 2008) Therefore, 
the datasets were analysed by sex. This analysis reduces the sample size and 
therefore the power of the analysis. Differences in allele and genotype frequencies 
did not significantly differ in male or female samples for the disease modifier 
analysis. Analysis of the disease subtype model found a significant association of 
LOAD+P with males (P =  0.04, OR = 1.53), although this association did not 
withstand correction for multiple comparisons (permuted P = 0.12). Sex analysis of 
the BDNF marker in LOAD showed a significant association with males (P = 0.04, 
OR = 1.3), which did not survive correction for multiple comparisons (permuted P = 
0.09) and did not surpass the association seen with LOAD irrelevant of sex (see 
Appendix Tables 3.13 - 3.16).
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Table 3.8a. MAF and genotype counts of tested B D N F  SNP. Table shows; SNP ID, minor allele, MAF and genotype counts in LOAD+P,
LOAD-P, LOAD and control samples.
MAF Genotype Counts
SNP
ID MA LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs6265 T 0.19 0.17 0.19 0.17 12/111/242 14/74/167 54/347/768 44/360/931
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Table 3.8b. Individual genotyping of B D N F  SNP through LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
SNP
ID
LOAD+P vs. LOAD-P LOAD+P vs. Control LOAD vs. Contro
Alleles Genotype Alleles Genotype Alleles Genotype
X2 P OR x2 P x2 P  OR x2 P X2 P OR X2 P
rs6265 0.44 0.51 1.1 (0.83-1.47) 1.85 0.4 1.19 0.28 1.13(0.91-1.39) 1.72 0.42 6.07 0.01 1.2(1.04-1.38) 5.92 0.05
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3.8.4. Discussion
The BDNF variant val66met (rs6265), previously associated with 
schizophrenia (Neves-Pereira et al. 2005) and bipolar disorder (Lohoff et al. 2005), 
does not associate with psychosis in LOAD in this study. Marker rs6265 does show 
significant association with LOAD with the met allele overrepresented in cases. The 
association appears to be stronger in males (P = 0.04) than females (P = 0.11), but 
does not exceed the association seen with full sample set irrespective of sex (P = 
0.01, OR = 1.2). Polymorphism rs6265 is a non-synonymous variant that causes a 
substitution of valine to methionine in a portion of the protein thought to play a role 
in cytoplasmic trafficking and activity-dependent secretion of BDNF (Egan et al.
2003). Variation at rs6265 may reduce protein function, which fits well with the 
oxidative stress hypothesis of AD aetiology. The variant has previously shown 
association to AD (Ventriglia et al. 2002) but this is set against numerous negative 
reports (Bodner et al. 2005; He et al. 2007; Tsai et al. 2004; Tsai et al. 2006). 
Investigation of rs6265 in independent LOAD datasets is warranted.
3.9. D-amino Acid Oxidase Activator
The D-amino acid oxidase activator (DAOA) encodes a protein that activates 
the enzyme D-amino acid oxidase (DAO). DAO degrades the gliotransmitter D- 
serine, a potent activator of NMDA type glutamate receptors, resulting in 
decreased NMDA receptor functioning.Hypof unction of the NMDA receptor is a 
well regarded model in the aetiology of psychosis (Farber 2003). A broad length of 
chromosome 13q (~50 cM), which harbours the DAOA gene, is implicated as a 
linkage region for both schizophrenia and bipolar disorder (Badner and Gershon 
2002; Berrettini 2003; Gershon and Badner 2001). Linkage of schizophrenia to 
chromosome 13q14-q22 was first reported by Lin and colleagues (Lin et al. 1995) 
in large pedigrees from the UK and Japan (MLS = 1.61). A meta-analysis of 44 
independent pedigrees found suggestive linkage with the maximum LOD score 
(MLS = 2.58) mapping to band 13q32 in a Caucasian but not an Oriental 
population (Lin et al. 1997). Significant (Blouin et al. 1998; Brzustowicz et al. 1999) 
and suggestive (Abecasis et al. 2004; Faraone et al. 2002; Shaw et al. 1998)
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evidence for linkage to 13q32 have been reported in multiple ethnic and 
geographical populations, using varying diagnostic phenotypes. Negative findings 
of linkage to this region in large schizophrenia samples are also apparent (Coon et 
al. 1994; DeLisi et al. 2000; Faraone et al. 1998; Gurling et al. 2001; Kaufmann et 
al. 1998; Kendler et al. 1996; Levinson et al. 2000; Mowry et al. 2000; Riley et al. 
1998; Schwab et al. 2000). Meta analyses of the region provide inconsistent 
results, with one positive (Badner and Gershon 2002) and one negative study 
(Lewis et al. 2003). The study of Lewis and colleagues (Lewis et al. 2003) is the 
more systematic of the two, being based on data collected using identical methods 
across many studies both published and unpublished, whereas Badner and 
Gershon (Badner and Gershon 2002) relied on published data that had been 
analysed using different methods (Owen 2005). Linkage evidence for chromosome 
13q32 in bipolar disorder is equally as inconsistent. Significant evidence for linkage 
was found in a small study under a broad phenotypic (Detera-Wadleigh et al. 1999) 
and suggestive linkage using a narrow diagnostic phenotype (bipolar I and 
schizoaffective disorder bipolar type) (Stine et al. 1997). Numerous bipolar disorder 
genome scans of substantial size and across multiple nationalities have not found 
evidence for linkage to the region (Bennett et al. 2002; Cichon et al. 2001; Coon et 
al. 1993; Foroud et al. 2000; Friddle et al. 2000). One meta-analysis has shown 
significant linkage with this region and bipolar disorder (Badner and Gershon
2002), but two more extensive and detailed meta-analyses produced negative 
findings (McQueen et al. 2005; Segurado et al. 2003).
Chumakov and colleagues (Chumakov et al. 2002) used linkage 
disequilibrium-based positional cloning to identify genes within the linkage region 
on chromosome 13q22-34. Two regions contained markers associated with 
schizophrenia in a French-Canadian sample, and two markers from the distal 
region replicated the association in a Russian sample. DAOA was identified as a 
gene residing within this region. Replication studies have subsequently reported 
positive associations of DAOA and schizophrenia in samples from Germany 
(Schumacher et al. 2004), China (Hong et al. 2006; Ma et al. 2006; Wang et al. 
2004; Yue et al. 2007; Zou et al. 2005), Ashkenazi Jew (Korostishevsky et al.
2004), Ireland (Corvin et al. 2007), Scotland (Ma et al. 2006), Korea (Shin et al. 
2007), the United States (Hall et al. 2004; Nicodemus et al. 2006) and South Africa 
(Hall et al. 2004), among others (Addington et al. 2004; Korostishevsky et al. 2005;
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Korostishevsky et al. 2006a; Shinkai et al. 2007; Zou et al. 2005). However, the 
associated alleles and haplotypes are not consistent across studies with some 
variants located outside the gene (Detera-Wadleigh and McMahon, 2006), and no 
pathologically relevant variant has yet been identified. Several studies show 
negative association of DAOA and schizophrenia (Liu et al. 2006), predominantly in 
samples from the United States (Fallin et al. 2005; Sanders et al. 2008; Wood et al.
2007), including those of mixed race (Mulle et al. 2005), and from Europe (Bakker 
et al. 2007; Vilella et al. 2008; Williams et al. 2006). There are three independent 
meta-analysis of DAOA in schizophrenia, all show association of several DAOA 
markers with disease, in both Asian and European samples (Detera-Wadleigh and 
McMahon 2006; Li and He 2007; Shi et al. 2008). However, there is no inter-study 
consensus as to the associated markers. Gene expression analysis of DAOA in a 
schizophrenia case-control sample has identified a tendency toward over­
expression of DAOA in prefrontal cortex samples of cases (Korostishevsky et al. 
2006b). Thus, supporting the biologic plausibility of DAOA as a candidate gene, 
based on NMDA receptor hypofunction. Association at the DAOA locus has been 
reported with bipolar disorder in two US family samples (Hattori et al. 2003), which 
replicated in a further US family sample (Chen et al. 2004c), German case-control 
samples (Schulze et al. 2005; Schumacher et al. 2004), a Polish case-control 
sample (Schulze et al. 2005) and UK case-control samples (Prata et al. 2008; 
Williams et al. 2006). In all studies, evidence for association came from individual 
SNPs as well as multivariant haplotypes, although there is variation between 
studies as to the specific SNPs and haplotypes showing association. One of the 
two bipolar disorder meta-analyses of DAOA shows positive association of several 
markers, albeit to a lesser extent than seen in schizophrenia (Detera-Wadleigh and 
McMahon 2006). The other meta-analysis found no overall association with bipolar 
disorder (Shi et al. 2008). Recently DAOA has shown association to AD with 
delusions in a cohort of 185 Alzheimer's disease patients (Di Maria et al. 2009).
The analysis demonstrated a nominally significant association (P < 0.05) with one 
SNP (rs2153674), with multivariate regression showing that the genotype accounts 
for up to 15% of the variance in delusions severity (Di Maria et al. 2009).
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3.9.1. Literature Summary
The data suggests DAOA as a strong functional and positional candidate 
gene for both schizophrenia and bipolar disorder. Association analyses in 
schizophrenia are inconsistent with both positive and negative associations seen 
across numerous populations. Studies in bipolar disorder are more consistent, with 
positive associations seen in all the published studies except the most recent meta­
analysis (Shi et al. 2008), although, the identified associations are generally 
weaker than those seen in schizophrenia. There is no consensus between studies 
in either disorder as to which variants and/or haplotypes are associated with 
disease status. Of recent interest is the study of Williams and colleagues (Williams 
et al. 2006) who analysed DAOA polymorphisms in both schizophrenia and bipolar 
disorder patients across traditional diagnostic categories and revealed significant 
evidence for association in a subset of cases in which episodes of major mood 
disorder had occurred (Williams et al. 2006). By contrast, no evidence for 
association was observed in the subset of cases in which psychotic features 
occurred (Williams et al. 2006). Thus, suggesting that variation at the DAOA locus 
does not primarily increase susceptibility to psychosis but instead influences 
susceptibility to episodes of mood disorder across the traditional categories of 
bipolar disorder and schizophrenia. However, this finding requires replication 
particularly as it conflicts a number of studies which find stronger DAOA 
associations in schizophrenia and not bipolar disorder (Detera-Wadleigh and 
McMahon 2006; Schumacher et al. 2004). One DAOA variant has recently shown 
evidence of association to AD with delusions (Di Maria et al. 2009). The identified 
polymorphisms are almost certainly not the true pathogenic variants, as even in the 
most convincing cases, the risk haplotypes appear to be associated with small 
effect sizes (Owen 2005), and do not account for the linkage observed.
Alternatively the linkage could in fact reflect variation at more than one 
susceptibility site within DAOA, or within a neighbouring gene(s).
3.9.2. Study Design
Nine variants were tested for association with LOAD+P and LOAD. Five 
markers were chosen from the study of Williams and colleagues (Williams et al.
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2006) to tag the DAOA gene and approximately 6 kb of flanking sequence. 
Variants were identified through sequence analysis of schizophrenia cases, 
marker-marker linkage disequilibrium was calculated, and the Haploview software 
(Barrett et al. 2005) used to examine the haplotype block structure and to select a 
set of maximally informative single-nucleotide polymorphisms (SNPs), with a minor 
allele frequency (MAF) greater than 10%, that tagged all of the haplotypes with a 
frequency greater than 5%. The remaining four polymorphisms (rs3918342, 
rs3916965, rs778293, and rs1421292) were selected from the Single Nucleotide 
Polymorphism Database (dbSNP) and genotyped to supplement the tag SNPs so 
that the markers spanned the DAOA locus at an average of 7.9 kb, these 
supplementary SNPs had also been shown to associate with schizophrenia 
(Chumakov et al. 2002). The LD structure across the DAOA locus and surrounding 
region, inclusive of the studied variants, according to the HapMap CEPH 
genotypes can be seen in Figure 3.9. All markers were genotyped using the 
Sequenom™ MassARRAY™ system (Sequenom, San Diego, California, USA) as 
described in chapter 2.7.3. The relative marker PCR and extension primers are 
shown in Appendix Table 3.17.
147
Chr13
104910k
N
o■'T
£
104920k 104930k 104940k
O)
o>
nco£
I I
44
DAOA 1 1
104950k
coCT>
CO
00p.
{2
1 1
Figure 3.9. The DAOA locus. Schematic shows chromosomal position (bp), the SNPs genotyped in this study (* indicates 
database SNP), with their position within the gene indicated by an arrow, the direction of transcription indicated by 
horizontal arrow, the DAOA gene with exons/UTR indicated by black bars (long/short bars respectively), and finally the LD 
plot of the region (r2).
rs
39
18
34
2
Chapter 3. Psychosis Candidate Gene Association Study
3.9.3. Results
Three variants within DAOA showed deviation from HWE in the LOAD-P 
dataset. These variants are the 3’UTR marker, rs778294 and rs954581, with p- 
values of 0.02, 0.04 and 0.01 respectively. None of these markers showed 
association with LOAD+P or LOAD. No variant showed a difference in allele or 
genotype frequency in the disease modifier analysis. A nominal allelic association 
was observed with marker rs778293 (P = 0.04) when LOAD+P cases were 
compared to controls, with the major A allele over-represented in cases by 4%.
This association does not survive correction for multiple testing (permuted P = 0.3). 
No difference in allele or genotype frequency was observed in the LOAD versus 
control analysis. The greatest trend towards association was with the novel UTR 
variant (allelic P = 0.07), see Tables 3.8a and 3.8b. Haplotype analysis revealed no 
further evidence for association (global P = 0.42, 0.74 and 0.48, for the disease 
modifier, disease subtype and LOAD analysis, respectively), see Appendix Table 
3.18.
3.9.4. Discussion
Our results provide no evidence for the involvement of the DAOA locus in 
LOAD+P, under either disease model. The DAOA locus has been comprehensively 
examined in this study, with coverage of all LD blocks within the region by both a 
“tagging” and “SNP per kb approach”. However variants with a MAF < 10% and 
rare haplotypes with frequency < 5% have not been analysed. Also, variants were 
selected by LD in the HapMap CEPH trios and in a schizophrenia and bipolar 
disorder case-control sample using phase 1 of the HapMap project. More recent 
HapMap phases include additional genotype data which may increase the number 
of markers required to tag the locus. Also, the LOAD sample used in this study may 
show a differing pattern of LD. However, the pattern of LD in the CEPH trios is 
highly concordant with that of the schizophrenia and bipolar disorder case-control 
samples, making it unlikely that the pattern of LD in our LOAD sample would be 
significantly different. Also the previously associated AD with delusion variant 
rs2153674 is in LD (D’ = 1, r2 = 0.6) with marker rs778294, suggesting that the 
previously identified association would not replicate in our sample set.
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Table 3.9a. MAF and genotype counts of tested DAO A  SNPs. Table shows; SNP ID, minor allele, MAF and genotype counts in LOAD+P,
LOAD-P, LOAD and control samples.
SNP ID MA
MAF Genotype
LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs3916965 A 0.39 0.37 0.38 0.38 56/163/134 35/112/101 149/485/385 163/546/443
rs1341402 C 0.23 0.24 0.24 0.22 19/128/216 16/91/146 64/372/606 60/409/712
rs2391191 A 0.38 0.36 0.38 0.38 55/159/140 32/104/99 143/475/386 165/540/447
3' UTR A 0.37 0.39 0.36 0.34 144/163/49 102/100/47 419/472/141 522/522/136
rs778294 A 0.31 0.32 0.31 0.29 175/148/40 125/97/33 506/425/113 605/488/107
rs954581 C 0.18 0.15 0.17 0.17 244/103/15 187/52/11 723/276/34 816/333/42
rs778293 G 0.41 0.38 0.39 0.38 58/181/124 42/107/106 168/487/393 182/547/464
rs3918342 A 0.51 0.49 0.51 0.49 99/171/94 64/125/67 264/508/275 311/592/283
rs1421292 A 0.47 0.49 0.48 0.47 81/171/107 62/115/69 244/498/283 264/582/334
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Table 3.9b. Individual genotyping of DAOA  SNPs through LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
LOAD+P vs. LOAD- LOAD+P vs. Control LOAD vs. Control
Alleles Genotype Alleles Genotype Alleles Genotype
SNP ID x2 P OR x2 P x2 P OR x2 P x2 P OR x2 P
rs3916965 0.63 0.43 1.1 (0.87-1.4) 0.61 0.74 1.41 0.24 1.12(0.93-1.34) 0.65 0.72 0.12 0.73 1.02 (0.9-1.16) 0.15 0.93
rs1341402 0.35 0.56 1.08 (0.83-1.41) 0.42 0.81 0.03 0.87 1.02 (0.83-1.25) 0.07 0.96 1.51 0.22 1.09 (0.95-1.25) 1.72 0.42
rs2391191 0.59 0.44 1.1 (0.86-1.4) 0.6 0.74 0.45 0.5 1.06 (0.89-1.28) 0.54 0.76 0.01 0.94 1 (0.89-1.14) 0.04 0.98
3' UTR 0.47 0.49 1.09 (0.86-1.38) 3.49 0.17 0.99 0.32 1.1 (0.91-1.32) 2.19 0.33 3.25 0.07 1.12(0.99-1.27) 4 0.14
rs778294 0.07 0.79 1.03 (0.81-1.32) 0.77 0.68 0.6 0.44 1.08 (0.89-1.3) 1.58 0.45 1.9 0.17 1.09 (0.96-1.24) 2.5 0.29
rs954581 2.56 0.11 1.29 (0.94-1.76) 4.59 0.1 0.64 0.43 1.1 (0.87-1.37) 0.36 0.84 0.57 0.45 1.06 (0.91-1.24) 0.58 0.75
rs778293 1.54 0.22 1.16(0.92-1.46) 4.24 0.12 4.33 0.04 1.21 (1.01-1.44) 2.7 0.26 0.48 0.49 1.04 (0.92-1.18) 0.54 0.76
rs3918342 0.2 0.66 1.05 (0.84-1.32) 0.39 0.82 0.03 0.85 1.02 (0.86-1.21) 1.03 0.6 1.3 0.26 1.07 (0.95-1.2) 1.73 0.42
rs1421292 0.6 0.44 1.1 (0.87-1.38) 0.61 0.74 0.07 0.79 1.02 (0.86-1.22) 0.38 0.83 0.58 0.45 1.05 (0.93-1.18) 0.64 0.72
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3.10. 2 \ 3'-Cyclic Nucleotide 31 Phosphodiesterase
The 9 kb 2', 3-cyclic nucleotide 3' phosphodiesterase (CNP) gene is located 
at chromosome 17q21 (Douglas et al. 1992; Monoh et al. 1993; Sprinkle et al.
1992) (Figure 3.10). There are two transcription start points and, in human brain, 
two forms of CNP mRNA are produced by alternative splicing (Monoh et al. 1993; 
Scherer etal. 1994). Region 17p11.2-q25.1 (44-97 cM) has shown highly 
suggestive evidence for linkage with schizophrenia (MLS = 3.35) in a UK sample 
(Williams et al. 2003b), although much of the linkage signal could be attributed to a 
single pedigree (MLS = 8.68) (Williams et al. 2003b). This region of chromosome 
17 overlaps a previously identified region showing significant evidence for linkage 
to schizophrenia following meta-analysis (Lewis et al. 2003). Peirce and colleagues 
(Peirce et al. 2006) identified a marker within CNP (rs2070106) that associates with 
schizophrenia in a Caucasian case-control sample (P =  0.04) (Peirce et al. 2006). 
The A allele of the marker is more common in affected individuals and is 
associated with lower CNP expression (P < 0.001) (Peirce et al. 2006). All affected 
siblings of the pedigree previously showing linkage to chromosome 17 p11.2-q25.1 
(Williams et al. 2003b) were homozygous for the lower-expression allele (Williams 
et al. 2003b). A significant effect of rs2070106 (P = 0.03) on CNP gene expression 
in the dorsolateral prefrontal cortex (DLPFC) grey matter, with the A allele 
correlating with reduced expression, provides independent support for this variation 
as a risk factor for schizophrenia (Mitkus et al. 2007). No significant association 
with schizophrenia was observed by single-marker or haplotype analysis of CNP in 
Japanese (Usui et al. 2006) or Han Chinese (Tang et al. 2007) populations. This 
failure to replicate the previous finding may be due to ethnic differences (Marchini 
et al. 2005), a theory supported by differences in the LD block structure of CNP 
between the studied populations in the HapMap database. Multiple microarray 
studies have reported the down regulation of oligodendrocyte and myelination 
related genes, including CNP, in the schizophrenic brain (Aston et al. 2004; Hakak 
et al. 2001; Katsel et al. 2005; Tkachev et al. 2003). Assessment of 
oligodendrocyte-related gene expression in white matter finds independent 
evidence of reduced CNP expression in the tissue of schizophrenic patients 
(Prabakaran et al. 2004; McCullumsmith et al. 2007). Down-regulation of CNP
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mRNA has been confirmed at the protein level, with reduced immunoreactivity of 
CNP in anterior frontal cortex of schizophrenics (Flynn et al. 2003).
The precise biological function of CNP is unclear. The two forms of CNP 
mRNA produce membrane-bound enzymes found abundantly in the cytoplasmic 
compartments of central nervous system (CNS) myelin (Esposito et al. 2008; 
O’Neill and Braun 2000). Developmentally, CNP is one of the earliest myelination- 
specific polypeptides synthesized by oligodendrocytes and its synthesis persists 
into adulthood, suggesting a role in the synthesis and maintenance of the myelin 
sheath (O’Neill and Braun 2000). In CNP deficient mice features identical to the 
pathology of schizophrenia are observed (Lappe-Siefke et al. 2003), and these 
mice have disrupted axon-glia interactions in the CNS, which may be involved in 
the aetiology of schizophrenia (Rasband et al. 2005). This schizophrenia pathology 
is followed by delayed onset neurodegenerative disease indicating the importance 
of CNP to the maintenance of myelin and axonal integrity (Rasband et al. 2005). 
Over-expression of human CNP in transgenic mice produces abnormalities of 
oligodendrocytes and their myelin sheaths (Gravel et al. 1996; Yin et al. 1997). 
Similar structural myelin abnormalities are observed in aged monkeys (Hinman et 
al. 2006), where CNP accumulates and CNP proteolysis is significantly increased 
(Hinman et al. 2007). This CNP accumulation is hypothesised to be a result of 
impairment of the ubiquitin proteasomal system (Hinman et al. 2007; Sandell and 
Peters 2003; Sloane et al. 2000). Changes in brain white matter are prominent 
features of the aging brain and include glial cell activation, disruption of myelin 
membranes and loss of myelinated fibers associated with inflammation and 
oxidative stress (Hinman et al. 2007). Abnormal changes of white matter are 
common in patients with AD (Brun and Englund 1986; Englund and Brun 1990; 
Fazekas et al. 1996; Scheltens et al. 1992; Scheltens et al. 1995; Steingart et al. 
1987), although the mechanisms for the development of these changes are not 
fully understood (Lee et al. 2006). Specific white matter changes have shown 
association with symptoms of psychosis in AD, particularly delusional 
misidentification (Binetti et al. 1995; Lee et al. 2006). CNP bioactivity is similar to 
that of other proteins implicated in neurodegenerative diseases, in particular a 
malfunction of CNP as a membrane-interacting peptide could reduce membrane 
plasticity (Esposito et al. 2008). Numerous groups have explored expression and 
activity of CNP in AD brains, with decreased levels found in frontal cortex of AD
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brains (Vlkolinsky et al. 2001). CNP activity, amount of myelin proteins and lipids 
have also been shown to be decreased in AD brains (Reinikainen et al. 1989; 
Svennerholm and Gottfries 1994; Wallin et al. 1989), indicating loss of myelin and 
thus myelinated axons in the affected brain regions (Reinikainen et al. 1989).
3.10.1. Literature Summary
Following evidence of suggestive linkage to chromosomal region 17p11.2- 
q25.1 with schizophrenia, association with the CNP locus was identified (Peirce et 
al. 2006). The associated marker is correlated with decreased CNP expression in 
peripheral blood (Peirce et al. 2006), and DLPFC grey matter (Mitkus et al. 2008). 
The genetic association with rs2070106 did not replicate in successive studies 
(Tang et al. 2007; Usui et al. 2006) probably due to ethnic differences across 
studies. CNP is a membrane-bound enzyme found predominantly in central 
nervous system myelin, where it is suggested to function in the onset and 
maintenance of the myelin sheath. Accumulation of CNP is noticeable in the aging 
brain. In animal models deficiency of CNP leads to a schizophrenia like pathology 
and neurodegeneration (Rasband et al. 2005). Over-expression of CNP produces 
altered cell morphology and oligodendrocyte and myelin abnormality (Gravel et al. 
1996; Yin et al. 1997). CNP functions in white matter maintenance and shows 
similarity to neurodegenerative proteins making CNP a putative functional 
candidate for AD. No genetic investigations into the role(s) of CNP in the aetiology 
of AD have been pursued, and the decrease in CNP levels and activity in AD 
brains are probably secondary to neuronal loss. However, CNP remains an 
interesting putative functional candidate gene for AD due to the similarity of its 
bioactivity to that of other proteins implicated in neurodegenerative diseases and 
its function in white matter maintenance, a process thought to be dysfunctional in 
the AD brain (Lee et al. 2006).
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3.10.2. Study Design
Ten SNPs at the CNP locus were examined for association with LOAD+P 
and LOAD, including marker rs2070106 which has previously shown association 
with schizophrenia (Peirce et al. 2006). Markers were identified from a previous 
study of CNP in Caucasian schizophrenics (Peirce et al. 2006). Variants included in 
the previous study were examined for LD across CNP (11 kb) in CEPH individuals 
using the HAPLOVIEW software (Barrett et al. 2005). Based on r2 > 0.8 and minor 
allele frequency (MAF) > 0.05, non-redundant markers were chosen for 
genotyping. Nine of the SNPs are available from public databases, the remaining 
SNP was identified by DNA screening of 14 schizophrenia patients in the previous 
study. All markers were genotyped using the Sequenom™ MassARRAY™ system 
(Sequenom, San Diego, California, USA) as described in chapter 2.7.3. Relative 
PCR and extension sequences are provided in Appendix Table 3.19.
3.10.3. Results
One CNP marker, rs4796750 showed deviation from HWE (P = 0.02) in the 
LOAD with psychosis dataset. Neither this variant nor any other variant tested 
showed a significant allelic or genotypic association with LOAD+P under either 
disease model (see Tables 3.10a and 3.10b). Haplotypic analysis of the CNP locus 
provided no further evidence for association with LOAD+P (global P = 0.6 and 0.55 
for LOAD+P vs. LOAD-P and LOAD+P vs. control analysis, respectively), see 
Appendix Table 3.20. None of the SNPs showed an allelic, genotypic or haplotypic 
(global P = 0.67) association with LOAD.
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Table 3.10a. MAF and genotype counts of tested C N P  SNPs. Table shows; SNP ID, minor allele, MAF and genotype counts in LOAD+P,
LOAD-P, LOAD and control samples.
SNP ID MA
MAF Genotype Counts
LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs4796750 A 0.27 0.25 0.27 0.26 32/105/177 12/79/117 75/329/482 70/384/568
rs10540926 - 0.2 0.18 0.19 0.18 15/99/201 8/59/142 31/252/580 29/261/649
rs12952915 A 0.19 0.15 0.18 0.17 14/92/208 5/54/149 35/245/606 38/278/706
3235AG G 0.27 0.26 0.26 0.26 27/125/183 12/93/124 65/395/539 72/445/613
rs12602950 G 0.27 0.25 0.27 0.26 31/108/175 12/80/116 72/334/480 71/288/563
rs2070106 A 0.35 0.32 0.33 0.33 42/136/136 24/87/97 103/386/397 102/464/456
rs11079028 A 0.19 0.19 0.2 0.22 12/97/205 9/60/139 38/272/576 57/327/638
rs35967904 A 0.14 0.13 0.14 0.14 10/66/238 2/51/155 23/198/665 17/248/757
rs 11296 C 0.05 0.06 0.05 0.06 0/33/281 1/23/184 3/91/792 4/112/906
rs4796751 T 0.14 0.13 0.15 0.14 8/70/236 2/50/156 16/225/645 17/258/747
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Table 3.10b. Individual genotyping of C N P  SNPs through LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
LOAD+P vs. LOAD-P LOAD+P vs. Control LOAD vs. Control
Alleles Genotype Alleles Genotype Alleles Genotype
SNP ID x2 P OR x2 P x2 P OR x2 P x2 P OR x2 P
rs4796750 0.6 0.44 1.12(0.84-1.49) 3.64 0.16 0.41 0.52 1.07 (0.87-1.31) 4.67 0.1 0.95 0.33 1.07 (0.93-1.24) 1.77 0.41
rs10540926 0.6 0.75 1.08 (0.7-1.42) 0.7 0.64 1.98 0.15 1.14(0.76-1.56) 1.7 0.39 0.19 0.84 1.02 (0.87-1.19) 1.86 0.4
rs12952915 2.39 0.12 1.3(0.93-1.81) 2.48 0.29 1.05 0.3 1.13(0.9-1.42) 1 0.61 0.14 0.71 1.03 (0.87-1.22) 0.13 0.94
3235AG 0.19 0.66 1.06 (0.81-1.39) 1.95 0.38 0.06 0.8 1.03 (0.84-1.25) 1.12 0.57 0.03 0.87 1.01 (0.88-1.16) 0.03 0.99
rs12602950 0.55 0.46 1.11 (0.84-1.48) 3.13 0.21 0.32 0.57 1.06 (0.87-1.3) 3.54 0.17 0.53 0.47 1.06 (0.91-1.22) 0.96 0.62
rs2070106 0.74 0.39 1.12(0.86-1.46) 0.71 0.7 1.2 0.27 1.11 (0.92-1.34) 2.9 0.24 0.23 0.63 1.03 (0.9-1.18) 1.56 0.46
rs11079028 0.04 0.83 1.03 (0.75-1.42) 0.3 0.86 1.54 0.21 1.15(0.92-1.44) 1.84 0.4 2.17 0.14 1.13(0.96-1.32) 2.33 0.31
rs35967904 0.05 0.83 1.04 (0.72-1.5) 3.4 0.18 0 0.95 1.01 (0.78-1.31) 3.92 0.14 0.0006 0.98 1 (0.83-1.21) 2.78 0.25
rs 11296 0.27 0.6 1.15(0.68-1.97) 1.56 0.46 0.34 0.56 1.12(0.76-1.67) 1.29 0.52 0.28 0.6 1.08 (0.82-1.42) 0.28 0.87
rs4796751 0.11 0.74 1.06 (0.74-1.53) 1.81 0.4 0.14 0.71 1.05 (0.81-1.36) 2 0.37 0.04 0.85 1.02 (0.85-1.22) 0.07 0.97
158
Chapter 3. Psychosis Candidate Gene Association Study
3.10.4. Discussion
CNP has previously show significant association with schizophrenia in a 
Caucasian case-control sample (Peirce et al. 2006), which correlates with 
decreased gene expression (Mitkus et al. 2008; Peirce et al. 2006). The ten 
markers genotyped in the Peirce and colleagues study, which tag the CNP locus, 
were investigated for association with LOAD+P. No significant association was 
found. It is unlikely that common genetic variation at the CNP locus contributes to 
the aetiology of psychosis in LOAD. However, rare variation may contribute to the 
aetiology of LOAD+P and the CNP locus should not be excluded from this type of 
future analysis.
3.11. Oligodendrocyte Lineage Transcription Factor 2
The oligodendrocyte lineage transcription factor 2 (OLIG2) was originally 
identified in rodents. The gene is located on the long arm of chromosome 21 at 
q22.11, a band commonly called the Down syndrome region, as translocation of 
chromosome 21 at q22.11 is sufficient to produce the Down syndrome phenotype. 
Most linkage studies do not support the involvement of the region containing the 
OLIG2 gene (21q22) in schizophrenia; but structural chromosomal aberrations in 
this region have been detected in schizophrenics (Demirhan and Tastemir 2003). 
Analysis of OLIG2 in a UK case-control sample (n = 1,400) revealed several SNPs 
to be associated with schizophrenia (minimum P = 0.0001, gene-wide P = 0.0009) 
(Georgieva et al. 2006). Genetic interaction between OLIG2 and two genes of 
relevance to oligodendrocyte function has also been identified (Georgieva et al. 
2006). Evidence for association of these genes with schizophrenia has previously 
been reported (Norton et al. 2006; Peirce et al. 2006). Thus, providing strong 
evidence that variation in OLIG2 confers susceptibility to schizophrenia alone and 
as part of a network of genes implicated in oligodendrocyte function. Two 
schizophrenia associated SNPs rs1059004 and rs9653711 predict low mRNA 
expression in DLPFC white matter. Post-hoc comparisons showed that these SNPs 
are in perfect linkage disequilibrium (r2 =1), and that individuals carrying the minor 
A allele at SNP rs1059004 and the C allele at SNP rs9653711 (enriched in cases)
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had lower OLIG2 mRNA levels than subjects homozygous for the major allele 
(Mitkus et al. 2008). The data remained significant after correcting for multiple 
comparisons. Exonic variant rs762178 replicated its significant genetic association 
to schizophrenia in a small sample set (n = 617; P = 0.005, Bonferroni corrected P  
= 0.015) (Huang et al. 2008). However, the associated allele was not consistent 
with that reported by Georgieva and colleagues (Georgieva et al. 2006); this may 
be attributed to genetic heterogeneity since the studies were carried out in distinct 
ethnic populations. A significantly associated haplotype was identified in the Huang 
and colleagues study (Bonferroni corrected P = 0.009), which may influence OLIG2 
expression through regulation of mRNA activity (Kuersten and Goodwin 2003). A 
negative finding of OLIG2 has been reported in a Japanese schizophrenia sample 
(Usui et al. 2006). Down-regulation of oligodendrocyte and myelination genes has 
been shown by 1 -65-fold (P = 0-0027) in schizophrenia and 2-46-fold (P = 0-0003) 
in bipolar disorder brains compared to controls (Tkachev et al. 2003).
OLIG2 (Figure 3.11a) encodes a 32 kDa basic helix-loop-helix (bHLH) 
transcription factor. Members of the bHLH transcription factor super-family are 
indicated to be important regulatory components in transcriptional networks, 
controlling a diversity of processes from cell proliferation to cell lineage 
establishment. OLIG2 is expressed exclusively in both the developing and mature 
vertebrate CNS (Ligon et al. 2006a), specifically in cells of the oligodendrocyte 
lineage (Tabu et al. 2006). It plays a key role in the cell fate specification of 
oligodendrocytes, the myelinating cell of the central nervous system (Ligon et al. 
2006a; Ligon et al. 2006b; Miller 2002; Pfeiffer et al. 1993). Overexpression of 
OLIG2 has been found in a wide spectrum of glial cell originating malignant cell 
lines, including leukaemia, non-small cell lung carcinoma, melanoma, and breast 
cancer cell lines (Lin et al. 2005b). The protein has also been implicated in the 
repair process after a traumatic injury (Magnus et al. 2007).
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Decreased expression of myelin and oligodendrocyte-related genes has 
been demonstrated in post-mortem prefrontal cortex samples of schizophrenic 
individuals (Hakak et al. 2001; Hof et al. 2003; Tkachev et al. 2003). Thus, 
suggesting that there is a disruption of oligodendrocyte function and/or a loss of 
oligodendrocytes in schizophrenia (Hof et al. 2003). Neuronal cell death following 
down-regulation of OLIG2 has been reported in AD models (Uchida et al. 2007; 
Waldau and Shetty 2008) and reduced expression of other myelination genes has 
been reported in AD (Katsel et al. 2005). In an AD mouse model, a decrease in 
OLIG2 cells can be observed in the cerebral cortex (Uchida et al. 2007), 
hypothesised to result from Ap42 cells down-regulating OLIG2, and switching the 
cell fate to death (Uchida et al 2007). Abnormal changes in white matter are 
common in patients with AD (Scheltens et al. 1992; Scheltens et al. 1995; Fazekas 
et al. 1996) and specific white matter changes have been shown to significantly 
correspond with psychosis score in AD (Lee et al. 2006), with a previous 
computerised tomography (CT) study suggesting a relationship between delusions 
and lacunar infarcts of white matter and AD (Binetti et al. 1995).
3.11.1. Literature Summary
OLIG2 plays a key role in the cell fate specification of oligodendrocytes, 
(Miller et al. 2002; Pfeiffer et al. 1993), acting in the development and maintenance 
of the myelin sheath (Ligon et al. 2006a; Ligon et al. 2006b). Several SNPs within 
OLIG2 have been found to be associated with schizophrenia (Georgieva et al.
2006), as have variants within OLIG2 interacting genes (Georgieva et al. 2006; 
Huang et al. 2008; Norton et al. 2006; Peirce et al. 2006). The polymorphic variants 
identified have been shown to significantly affect gene expression (Mitkus et al.
2008). Neuronal cell death following down-regulation of OLIG2 has been reported 
in AD models (Uchida et al. 2007; Waldau and Shetty 2008) and reduced 
expression of other myelination genes has been reported in AD (Katsel et al.
2005). White matter changes in the AD brain have been shown to significantly 
correlate with degree of psychosis (Binetti et al. 1995; Lee et al. 2006)
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3.11.2. Study Design
Eleven SNPs were examined in 0LIG2, some of which have previously 
shown association to schizophrenia (Georgieva et al. 2006), were tested for 
association with LOAD+P and LOAD. Markers were identified from the previous 
study of OLIG2 in Caucasian schizophrenics (Georgieva et al. 2006). Variants 
included in the previous study were examined for LD across OLIG2 (3.2 kb) plus ± 
20 kb in CEPH individuals using the HAPLOVIEW software (Barrett et al. 2005). 
Based on r2 > 0.8 and minor allele frequency (MAF) > 0.05, non-redundant markers 
were chosen for genotyping in this study. Seven of the SNPs are available from 
public databases. The remaining 4 SNPs were identified by DNA screening of 14 
schizophrenia patients in the previous study (Georgieva et al. 2006). All markers 
were genotyped using the Sequenom™ MassARRAY™ system (Sequenom, San 
Diego, California, USA) as described in chapter 2.7.3. Relative PCR and extension 
sequences are provided in Appendix Table 3.21.
3.11.3. Results
Four markers show significant evidence for association with LOAD+P under 
the disease modifier model (Tables 3.11a and 3.11b). Marker rs762237 showed 
the most significant evidence for association (P = 0.002, OR = 1.42) which 
remained significant after correction for multiple testing (P = 0.04).This variant is 
located 6.7 kb from the 3’ end of OLIG2. It has a minor T allele frequency of 36% 
(according to HapMap CEPH data), with the C allele associated with LOAD+P 
status. Polymorphism rs2834072 (P= 0.004, OR = 1.41) also shows significant 
evidence for association with LOAD+P which withstands correction for multiple 
testing (P = 0.05). It has a minor G allele frequency of 48% (according to HapMap 
CEPH data), with the A allele being associated with LOAD+P status. Markers 
rs13046814 (P= 0.03, OR = 1.30) and rs62216115 (P= 0.04, OR = 1.41) show 
association, but these do not withstand correction for multiple testing (P = 0.3 and 
P = 0.39 respectively). Variant rs13046814 is located within the 3’ UTR of OLIG2 
and polymorphism rs62216115 is located 1 kb 3’ of the gene. Disease subtype 
analysis yielded no significant association with any of the tested SNPs and none of 
the SNPs showed an allelic or genotypic association with LOAD. Haplotype
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analysis of each dataset revealed no greater evidence for association at the OLIG2 
locus than that seen with marker rs762237 in the disease modifier analysis 
(disease modifier global P = 0.004; disease subtype global P  = 0.17; LOAD global 
P = 0.11) (Appendix Table 3.22).
The LD structure across the OLIG2 locus was investigated using the 
HAPLOVIEW software (Barrett et al. 2005) and data from the HapMap project (The 
International HapMap Consortium 2005). All markers showing r2 > 0.3 with an 
associated variant were investigated (Table 3.11c). The Evolutionary Conservation 
of Genomes (ECR) browser (Figure 3.11b), and the UCSC most conserved track 
(Figure 3.11c), were used to highlight regions of high conservation, in conjunction 
with Cluster Buster (http://zlab.bu.edu/cluster-buster/cbust.html) to identify 
transcription factor binding sites (Figure 3.11d). No associated variant, nor a LD 
proxy, reside in a promoter region, a region of high conservation (>80%) or a 
predicted transcription factor binding site.
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Table 3.11a. MAF and genotype counts of tested O L IG 2  SNPs. Table shows; SNP ID, minor allele, MAF and genotype counts in LOAD+P,
LOAD-P, LOAD and control samples.
SNP ID MA
Alleles Genotype Counts
LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs2834070 T 0.34 0.31 0.32 0.33 151/165/38 115/117/20 473/459/98 522/530/123
rs11701698 G 0.23 0.23 0.22 0.23 209/140/13 149/96/10 631/369/49 693/430/61
rs1005573 C 0.3 0.29 0.3 0.3 176/145/36 131/99/23 502/430/98 564/502/102
rs762178 A 0.42 0.41 0.41 0.41 116/172/62 84/121/40 345/478/174 400/539/202
rs1059004 C 0.43 0.44 0.44 0.43 108/183/62 76/123/48 320/501/191 390/564/221
rs13046814 G 0.38 0.32 0.35 0.36 130/179/47 112/111/24 426/475/122 472/556/146
F16GA A 0.17 0.22 0.2 0.19 248/107/10 153/93/9 662/340/42 778/366/46
rs11701762 A 0.11 0.1 0.11 0.12 283/71/2 205/41/5 819/202/13 915/244/24
rs881666 C 0.45 0.4 0.42 0.42 113/174/76 92/121/41 352/494/194 416/565/218
rs762237 T 0.34 0.42 0.38 0.36 160/161/41 80/139/38 407/492/146 491/565/150
rs2834072 G 0.55 0.47 0.52 0.54 110/179/71 50/136/64 276/498/239 334/589/243
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Table 3.11b. Individual genotyping of O L IG 2  SNPs through LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
LOAD+P vs. LOAD-P LOAD+P vs. Control LOAD vs. Control
Alleles Genotype Alleles Genotype Alleles Genotype
SNP ID x2 P OR x2 P x2 P OR x2 P x2 P OR x2 P
rs2834070 1.11 0.29 1.13(0.89-1.46) 1.5 0.47 0.11 0.74 1.03 (0.86-1.24) 0.2 0.9 0.75 0.39 1.06 (0.93-1.2) 0.81 0.67
rs11701698 0.01 0.92 1.01 (0.77-1.32) 0.1 0.95 0.23 0.63 1.05 (0.86-1.29) 1.38 0.5 1.15 0.28 1.09 (0.96-1.25) 1.31 0.52
rs1005573 0.66 0.42 1.1 (0.85-1.4) 0.41 0.81 0.38 0.54 1.06 (0.88-1.28) 1.6 0.45 0.01 0.91 1.01 (0.89-1.15) 0.59 0.75
rs762178 0.15 0.7 1.05 (0.83-1.33) 0.22 0.9 0.09 0.76 1.03 (0.86-1.23) 0.44 0.8 0.004 0.95 1.01 (0.89-1.13) 0.11 0.95
rs1059004 0.13 0.72 1.04(0.82-1.3) 0.4 0.82 0.37 0.54 1.06 (0.89-1.26) 1.2 0.55 0.3 0.59 1.05 (0.93-1.18) 0.67 0.72
rs13046814 4.81 0.03 1.3(1.03-1.67) 5.2 0.07 0.62 0.43 1.07 (0.9-1.28) 0.81 0.67 0.45 0.5 1.07 (0.95-1.21) 0.49 0.78
F16GA 4.26 0.04 1.36(1.03-1.82) 5.2 0.07 1.63 0.2 1.16(0.92-1.45) 1.64 0.44 0.79 0.37 1.07 (0.92-1.24) 0.95 0.62
rs11701762 0.03 0.87 1.04 (0.72-1.52) 3.74 0.15 1.7 0.19 1.2 (0.91-1.58) 3.74 0.15 1.85 0.17 1.08 (0.9-1.29) 2.54 0.28
rs881666 2.93 0.09 1.23 (0.97-1.54) 2.98 0.23 2.3 0.13 1.14(0.96-1.36) 2.31 0.32 0.2 0.66 1.03 (0.91-1.16) 0.2 0.9
rs762237 10.1 0.002 1.42(1.13-1.8) 10.9 0.004 1.83 0.18 1.14(0.94-1.37) 1.98 0.37 1.31 0.25 1.07 (0.95-1.21) 1.45 0.49
rs2834072 8.61 0.004 1.41 (1.12-1.79) 9.55 0.008 0.65 0.42 1.07 (0.9-1.28) 0.78 0.68 1.88 0.17 1.1 (0.98-1.23) 2.44 0.3
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Table 3.11c. Marker and chromosomal position of all markers in r > 0.3 with either 
rs2834072 or rs762237, ranged by r2, according to the HapMap.
Marker 1 Position 1 Marker 2 Position 2 D' r2
rs2834072 33332334 rs9984627 33393473 0.748 0.3
rs762237 33330047 rs2834076 33338971 1 0.3
rs2834072 33332334 rs2834088 33388132 0.741 0.302
rs2834065 33301570 rs762237 33330047 0.801 0.306
rs881666 33327136 rs2834072 33332334 0.714 0.307
rs2834072 33332334 rs928736 33361759 0.711 0.31
rs4817516 33307299 rs2834072 33332334 0.859 0.311
rs762237 33330047 rs2834081 33354662 0.674 0.336
rs762237 33330047 rs7276171 33385508 0.609 0.345
rs762237 33330047 rs2834088 33388132 0.633 0.359
rs881666 33327136 rs762237 33330047 1 0.373
rs2834072 33332334 rs2834076 33338971 1 0.486
rs762237 33330047 rs12233311 33331127 0.952 0.57
rs762237 33330047 rs6517138 33334005 1 0.614
rs2834072 33332334 rs2834077 33344608 1 0.619
rs762237 33330047 rs11088236 33338057 1 0.619
rs762237 33330047 rs12053728 33338217 1 0.619
rs762237 33330047 rs12482007 33335893 1 0.619
rs762237 33330047 rs2834072 33332334 1 0.619
rs13051692 33327883 rs762237 33330047 1 0.639
rs7275842 33327713 rs762237 33330047 1 0.641
rs743309 33329131 rs2834072 33332334 1 0.661
rs762237 33330047 rs12481989 33335770 1 0.673
rs13051692 33327883 rs2834072 33332334 0.851 0.698
rs7275842 33327713 rs2834072 33332334 0.851 0.699
rs762237 33330047 rs1892658 33336472 1 0.755
rs762237 33330047 rs2834074 33337172 1 0.757
rs2834072 33332334 rs915534 33347504 1 0.76
rs762237 33330047 rs 12053659 33339412 1 0.776
rs2834072 33332334 rs12053659 33339412 1 0.782
rs762237 33330047 rs915534 33347504 1 0.807
rs2834072 33332334 rs 1892658 33336472 1 0.815
rs2834072 33332334 rs2834074 33337172 1 0.817
rs743309 33329131 rs762237 33330047 1 0.961
rs2834072 33332334 rs12481989 33335770 1 0.965
rs12233311 33331127 rs2834072 33332334 1 0.966
rs2834072 33332334 rs11088236 33338057 1 1
rs2834072 33332334 rs 12053728 33338217 1 1
rs2834072 33332334 rs12482007 33335893 1 1
rs2834072 33332334 rs6517138 33334005 1 1
rs743331 33329836 rs2834072 33332334 1 1
rs762237 33330047 rs2834077 33344608 1 1
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Cluster: 3032 to 3276 Score: 11.5 Cluster: 7554 to 7850 Score: 5.69
to
Position in Sequence 
Motif Position StrandScore Sequence
Q
Position in Sequence 
Motif Position StrandScore Sequence
CCAAT3032 to 3047 - 10.2 cacaaccaat gggcgc EtS 7554 to 7564 - 9.25 agcaggaagtg
Sp1 3049 to 3061 + 6.33 gcagggaggaggc NF-1 7581 to 7598 - 6.91 11 c t  ggccagcag t  ccga
Ets 3088 to 3098 + 7.15 gag cggaatta Sp1 7720 to 7732 - 6.23 gggggcaggaggc
CRE 3104 to 3115 + 7.16 gatgacatcagc Sp1 7721 to 7733 - 6.96 tgggggcaggagg
CRE 3104 to 3115 - 7.49 g c tg a tg tc a tc LSF 7724 to 7738 - 6.25 ggtggtgggggcagg
CCMT3137 to 3152 - 9.27 cc t  cgccaa t gage t  g Sp1 7727 to 7739 - 6.47 gggtggtgggggc
Sp1 3184 to 3196 - 6.08 egggggeggggge Myc 7747 to 7756 + 7.09 g ccatg tg aa
TATA 3224 to 3238 - 6 g t 111 ta tagcccgg TATA 7782 to 7796 - 8.96 gaa t  aaaaacgac t  a
TATA 3229 to 3243 + 11.4 c t  a t  aaaaaccggcc LSF 7836 to 7850 + 9.81 ac t ggg t  ccagc t  gc
TATA 3260 to 3274 - 8.39 c ta ta a ta a g c a tc c
Mef-2 3264 to 3275 + 6.01 g e t ta t ta ta g a
SRF 3264 to 3276 - 6.19 a tc ta ta a ta a g c
Mef-2 3265 to 3276 - 8.13 a tc ta ta a ta a g
Figure 3.1 Id . Output from Cluster Buster transcription factor m otif identifying software for the OLJG2  gene and 
surrounding region. Coloured blocks relate to the specific binding motifs listed below. Position relates to O L IG 2  
sequence, starting at -20kb.
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3.11.4. Further Work
To decipher the functional relevance of the genetic association to marker 
rs762237 the study was extended to genotype tag markers for the oligodendrocyte 
lineage transcription factor 1 (OLIG1) gene (Figure 3.11e). This gene resides 34.4 
kb distal to the associated OLIG2 variant and 41.1 kb from OLIG2. OLIG1 is a 
bHLH transcription factor which has a similar role to OLIG2 (Lu et al. 2000; Zhou et 
al. 2000). The two genes are differentially expressed during development and are 
thought to act in unison to specify motoneuron and oligodendrocyte fate (Zhou and 
Anderson 2002), with OLIG1 having specific action within the brain (Lu et al. 2002). 
Fifteen SNPs were genotyped to tag the OLIG1 gene + 20 kb 3 prime and 35 kb 5 
prime of the gene with parameters set at r2 > 0.8 and MAF > 0.05. This 
methodology tags the OLIG1 locus plus the region immediately neighbouring the 
OLIG2 association signal. All markers except rs11088236 were genotyped using 
the Sequenom™ MassARRAY™ genotyping system (chapter 2.7.3). Variant 
rs11088236 was genotyped using Amplifluor™ chemistry on a 60°C program with 
22 cycles (chapter 2.7.2), the relative PCR and extension primers are provided in 
Appendix Table 3.23. All markers passed the stringent quality control measures 
(see chapter 2.7.4) (Table 3.11 d). Four significant allelic associations with markers 
rs11088236 (P=  0.007; OR = 0.72), rs2834076 (P= 0.04; OR = 1.29), rs2834083 
(P= 0.02; OR = 0.75) and rs8131457 (P= 0.03; OR = 0.77) were seen in the 
disease modifier analysis (Tables 3.11e and 3.11f). Only the association with 
variant rs11088236 survives correction for multiple testing (permuted P = 0.02) 
(rs2834076 permuted P =  0.4; rs2834083 permuted P =  0.15; rs8131457 permuted 
P = 0.39). Upon further investigation marker rs11088236 was found to be a proxy 
SNP for rs762237 (D’ = 1 and r2 = 1 in the CEPH). Therefore rs762237 remains the 
most significantly associated marker. In the disease subtype analysis rs7276171 
showed a significant association (allelic P = 0.006; OR = 0.77, genotypic P =
0.005), with the minor G allele and GG genotype under-represented in LOAD+P 
cases. However, this association did not survive permutation correction for multiple 
testing (allelic P = 0.07; genotypic P = 0.06). No variant showed significant 
association to LOAD and no haplotypic analysis produced a significant association 
(disease modifier global P = 0.57; disease subtype global P = 0.68; LOAD global P  
= 0.86) (Appendix Table 3.24).
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Table 3.l id .  OLIG 1  variants genotyped in this study. Table provides SNP ID, base 
position, nucleotide change, % genotyped, and HWE p-values for each tested dataset.
SNP BP %Geno
HWE
LOAD+P LOAD-P LOAD Control
rs17632819 33336721 G/A 99.5 0.80 0.27 0.82 1.00
rs 11088236 33338057 C/T 99.3 0.50 0.24 0.35 0.45
rs2834076 33338971 G/A 97.6 0.67 1.00 0.69 0.57
rs 10483016 33339071 T/C 97.4 0.67 0.17 0.47 0.73
rs2834079 33352040 A/G 96.9 0.74 0.48 0.10 0.77
rs2834083 33358843 A/G 96.4 0.32 1.00 0.80 0.10
rs928736 33361759 T/C 95.1 0.56 0.49 0.88 0.50
rs7278735 33366952 C/T 98.2 1.00 0.71 1.00 0.62
rs11088237 33372448 T/C 99.5 0.90 0.47 0.63 0.40
rs8131457 33375767 T/C 98 0.73 0.68 0.38 0.16
rs7276171 33385508 A/G 99.8 1.00 1.00 0.43 0.08
rs4817527 33385955 G/A 97.6 0.75 0.16 0.85 0.07
rs2834086 33387137 C/T 96.9 0.20 0.89 0.69 1.00
rs2834087 33387301 G/A 98.5 0.92 0.60 0.25 0.92
rs12481815 33387990 T/C 99.7 0.91 0.89 0.62 0.63
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Table 3.1 le. MAF and genotype counts of tested O L IG l SNPs. Table shows; SNP ID, minor allele, MAF and genotype counts in LOAD+P,
LOAD-P, LOAD and control samples.
SNP MA
MAF Genotype Counts
LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs17632819 A 0.07 0.07 0.07 0.07 2/41/293 1/30/202 6/143/888 5/145/949
rs11088236 T 0.43 0.52 0.47 0.46 62/167/106 58/124/51 223/532/280 228/548/324
rs2834076 A 0.4 0.34 0.37 0.36 54/156/124 24/107/100 142/466/405 146/491/448
rs10483016 C 0.06 0.04 0.05 0.05 1/35/300 0/20/213 3/89/938 1/96/999
rs2834079 G 0.1 0.1 0.11 0.11 2/64/269 0/48/185 6/205/815 13/217/863
rs2834083 G 0.42 0.49 0.45 0.44 58/167/111 55/118/58 209/505/316 206/562/327
rs928736 C 0.29 0.34 0.31 0.31 26/140/166 24/109/98 98/440/480 113/461/522
rs7278735 T 0.19 0.19 0.18 0.18 11/105/219 9/69/153 34/304/683 37/316/744
rs11088237 C 0.04 0.04 0.03 0.03 0/26/310 0/17/216 0/71/964 0/75/1025
rs8131457 C 0.43 0.5 0.46 0.46 58/173/105 62/107/64 220/495/311 236/525/336
rs7276171 G 0.29 0.34 0.32 0.35 22/150/164 27/103/103 102/466/471 142/476/482
rs4817527 A 0.46 0.43 0.44 0.43 70/172/94 42/118/73 197/497/323 218/519/363
rs2834086 T 0.37 0.36 0.36 0.35 47/155/133 32/103/97 140/470/418 134/497/459
rs2834087 A 0.21 0.16 0.18 0.18 14/110/210 6/64/162 40/297/688 39/335/720
rs12481815 C 0.04 0.03 0.03 0.03 0/25/311 0/15/217 0/66/972 0/78/1112
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Table 3.1 If. Individual genotyping of O L IG 2  SNPs through LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
LOAD+P vs. LOAD-P LOAD+P vs. Control LOAD vs. Control
Alleles Genotype Alleles Genotype Alleles Genotype
SNP x2 P OR x2 P x2 P OR x2 P x2 P OR x2 P
rs17632819 0.01 0.91 0.97 (0.61-1.56) 0.13 0.94 0.1 0.75 0.95 (0.67-1.33) 0.32 0.85 0.67 0.41 1.1 (0.88-1.38) 0.73 0.69
rs11088236 7.19 0.007 0.72 (0.57-0.92) 7.69 0.02 1.01 0.32 0.91 (0.77-1.09) 1.04 0.6 0.6 0.44 1.05 (0.93-1.18) 0.65 0.72
rs2834076 4.17 0.04 1.29(1.01-1.66) 4.62 0.1 2.59 0.11 1.16(0.97-1.38) 2.55 0.28 0.3 0.58 1.04 (0.91-1.17) 0.31 0.86
rs10483016 0.85 0.36 1.3(0.74-2.27) 1.24 0.54 1.23 0.27 1.25 (0.84-1.84) 1.66 0.44 0.02 0.88 1.02 (0.77-1.36) 1.14 0.57
rs2834079 0.01 0.93 0.98 (0.67-1.45) 1.56 0.46 0.49 0.48 0.9(0.68-1.2) 0.99 0.61 0.29 0.59 0.95 (0.78-1.15) 1.75 0.42
rs2834083 5.79 0.02 0.75 (0.59-0.95) 5.88 0.05 1.17 0.28 0.91 (0.76-1.08) 1.31 0.52 0.05 0.83 1.01 (0.9-1.14) 1.97 0.37
rs928736 3.27 0.07 0.79 (0.61-1.02) 3.45 0.18 1.41 0.24 0.89 (0.74-1.08) 1.91 0.39 0.03 0.87 0.99 (0.87-1.12) 0.39 0.82
rs7278735 0.003 0.96 1.01 (0.74-1.37) 0.26 0.88 0.48 0.49 1.08 (0.87-1.35) 0.8 0.67 0.13 0.72 1.03 (0.88-1.2) 0.25 0.88
rs11088237 0.04 0.85 1.06 (0.57-1.98) 0.04 0.84 0.32 0.57 1.14(0.72-1.8) 0.33 0.56 0.03 0.86 0.97 (0.7-1.34) 0.001 0.97
rs8131457 4.78 0.03 0.77 (0.61-0.97) 7.23 0.03 1.23 0.27 0.91 (0.76-1.08) 2.99 0.22 0.02 0.9 0.99 (0.88-1.12) 0.12 0.94
rs7276171 3 0.08 0.8(0.62-1.03) 4.69 0.1 7.48 0.006 0.77 (0.64-0.93) 10.66 0.005 2.51 0.11 0.9(0.8-1.02) 5.7 0.06
rs4817527 1.06 0.3 1.13(0.89-1.44) 1.09 0.58 1.9 0.17 1.13(0.95-1.34) 3.03 0.22 0.12 0.72 1.02 (0.91-1.15) 1.2 0.55
rs2834086 0.16 0.69 1.05 (0.82-1.35) 0.26 0.88 0.96 0.33 1.09 (0.91-1.31) 0.99 0.61 1.34 0.25 1.08 (0.95-1.22) 1.4 0.5
rs2834087 3.27 0.07 1.33 (0.98-1.81) 3.28 0.19 1.05 0.31 1.12(0.9-1.39) 1.05 0.59 0.001 0.97 1 (0.86-1.17) 0.56 0.76
rs12481815 0.19 0.66 1.16(0.6-2.22) 0.2 0.66 0.39 0.53 1.16(0.73-1.84) 0.4 0.53 0.03 0.85 0.97 (0.69-1.35) 0.04 0.85
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3.11.5. Discussion
Four polymorphisms have been identified at the OLIG2 locus which 
associate with psychosis in LOAD. Interestingly the most significantly associated 
LOAD+P markers rs762237 (P = 0.002) and rs2834072 (P = 0.004) do not show an 
association with schizophrenia (P = 0.35 and P = 0.78 respectively), and the 
associated schizophrenia polymorphisms, rs1059004 (P= 0.0001) and rs762178 
(P = 0.0005), do not show an association with LOAD+P (P = 0.72 and P = 0.7 
respectively) (Georgieva et al. 2006). This study has power of 0.71 to detect the 
previously observed associations (OR = 1.33, MAF = 0.47) Polymorphism 
rs13046814 shows association in the same direction to schizophrenia (P = 0.002) 
and LOAD+P (P = 0.03). While variant rs62246115 shows no association with 
schizophrenia (P = 0.75) and a nominal association with LOAD+P (P = 0.04). 
Independent loci within the same gene have previously been shown to increase 
risk for, or cause distinct diseases. For example, multiple differing mutations within 
the gene (GJB3) encoding connexin 31 (Cx31) have been shown to increase risk 
for skin disease (Di et al. 2002) including erythrokeratodermia variabilis (Richard et 
al. 1998), and hearing impairment (Rabionet et al. 2002). While, mutations in the 
gene encoding tripartite motif-containing 32 (TRIM32) independently cause 
Bardet-Biedl syndrome (BBS) (Chiang et al. 2006) and Limb-girdle muscular 
dystrophy type 2H (LGMD2H) (Frosk et al. 2005). While noting that replication in 
independent samples is essential, the data provide preliminary evidence that 
genetic variation in OLIG2 modifies psychosis in LOAD, albeit by a varying 
mechanism to that seen in schizophrenia, and suggests a possible role for white 
matter abnormalities in the aetiology of a psychosis subtype of LOAD, but not 
LOAD perse. The significant association seen with a variant in OLIG1 does not 
exceed that seen at the OLIG2 locus and owing to LD across the region indirectly 
supports the association with rs762237 in this dataset. On a cautionary note,
OLIG2 is located 6.8 Mb telomeric of the amyloid precursor protein (APP) gene. 
APP is well established as a disease risk gene for early onset Alzheimer’s disease 
(EOAD). The genetic associations of APP and OLIG2 are unlikely to be related as 
their chromosomal locations lie far outside the range of LD, however, the possibility 
that these genes interact cannot be excluded. No functional variant could be 
identified at the OLIG2 locus that explains the association findings; therefore
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further exploration of the OLIG2 region is warranted. Future work at this locus will 
include analysis of OLIG2 in the LOAD+P GWAS described in chapter 5. Following 
replication of the genetic association of OLIG2 with LOAD+P, future work could 
entail exploration of the locus to identify a coding variant or an effect on gene 
expression. The examination of other OMR genes with respect to LOAD+P could 
prove fruitful in further dissecting the aetiology of this disease.
3.12. Catechol-O-methyl Transferase
Catechol-O-methyl transferase (COMT) is an enzyme involved in the 
breakdown of the catecholamine neurotransmitters (dopamine, epinephrine and 
norepinephrine). These neurotransmitters are paramount to the signaling pathways 
thought to be perturbed in numerous psychotic disorders. The COMT gene (Figure 
3.12) is located at chromosome 22q11.21-11.23 a region renowned for a common 
microdeletion (Singh et al. 2002) which has shown association to psychosis. 
Several early schizophrenia and bipolar disorder analyses found positive linkage to 
22q11-q12 (Gill et al. 1995; Lachman et al. 1997; Lasseteret al. 1995; Hovatta et 
al. 1998), Suggestive evidence for linkage to chromosome 22q11 with psychosis 
was identified by Hamshere and colleagues (Hamshere et al. 2005b) in UK patients 
with schizoaffective disorder (LOD = 1.96). No linkage was observed in this region 
in the group’s original schizophrenia or bipolar disorder scans, suggesting the 
existence of loci that influence susceptibility to a broad functional psychosis, rather 
than distinct phenotypes. However, linkage of the region to schizophrenia and 
bipolar disorder is supported by multiple meta-analyses (Badner and Gershon 
2002; Holmans et al. 2009a; Lewis et al. 2003). Most association studies have 
focused upon the valine to methionine change at codon 158 of the brain- 
predominant membrane-bound form of COMT and codon 108 of the soluble form. 
The valine allele confers higher activity and thermal stability (Chen et al. 2004a) 
and has been fairly consistently associated with reduced performance in tests of 
frontal lobe function (Egan et al. 2001; Malhotra et al. 2002). The findings in 
schizophrenia are mixed, the vast majority of case-control studies have failed to 
find evidence for association (Williams et al. 2005a), and meta-analyses report no 
overall evidence for association (Fan et al. 2005; Glatt et al. 2003; Munafo et al.
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2005). Some studies find stronger evidence for association between haplotypes at 
COMT than for the val/met polymorphism alone (Chen et al. 2004b; Handoko et al. 
2005; Sanders et al. 2005; Shifman et al. 2002), with the most studied being the 
‘Shifman haplotype’. This haplotype shows association to schizophrenia in at least 
two studies (Chen et al. 2004b; Handoko et al. 2005). The finding that this 
haplotype shows greater association to disease than the functional polymorphism 
is difficult to explain, given that activity at the COMT locus is largely dictated by this 
marker. The val/met variant may confer a small effect on susceptibility or have a 
role in phenotype modification. It also remains possible that variation elsewhere in 
COMT or in a neighbouring gene confers psychosis susceptibility (Craddock et al.
2006). The COMT gene has not been studied extensively in bipolar disorder. 
Borderline evidence for association with the met allele was found in one meta­
analysis (OR = 1.18) (Craddock et al. 2001) which did not replicate in a later meta­
analysis (Craddock et al. 2006). The COMT locus has been studied in a AD case- 
control sample of 373 individuals. The val/met variant showed modest association 
to AD+P in females and a 4 marker haplotype showed significant evidence for 
association irrespective of sex (Sweet et al. 2005). It is likely that genetic variation 
in this region influences susceptibility across the psychosis spectrum, although 
whether COMT is the only (or the major) susceptibility gene at this locus is unclear. 
If it is, the mechanism is complex and the phenotype not yet adequately defined 
(Craddock et al. 2006).
The catechol-O-methyl transferase (COMT) enzyme degrades 
catecholamines including dopamine. Two main COMT protein isoforms are known, 
in most tissues the soluble cytoplasmic form predominates, whereas in brain the 
longer membrane bound form is the major species (Tenhunen et al. 1994). 
Although expressed widely, COMT is a minor player in dopamine clearance 
compared with neuronal synaptic uptake by the dopamine transporter (Huotari et 
al. 2002), except in the prefrontal cortex where expression of the dopamine 
transporter is low (Sesack et al. 1998), subsequently increasing the importance of 
COMT (Gogos et al. 1998; Tunbridge et al. 2004). Differential expression of the 
COMT transcripts in different tissues maybe explained by the identification of a 
number of putative regulatory elements within and neighbouring the gene 
(Tenhunen et al. 1994), which include numerous oestrogen response elements 
(Xie et al. 1999).
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3.12.1. Literature Summary
Catechol-O-methyl transferase (COMT) is an enzyme involved in the 
breakdown of the catecholamine neurotransmitters (dopamine, epinephrine and 
norepinephrine). These neurotransmitters are paramount to the signaling pathways 
thought to be perturbed in numerous psychotic disorders. Multiple schizophrenia, 
schizoaffective disorder and bipolar disorder analyses have found positive linkage 
to the 22q11—q12 region (Gill et al. 1996; Lachman et al. 1997; Lasseter et al.
1995; Hamshere et al. 2005b; Hovatta et al. 1998), but the results of association 
analyses have been mixed. Most studies have focused upon the val/met 
polymorphism, the valine allele of which confers higher activity and thermal stability 
(Chen et al. 2004a) Some studies find stronger evidence for association between 
haplotypes at COMT than for the val/met polymorphism alone (Chen et al. 2004b; 
Handoko et al. 2005; Sanders et al. 2005; Shifman et al. 2002), with the most 
studied being the ‘Shifman haplotype’ which shows association to schizophrenia in 
at least 2 studies (Chen et al. 2004b; Handoko et al. 2005). The COMT locus has 
been studied in AD+P with the val/met variant showing modest association to 
AD+P in females and a 4 marker haplotype showing significant evidence for 
association irrespective of sex (Sweet et al. 2005).
3.12.2. Study Design
In an attempt to replicate the previous association of COMT with psychosis 
in AD (Sweet et al. 2005), 4 SNPs were genotyped and analysed. Three of these 
SNPs represent the ‘Shifman’ haplotype (rs4680, rs165599 and rs73765), and 
include the val/met SNP (rs4680). The additional variant, rs2020917 is a promoter 
variant that is adjacent to an oestrogen response element (ERE6) which is 
hypothesised to be involved in regulation of gene expression (Tenhunen et al. 
1994). All SNPs were genotyped using the Sequenom™ MassArray™ platform 
(chapter 2.7.3), the relevant PCR and extension primer sequences are provided in 
Appendix Table 3.25.
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3.12.3. Results
One variant (rs165599) showed nominal deviation from HWE in the 
LOAD+P dataset (P = 0.01). This variant is essential to complete the investigated 
haplotype therefore it was not excluded from further analysis. Neither of the 
LOAD+P association analyses undertaken yielded a significant association with 
any of the tested SNPs (Tables 3.12a and 3.12b), with the val/met variant (rs4680) 
having a p-value of 0.65 (OR= 1.06) in the disease modifier analysis. No variant 
showed a significant association with LOAD alone. Haplotype analyses of the 4 
variants in all datasets also failed to generate a significant association (global P = 
0.77 in the disease modifier analysis, global P = 0.96 in the disease subtype 
analysis and global P =  0.71 in the LOAD analysis (Appendix Table 3.30). Due to 
the sex differences previously observed at the COMT locus in LOAD+P, the 
datasets were analysed by sex. No significant association was seen in allelic, 
genotypic or haplotypic analyses (see Appendix Tables 3.26 - 3.29 and 3.31 - 
3.32).
3.12.4. Discussion
The val/met marker and a 4 marker haplotype have previously shown 
association with LOAD+P (Sweet et al. 2005). These markers were genotyped in 
this study. This study does not replicate the findings of Sweet and colleagues 
(Sweet et al. 2005), despite using a more powerful dataset. However, this dataset 
is still underpowered to detect the associations. The findings of Sweet and 
colleagues may prove to be false positive. However, one of the genotyped markers 
shows deviation from HWE in this study. Also, confounding factors such as 
population differences between the studies have not been accounted for. The 3 
marker “Shifman haplotype” was also analysed in this study with no significant 
findings.
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Table 3.12a. MAF and genotype counts of tested C O M T  SNPs. Table shows; SNP ID, minor allele, MAF and genotype counts in LOAD+P,
LOAD-P, LOAD and control samples.
SNP ID MA
MAF Genotype Counts
LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs2020917 T 0.28 0.29 0.29 0.28 28/125/166 26/81/120 85/366/481 90/410/570
rs737865 C 0.29 0.3 0.29 0.28 30/123/166 27/81/119 88/365/479 91/413/566
rs4680 G 0.48 0.46 0.48 0.48 78/148/93 51/108/68 227/434/271 249/526/295
rs165599 G 0.3 0.29 0.3 0.29 27/136/156 13/107/107 82/402/448 102/425/543
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Table 3.12b. Individual genotyping of O L IG 2  SNPs through LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
LOAD+P vs. LOAD- LOAD+P vs. Control LOAD vs. Control
Alleles Genotype Alleles Genotype Alleles Genotype
SNP ID x2 P OR x2 P x2 P OR x2 P x2 P OR x2 P
rs2020917 0.11 0.74 1.05 (0.8-1.36) 1.41 0.49 0.16 0.69 1.04 (0.85-1.27) 0.16 0.92 0.69 0.41 1.06 (0.92-1.22) 0.67 0.72
rs737865 0.14 0.71 1.05 (0.81-1.37) 1.09 0.58 0.19 0.66 1.04 (0.86-1.27) 0.26 0.88 0.73 0.39 1.06 (0.93-1.22) 0.75 0.69
rs4680 0.21 0.65 1.06 (0.83-1.35) 0.29 0.87 0.01 0.93 1.01 (0.84-1.2) 0.75 0.69 0.02 0.89 1.01 (0.89-1.14) 1.35 0.51
rs 165599 0.03 0.86 1.02 (0.79-1.33) 2.05 0.36 0.04 0.85 1.02 (0.84-1.24) 0.98 0.61 0.45 0.5 1.05 (0.91-1.2) 2.42 0.3
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3.13. Discussion
In this chapter specific markers that have been directly or indirectly 
associated with psychosis were investigated for association with LOAD+P. These 
variants were tested under the hypothesis that psychosis susceptibly genes may 
act across diseases, modifying psychotic symptoms in multiple distinct disorders. 
The markers were also investigated for association with LOAD+P as a sub-form of 
LOAD. Markers at 11 loci, DISC1, DTNBP1, GRIK2, GRM3, NRG1, BDNF, DAO A, 
CNP, OLIG2, OLIG1 and COMT, were investigated for association with LOAD+P 
and LOAD. Two previously published associations of COMT and NRG1 with AD+P 
failed to replicate in this study. Variant rs12525702 at the DTNBP1 locus shows 
nominal evidence for a role in the aetiology of LOAD+P, with a 4% difference in 
allele frequency and a trend towards association in the disease modifier analysis. 
One synonymous GRM3 variant (rs2228595) shows evidence for association to 
LOAD+P under both disease models, but also shows deviation from HWE. Four 
GRM3 variants showed significant association to LOAD, two of which survived 
correction for multiple testing. A haplotype of these markers shows the strongest 
association, however, variant rs6465084, which is included in the multi-marker 
haplotype, shows deviation from HWE. The BDNF val66met polymorphism does 
not show an association to LOAD+P, but does show significant evidence for 
association with LOAD alone (P= 0.01, OR = 1.2). This variant may reduce protein 
function of the gene, whose activity fits well with the oxidative stress hypothesis of 
LOAD aetiology. Four polymorphisms in the OLIG2 gene showed significant 
association with psychosis in LOAD, two of which survive correction for multiple 
testing. These markers differ to those associated in schizophrenia (Georgieva et al. 
2006), but provide preliminary evidence that genetic variation in OLIG2 modifies 
psychosis in LOAD, albeit by a varying mechanism to that seen in schizophrenia, 
and suggests a possible role for white matter abnormalities in the aetiology of a 
psychosis subtype of LOAD.
This study used a sample set of 1,205 LOAD patients, 379 of which have 
experienced psychosis and 269 who have never had a psychotic episode, plus 
1,305 matched controls. The disease modifier analysis had a limited power of 34% 
to detect an association with an effect size of 1.3 with a risk variant frequency of
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30%, while the disease subtype analysis had an increased power of 57%. The 
power of the sample set is a limitation of this study, which means that a true 
association may be missed. A larger sample-set would greatly increase the study 
power. However, this would require recruitment of around 5000 LOAD patients with 
data on occurrence of psychotic symptoms to produce a more suitably powered 
dataset. This limitation is partially assessed in chapter 5, where genotype data from 
543 LOAD+P cases, 417 LOAD-P cases and 4,706 control individuals is 
investigated. This dataset provides an increase in power of 13% and 21% for the 
disease modifier and disease subtype analyses respectively. At the time of study 
commencement the sample utilised in this chapter was the largest LOAD+P 
sample of any published study, and it remains substantial in comparison to other 
LOAD+P datasets (Wilkosz et al. 2007). The methodology of marker selection in 
this study was not ideal as for numerous loci the coverage of the locus was poor 
meaning that risk factors for disease susceptibility may be missed. However, this 
study took a novel approach to investigate multiple putative psychosis susceptibility 
genes. Common functional polymorphisms and polymorphisms previously 
associated with psychosis were prioritised for investigation. It is also worth 
remembering that rare variation at the tested loci may have an effect on psychosis 
susceptibility but that this study is not designed or powered to detect such an 
association.
Future work will include the analysis of the investigated loci, specifically 
OLIG2, in the LOAD+P GWAS described in chapter 5. Other oligodendrocyte and 
myelination related genes will also be prioritised for investigation in this dataset 
which could prove fruitful in further dissecting the aetiology of this disease. Further 
exploration of the OLIG2 region is also warranted as the associated variants have 
no apparent functional role. This work may include studies to identify novel variants 
at the locus through screening and sequencing, and investigation of c/s-acting 
variants through allelic expression assays.
While noting that replication in independent samples is essential, the 
identification of a novel association of OLIG2 to LOAD+P is extremely interesting. 
This data suggests a possible role for white matter abnormalities in the aetiology of 
a psychosis subtype of LOAD, support for which is provided by functional studies
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which show that white matter changes show significant correspondence with 
psychosis score in LOAD (Lee et al. 2006). This finding also supports the 
methodology of investigating schizophrenia and bipolar disorder susceptibility 
genes across disorders in which psychosis is a symptom.
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4. Replication of Schizophrenia GWAS
4.1 Introduction
In the previous chapter the hypothesis that specific susceptibility variants for 
neurodevelopmental psychosis may be associated with risk of developing 
psychosis in LOAD was tested. The investigation of these putative psychosis 
candidate polymorphisms led to the successful identification of OLIG2 as a 
psychosis modifier gene in LOAD (see chapter 3.11). Following this finding it 
seemed logical to extend this approach and investigate polymorphisms recently 
found to be associated with schizophrenia in a large individual case-control 
genome-wide association study (GWAS) of the disease (O’Donovan et al. 2008) 
(referred to hereafter as the O’Donovan GWAS). This genome-wide association 
study of schizophrenia is discussed along with other published schizophrenia 
GWAS.
Numerous GWA studies have utilised a DNA pooling methodology (Baum et 
al. 2008; Butcher and Plomin 2008; Hui et al. 2008; Kirov et al. 2009; Shifman et al. 
2008). Pooled DNA genotyping offers the possibility of applying the same 
technologies to large samples at a fraction of the cost. Evidence shows that the 
pooling methodology is accurate (Norton et al. 2004), and that the accuracy of 
estimating differences in allele frequency between pools using ultra-high 
throughput platforms is comparable with lower throughput platforms (Kirov et al.
2006). Two groups have applied the DNA pooling methodology to GWAS of 
schizophrenia. Kirov and colleagues (Kirov et al. 2009) used a parent-offspring trio 
design with pools constructed from 605 unaffected controls, 574 schizophrenia 
patients and a third pool from the parents of the patients. Sixty-three SNPs were 
selected for individual genotyping in 574 trios and the results analysed with the 
transmission disequilibrium test (Kirov et al. 2009). No result reached genome-wide 
significance, although forty were significant at P < 0.05. The best result was with 
rs11064768 (P = 1.2 xIO"6), a SNP within the gene coiled-coil domain containing 60 
gene (CCDC60) on chromosome 12. The third best SNP (P = 0.00016) was 
rs893703. This SNP lies within AT rich interactive domain 4A (ARID4A) an inhibitor
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of the PI3K/Akt signalling pathway, members of which have been implicated in 
schizophrenia (Kalkman 2006).
Shifman and colleagues (Shifman et al. 2008) performed a genome-wide 
association (GWA) scan for schizophrenia using the Affymetrix 5.0 SNP array in an 
Ashkenazi Jewish population of 419 male case, 241 female case, 1,807 male 
control and 964 female control pools. One hundred and ninety four SNPs were 
selected for individual genotyping, 167 SNPs passed quality control measures, 52 
of these showed p-values below 0.05 in at least one of the tests (male, female and 
combined), and 9 SNPs had p-values below 0.005 (Shifman et al. 2008). A female- 
specific association was found with rs7341475, (P = 2.9 x 10~5) which replicated (P 
= 2.1 x 10"3) in 4 additional populations, totalling 2,274 cases and 4,401 controls. 
Meta-analysis drives the association close to genome-wide statistical significance 
with an estimated relative risk of 1.58 (P = 8.8 x 10-7) for women carrying the 
common genotype (Shifman et al. 2008). Polymorphism rs7341475 is located in 
the fourth intron of the reelin (RELN) gene on chromosome 7. RELN is a serine 
protease known to be part of the apolipoprotein E (APOE) biochemical pathway 
that is involved in the pathogenesis of Alzheimer's disease (Seripa et al. 2008).
The gene has previously shown association to AD specifically in females (Seripa et 
al. 2008). Although, rs7341475 was not an associated variant and is not in LD with 
any of the identified AD associated variants.
At the time of study commencement 4 individually genotyped GWAS of 
schizophrenia had been published including the O’Donovan GWAS. The study by 
Mah and colleagues (Mah et al. 2006) used a modest schizophrenia sample of 
European descent (320 cases and 325 matched controls) to genotype over 25,000 
SNPs located within approximately 14,000 genes. Despite the small number of 
variants tested, 62 markers were found to be nominally associated with disease 
status. The most consistent finding was for a candidate locus (PLXNA2) on 
chromosome 1q32. The marker rs752016 showed suggestive association (P = 
0.006; OR = 1.49) (Mah et al. 2006), and a trend towards association in an 
independent case-control sample of European Americans (P = 0.07; OR = 1.38) 
(combined P = 0.035; OR = 1.38). Similar genetic effects were observed in smaller 
subsets of Latin Americans (OR = 1.26) and Asian Americans (OR = 1.37) but 
these did not reach statistical significance (P = 0.35 and P = 0.22 respectively), 
and there was no supporting evidence from two family-based collections (P = 0.34,
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OR = 1.31 and P  = 0.52, OR = 0.87) (Mah et al. 2006). The plexin A2 (PLXNA2) 
gene is a member of the transmembrane semaphorin receptor family that is 
involved in axonal guidance during development and may modulate neuronal 
plasticity and regeneration. Interestingly, a PLXNA2 ligand, semaphorin 3A, has 
been shown to be upregulated in the cerebellum of individuals with schizophrenia 
(Eastwood et al. 2003). However, the p-values identified by Mah and colleagues 
(Mah et al. 2006) are small, and are unlikely to survive correction for multiple 
testing.
Lencz and colleagues (Lencz et al. 2007) conducted a GWAS, examining 
approximately 500,000 markers in a small Caucasian sample of 178 cases and 144 
controls. A strong effect (P = 3.7 x 10"7) of a novel locus (rs4129148) was revealed 
near the colony stimulating factor, receptor 2 alpha gene (CSF2RA) in the pseudo- 
autosomal region PAR1 of the X and Y chromosomes. However, this association 
did not replicate in an additional 102 subjects, and no neighbouring SNPs on the 
genotyping platform supported the association (Lencz et al. 2007). Sequencing of 
CSF2RA and its neighbour, interleukin 3 receptor alpha (IL3RA), in an independent 
case-control cohort revealed common intronic haplotypes and novel rare missense 
variants which associated with schizophrenia (Lencz et al. 2007). However, the 
haplotypic global p-values are not striking (best P = 0.016) and no correction for 
multiple comparisons was made.
Sullivan and colleagues (Sullivan et al. 2008) genotyped 738 cases with 
DSM-IV schizophrenia and 733 group-matched controls for 492,900 SNPs using an 
Affymetrix two-chip platform plus a custom fill-in chip. No SNP or multimarker 
combination of SNPs achieved genome-wide statistical significance (Sullivan et al. 
2008). The lack of genome-wide significant association is not unexpected due to 
the moderate sample size employed by this study.
O’Donovan and colleagues (O’Donovan et al. 2008) used a multistage 
association study founded upon a GWAS (O’Donovan et al. 2008). The initial 
sample consisted of 642 UK cases, 479 of which were genotyped with the 
Affymetrix GeneChip® 500K Mapping Array allowing comparison of allele 
frequencies with 2937 controls from the Wellcome Trust Case Control Consortium 
study (WTCCC 2007). Three-hundred and sixty-two thousand, five hundred and 
thirty-two SNPs passed the stringent quality control measures. In concordance with 
the WTCCC, loci reaching thresholds of P  < 1x1 O'5 and P  <5x10‘7 were considered
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to show suggestive and moderately strong evidence for association respectively. 
Twelve loci surpassed the threshold for suggestive association (P < 1x10‘5) and 
were selected for follow up genotyping using the Sequenom™ MassARRAY™ 
system. One SNP per loci was tested in replication sample 1 which comprised 
1664 cases and 3541 controls. For 6 of the 12 SNPs the association was in the 
same direction as that seen in the GWAS (O’Donovan et al. 2008). These 6 SNPs 
were tested in an additional 4,143 cases and 6,515 controls, named replication 
sample 2, giving a total replication data set of 6,666 cases and 9,897 controls. 
Replication sample 2 included out-bred European populations, individuals from 
China, Japan, and Ashkenazi Jews. The full replication dataset provided strong 
independent support for susceptibility variants for schizophrenia at three loci; zinc 
finger protein 804A (ZNF804A) on 2q32.1 and intergenic regions on 11p14.1 at
29.1 Mb and 16p13.12 at -13  Mb. Two additional loci remained nominally 
significant; 16q12.2 in retinitis pigmentosa GTPase regulator interacting protein 1 -  
like (RPGRIP1L) and 11q25 in opioid binding protein/cell adhesion (OPCML).
4.2. Study Design
This study is based on the hypothesis that psychosis susceptibly genes may 
act across disease divides, thus modifying psychotic symptoms in multiple distinct 
disorders. This design of this study is to investigate polymorphisms found to be 
associated with schizophrenia in the large individual case-control O’Donovan 
GWAS of the disease (O’Donovan et al. 2008). The primary hypothesis is that 
these polymorphisms may contribute to the aetiology of psychosis in LOAD under a 
‘disease modifier’ model, i.e. that these variants modify the psychosis phenotype in 
LOAD independent of the susceptibility variants for neurodegenerative disease. An 
alternate hypothesis is that these putative schizophrenia susceptibility variants may 
be involved in the aetiology of LOAD+P under a ‘disease subtype’ model i.e. that 
these markers increase susceptibility of developing a form of LOAD with psychotic 
symptoms. The replication samples used in the O’Donovan GWAS utilised 
individuals from numerous populations, including Chinese, Japanese, out bred 
Europeans and Ashkenazi Jews. Differences in allele frequencies across
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populations is a well documented phenomena that can create false positive or false 
negative associations (discussed in chapter 1.4.6), Therefore, in this study the 
SNPs identified in the initial UK stage of the O’Donovan GWAS were genotyped. 
This strategy aimed to avoid missing a true association due to differences in allele 
frequencies across populations. Twelve loci were identified as showing suggestive 
and moderately strong evidence (P <0.01) for association to schizophrenia in the 
UK sample of the O’Donovan GWAS. A total of 21 polymorphisms across these 12 
loci were genotyped. These variants are listed in Table 4.2.
4.3 Genotyping Strategy
All SNPs were genotyped using the Sequenom™ iPlexGOLD™ 
MassARRAY™ system as previously described (see chapter 2.7.3). Details of the 
marker flanking sequences can be found in Appendix Table 4.1. The PCR and 
extension primers designed for each variant can be found in Appendix Table 4.2. 
Quality control measures were as stated in chapter 2.7.4. SNPs were tested for 
deviation from HWE and statistically significant association using the methods 
described in chapter 2.7.4 and 2.9 respectively. Conserved regions and binding 
motifs were determined as described in chapter 2.11. Linkage disequilibrium 
between markers was determined using the HapMap LD Data download facility 
(www.hapmap.org). Markers were considered to be in “high LD” if they met 
threshold criteria of D’ = 1 and r2 > 0.7. Power was calculated using the PS 
program described in chapter 2.9.6.
191
Chapter 4. Replication o f Schizophrenia Genome-Wide Association Study
Table 4.2. The 21 SNPs genotyped in this study from the 12 chromosomal loci, identified 
in the UK stage of the O’Donovan GWAS. Table includes the relative chromosome, gene, 
base position (BP), and p-value (.P) and odds ratio (OR) from the O’Donovan GWAS.
Chr SNP ID Gene BP UK P UK OR
1 rs7546928 AGBL4 73023563 1.29E-04 0.76
1 rs11162231 ST6GALNAC5 77040318 3.22E-04 0.71
2 rs16984718 intergenic 18430882 5.94E-04 2.1
2 rs2890738 intergenic 144390753 1.73E-08 1.44
2 rs12613195 ZNF804a 185314727 2.05E-05 0.72
2 rs1344706 ZNF804a 185603934 1.47E-06 0.7
3 rs12629685 TRIM71 32855082 5.39E-05 1.33
3 rs9870579 CLSTN2 141162314 4.72E-05 0.56
8 rs10103330 CSMD1 4167498 4.03E-06 1.47
9 rs2210539 c9orf39 17158867 1.38E-03 0.73
9 rs10869675 PCSK5 75819589 1.29E-05 1.38
10 rs17101921 FGFR2 123143285 6.00E-03 1.73
11 rs10835482 intergenic 29079278 7.83E-05 1.45
11 rs1602565 intergenic 29118712 9.04E-06 1.55
11 rs3016384 OPCML 132078600 7.83E-06 0.73
12 rs6490121 NOS1 116192578 4.72E-07 1.43
13 rs4238270 IRS2 109268029 2.87E-05 0.72
15 rs3784397 PLCB2 38384136 2.05E-05 1.35
16 rs7192086 intergenic 12969112 1.15E-06 1.45
16 rs9922369 RPGRIP1L 52205983 2.59E-07 2.26
18 rs1893146 intergenic 8977427 6.37E-0 7 1.55
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4.4. Results
Twenty-one putative schizophrenia susceptibility variants were tested for 
association with LOAD+P through genotyping of 379 LOAD+P cases, 269 LOAD-P 
cases, and 1,361 controls. For a common genetic variant (MAF 30%) and a fairly 
large effect size of 1.3 the disease modifier analysis has power of 34% and the 
disease subtype analysis 57% at a significance level of 0.05. The LOAD 
(n=1,205) versus control analysis has a power of 88% to detect the same 
association. All SNPs had a genotyping success rate of > 95% in the full sample 
(Table 4.4a). Two SNPs were found to deviate from HWE in one dataset (Table 
4.4a). SNP rs1344706 showed deviation from HWE in the control sample (P = 
0.004; x2 = 8.18). The raw genotypes for this marker may not be trust worthy and 
the association analysis results for rs1344706 in the LOAD+P vs. control and the 
LOAD vs. control analysis were therefore taken with caution. Variant rs1893146 
shows deviations from HWE in the LOAD+P subgroup (P = 0.02; x2 = 5.64). 
Therefore the association findings for rs1893146 in the LOAD+P vs. LOAD-P and 
the LOAD+P vs. control analyses were taken with caution. HWE states that both 
allele and genotypes frequencies in a population remain constant or are in 
equilibrium from generation to generation. Possible explanations for the deviation 
from HWE at these SNPs were explored. No genotyping error was found, 
genotypes of HapMap samples included on the genotyping plates were checked 
and confirmed against HapMap data. Neither of the SNPs were found to have a 
non-specific assay (where a primer shows high homology to multiple genomic 
regions) or a primer covering a known variant. Therefore, no reasons for the 
observed deviations from HWE could be identified. The MAF and genotype counts 
for each of the tested variants are provided in Table 4.4b.
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Table 4.4a. Quality control Measures for all tested variants. Table includes chromosome, SNP name, gene name, base position, nucleotide 
change, percentage genotyped in full sample, and HWE p-values for each data subset.
Chr SNP ID Gene BP % Gen
HWE
LOAD+P LOAD-P LOAD Control
1 rs11162231 ST6GALNAC5 77040318 T/G 98.3 0.20 0.85 0.57 0.60
1 rs7546928 AGBL4 73023563 G/A 97.2 0.74 0.61 0.90 0.31
2 rs12613195 ZNF804A 185197466 C/G 98.4 0.08 0.36 0.06 0.42
2 rs1344706 ZNF804A 185603934 A/C 96.6 0.17 0.79 1.00 0.004
2 rs16984718 Intergenic 18430882 G/A 98.8 1.00 1.00 1.00 1.00
2 rs2890738 Intergenic 144390753 C/T 97.8 0.56 0.88 0.94 0.59
3 rs12629685 TRIM71 32855082 G/A 96.9 0.48 0.18 0.09 0.17
3 rs9870579 CLSTN2 141162306 T/C 98.2 0.80 0.38 0.36 0.20
8 rs10103330 CSMD1 4167498 T/A 97.7 0.85 0.83 0.74 0.75
9 rs2210539 c9orf39 17158867 G/A 98.0 0.06 1.00 0.84 0.85
9 rs10869675 PCSK5 77779855 A/G 96.5 0.49 0.74 0.48 0.23
10 rs17101921 FGFR2 123143285 G/A 98.5 0.23 1.00 0.36 0.56
11 rs10835482 Intergenic 29079278 C/T 97.0 1.00 0.27 0.50 0.89
11 rs1602565 Intergenic 29118712 T/C 98.5 1.00 0.33 1.00 1.00
11 rs3016384 OPCML 132078600 T/C 97.6 0.67 0.30 0.65 0.81
12 rs6490121 NOS1 116192578 A/G 96.6 1.00 0.45 0.94 0.29
13 rs4238270 IRS2 109268029 G/T 97.4 1.00 0.47 0.62 0.58
15 rs3784397 PLCB2 38384136 T/C 98.3 0.82 0.34 0.84 0.32
16 rs7192086 Intergenic 12969112 A/T 95.4 0.67 0.12 0.15 0.46
16 rs9922369 RPGRIP1L 52205983 G/A 98.8 1.00 1.00 0.53 1.00
18 rs1893146 Intergenic 8977427 G/A 98.7 0.02 0.78 0.05 0.48
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Table 4.4b. Chromosome number, SNP name, minor allele, minor allele frequency and genotype counts for LOAD+P, LOAD-P, LOAD and
Control datasets.
Chr SNP ID MA
MAF Genotype Counts
LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
1 rs11162231 G 0.22 0.22 0.21 0.22 20/108/216 11/84/144 48/325/615 51/391/677
1 rs7546928 A 0.45 0.48 0.47 0.47 72/166/104 53/124/62 221/488/274 237/572/304
2 rs12613195 G 0.32 0.3 0.33 0.35 26/162/153 19/105/104 90/452/422 125/509/464
2 rs1344706 C 0.39 0.41 0.4 0.42 58/150/132 38/118/82 159/471/351 219/492/395
2 rs 16984718 A 0.02 0.02 0.02 0.02 0/13/331 0/8/231 0/34/954 0/44/1075
2 rs2890738 T 0.36 0.32 0.36 0.33 41/164/139 24/107/108 125/450/410 127/488/504
3 rs 12629685 A 0.36 0.4 0.37 0.37 40/164/138 32/123/80 123/484/374 158/492/457
3 rs9870579 C 0.13 0.08 0.1 0.09 6/74/263 0/39/200 6/179/802 12/173/932
8 rs10103330 A 0.17 0.18 0.18 0.17 10/95/237 7/73/157 32/281/668 31/322/763
9 rs2210539 A 0.17 0.21 0.19 0.2 5/109/227 10/77/141 34/303/627 45/361/692
9 rs 10869675 G 0.27 0.27 0.28 0.31 27/127/184 15/95/125 82/384/503 96/490/523
10 rs 17101921 A 0.03 0.03 0.02 0.03 1/17/326 0/13/225 1/40/945 1/58/1060
11 rs 10835482 T 0.11 0.13 0.14 0.13 4/70/267 2/60/166 15/234/715 19/246/833
11 rs 1602565 C 0.11 0.11 0.12 0.11 4/65/275 1/51/187 14/214/760 14/223/882
11 rs3016384 C 0.48 0.46 0.48 0.49 78/176/89 54/110/74 228/483/272 270/562/282
12 rs6490121 G 0.33 0.3 0.33 0.34 37/152/154 19/106/113 105/431/447 139/484/487
13 rs4238270 T 0.32 0.34 0.33 0.32 35/150/158 30/102/107 105/445/434 115/475/528
15 rs3784397 C 0.4 0.38 0.39 0.41 55/162/127 38/105/96 153/467/367 180/558/381
16 rs7192086 T 0.26 0.29 0.28 0.24 25/128/186 25/87/123 84/369/513 68/393/640
16 rs9922369 A 0.03 0.03 0.03 0.03 0/18/326 0/16/223 1/52/935 0/63/1058
18 rs1893146 A 0.15 0.13 0.13 0.12 2/98/244 3/56/180 10/240/738 19/233/868
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Polymorphism rs9870579 showed an allelic (P =  0.02; OR = 1.61) and 
genotypic (P = 0.009) association to LOAD+P under the disease modifier model. 
The minor C allele showed a 5% over representation to LOAD cases with 
psychosis when compared to LOAD cases without psychosis (Table 4.4c). This 
variant also showed an allelic (P = 0.004; OR = 1.48) and genotypic (P = 0.02) 
association to LOAD+P under the disease subtype model. The minor C allele had 
an increased frequency of 4% in LOAD cases with psychosis compared to controls. 
The most significant allelic association was with the disease subtype model. 
However, marker rs9870579 appears to have the largest effect on LOAD+P under 
the disease modifier model, with a greater over representation of the minor C 
allele. None of the observed associations survive correction for multiple testing. 
Polymorphism rs9870579 is an intronic marker in the calsyntenin 2 CLSTN2 gene. 
CLSTN2 is a large gene of 632 kb situated on chromosome 3q23. There is one 
known gene transcript which is expressed exclusively in brain. The calsyntenin 
family of proteins are predominantly postsynaptic membrane proteins of excitatory 
CNS synapses with putative calcium binding capacity (Hintsch et al. 2002). 
However, the highest levels of CLSTN2 protein are found in GABAergic neurons 
(Hintsch et al. 2002), i.e. neurons that produce GABA as their output. GABA 
(Gamma-aminobutyric acid) is the chief inhibitory neurotransmitter in the 
mammalian CNS. Disrupted GABAergic signalling has been implicated in 
numerous and varied neurological and psychiatric pathologies including 
schizophrenia. The 3q23 region has previously shown linkage to LOAD and the 
CLSTN2 gene has shown significant association to cognitive function (Liu et al.
2007). Thus, CLSTN2 can be considered a putative functional and positional 
candidate gene for LOAD and psychosis. The functional relevance of the observed 
association was investigated. The marker is not within a conserved region or any 
known binding motif according to the UCSC most conserved track, ECR browser 
(http://ecrbrowser.dcode.org/) or cluster buster databases
(http://zlab.bu.edu/cluster-buster/index.html) (Figure 4.4a). Variants in high LD with 
rs9870579, according to the HapMap CEU data (Table 4.4d), were investigated for 
functional relevance, location in conserved regions or known binding motifs. One 
SNP rs11927384, in D’ = 1.0 and r2 = 0.83 with variant rs9870579, appears to lie in 
a conserved region according to the UCSC most conserved track and ECR 
browser (Figure 4.4a). This SNP also lies within intron 1 of the CLSTN2 gene.
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Conservation suggests that this variant or the region in which it lies may have a 
functional role. For example, the conserved region may act as a binding site for 
transcription factors involved in regulation of gene expression. However, there is no 
known function of this specific region of conservation.
Variant rs1893146 showed significant genotypic association with LOAD+P in 
the disease subtype analysis (P = 0.005), and a trend towards allelic association (P 
= 0.06; OR = 1.26) with a 3% increase in the minor A allele in the LOAD+P 
subgroup compared to controls. This association does not survive correction for 
multiple comparisons and variant rs1893146 shows deviation from HWE in the 
LOAD+P subgroup (P = 0.02; x2 = 5.64), meaning that this finding may not be 
trustworthy.
Polymorphism rs7192086 showed an allelic (P=  0.01; OR = 1.22) and 
genotypic (P = 0.02) association to LOAD, with the minor T being over represented 
in cases with an allele frequency difference of 4%. However, the association did 
not survive permutation correction for multiple testing (allelic P = 0.3; genotypic P = 
0.21). SNP rs7192086 is an intergenic SNP on chromosome 16. According to the 
UCSC conserved region track the SNP lies in a region of low conservation (see 
Figure 4.4b). No other tested polymorphism was shown to associate with LOAD.
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Table 4.4c. Chromosome number, SNP name, allelic and genotypic statistics for LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs.
control analyses.
LOAD+P vs. LOAD-P LOAD+P vs. control LOAD vs. control
Alleles Genotype Alleles Genotype Alleles Genotype
SNP ID x2 P OR x2 P X2 P OR x2 P x2 P OR X P
rs11162231 0.07 0.79 0.96 (0.73-1.28) 1.14 0.57 0.09 0.77 0.97 (0.79-1.19) 2.07 0.36 0.34 0.56 0.96 (0.83-1.11) 1.04 0.6
rs7546928 0.88 0.35 0.89 (0.71-1.13) 1.38 0.5 0.55 0.46 0.94 (0.79-1.11) 1.32 0.52 0.05 0.81 1.02 (0.9-1.15) 0.77 0.68
rs12613195 0.2 0.65 1.06 (0.82-1.37) 0.25 0.88 1.88 0.17 0.88 (0.73-1.06) 2.21 0.33 1.13 0.29 0.93 (0.82-1.06) 1.44 0.49
rs1344706 0.31 0.58 0.93 (0.74-1.19) 1.72 0.42 1.77 0.18 0.89 (0.74-1.06) 1.66 0.44 1.36 0.24 0.93 (0.82-1.05) 4.93 0.08
rs16984718 0.07 0.79 1.13(0.47-2.75) 0.08 0.78 0.02 0.9 0.96 (0.51-1.79) 0.02 0.9 0.35 0.55 0.87 (0.56-1.37) 0.36 0.55
rs2890738 1.39 0.24 1.16(0.91-1.49) 1.46 0.48 1.61 0.2 1.12(0.94-1.34) 2.38 0.3 2.66 0.1 1.11 (0.98-1.26) 2.74 0.25
rs12629685 2.02 0.16 0.84 (0.66-1.07) 2.42 0.3 0.17 0.68 0.96 (0.81-1.15) 2.02 0.36 0.21 0.65 1.03 (0.91-1.17) 5.06 0.08
rs9870579 5.63 0.02 1.61 (1.08-2.4) 9.52 0.009 8.25 0.004 1.48(1.13-1.94) 8.14 0.02 0.9 0.34 1.11 (0.9-1.36) 3.81 0.15
rs10103330 0.46 0.5 0.9 (0.66-1.22) 0.63 0.73 0.05 0.83 0.97 (0.78-1.23) 0.14 0.93 0.12 0.73 1.03 (0.88-1.21) 0.42 0.81
rs2210539 3.15 0.08 0.77 (0.57-1.03) 5.96 0.05 3.49 0.06 0.81 (0.65-1.01) 5.83 0.05 0.6 0.44 0.94 (0.81-1.1) 0.62 0.73
rs10869675 0.005 0.95 1.01 (0.77-1.32) 0.82 0.66 3.87 0.05 0.82 (0.68-1) 5.53 0.06 2.99 0.08 0.89 (0.78-1.02) 4.84 0.09
rs17101921 0.001 0.98 1.01 (0.49-2.07) 1.18 0.56 0.01 0.91 1.03 (0.61-1.74) 0.81 0.67 1.36 0.24 0.79 (0.53-1.18) 1.52 0.47
rs10835482 0.61 0.43 0.87 (0.6-1.24) 0.78 0.68 0.98 0.32 0.87 (0.67-1.14) 1.36 0.51 0.68 0.41 1.08 (0.9-1.29) 1.06 0.59
rs1602565 0.07 0.8 0.95 (0.65-1.38) 1.39 0.5 0.2 0.65 0.94 (0.71-1.24) 0.21 0.9 1.06 0.3 1.1 (0.91-1.33) 1.09 0.58
rs3016384 0.76 0.38 1.11 (0.88-1.4) 2.07 0.36 0.24 0.63 0.96 (0.81-1.14) 0.33 0.85 1.21 0.27 0.93 (0.83-1.06) 1.49 0.47
rs6490121 0.94 0.33 1.13(0.88-1.46) 1.35 0.51 0.46 0.5 0.94 (0.78-1.13) 0.76 0.69 1.43 0.23 0.92 (0.81-1.05) 1.86 0.4
rs4238270 0.42 0.52 0.92 (0.72-1.18) 0.78 0.68 0.08 0.78 1.03 (0.85-1.23) 0.19 0.91 1.5 0.22 1.08 (0.95-1.23) 2.14 0.34
rs3784397 0.33 0.57 1.07 (0.84-1.36) 0.7 0.71 0.45 0.5 0.94 (0.79-1.12) 1.04 0.6 1.43 0.23 0.93 (0.82-1.05) 2.23 0.33
rs7192086 1.17 0.28 0.87 (0.67-1.13) 1.88 0.39 1.36 0.24 1.13(0.92-1.37) 1.34 0.51 7.56 0.01 1.22 (1.06-1.4) 7.56 0.02
rs9922369 0.53 0.47 0.78 (0.39-1.54) 0.55 0.46 0.08 0.78 0.93 (0.55-1.58) 0.08 0.78 0.02 0.88 0.97 (0.67-1.4) 1.8 0.41
rs1893146 0.8 0.37 1.17(0.83-1.64) 2.49 0.29 3.49 0.06 1.26 (0.99-1.62) 10.61 0.005 1.05 0.31 1.1 (0.92-1.32) 5.14 0.08
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Table 4.4d. Markers in high LD with variant rs9870579. The relevant gene, function, 
nucleotide change and base position are shown. D’ and r2 values are for the HapMap CEU 
population. SNP rsl 1927384 is highlighted in bold font as it has been found to lie in a 
region of high conservation.
SNP Gene Function BP D’ r2
rs7355825 Intergenic A/G 141118491 1 0.69
rs980337 Intergenic A/G 141126259 1 0.69
rs9821898 CLSTN2 Intronic A/G 141146198 1 0.69
rs9824931 CLSTN2 Intronic err 141142693 1 0.69
rs9835329 CLSTN2 Intronic C/T 141144636 1 0.69
rs 17397077 CLSTN2 Intronic A/C 141177598 1 0.69
rs9824300 CLSTN2 Intronic ATT 141148245 1 0.71
rs9821561 CLSTN2 Intronic A/C 141169098 1 0.82
rs10935363 CLSTN2 Intronic A/T 141178433 1 0.83
rs11927306 CLSTN2 Intronic C/G 141166429 1 0.83
rs11927384 CLSTN2 Intronic A/G 141166481 1 0.83
rs6439886 CLSTN2 Intronic A/G 141165193 1 0.83
rs7637853 CLSTN2 Intronic C/G 141167105 1 0.83
rs9859388 CLSTN2 Intronic A/G 141168906 1 0.83
rs7617850 CLSTN2 Intronic A/G 141167334 1 0.87
rs7356017 CLSTN2 Intronic A/G 141161986 1 1
rs9852679 CLSTN2 Intronic C/G 141157433 1 1
rs9860322 CLSTN2 Intronic G/T 141160536 1 1
rs9864420 CLSTN2 Intronic C/T 141160744 1 1
rs9870376 CLSTN2 Intronic C/T 141162167 1 1
rs9870392 CLSTN2 Intronic C/T 141162204 1 1
rs9813092 CLSTN2 Intronic A/G 141162442 1 1
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1-411650081
Simple- N u c le o tid e  Polym orphism s <dbSNP b u i ld  129>
rs5852959 | rs35332927 | r-S9859388 | rs 6 8 06737 | r s 7 17943 |
rs874151 | rs5 7998218 | PS9821561 | rs3S9S9656 | PS717942
i | PS585296 0 | rs98213S 6| PS28397957| PS62271927 |
499 | rs966866 | rs5794S018 | rS34743059| rs59189315 |
>133 | PS61671749 | rs7637853 | TS6778316| rs6439887 |
35761751| r s 11927306 | rs9 87198 | rs6439888 |
rs6 439886 | r s 17337386| rs l2 1 0 7 8 3 9 | r s l l7 1 9 4 7 1 |
rs56232759 | PS7617850 | rs62271926 | rs 3 4 4 00433|
rs55878029 | r s 17337414| rs7649717 | rs5852961 |
rs59643746 | rs7649719 | rs35635508
rS34820038 | 
r s 17396896 |
rs6785630 | 
rsS 7S04739| 
r s l 1707973| 
r s 6 0712286 |
Figure 4.4a. Schematic o f variant rs l 1927384 (highlighted in black w ith white font) which 
is in high LD w ith rs9870579 (indicated by *) and resides in a region o f mammalian 
conservation. Diagram shows the chromosomal position o f both variants, their locations in 
intron 1 o f CLSTN2, the mammalian conservation in the region and the neighbouring SNPs. 
Lower part o f diagram shows LD across the region, the blacker the square the higher the r2 
between SNPs [Figure produced using the UCSC genome browser, HapMap data and 
HAPLOVIEW  HapMap format software].
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Chrl6: | 129686001 129690001 129700001 12971000|
UCSC Genes Based on RefSeq, UniProt, GenBank, CCDS and Comparative Genomics
RefSeq Genes
RefSeq Genes
Mammal Cons li .1 J
rsl501317
Simple Nucleotide Polymorphisms (dPSNP Puild 129) 
rs34273614| rs34879047 | rs9923386 | rs 12931280 |
rs56853549 | rs35371266 | rs4781366 | rs62029758 |
rs62029757 | rs6 0 05327 0 | rs7196612 j
|| rs71981781
r s l 1641457| 
r s l 1647065 I 
r s l2926563|
 rs.575.57069 I__________________
rs8056296|
Figure 4.4b. Schematic o f variant rs7192086; highlighted in black w ith white font. 
Diagram shows the chromosomal position o f the variant, its location in an intergenic 
region, the mammalian conservation in the region and the neighbouring SNPs. [Figure 
produced using the UCSC genome browser].
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4.4.1. Comparison with O’Donovan GWAS
The O’Donovan GWAS revealed one loci ZNF804A (rsl 344706; P =
1.61x10“7) that surpassed the P < 5x10'7 benchmark corresponding to strong 
evidence for association in genome-wide studies (O’Donovan et al. 2008). A 
secondary analysis, added additional data from 1865 bipolar disorder patients from 
the WTCCC study (WTCCC 2007). There was no evidence for shared risk for most 
of the loci, but for the ZNF804A locus, the evidence for association substantially 
strengthened (rsl 344706; P -  9.96x1 O'9), suggesting alleles in the vicinity of 
ZNF804A influence risk to a broad psychosis phenotype. ZNF804A maps to 
chromosome 2 at 185.1-185.5 Mb. The encoded protein is uncharacterized, has no 
known function, but contains predicted zinc ion and DNA binding domains, 
suggesting a possible role as a regulator of gene expression. Neither of the 
ZNF804A variants tested in this study, rsl 344706 and rs12613195, showed any 
evidence for association to LOAD+P. In fact, marker rsl 344706 showed deviation 
from HWE in the control sample of this study (P = 0.004).
The only marker to show association to LOAD with psychosis is rs9870579. 
In the O’Donovan GWAS discovery sample this marker had a significant p-value of 
4.72 x 10'5. However, the association did not survive meta-analysis of the 
discovery sample plus the independent replication samples (O’Donovan et al.
2008). In the O’Donovan GWAS the major T allele was over-represented in the 
case sample. The allele associated to LOAD+P is the minor C allele. Therefore, the 
association seen in LOAD+P is in the opposite direction to that seen in 
schizophrenia. A possible explanation for this finding could be that rs9870579 
influences susceptibility to psychosis in neurodevelopmental and 
neurodegenerative disease by varying mechanisms. Alternatively, at least one of 
the observed rs9870579 associations could be a false positive.
Marker rs7192086 shows nominal association to LOAD. The associated 
allele is the minor T allele. This variant was the 5th most significant marker in the 
O’Donovan GWAS discovery sample, the 3rd most significant finding in the meta­
analysis of the discovery and replication samples and the 5th most significant 
finding in the combined analysis with data from the WTCCC study of bipolar 
disorder (WTCCC 2007). The associated allele in all analyses was the minor T 
allele. Therefore, the T allele is associated with psychosis in a schizophrenia and
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bipolar disorder dataset, but with LOAD and not psychosis in LOAD in this sample. 
It is noteworthy that the association seen in this LOAD dataset is nominal and does 
not survive correction for multiple tests. Therefore, it is possible that this 
association is a type 1 error and that the T allele is likely to be associated with a 
broad phenotype of psychosis as the data from the O’Donovan GWAS suggests.
4.5. Discussion
This study tested 21 markers for association with LOAD+P. These variants 
were identified from the O’Donovan schizophrenia GWAS. No marker showed a 
significant association, in any analysis that survived correction for multiple testing. 
The lack of significant evidence for association is not unexpected due to the limited 
power of this study. The most significant association was seen with variant 
rs9870579 in the LOAD+P vs. control analysis (allelic P  = 0.004; OR = 1.48). 
However, rs9870579 appears to have a greater effect on LOAD+P under a disease 
modifier model (OR = 1.61 versus 1.48 for the disease subtype analysis), with an 
increase in the over representation of the minor C allele in LOAD+P (5% compared 
to 4% in the disease subtype analysis). Marker rs9870579 is located in intron 1 of 
the calsyntenin 2 gene. CLSTN2 is a large gene situated on chromosome 3q23. 
There is one known gene transcript which is expressed exclusively in brain. The 
calsyntenin family of proteins are predominantly postsynaptic membrane proteins 
of excitatory CNS synapses with putative calcium binding capacity (Hintsch et al.
2002). However, the highest levels of CLSTN2 protein are found in GABAergic 
neurons (Hintsch et al. 2002), i.e. neurons that produce GABA as their output. 
GABA (Gamma-aminobutyric acid) is the chief inhibitory neurotransmitter in the 
mammalian CNS. Disrupted GABAergic signalling has been implicated in 
numerous and varied neurological and psychiatric pathologies including 
schizophrenia. The 3q23 region has previously shown linkage to LOAD and the 
CLSTN2 gene has shown significant association to cognitive function (Liu et al.
2007). Thus, CLSTN2 can be considered a putative functional and positional 
candidate gene for LOAD and psychosis. Marker rs9870579 appears to have no 
functional relevance and does not lie in a region of conservation or in a binding
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motif. However the variant is in high LD (D’ = 1.0 and r2 = 0.83) with polymorphism 
rsl 1927384 which resides within a conserved region of intron 1 of the CLSTN2 
gene. Conservation suggests that this variant or the region in which it lies may 
have a functional role. For example, the conserved region may act as a binding site 
for transcription factors involved in regulation of gene expression. In the 
O’Donovan discovery sample this marker had a significant p-value of 4.72 x 10'5. 
However, this association did not survive a meta-analysis of the discovery sample 
plus independent replication samples (O’Donovan et al. 2008). The association of 
rs9870579 with LOAD+P is in the opposite direction to that seen in schizophrenia. 
This suggests that rs9870579 influences susceptibility to psychosis in 
neurodevelopmental and neurodegenerative disease by varying mechanisms, or 
that at least one of the observed rs9870579 associations is a false positive finding.
Variants at the ZNF804A gene were identified as the ‘top hits’ in the 
O’Donovan GWAS. Neither of the ZNF804A variants tested in this study, 
rs1344706 and rs12613195, showed any evidence for association with LOAD+P. 
However, rsl 344706 has not been adequately investigated as a susceptibility 
variant for LOAD with psychosis as a sub-form of LOAD as the marker deviates 
from HWE in the control sample.
Marker rs7192086 showed association with LOAD (allelic P = 0.01; OR = 
1.22 and genotypic P = 0.02). However, the association does not survive correction 
for multiple testing. The marker is located on 16p13.12 in an intergenic region at 
least 56 kb from the nearest known gene AK000877. There is low conservation 
across the region and no recognised binding motifs.
It is likely that there are true schizophrenia susceptibility loci yet to be 
identified that may associate with psychosis in LOAD. None of the published 
schizophrenia GWAS identify a schizophrenia susceptibility locus which replicates 
in independent studies. It is probable that the moderately sized samples used 
across the studies, and therefore the resultant power of each study, is inadequate 
to identify a novel susceptibility gene for schizophrenia with definitive confidence. 
Power calculations show that to achieve a significant association with an effect size 
of 1.2 in a complex genetic disorder a minimum sample size of 1300 cases and 
1300 controls is required (Faul et al. 2007). Power is further reduced in the pooled 
DNA studies by the additional inaccuracy, albeit small, of the pooled DNA 
methodology. Significant association to disease, identified by GWAS, is often the
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result of very small differences in allele frequencies. Therefore, despite the mean 
error rate of the pooled DNA methodology being extremely small (Hoogendoorn et 
al. 2000; Le Hellard et al. 2002; Meaburn et al. 2005; Norton et al. 2002; Sham et 
al. 2002), in GWAS this can prove to be a highly substantial inaccuracy and lead to 
the production of both false positive and false negative associations.
Additional genotyping of the CLSTN2 gene should be undertaken. The aim 
of this would be to identify a functional variant associated with disease. Depending 
on the results of this genotyping, additional work maybe to screen and sequence 
regions of the gene to identify novel variants which would then be tested for 
association with disease. Investigation of gene expression differences which 
associate with disease could be undertaken by cis-acting allelic expression assays 
(Bray et al. 2003b). The CLSTN2 gene plus other putative psychosis susceptibility 
genes, including those identified by the O’Donovan GWAS, will be explored further 
in the first GWAS of LOAD+P described in chapter 5. The marker rs9870579 is not 
included on the lllumina HD Human610 beadchip, however, a suitable proxy can 
be identified.
This is the first study to utilise the novel approach of using the results of a 
schizophrenia GWAS to interrogate psychosis susceptibility variants for association 
with psychosis in LOAD. This is a conservative hypothesis being tested. However, 
it seems a sensible approach to undertake in one of the early genetic association 
studies of psychosis in AD, drawing vital information from the established field of 
schizophrenia genetics to inform the choice of genetic variants to test. Due to the 
lack of consistency across schizophrenia GWAS, and the lack of identification of 
any loci which show replicated genome-wide significant association to 
schizophrenia, this study utilises the results of the O’Donovan GWAS, whose 
sample set most closes matches the LOAD+P sample used in this study. This 
approach means that true positive associations with schizophrenia, identified by 
other schizophrenia GWAS, were excluded from this analysis. Also, only specific 
gene variants have been tested, assuming that either these polymorphisms or 
markers in LD with them are associated with disease. It is feasible that a common 
gene(s) is involved in the aetiology of schizophrenia and LOAD+P, but that 
alternate polymorphisms at the loci increase the risk for alternate phenotypes.
Using this strategy this theory cannot be tested and these genes cannot be 
excluded as susceptibility loci for LOAD+P. A preferable approach would be to
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genotype ‘tag’ SNPs across the gene(s) of interest with the aim of identifying either 
direct or indirect association. However, this methodology is time consuming and 
not financially viable. Also, this sample size is small and therefore insufficiently 
powered to detect susceptibility variants of moderate effect size hypothesised to 
act in complex diseases. Future meta-analyses of multiple LOAD+P studies 
investigating overlapping genetic markers may prove more fruitful in identifying 
susceptibility factors for this form of LOAD.
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5. Genome-Wide Association Study of LOAD with Psychosis
5.1. Introduction
Since 2005, genome-wide association studies (GWAS) have produced 
strongly significant evidence that common DNA sequence variation influences 
genetic susceptibility to more than 40 different common phenotypes (Manolio et al.
2008). Many of these findings implicate previously unsuspected candidate genes 
and new pathophysiological hypotheses (Cichon et al. 2009). Findings for type 2 
diabetes (T2D) particularly highlight the success of GWAS and illustrate the 
importance of large sample size in identifying common genetic variants with small 
to moderate effect size. For example, rs7903146 at the TCF7L2 gene locus was 
found to be associated with T2D. This SNP has an overall odds ratio of 1.37 
(Frayling 2007), and was detected by most but not all previous T2D association 
studies. The other 10 loci identified (with odds ratios from 1.05 to 1.25) that 
contribute to the aetiology of T2D were missed by most single studies due to a lack 
of sample power. Allelic odds ratios between 1.1 and 1.2 require from 10,000 to 
well over 20,000 total subjects for 80% power (Cichon et al. 2009). In the Wellcome 
Trust Case Control Consortium study, the T2D susceptibility loci were ranked from 
2 to 26,017 in their strength of association (Frayling 2007). A meta-analysis 
combining over 60,000 subjects implicated eight genes achieving p-values < 5x10"® 
(with odds ratios from 1.09 to 1.15), which had not previously reached genome- 
wide significance in individual studies (Zeggini et al. 2008).
There have been 9 published GWAS of LOAD that analysed individual 
genotypes (Lambert et al. 2009; Beecham et al. 2009; Bertram et al. 2008; 
Carrasquillo et al. 2009; Coon et al. 2007; Feulner et al. 2009; Harold et al. 2009;
Li et al. 2008; Reiman et al. 2007), a report of a study that genotyped pooled 
samples (Abraham et al. 2008) and a study which used a pooling strategy to 
investigate potentially functional SNPs across the genome (Grupe et al. 2007). All 
studies identified the APOE association, proving the power of the approach under 
the 'common disease - common variant' hypothesis (Avramopoulos 2009), at least
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for relatively large effect sizes. Excluding Lambert et al. (2009) and Harold et al. 
(2009), none of the studies exceeded a sample size of 2,500 (cases and controls) 
making them of modest size for the purpose of a GWAS. None of these studies 
found a genome-wide significant association (except with APOE) in their primary 
analysis. The study by Carrasquillo and colleagues did identify genome-wide 
significance with rs5984894 at the PCDH11X locus when stage 1 and stage 2 
datasets were combined and adjusted for sex (P = 3.9 x 10'12) (Carrasquillo et al. 
2009). One of the two larger studies is a two-stage LOAD GWAS (Harold et al. 
2009). This drew upon on a combined sample of 19,000 subjects, and produced 
evidence for two novel susceptibility loci: rsl 1136000 in the CLU gene (P = 1.4 x 
1CT9) and rs3851179, a SNP 5’ to the PiCALM gene (P = 1.9 x 10‘8) (Harold et al. 
2009). Both novel associations were supported in an independent replication 
sample producing compelling evidence for association with LOAD (Harold et al.
2009). The study of Lambert and colleagues (Lambert et al. 2009) supports the 
identification of CLU as a susceptibility gene for AD. With genome-wide significant 
evidence for association of rsl 1136000 (P = 7.5 x 10*9; OR = 0.86) in the same 
direction. The study of Lambert and colleagues also identifies the CR1 gene 
(rs6656401; P =  3.7 x 10'9; OR = 1.21) as a novel susceptibility gene for AD 
(Lambert et al. 2009). This finding is supported by the study of Harold and 
colleagues (rsl408077; P = 8.3 * 10'6) (Harold et al. 2009). In addition to SNPs 
meeting stringent criteria for genome wide significance a significant excess of loci 
showing ‘sub-threshold’ association (p< 1x10‘5) with AD were also observed, 
providing strong evidence that there are several genes associated with LOAD that 
remain to be identified (Harold et al. 2009; Lambert et al. 2009).
GWAS in numerous disorders have shown that traditional psychiatric 
diagnostic phenotypes might not provide the most powerful means of mapping 
disease loci (Sabb et al. 2009). For example, it is becoming increasingly apparent 
that within diagnostic categories, such as bipolar disorder and schizophrenia, 
extensive aetiological and genetic heterogeneity operates (O’Donovan et al. 2009). 
Secondary analysis of a major depressive disorder GWAS with a narrower, more 
homogeneous phenotype produced genome-wide significant association with a 
variant located in the piccolo (PCLO) gene which replicated in additional samples 
(Sullivan et al. 2009). As a result, there is increasing emphasis on the use of 
endophenotypes and sub phenotypes to elucidate genotype-phenotype
208
Chapter 5. Genome-Wide Association Study o f LOAD with Psychosis
relationships. As psychotic symptoms in LOAD have been proposed as a marker 
for a purer form of the disease suitable for gene mapping efforts (Sweet et al.
2003), the sub-phenotype of LOAD with psychosis was used here to search for 
susceptibility genes. There are at least two models which could explain how 
genetic variation relates to psychosis in LOAD (Sweet et al. 2003). First, disease 
modifier genes could influence susceptibility to psychotic symptoms in the 
presence of neurodegeneration caused by LOAD resulting from other 
environmental or genetic factors (‘disease modifier’ model). Given such a scenario, 
one would expect to observe differences between LOAD cases with and without 
psychotic symptoms, but not necessarily between LOAD cases with psychosis and 
healthy controls. Second, LOAD characterized by the presence of psychotic 
symptoms maybe a biologically distinct phenotype, for which one or more 
susceptibility genes may exist (LOAD+P ‘disease subtype’ model). The comparison 
of LOAD+P cases with healthy controls will allow for the detection of such 
associations. Using the data from the Harold and colleagues (Harold et al. 2009) 
GWAS of LOAD (referred to hereafter as the main LOAD GWAS), variation that 
may influence susceptibility to psychotic symptoms in the presence of AD was 
investigated. Given the two possible aetiological models of LOAD+P, two separate 
analyses were undertaken. First the disease modifier hypothesis was explored by 
testing for genetic association with LOAD+P in a within LOAD case analysis, thus 
comparing LOAD cases with psychosis against LOAD cases without psychosis 
(LOAD+P vs. LOAD-P). Secondly the disease subtype model was tested by 
analysing LOAD cases with psychosis against both elderly screened and 
population controls (LOAD+P vs. control). The aim of these analyses was to 
identify LOAD+P modifier and/or susceptibility genes, and attempt to elicit the 
biological functions which contribute to the aetiology of LOAD+P, a severe form of 
LOAD. These primary analyses will be presented in Section 1 of this chapter.
The hypothesis-free nature of GWAS analysis must be considered one of its 
advantages; nevertheless, incorporating prior biological knowledge can prove 
fruitful (Holmans et al. 2009b). Therefore, the results of the LOAD+P analyses 
were examined to determine if significant associations existed at biologically 
plausible candidates. For example, the ‘top results’ from the schizophrenia forum 
‘szgene’ database (Allen et al. 2008). These secondary analyses will be presented 
in Section 2 of this chapter.
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Section 1: LOAD+P GWAS
5.2. Materials and Methods
5.2.1. Sample Ascertainment and Diagnostic Criteria
Due to the unavailability of complete phenotypic data, only a subset of the 
sample used in the main LOAD GWAS that had complete NPI data for delusions 
and hallucinations was used in these analyses. This study comprised a total of 
1,671 LOAD cases and 5,167 controls. All individuals were drawn from the United 
Kingdom, were of Caucasian ancestry and included 1,208 cases and 1,044 
screened controls from the MRC genetic resource for LOAD (Cardiff University; 
Institute of Psychiatry, London; Cambridge University; Trinity College, Dublin) 
(Morgan et al. 2007) previously used in this thesis. Additional samples were 
recruited by Queen’s University Belfast (Carson et al. 2008), University of 
Southampton (McCulley et al. 2004) and the London and the South East Region 
LOAD project (LASER-AD) (Livingston et al. 2007). LOAD cases met criteria for 
either probable (NINCDS-ADRDA (McKhann et al. 1984}, DSM-IV) or definite 
(CERAD) (Mirra et al. 1991) AD. A total of 1,135 elderly screened controls were 
ascertained from the MRC Genetic resource for LOAD and by Queen’s University, 
Belfast. All elderly screened controls were 60 years or above and were screened 
for cognitive decline using the Mini-Mental State Examination (Folstein et al. 1975). 
In addition, 4,032 population controls were drawn from the 1958 British Birth 
Cohort (1958BBC) (http://www.b58cgene.sgul.ac.uk). Psychotic symptoms were 
assessed using the Neuropsychiatric Inventory (NPI) (Cummings 1994) whose 
reliability and validity are well established (Cummings et al. 1997), and is 
comprehensively described in chapter 2.2. The threshold domain score for 
psychosis in LOAD implemented in the LOAD+P GWAS is slightly different from 
that used in the rest of this thesis. LOAD+P was defined as either the presence of 
delusions and hallucinations, or where only one symptom was present a delusion 
domain score greater than or equal to 4 or a hallucination domain score greater 
than or equal to 2. A more stringent cut off for delusions was adopted because
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delusional behaviour among LOAD sufferers is often a form of confabulation 
secondary to amnesia and is therefore likely to have a different aetiology to other 
psychotic features (Hollingworth et al. 2006). LOAD cases who had not displayed 
any hallucinations or delusions were coded as LOAD with no psychosis (LOAD-P). 
As psychotic symptoms typically emerge in the moderate stages of LOAD 
(Hollingworth et al. 2006; Paulsen et al. 2000b) those LOAD-P cases in the mild 
stages of disease were considered to be at substantial risk of going on to develop 
delusional or hallucinatory behaviour and were therefore excluded from the 
analysis. Subjects with a known previous history of mood disorders, bipolar 
disease, unipolar disease, or an anxiety disorder were also excluded from all 
analyses. A total of 645 cases met criteria for LOAD+P, 505 individuals were 
characterised as LOAD-P.
5.2.2. Sample Sets
One thousand six hundred and seventy one LOAD cases and 1,135 elderly 
screened controls included in this study were genotyped on the lllumina 610-quad 
chip. The remaining 4,032 population controls from the 1958BBC were previously 
genotyped using the lllumina HumanHap550. The following sample preparation 
and laboratory quality control measures refer to the samples genotyped on the 
lllumina 610-quad chip only.
5.2.3. DNA Extraction. Sample Preparation and Laboratory Quality Control
DNA was obtained from blood samples from each participant and extraction 
was completed by phenol/chloroform methodology as previously described 
(chapter 2.4). DNA quantification and concentration dilution was also as described 
(chapter 2.4), with a final sample dilution of 50 ng/pl. DNA quality was assessed by 
2% agarose gel electrophoresis under standard conditions (described in chapter 
2.6). Samples showing no evidence of degradation were then genotyped in a panel 
of 30 SNPs using the Sequenom™ MassARRAY™ and iPlex™ systems 
(Sequenom™, San Diego, CA) (chapter 2.7.3). This allowed sex to be checked and 
permitted sample identity checks after re-aliquoting for GWAS genotyping.
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5.2.4. Genotyping
Genotyping on the lllumina 610-quad Beadchips was performed at the 
Sanger Institute, UK. All samples were re-aliquoted for GWAS genotyping using a 
Biomek® FX Laboratory Automation Workstation (Beckman Coulter®, Inc.,
Fullerton, CA) into 96 well plate formats. 200 ng of input DNA per sample was used 
and prepared for genotyping using the lllumina Infinium™ system (lllumina® Inc., 
San Diego, CA, USA). Manufacturer’s protocols were followed throughout. Briefly, 
DNA was isothermally amplified overnight then enzymatically fragmented, alcohol 
precipitated and resuspended. The lllumina Human 610-Quad BeadChips 
(lllumina® Inc., San Diego, CA, USA) were prepared for hybridisation in a capillary 
flow-through chamber. The amplified and fragmented DNA samples were 
hybridised to the bead chips using a Tecan robot and an enzymatic base extension 
used to confer allele specificity. The chips were subsequently stained and scanned 
using an iSCAN reader (lllumina® Inc., San Diego, CA, USA) to detect 
fluorescence at each bead. Data were loaded into Beadstudio and final call reports 
containing X, Y, X-Raw and Y-Raw outputted. The llluminus algorithm for cluster 
analysis was used for genotype calling (Teo et al. 2007). In addition, 4,032 
population controls from the 1958 birth cohort (1958BBC) previously genotyped 
using the lllumina HumanHap550 were included in this study. The 1958BBC were 
genotyped by the Wellcome Trust Case Control Consortium (WTCCC) (WTCCC 
2007) or the Type 1 Diabetes Genetics Consortium (T1DGC), who used version 1 
and version 3 of the lllumina HumanHap550 array, respectively. There was no 
sample overlap across the WTCCC and T1DGC studies meaning that the 
1958BBC genotypes from the WTCCC and T1DGC were treated as independent 
samples.
5.2.5. Individual Quality Control
The main LOAD GWAS had already undergone stringent quality control 
(QC) (Harold et al. 2009), meaning that individual QC was already complete for the 
sub-sample employed in this study. This individual QC for the main LOAD GWAS 
is described as follows. Genotypes were derived from 8 separate datasets/studies, 
making the application of stringent QC filters important, as differential genotyping 
error rates between studies could result in spurious associations when the data are
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combined (Clayton et al. 2005; Moskvina et al. 2006). These filters were applied 
separately to each of these 8 datasets to remove poorly performing samples using 
tools implemented in PLINK (v1.05) (http://pnqu.mqh.harvard.edu/~purcell/plink) 
(Purcell et al. 2007). Briefly, a missing genotyping rate of > 0.01 was applied 
excluding 1,469 individuals; a filter based on mean autosomal heterozygosity was 
applied excluding 578 individuals with values above or below empirically 
determined thresholds. The specific QC thresholds applied and the breakdown of 
samples excluded in this study are given in Tables 5.2a and 5.2b, respectively. 
Seventy-one individuals with inconsistencies between reported sex and genotype- 
determined sex and 22 individuals with ambiguous genotype-determined sex were 
removed from the main LOAD GWAS. Potential genetic relatedness was examined 
by calculating identity by descent (IBD) estimates for all possible pairs of 
individuals in PLINK, and removing one of each pair with an IBD estimate £ 0.125 
(the level expected for first cousins). IBD estimates were calculated in the main 
LOAD GWAS using SNPs that were common to all lllumina chips used in the 
study, with a genotype missing data rate < 0.01, Hardy-Weinberg Equilibrium 
1x1 O'5 and a minor allele frequency > 0.01. As a result, 506 individuals were 
excluded from these analyses. Non-European ancestry was detected by merging 
genotype data from SNPs typed in all cohorts with genotypes at the same SNPs 
from 210 unrelated European (CEU), Asian and Yoruban samples from the 
HapMap project. Subsequent to removing SNPs in extensive regions of linkage 
disequilibrium (chr5: 44-51.5 Mb; chr6: 25-33.5 Mb; chr8: 8-12 Mb; chr11: 45-57 
Mb) (Price et al. 2008), SNPs were pruned if any pair within a 50-SNP window had 
r2 > 0.2. Genome-wide average identity by state (IBS) distance was calculated in 
PLINK between each pair of individuals in the resulting dataset, based on 57,966 
SNPs (all with a genotype missing data rate < 0.01, Hardy-Weinberg Equilibrium P 
> 1x1 O'5 and a minor allele frequency > 0.01). The resulting matrix of IBS distances 
was used as input for classical multi-dimensional scaling (MDS) in R (v2.7.1) 
(http://www.r-proiect.org). When the first two dimensions were extracted and 
plotted against each other, three clusters were observed corresponding to the 
European, Asian and Yoruban samples. Sixteen samples which appeared to be 
ethnic outliers from the European cluster were excluded. Population structure was 
assessed within the data using principal components analysis (PCA) as 
implemented in EIGENSTRAT (Price et al. 2006) to infer continuous axes of
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genetic variation. Eigenvectors were calculated based on the previously described 
LD-pruned subset of 57,966 SNPs common to all arrays. The EIGENSTRAT 
program also identifies genetic outliers, which are defined as individuals whose 
ancestry is at least 6 standard deviations from the mean on one of the top ten axes 
of variation, these outliers were identified and excluded. Following individual QC 
543 LOAD+P cases, 417 LOAD-P cases and 4,706 controls were included in the 
analysis.
5.2.6. SNP Quality Control
Due to unresolved genotype-calling issues with a proportion of SNPs on the 
sex chromosomes, only autosomal SNPs were included in this analysis. Individuals 
included in this study were genotyped on either the lllumina 610-quad array 
specifically for the main LOAD GWAS, or were previously genotyped on the 
lllumina HumanHap550, and the genotypes made available to us. SNPs in the 
1958BBC datasets were filtered prior to inclusion in this study. This filtering 
included expulsion of SNPs not common to both versions of the lllumina 
HumanHap550 chip (v1 and v3), or not also present on the lllumina 610-quad chip. 
The 610-quad data and the 1958BBC data were merged, and were subsequently 
QC-filtered prior to the association analyses presented here. While SNP QC had 
been performed as part of the main LOAD GWAS, additional QC was employed 
here to remove poorly performing SNPs specific to the LOAD+P, LOAD-P and 
control datasets. Harold and colleagues (Harold et al. 2009) assessed the effects 
of different missing data rate and Hardy-Weinberg filters, and the filters chosen 
were also applied to the sub-sample used here. For each of the SNP categories, 
markers were excluded if they had a minor allele frequency (MAF) < 0.01 or a 
Hardy-Weinberg Equilibrium P < 1x1 O'5, in either cases or controls. SNPs with a 
MAF > 0.05 were excluded if they had a genotype missing rate of > 0.03 in either 
cases or controls; for SNPs with a MAF between 0.01 and 0.05, a more stringent 
genotype missing rate threshold of 0.01 was employed. As a result of this basic 
SNP QC 43,542 SNPs were excluded. SNPs included in this study fell into 2 
categories: 1) 456,449 SNPs common to both the lllumina HumanHap550 and 
lllumina 610-quad arrays, 2) 72,756 SNPs with genotypes only from the lllumina
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610-quad array. As a result of the additional SNP QC, an extra 2,651 SNPs were 
excluded. Ten principal components (PCs) were extracted using EIGENSTRAT, on 
the main LOAD GWAS dataset (Harold et al. 2009). To determine if these PCs 
could assuage any population structure within the sample, logistic regression tests 
of association with LOAD+P were performed, sequentially including between 0 and 
10 of the top PCs as covariates. The impact of including the PCs was evaluated by 
calculating the genomic control inflation factor, X (Devlin and Roeder 1999). 
Including the first 1 PC as a covariate had the maximum impact on X in both the 
within case and case-control analysis (see Tables 5.6c and 5.6d, respectively). To 
minimise inter-chip and inter-cohort differences that could result in an inflation of 
type I error rate, minor allele frequencies had previously been compared between 
controls in the different groups using logistic regression analysis (Harold et al.
2009). For each of the SNP categories, a quantile-quantile (QQ) plot was produced 
for each cohort control comparison, and the significance threshold employed to 
exclude SNPs was based on where the observed %2 statistics departed from the 
null expectation (see Appendix Table 5.1 and Appendix Figure 5.1). A total of 
9,828 SNPs were excluded as a result of these comparisons. Thus, the final 
‘LOAD+P versus LOAD-P’ and ‘LOAD+P versus control’ GWAS included 526,554 
SNPs.
5.2.7. Study Power
Study power was calculated using the PS power and sample size program 
(v3.0) (Dupont and Plummer 1998), freely available at 
http://biostat.mc.vanderbilt.edu/PowerSampleSize.
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Table 5.2a. Table shows quality control filters applied to individuals in each cohort. N = number of individuals; Chr = chromosome.
Cohort N Chip MissingGenotype
Autosomal
Heterozygosity
X-Chr Heterozygosity: 
Males
X-Chr Heterozygosity: 
Females
610 2806 610 <0.01 0.325-0.337 <0.02 0.25-0.4
1958BBC
(T1DGC) 2596 550 <0.01 0.33-0.34 <0.007 0.294-0.37
1958BBC
(Sanger) 1436 550 <0.01 0.329-0.34 <0.011 0.295-0.38
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Table 5.2b. Table shows samples excluded from each cohort follow ing application o f the quality control measures listed in Table 5.2a. N = 
number o f individuals. Auto Het = mean autosomal heterozygosity. X-Chr Het = mean X  chromosome heterozygosity. * Population controls were 
not excluded i f  there was a discrepancy between reported sex and genotype-determined sex. Outliers identified by EIGENSTRAT.
~ N before Missing * * u * v 0 0 . . . Non- Genetic N afterGroup „  ^ Auto Het X-Chr Het Sex Relatedness c -  ...r__________QC_____Genotype_________________________________  European Outlier___QC
610 2304 248 39 2 46 47 0 7 1915
1958BBC
(T1DGC) 2596 57 2 2 1* 4 0 12 2519
1958BBC
(Sanger) 1436 87 108 4 0 1 0 4 1232
217
Chapter 5. Genome-Wide Association Study o f LOAD with Psychosis
Table 5.2c. LOAD+P vs. LOAD-P. Table shows the effect o f varying the number o f 
principal component (PCs), extracted from  EIGENSTRAT, on the genomic control 
infla tion factor, X. These values are based on analysis o f SNPs common to the lllum ina 
610-quad and HumanHap550 chips.
Principal Components Included X
0 1.004
1 1.002
1-2 1.003
1-3 1.004
1-4 1.005
1-5 1.007
1-6 1.006
1-7 1.007
1-8 1.009
1-9 1.010
1-10 1.011
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Table 5.2d. LOAD+P vs. control. Table shows the effect o f varying the number o f 
principal component (PCs), extracted from EIGENSTRAT, on the genomic control 
infla tion factor, X. These values are based on analysis o f SNPs common to the lllum ina 
610-quad and HumanHap550 chips.
Principal Components Included X
0 1.021
1 1.006
1-2 1.007
1-3 1.007
1-4 0.994
1-5 0.993
1-6 0.994
1-7 0.993
1-8 0.993
1-9 0.992
1-10 0.992
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5.2.8. Association Analyses.
SNPs were tested for association with LOAD+P using logistic regression, 
assuming an additive model. Following analysis, 140 cluster plots were visually 
inspected for SNPs with a p-value < 1x1 O'5 (7 SNPs were represented in both 
analyses). One SNP showed poorly formed clusters and was excluded. A 
conservative genome-wide significance threshold of 0.05/526554 = 9.5 x 10'8 was 
employed. To detect statistical significance at this threshold this study has power of 
0.001 and 0.007 to detect an association with MAF of 0.3 and effect size of 1.3 in 
the disease modifier and disease subtype analysis, respectively. To detect a 
significant association of the same effect size at P < 0.05 this study has 47% and 
78% power for the disease modifier and disease subtype analysis, respectively.
The study design is illustrated in Figure 5.2a.
A set based analysis was undertaken to determine if the top hits were 
significant at the gene-wide level. The WGAViewer program (Ge et al. 2008) was 
used to identify SNPs within the locus of interest (the gene + 40 kb of flanking 
sequence), genotyped in this study. For each of the two LOAD+P GWAS datasets, 
a set-based logistic regression analysis was run using PLINK (v1.05) (Purcell et al. 
2007), including the 1 PC included in the primary association analysis. Parameters 
were set at maximum set = 1, and number of permutations = 1,000,000. Gene 
coverage was determined by download of phase 1 and 2 CEPH genotype data, for 
the gene locus of interest, from the HapMap database (The International HapMap 
Consortium 2007), this was loaded into the HAPLOVIEW (v4.0) program (Barrett et 
al. 2005), with the list of the SNPs genotyped at the locus force included into the 
tagger tab of the software at MAF > 0.05 and r2 > 0.8.
Overlap analysis was undertaken to determine if any identified SNP showed 
evidence for association in a previous schizophrenia (O’Donovan et al. 2008) and 
bipolar (WTCCC 2007) dataset. The top 100 hits from both ‘disease modifier’ and 
‘disease subtype’ GWAS were taken and where possible an Affymetrix proxy for 
each SNP was determined using the SNP Annotation and Proxy Search (SNAP) 
(v2.1) from the Broad Institute (http://www.broadinstitute.org/mpq/snap/) (Johnson 
et al. 2008). These SNP IDs were used to mine the schizophrenia and bipolar 
disorder GWAS datasets. It was then determined if any investigated SNP showed 
evidence for association with schizophrenia or bipolar disorder at P <  0.1.
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main GWAS
PostQC  
3,941 cases, 7,848 controls
1,412 cases 
4,706 controls
5 4 3 A D + P  
4 1 7 A D - P  
4 , 7 0 6  c o n t r o l s
Logistic Regression 
Including 1 EIGENSTRAT  
principal component
PostQC  
529,205 SNPs
A d d i t i o n a l  Q C
i
Call Rate < 97%  for 
SNPs with MAF>5%  
Call Rate < 99%  for 
SNPs with 
1 % <MAF>5%
MAF<1 %
Hardy-Weinberg
P<1x10'5
Additional checks 
e.g. comparison of 
controls, cluster plot 
inspection
▼
5 2 6 , 5 5 3  S N P s
Figure 5.2a Schematic o f study design. Diagram shows number o f samples (with complete 
N P I data) and SNPs taken from main GW AS and the additional SNP QC employed 
resulting in the loss o f 2,651 SNPs.
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5.3. Results
Following individual QC 543 LOAD+P cases, 417 LOAD-P cases and 4,706 
controls were included in further analysis. Clinical characteristics of the sample can 
be found in Table 5.3a, and a full breakdown of psychosis classification in LOAD 
cases by study can be seen in Appendix Table 5.2. A total of 526,554 SNPs were 
analysed. The quantile-quantile (QQ) plots for the ‘LOAD+P versus LOAD-P’ and 
‘LOAD+P versus controls’ analyses can been seen in Figures 5.3a and 5.3b 
respectively. The genomic control inflation factors (A) (Devlin and Roeder 1999) 
were 1.002 and 1.006 respectively, suggesting little evidence for residual 
stratification. Tables 5.3b and 5.3c list the top 20 hits in the LOAD+P vs. LOAD-P 
and LOAD+P vs. controls analysis, respectively. Figures 5.3c and 5.3d show the 
Manhattan plots for the LOAD+P vs. LOAD-P and LOAD+P vs. control analyses, 
respectively. Results for all SNPs with p-values < 1x1 O'4 can be found for LOAD+P 
versus LOAD-P and LOAD+P versus control analyses in Appendix Tables 5.3 and
5.4, respectively. A breakdown of minor allele frequencies in all datasets is shown 
for SNPs with a p-value < 1x1 O'4 in Appendix Table 5.5. Note that there was no 
significant difference in allele frequencies between elderly, screened controls and 
population controls for any SNP with a p-value < 1x10'4, and the QQ plots of the 
different control sets (screened vs. WTCCC population controls, screened vs. 
T1DGC population controls, WTCCC population controls vs. T1DGC population 
controls) shows no deviation of the observed chi-square from that expected, see 
Appendix Figure 5.2.
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Table 5.3a. Basic clinical characteristics and description of sample.
LOAD
Cases* LOAD+P LOAD-P
Screened
Controls
Population
Controls
n (n before QC) 1412(1671)
543
(645)
417
(505)
937
(1135)
3751
(4032)
Sex, % Female 71.1 73.1 68.3 61.9 50.8
Mean age at
assessment 80.87 80.85 80.69 75.92 44.50
(years)
Mean age at onset 
(years) 75.85 75.54 76.13 - -
Mean MMSE 11.33 9.93 12.25 29.19
* Total number of LOAD cases with available Neuropsychiatric Inventory and genotype 
data.
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Figure 5.3a. LOAD+P vs. LOAD-P. Quantile-quantile (QQ) plot of 526,554 observed 
genome wide association ^  test statistics (y-axis) against those expected under the null 
expectation (x-axis). The line of equality is colored red. (X = 1.002).
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Figure 5.3b. LOAD+P vs. control, a) Quantile-quantile (QQ) plot of 526,554 observed 
genome wide association x2 test statistics (y-axis) against those expected under the null 
expectation (x-axis). The line of equality is colored red. (1 = 1.006). b) QQ plot after 
removal of 168 SNPs at the APOE  locus. 526,386 SNPs remain (X =  1.006).
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Table 5.3b.Top 20 hits in the LOAD+P vs. LOAD-P analysis. Table shows SNP rank, chromosome, SNP ID, base position, gene name, SNP
type, associated allele, p-value and OR in LOAD+P vs. LOAD-P and LOAD+P vs. control analysis.
Rank Chr SNP BP Gene Type Allele P OR
LOAD+Pvs. 
Control P
LOAD+Pvs. 
Control OR
1 8 rs2034140 6224172 MCPH1 INTERGENIC G 7.62E-06 0.33 1.93E-04 0.46
2 6 rs11756091 39390784 KCNK16 NON-SYNONYMOUS T 8.06E-06 1.53 2.76E-03 1.21
3 8 rs10956535 131623943 ASAP1 INTERGENIC C 8.79E-06 1.54 5.71 E-05 1.30
4 4 rs753129 56363188 AC110611.3-1 DOWNSTREAM G 9.98E-06 1.62 2.04E-05 1.36
5 9 rs960644 105060805 RP11-341A22.1 INTERGENIC G 1.04E-05 0.55 5.67E-04 0.70
6 12 rs2682778 117544535 SUDS3 INTERGENIC T 1.45E-05 0.60 3.65E-02 0.84
7 10 rs 1444400 52904161 PRKG1 INTRONIC G 1.48E-05 1.58 7.23E-03 1.25
8 10 rs 1444401 52904934 PRKG1 INTRONIC A 1.50E-05 1.58 4.51E-03 1.21
9 10 rs6480276 52907458 PRKG1 INTRONIC G 1.59E-05 1.57 6.09E-03 1.20
10 2 rs11680774 158954231 CCDC148 INTRONIC C 2.00E-05 0.63 1.74E-02 0.83
11 2 rs2883854 158947298 CCDC148 INTRONIC C 2.07E-05 0.64 1.29E-02 0.83
12 6 rs3734618 39392162 KCNK16 SYNONYMOUS C 2.09E-05 1.50 3.36E-03 1.21
13 1 rs12045777 29301591 EPB41 INTRONIC G 2.18E-05 1.52 1.12E-01 0.90
14 12 rs1520780 117524108 SUDS3 INTERGENIC A 2.75E-05 0.62 4.57E-02 0.85
15 4 rs2695234 24413336 SOD3 DOWNSTREAM T 3.39E-05 0.47 2.03E-03 0.65
16 4 rs 12648438 188865648 AC115540.3 INTERGENIC A 3.40E-05 1.66 2.57E-02 1.19
17 6 rs13201744 6071844 F13A1 INTERGENIC T 4.31 E-05 0.55 2.18E-02 0.77
18 4 rs2100889 88917369 IBSP INTERGENIC A 4.51 E-05 0.66 4.68E-02 0.87
19 2 rs3771599 159105674 PK4P;PKP4 INTRONIC G 4.88E-05 0.67 3.12E-01 0.92
20 2 rs11674284 159081135 PK4P;PKP4 INTRONIC C 4.90E-05 0.65 1.04E-01 0.89
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Table 5.3c.Top 20 hits in the LOAD+P vs. control analysis. Table shows SNP rank, chromosome, SNP ID, base position, gene name, SNP type,
associated allele, p-value and OR in LOAD+P vs. control, LOAD+P vs. LOAD-P and LOAD analysis.
Chr SNP BP Gene Type Allele OR P LOAD GWAS P
LOAD 
GWAS OR
LOAD+Pvs. 
LOAD-P P
LOAD+Pvs. 
LOAD-P OR
19 rs2075650 50087459 TOMM40 INTRONIC C 2.47 3.60E-34 1.8E-157 2.53 7E-01 1.04
19 rs157580 50087106 TOMM40 INTRONIC G 0.62 1.96E-11 9.62E-54 0.63 3.6E-01 0.91
19 rs6859 50073874 PVRL2 3PRIMEJJTR T 1.54 3.54E-11 6.95E-41 1.46 8.3E-0.1 0.98
19 rs439401 50106291 APOE;PKP2 UPSTREAM T 0.68 5.94E-08 2.65E-23 0.72 4.6E-01 1.16
19 rs8106922 50093506 TOMM40 INTRONIC G 0.69 6.05E-08 5.37E-39 0.68 8.5E-01 0.98
15 rs8038077 58791939 RORA INTRONIC G 1.78 1.56E-07 2.1E-02 1.13 4.5E-03 1.63
19 rs405509 50100676 APOE;PKP2 UPSTREAM A 1.37 1.20E-06 4.88E-37 0.7 5.6E-02 1.21
7 rs868055 129222427 MIRN183 INTERGENIC T 1.62 1.80E-06 4.11E-04 1.21 2E-03 1.65
12 rs1906950 25408885 AC092451.12-2 INTERGENIC A 1.35 4.88E-06 9.07E-04 1.1 9E-03 1.29
8 rs4527852 125542605 TRMT12 INTERGENIC T 1.61 5.56E-06 1.85E-01 1.07 1E-02 1.5
2 rs1430170 133749869 AC010974.1 INTRONIC G 0.71 9.29E-06 1.09E-02 0.92 3E-03 0.73
8 rs 10094093 4493322 AC019176.4-2 INTERGENIC T 0.68 9.93E-06 6.03E-02 0.94 2E-02 0.76
3 rs9289666 144727672 SLC9A9 INTRONIC A 1.49 1.31 E-05 2.48E-02 1.11 1.7E-03 1.57
19 rs10402948 490266 CDC34 INTRONIC T 1.63 1.35E-05 1.49E-01 1.09 3.8E-02 1.42
2 rs4671328 58788786 IK INTERGENIC A 0.75 1.39E-05 4.18E-03 0.92 7E-02 0.84
7 rs4726443 140618341 AC005692.1 INTERGENIC T 2.51 1.39E-05 1.68E-02 1.46 5E-02 1.6
8 rs16899656 125602072 TATDN1 INTRONIC G 1.58 1.42E-05 6.99E-02 1.11 3E-02 1.42
16 rs11648322 10082553 GRIN2A INTRONIC T 1.33 1.56E-05 2.51 E-02 1.07 1E-01 1.17
10 rs6482252 23397218 AL139815.12-3 INTERGENIC G 1.33 1.58E-05 3.29E-03 1.09 6E-03 0.77
10 rs7902903 23398083 AL139815.12-3 INTERGENIC C 1.33 1.69E-05 8.54E-03 1.08 3E-03 0.76
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Figure 5.3c. Manhattan plot o f chromosomal position (x-axis) against -log  10 GWAS p- 
value (y-axis) for LOAD+P vs. LOAD-P analysis. The threshold for genome-wide 
significance (P < 9.5x1 O'8) is indicated by the red horizontal line. 55 SNPs w ith P < lx lO '4 
lie above the blue horizontal line and are listed in Appendix Table 5.3. Plot produced using 
HAPLOVIEW  (v4.0) (http://www.broad.mit.edu/mpg/haploview/) .
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Figure 5.3d. Manhattan plot o f chromosomal position (x-axis) against -log  10 GWAS p- 
value (y-axis) for LOAD+P vs. control. The y-axis scale has been limited to 8 (P =1.0xl0‘8) 
although highly significant association was observed w ith SNPs in the vicinity o f the APOE 
locus. The threshold for genome-wide significance (P < 9.5x10'8) is indicated by the red 
horizontal line. Ninety-one SNPs w ith P < lx lO "4 lie above the blue horizontal line and are 
listed in Appendix Table 5.4. Plot produced using HAPLOVIEW  (v4.0) 
(http://www.broad.mit.edu/mpg/haploview/).
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Genome wide significance (GWS) was observed with five SNPs when 
comparing LOAD+P cases with controls (p-values ranging from 6.05 x 10'8 -  3.59 x 
10'34). These markers, and another showing a p-value close to the GWS threshold, 
were located in close proximity to the A P O E  locus. All of these markers showed 
similar patterns of effect and more compelling evidence of association in the main 
LOAD GWAS (p-values ranging from 2.65 x 10'23 -  1.75 x10'157) (Harold et al.
2009). Furthermore none of these SNPs showed evidence for association with 
LOAD+P when compared to LOAD-P (P  > 0.163), indicating that the APOE locus is 
associated with LOAD, unconditional of psychosis status. Excluding the APOE 
region, the most significant SNP (rs8038077) had a p-value of 1.56 x 10‘7 (OR = 
1.78) and was associated with LOAD+P when compared to controls. This marker 
rs8038077 is within an intron of the RAR-related orphan receptor A (RORA) gene 
on chromosome 15q. The same SNP showed some evidence for association in 
analysis o f‘LOAD+P versus LOAD-P’ (P =  0.005; OR= 1.63). Polymorphism 
rs17237486, located 200 kb distal to rs8038077 (LD; D’ = 0.08, r2 = 0) within the 
RORA gene, also showed association at P  = 9.03 x 10'5 (OR= 1.63) in the 
LOAD+P vs. LOAD-P analysis. Other SNPs of interest highlighted by the LOAD+P 
vs. control analysis include rs1430170 (P = 9.29 x 10'6; OR = 0.71), an intronic 
SNP within the Nek associated protein 5 (NAP5) gene on chromosome 2 and 
polymorphism rs9289666 (P = 9.29 x 10'6; OR = 1.49) which resides within an 
intron of the solute carrier family 9 (SLC9A9) gene. The most significant SNP in 
LOAD+P versus LOAD-P analysis was rs2034140 located 27 kb 5 prime of the 
microcephalin (MCPH1) gene, P = 7.02 x 10"6; OR = 0.33. This SNP also showed 
evidence of association with LOAD+P when compared to controls, P = 1.93 x 10-4; 
OR = 0.45. A potential functional risk variant is marker rs11756091 (P = 8.06 x 10"
6; OR = 1.53), a non-synonymous SNP within the potassium channel, subfamily k, 
member 16 (KCNK16) gene. The rs11756091 variant converts amino acid 301 
from a proline to a histidine which may have an effect on structure and charge of 
the protein. This SNP is also in high linkage disequilibrium (LD) (D’ = 1, r2 = 0.967) 
with a synonymous variant rs3734618 predicted to be an exon splicing enhancer 
(Conde et al. 2006). The third most significant result is with marker rs10956535 (P 
= 8.79 x 10'6; OR = 1.54), 140 kb 5 prime of the development and differentiation 
enhancing factor (AS A P 1 ). Despite none of these associations reaching genome-
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wide significance, KCNK16, MCPH1 and RORA  are all significantly associated with 
LOAD+P at the gene-wide level (Table 5.3d).
Of the top 100 hits from this study, two SNPs showed overlap between 
LOAD+P, schizophrenia (O’Donovan et al. 2008) and bipolar disorder (WTCCC 
2007) (Table 5.3e). Polymorphism rs17443484 (proxy rs17502679; D’ = 1, r2 = 1) is 
an intergenic marker on chromosome 3 which shows association at P = 8.26 x 10'5 
(OR = 0.6) in the within case analysis. In the bipolar disorder and schizophrenia 
datasets the Affymetrix proxy for this SNP showed association, in the same 
direction, at P = 2 x 10'2 (OR = 1.16) and P = 4 x 10'3 (OR = 1.33), respectively. 
Variant rs11122300 (proxy rs11122275; D’ = 1, r2 =0.817) is an intronic SNP in the 
polypeptide N-acetylgalactosaminyltransferase 2 (GALNT2) gene on chromosome 
1. This SNP shows association to LOAD+P as a subtype of disease P = 1.3 x 10’4 
(OR = 1.34). The affymetrix proxy for this SNP showed association, in the same 
direction, at P =  2.2 x 10'3 (OR = 0.84) and P = 9 x 10‘2 (OR = 0.85), for bipolar 
disorder and schizophrenia respectively.
In the main LOAD GWAS, SNPs at two novel loci showed genome-wide 
significant association to LOAD; rs11136000 in the CLU  gene (P= 1.4x10‘9) and 
rs3851179, a SNP 5’ to the PIC ALM  gene (P =  1.9x10'8) (Harold et al. 2009). In the 
LOAD+P vs. control subset of that data, representing 44.5% of the original sample, 
a similar pattern of effect (P = 0.016, OR = 0.85; P = 0.005, OR = 0.83, for 
rs11136000 and rs3851179, respectively) was noted. When comparing LOAD+P 
and LOAD-P cases neither rs1113600 nor rs3851179 showed evidence for 
association, P = 0.74 and P = 0.94, respectively.
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Table 5.3d. Gene-wide analysis of the 6 genes showing most evidence for association to LOAD+P in either LOAD+P vs. LOAD-P or LOAD+P
vs. LOAD-P analysis. Table shows gene name, gene coverage, number of SNPs genotyped, number of significant SNPs, number of independent
SNPs, empirical p-value, and associated SNP for each analysis.
Gene Coverage n SNP
LOAD+P vs. LOAD-P LOAD+P vs. Control
n Sig n Ind Emp P Ass. SNP n Sig n Ind Emp P Ass. SNP
ASAP1 0.97 86 1 1 0.062 rs11777289 0 0 1 n/a
KCNK17 0.69 23 1 1 0.0004 rs11756091 1 1 0.04 rs11756091
MCPH1 0.9 166 1 1 0.022 rs6559175 0 0 1 n/a
NAP5 0.37 68 1 1 0.1 rs1430170 0 0 1 n/a
RORA 0.71 318 1 1 0.02 rs17237486 1 1 0.0001 rs8038077
SLC9A9 0.9 511 1 1 0.37 rs9289666 0 0 1 n/a
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Table 5.3e. Results o f the overlap analysis for the top 100 SNPs from both the LOAD+P 
vs. LOAD-P and LOAD+P vs. control analyses. Table shows SNP ID , chromosome, base 
position, A ffym etrix proxy, proxy base position, r2 and D ’ between original SNP and 
proxy, p-value and OR for LOAD+P vs. LOAD-P and LOAD+P vs. control analysis, and p- 
value and OR from the O ’Donovan schizophrenia (O ’Donovan et al. 2008) and WTCCC 
bipolar disorder (WTCCC 2007) studies.
LOAD+P vs. LOAD-P
LOAD+P vs. Control
schizophrenia
bipolar disorder
SNP
Chr
BP
Proxy
BP
r2
D*
P
OR
P
OR
P
OR
P
OR
rs11122300
1
228287788 
rs11122275 
226519268
0.82
1
0.22
1.15
1 x 10-4 
1.34
0.09
0.85
0.002
0.84
rs17443484
163156164 
rs 17502679 
163143417
1
1
8.26 x 10'5 
0.6
0.28
0.9
0.004
1.33
0.02
1.16
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Section 2: Secondary Analyses
5.4. Introduction
It might be expected that disease modifying alleles, or alleles associated 
with an LOAD+P subtype may also contribute risk for idiopathic psychoses, such 
as schizophrenia. Variants Identified as novel LOAD+P susceptibility markers could 
be further explored across traditional psychiatric diagnostic boundaries, to 
determine if these causative pathways are common to a broad psychosis 
phenotype. Secondary analyses were undertaken using both LOAD+P GWAS 
datasets to determine whether there is an overlap between the identified 
susceptibility loci for LOAD+P, schizophrenia, and bipolar disorder. The first, a 
SNP based analysis, investigated (i) variants which have previously shown 
association to LOAD+P, (ii) interesting putative psychosis susceptibility variants 
investigated in chapter 3, (iii) variants investigated in chapter 4 from the O’Donovan 
et al. schizophrenia GWAS (O’Donovan et al. 2008), (iv) variants from the szgene 
database (Allen et al. 2008), (v) associated variants from a recently published 
schizophrenia meta-analysis (Stefansson et al. 2009), and (vi) associated variants 
from a bipolar disorder meta-analysis (Ferreira et al. 2008). The second analysis 
used PLINK (v1.05) (Purcell et al. 2007) to investigate candidate genes by a set 
based method. This analysis was used to determine if a SNP within a gene region 
(gene ± 20kb) is significantly associated with disease after correcting for the 
number of variants tested at that locus. This analysis was performed to investigate 
genes which have (i) previously shown published association to LOAD+P, (ii) the 
putative psychosis candidate genes investigated in chapter 3 (iii) 
oligodendrocyte/myelin related (OMR) genes known to interact with OL/G2, 
identified from the STRING database (v8.1) (http://strinq.embl.de/) . (iv) genes 
identified by the O ’Donovan schizophrenia GWAS investigated in chapter 4, (v) the 
genes identified as ‘top results’ by the szgene database (Allen et al. 2008), (vi) 
associated genes from a recently published schizophrenia meta-analysis 
(Stefansson et al. 2009), and (vii) associated genes from a bipolar disorder meta­
analysis (Ferreira et al. 2008).
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5.5 Materials and Methods
For the SNP based analysis, a list of 191 SNPs was compiled for 
investigation. The WGAViewer program (v1.25) (Ge et al. 2008) was used to 
search for the original SNP and proxies at r2 > 0.3. The program identifies the r2 
between SNPs by accessing the HapMap database. Once the SNP of interest or a 
suitable proxy was identified, p-values and ORs were retrieved from the logistic 
regression file for each GWAS dataset. One hundred and forty six SNPs were 
successfully investigated. For the gene set based analysis PLINK (v1.05) (Purcell 
et al. 2007) was used to determine if a SNP within the gene region (gene ± 20kb) 
was significantly associated with disease after correcting for the number of variants 
tested at the locus. A list of 89 candidate genes was compiled and the WGAViewer 
program (Ge et al. 2008) used to identify genotyped SNPs within the locus of 
interest (the gene + 40 kb of flanking sequence). The SNP list was used in a set- 
based logistic regression analysis, using the 1 principal component (PC) included 
in the primary association analysis, for each of the two LOAD+P GWAS datasets. 
Parameters were set at maximum set = 1, and number of permutations = 10,000 
(re-run at 1,000,000 for significant results). Gene coverage was determined using 
the phase 1 and 2 CEPH genotype data, for the gene locus of interest, from the 
HapMap database (The International HapMap Consortium 2007), this was loaded 
into the HAPLOVIEW (v4.0) program (Barrett et al. 2005), with SNPs genotyped at 
the locus force included into the tagger tab at MAF > 0.05 and r2 £ 0.8.
5.6 Results
5.6.1 SNP Based Analyses
The SNP analysis was performed for 5 separate datasets. The first 
comprised 9 SNPs identified from the literature as previously associated with 
LOAD+P (Borroni et al. 2004; Borroni et al. 2006; Carson et al. 2008; Craig et al. 
2004b; Go et al. 2005; Sweet et al. 1998; Wilkosz et al. 2007; Zdanys et al. 2007) 
and 4 SNPs identified as putative susceptibility variants in chapter 3. None of the 
tested SNPs showed an association to LOAD+P in either the ‘disease modifier’ or 
‘disease subtype’ analysis (Table 5.6a), including the OLIG2 variant rs762237.
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The second analysis took the 126 SNPs which underwent meta-analysis to 
create the szgene ‘top results’ list. Eighty seven of these variants were successfully 
investigated, the remaining variants, or a suitable proxy, were not present on the 
lllumina 610-quad chip. Two SNPs showed association with LOAD+P under the 
‘disease subtype’ model. Marker rs4733376 (P = 0.038; OR = 1.24) is located in 
intron 6 of the long transcript of neuregulinl. Marker rs1806201 (P= 0.046; OR = 
1.15) is a synonymous variant in the glutamate receptor N-methyl-D-aspartate 
receptor subunit 2B (GRIN2B). Table 5.6b shows the 4 SNPs which show p-values 
<0.1 in either the ‘disease modifier’ or ‘disease subtype’ analyses. No association 
survives a conservative Bonferroni correction for multiple testing. The full results 
are given in Appendix Table 5.6.
The third analysis investigated the markers tested in chapter 4. These 
variants were identified as being associated to schizophrenia in stage 1 of the 
recent O’Donovan GWAS (O’Donovan et al. 2008). One SNP, rs9870579, showed 
evidence for association at P < 0.05 in both the within case (P = 0.012; OR = 1.51) 
and case-control analysis (P = 0.03; OR = 1.23), see Table 5.6c. This marker 
showed evidence for association in the MRC genetic resource for LOAD sample 
tested in chapter 4 (allelic P = 0.02, OR = 1.61: allelic P = 0.004, OR = 1.48, in 
LOAD+P vs. LOAD-P and LOAD+P vs. control analysis, respectively). However, 
neither of the observed associations survived a conservative Bonferroni correction 
for multiple testing.
A recent meta-analysis of schizophrenia combined data from 1500 markers 
genotyped as part of three GWAS of schizophrenia (Purcell et al. 2009; Shi et al. 
2009; Stefansson et al. 2009). Eighteen independent markers had p-values < 1 x 
10'5 in the combined results and were followed up in additional samples 
(Stefansson et al. 2009). Analysis of these SNPs in the LOAD+P GWAS showed 
some evidence for association of two variants under the disease subtype model (P 
= 0.03; OR = 0.87 and P =  0.04; OR = 1.32, for rs1572299 and rs9960767, 
respectively), see Table 5.6d. Variant rs1572299 is an intergenic SNP on 
chromosome 9, while rs9960767 is an intronic SNP in the transcription factor 4 
(TCF4) gene. The TCF4 protein is a basic helix-turn-helix transcription factor, 
defects in which are a cause of Pitt-Hopkins syndrome, symptoms of which include 
epilepsy. However, neither association would survive a Bonferroni correction for 
multiple testing.
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Table 5.6a. SNP based analysis of previous LOAD+P associated variants and candidate 
SNPs from chapter 3. The first 4 markers were implicated in chapter 3, while the remaining 
9 SNPs have previously shown association to LOAD+P. Table shows gene name, SNP ID, 
SNP proxy, relative D’ and r“ value, p-value and OR in within case, and case-control 
analysis
Gene D' r2
LOAD+P vs. 
LOAD-P
LOAD+P vs. 
Control
SNP Proxy P OR P OR
DTNBP1 rs12525702 n/a n/a n/a 0.74 1.05 0.86 0.98
GRM3 rs2228595 rs17608250 1 0.85 0.12 1.35 0.09 1.24
0LIG2 rs2834072 n/a n/a n/a 0.29 0.90 0.70 0.98
0LIG2 rs762237 rs2834077 1 1 0.16 0.87 0.86 0.99
APOE rs7412 n/a n/a n/a n/a n/a n/a n/a
APOE rs429358 n/a n/a n/a n/a n/a n/a n/a
CHRNA7 rs6494223 n/a n/a n/a 0.60 0.96 0.32 0.94
COMT rs4680 n/a n/a n/a 0.93 0.99 0.38 1.06
DRD1 B2 (rs4532) n/a n/a n/a 0.24 1.08 0.55 1.05
DRD3 Ball (rs6280) n/a n/a n/a 0.21 0.88 0.08 0.89
HTR2A T102C (rs6313) n/a n/a n/a 0.76 1.04 0.75 1.02
IL-1|3 -511 (rs16944) rs10169916 1 1 0.36 1.10 0.49 1.05
NRG1 rs392499 n/a n/a n/a 0.33 0.91 0.96 1.00
n/a = not applicable
237
Table 5.6b. Top 4 results of the SNP based analysis for the szgene markers. Table shows gene name, gene position in ‘top result’ table, SNP ID,
relative D ’ and r2 value, p-value and OR in within case analysis and case-control analysis, and szgene OR and 95% confidence interval.
LOAD+P vs. 
LOAD-P
LOAD+P vs.
Control Szgene
Gene ‘top result' SNP Proxy D' r2 P OR P OR OR 95% Cl
NRG1 19 rs4733376 rs3757934 1 1 0.15 1.25 0.038 1.24 1.08 0.94<OR<1.24
GRIN2B 7 rs1806201 n/a n/a n/a 0.16 1.16 0.046 1.15 1.08 0.96<OR<1.22
TPH1 11 rs1800532 rs2670765 1 1 0.07 1.19 0.31 1.08 1.25 1,08<OR<1.44
1L1B 20 rs1143634 n/a n/a n/a 0.09 1.20 0.22 1.10 0.96 0.82<OR<1.11
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Table 5.6c. Results of the SNP based analysis for the markers identified from the O’Donovan schizophrenia GWAS (O’Donovan et al. 2008).
Table shows SNP ID, SNP proxy, relative D ’ and r2 value, p-value and OR in within case, and case-control analysis, and published O’Donovan
p-value and OR.
SNP Proxy D' r2
LOAD+P vs. 
LOAD-P LOAD+P vs. Control O'Donovan et al. 2008
P OR P OR P OR
rs9870579 rs9860322 1 1 0.012 1.51 0.03 1.23 4.72 x 10'5 0.56
rs12613195 rs7557843 1 1 0.11 0.85 0.12 0.88 2.1 x 10‘5 0.72
rs 12629685 rs6809722 1 0.73 0.12 0.86 0.22 0.92 5.4 x 10'5 1.33
rs7192086 rs7189560 1 0.96 0.16 0.87 0.91 1 1.15 x 10'6 1.45
rs6490121 n/a n/a n/a 0.17 1.15 0.99 1 4.72 x 10’7 1.43
rs 1344706 rs 1366840 1 0.69 0.23 1.12 0.91 1 1.47 x 10'6 0.7
rs10103330 rs10503253 1 1 0.29 0.88 0.51 0.95 4.03 x 10'6 1.47
rs2890738 n/a n/a n/a 0.36 0.91 0.95 1 1.73 x 10'8 1.44
rs11162231 rs 12082120 1 0.73 0.48 0.91 0.25 0.9 3.22 x 10'4 0.71
rs3784397 rs1869901 1 0.94 0.49 0.94 0.1 0.89 2.1 x 10’5 1.35
rs10869675 n/a n/a n/a 0.49 0.93 0.22 0.91 1.29 x 10’5 1.38
rs 16984718 rs1516922 1 0.66 0.53 1.16 0.75 1.06 5.94 x 10'4 2.1
rs2210539 n/a n/a n/a 0.61 0.94 0.71 0.97 1.38 x 10'3 0.73
rs1893146 rs 10502389 1 0.78 0.7 1.06 0.53 1.07 6.37 x 107 1.55
rs4238270 rs336230 1 0.74 0.71 0.96 0.99 1 2.67 x 10'5 0.72
rs3016384 n/a n/a n/a 0.76 1.03 0.35 0.93 7.83 x 10‘6 0.73
rs9922369 rs2111119 1 0.25 0.78 0.96 0.85 0.98 2.59 x 10'7 2.26
rs7546928 rs10889994 1 1 0.97 1 0.98 1 1.29 x 10-4 0.76
rs1602565 rs7938219 1 1 0.99 1 0.45 1.09 9.04 x 10'6 1.55
rs 17101921 n/a n/a n/a n/a n/a n/a n/a 6 x 10'3 1.73
rs10835482 n/a n/a n/a n/a n/a n/a n/a 7.83 x 10'5 1.45
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Table 5.6d. Results of the SNP based analysis for the markers identified from the Stefansson schizophrenia meta-analysis (Stefansson et al. 
2009). Table shows SNP ID, p-value and OR in within case, and case-control analysis, and published Stefansson p-value and OR.
LOAD+P vs. LOAD-P LOAD+P vs. Control Stefansson et al. 2009
SNP P OR P OR P OR
rs1572299 0.1 0.86 0.03 0.87 5.2 x 10'6 1.08
rs9960767 0.11 1.4 0.04 1.32 5.7x1 O’9 1.23
rs7776351 0.92 1.01 0.11 1.12 1.3 x 10'6 1.1
rs13219354 0.27 1.16 0.15 1.14 1.5 x 10‘1° 1.2
rs 12807809 0.09 1.24 0.18 1.12 2.3 x 10'9 1.15
rs13211507 0.37 1.14 0.47 1.07 1.1 x 10‘1° 1.24
rs3747600 0.11 0.85 0.53 0.96 1.1 x 104 1.07
rs1487222 0.71 0.97 0.58 1.04 1.6 x 10-4 1.07
rs1010471 0.06 0.84 0.6 0.97 1.9 x 10’5 1.08
rs7289747 0.76 1.06 0.6 1.07 1.6 x 102 1.09
rs6913660 0.46 1.09 0.61 1.04 2.5 x 10'9 1.15
rs2312147 0.19 1.13 0.69 1.03 3.3 x 10"7 1.09
rs6932590 0.8 1.03 0.76 1.02 5.9 x 10'12 1.15
rs3131296 0.32 1.14 0.79 0.98 2.2 x 101° 1.19
rs 1502844 0.84 0.98 0.83 0.99 1.2 x 10’6 1.09
rs7863476 0.39 0.9 0.84 1.02 8.2 x 10'5 1.09
rs10812518 0.57 0.94 0.84 1.02 1.9 x 10'4 1.08
rs 17594721 0.09 1.73 0.9 0.97 5.1 x 107 1.28
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A meta-analysis of three bipolar disorder GWAS (Ferreira et al. 2008; Sklar 
et al. 2008; WTCCC 2007), resulting in a sample of 4,387 cases and 6,209 
controls, genotyped on 325,690 SNPs, identified 39 SNPs (21 independent) 
showing a P  < 10'6 (Ferreira et al. 2008). Investigation of the 21 independent SNPs 
in the LOAD+P GWAS datasets showed evidence for association of two variants 
(Table 5.6e). Marker rs2314398 (proxy rs6746896) showed evidence for 
association in the within case analysis at P  = 0.016 (OR = 1.28), while marker 
rs12899449 (proxy rs12903120) showed evidence for association in both the within 
case and case-control analysis, P = 0.025 (OR = 0.8) and P -  0.03 (OR = 0.86), 
respectively. Both rs2314398 and rs12899449 are intergenic SNPs on 
chromosomes 2 and 15 respectively. Neither association survives Bonferroni 
correction for multiple testing.
5.6.2. Gene Based Analyses
Gene based analysis was performed for 9 different SNP sets. The majority 
of genes analysed by this methodology had good gene coverage. The exceptions 
are the CNP gene with 27% coverage, the OLIG2 gene, which has previously 
shown association to LOAD+P, with 40% coverage, and the gene encoding the 
OLIG2 interactor NKX2-2 with 8% coverage. The coverage of the c16orf5, 
HIST1H2BJ and HIST1H2BL genes were not determined. The extensive size of 
these loci meant that the HAPLOVIEW program was unable to fully load the 
genotype data. The first SNP set investigated genes previously associated with 
LOAD+P (Borroni et al. 2004; Borroni et al. 2006; Carson et al. 2008; Craig et al. 
2004b; Go et al. 2005; Sweet et al. 1998; Wilkosz et al. 2007; Zdanys et al. 2007), 
as well as genes implicated as possible LOAD+P susceptibility genes in chapter 3 
of this thesis (Table 5.6f). As expected, the APOE locus showed association to 
LOAD+P when compared to controls, but this did not surpass the associations 
seen with LOAD alone. The BDNF gene is the only other gene to show gene-wide 
evidence for association to LOAD+P with an empirical p-value of 0.01 for marker 
rs2203877. Neither the OLIG2 nor OLIG1 loci show any evidence for association. 
However, the gene coverage of OLIG2 is low at 40%.
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Table 5.6e. Results of the SNP based analysis for the markers identified from the Ferreira bipolar disorder meta-analysis (Ferreira et al. 2008).
Table shows SNP ID, SNP proxy, relative D’ and r2 value, p-value and OR in within case, and case-control analysis, and published Ferreira p-
value and OR.
SNP Proxy D' r2
LOAD+P vs. LOAD-P LOAD+P vs. Control Ferreira et al. 2008
P OR P OR P OR
rs2314398 rs6746896 1 0.88 0.016 1.28 0.52 1.05 2.8 x 10'6 0.85
rs12899449 rs12903120 1 0.95 0.025 0.80 0.03 0.86 3.5 x 10"7 0.84
rs216345 n/a n/a n/a 0.08 0.94 0.54 0.88 4.1 x 10’6 1.15
rs7042161 n/a n/a n/a 0.11 0.85 0.31 0.93 5.8 x 10'6 0.87
rs2278702 rs8041826 1 0.81 0.12 0.83 0.07 0.85 6.3 x 10'6 0.83
rs4130590 n/a n/a n/a 0.13 0.87 0.09 0.90 3.1 x 10‘6 0.86
rs17082664 rs2092602 1 1 0.16 1.19 0.55 1.05 3.6 x 10'6 1.22
rs 11720452 rs13061121 0.93 0.86 0.17 0.88 0.64 0.96 5.3 x 10'6 0.87
rs7226677 rs8096369 1 0.80 0.25 1.19 0.76 1.03 6.7 x 10'6 1.24
rs12290811 rs1944449 1 1 0.27 1.15 0.38 1.08 3.6 x 10‘6 1.2
rs16966460 rs997406 1 0.93 0.38 0.88 0.57 0.94 3.7 x 10‘6 1.26
rs 1948368 rs1777894 1 1 0.48 0.93 0.56 0.96 5.6 x 10'6 0.87
rs8015959 rs7142052 1 1 0.50 1.21 0.24 1.31 4.7 x 10*6 1.59
rs4380451 n/a n/a n/a 0.60 1.06 0.90 1.01 3.9 x 10'6 0.85
rs544368 n/a n/a n/a 0.71 1.05 0.72 0.97 6 x 10'6 1.22
rs1006737 rs10774035 1 1 0.71 1.04 0.66 0.97 7 x 10'8 1.18
rs10994336 rs4948418 1 1 0.76 0.95 0.56 1.08 9.1 x 10'9 1.45
rs3821396 n/a n/a n/a n/a n/a n/a n/a 4.6 x 10'6 1.23
rs12436436 n/a n/a n/a n/a n/a n/a n/a 4.9 x 10'6 1.3
rs1601875 n/a n/a n/a n/a n/a n/a n/a 6.9 x 10'6 0.87
rs703965 n/a n/a n/a n/a n/a n/a n/a 7.5x1 O'6 0.87
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Table 5.6f. Results of the gene based analysis for previously associated LOAD+P genes (top 6 genes) and the putative candidate genes 
investigated in chapter 3. Table shows gene name, gene coverage, number of genotyped SNPs, number of significant SNPs, number of 
independent SNPs, empirical p-value and associated SNP for both LOAD+P vs. LOAD-P and LOAD+P vs. control analysis.
Gene Coverage n SNP
LOAD+P vs. LOAD-P LOAD+P vs. Control
n Sig n Ind Emp P Ass. SNP n Sig n Ind Emp P Ass. SNP
APOE 0.42 5 0 0 1 n/a 1 1 1 x 10-4 rs2075650
IL-1P 0.82 11 1 1 0.18 rs 11680809 1 1 0.12 rs11680809
HTR2A 0.8 52 1 1 0.65 rs 12584920 1 1 0.31 rs4942576
CHRNA7 0.81 28 1 1 0.38 rs 11071515 0 0 1 n/a
DRD1 0.7 24 1 n/a 0 0 1 n/a
DRD3 0.94 289 1 1 0.77 rs 1486009 0 0 1 n/a
BDNF 0.73 10 1 1 0.01 rs2203877 0 0 1 n/a
OLIG1 1 8 1 1 0.14 rs4817527 0 0 1 n/a
GRM3 0.85 37 1 1 0.31 rs10952890 0 0 1 n/a
DISC1 0.9 31 1 1 0.33 rs17804163 0 0 1 n/a
DAOA 0.71 58 1 1 0.46 rs1041247 0 0 1 n/a
DTNBP1 0.79 32 1 1 0.47 rs17391774 0 0 1 n/a
NRG1 0.9 284 1 1 0.83 rs 12680514 0 0 1 n/a
GRIK2 0.89 161 0 0 1 n/a 1 1 0.81 rs1360790
OLIG2 0.4 13 0 0 1 n/a 0 0 1 n/a
CNP 0.27 4 0 0 1 n/a 0 0 1 n/a
COMT 0.8 27 0 0 1 n/a 0 0 1 n/a
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The second gene based analysis investigated predicted OLIG2 protein 
functional partners; see Figure 5.6a, identified from the STRING - Known and 
Predicted Protein-Protein Interactions database (v8.1) (http://string.embl.de/). This 
approach was adopted as over 300 oligodendrocyte and myelination genes have 
been identified. Analysing all of these loci would be computationally challenging at 
this time. Nine genes were investigated in this analysis, none show evidence for 
association to LOAD+P in either the disease modifier or disease subtype model 
(Table 5.6g).
The third gene based analysis investigated the genes from the szgene ‘top 
results’ list (Table 5.6h). Twenty-seven genes were tested as ‘top results’ 5, 14 and 
27 actually represent chromosomal regions 10q26.13, 11p14.1 and 16p13.12, 
respectively. These loci were not analysed as the specific region of interest could 
not be accurately determined. As expected, the A P O E  locus showed significant 
evidence for association in the case-control analysis (empirical P  = 1 x 1CT4). Two 
other genes, TP H 1  (tryptophan hydroxylase 1) and O P C M L  (opioid binding 
protein/cell adhesion molecule-like) show gene-wide evidence for association in 
the within case analysis (empirical P -  8 x 1CT4 and 3 x 10'2, respectively). The 
association with TP H 1, but not O P C M L , withstands Bonferroni correction for the 27 
genes tested (corrected P  = 0.02 and 0.81 respectively). The specific intronic T P H 1  
variant (rs17794760) showing association to LOAD+P has not been tested for 
association with schizophrenia.
The 12 genes identified by stage 1 of the O’Donovan schizophrenia GWAS 
(O’Donovan et al. 2008) were investigated in the LOAD+P GWAS datasets. Three 
genes C L S T N 2  (calsyntenin 2), C N T L N  (centlein, centrosomal protein) and 
OPCM L  (opioid binding protein/cell adhesion molecule-like) showed evidence for 
association (Table 5.6i). The O P C M L  gene has previously been discussed 
following the szgene analysis, Both C L S T N 2  and C N T L N  show evidence at an 
empirical p-value of 0.02, C L S T N 2  in the case-control analysis and C N T L N  in the 
within case analysis. Neither association survives Bonferroni correction for multiple 
testing (corrected P  = 0.22).
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Figure 5.6a. Schematic of predicted OLIG2 functional partners. [Figure produced by STRING - Known and Predicted Protein-Protein 
Interactions database (v8.1) (http://string.embl.de/)!.
Table 5.6g. Results o f the gene based analysis for the genes predicted to be OLIG2 functional partners. Table shows gene name, gene coverage,
number of genotyped SNPs, number of significant SNPs, number of independent SNPs, empirical p-value and associated SNP for both LOAD+P
vs. LOAD-P and LOAD+P vs. control analysis.
Gene Coverage n SNP
LOAD+P vs. LOAD-P LOAD+P vs. Control
n Sig n Ind Emp P Ass. SNP n Sig n Ind Emp P Ass. SNP
C10RF27 0.81 289 1 1 0.57 rs 1474864 0 0 1 n/a
CSPG4 0.72 275 1 1 0.13 rs4886490 0 0 1 n/a
EXOSC10 0.82 10 0 0 1 n/a 0 0 1 n/a
ISL1 0.8 10 0 0 1 n/a 0 0 1 n/a
NKX2-2 0.08 102 1 1 0.56 rs10225087 0 0 1 n/a
PHOX2B 0.87 69 0 0 1 n/a 0 0 1 n/a
SHH 0.65 102 1 1 0.56 rs10225087 0 0 1 n/a
SIM1 0.94 50 1 1 0.44 rs1506084 0 0 1 n/a
SOX10 0.88 69 0 0 1 n/a 0 0 1 n/a
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Table 5.6h. Results of the gene based analysis for the szgene ‘top results’. Table shows gene name, gene coverage, number of genotyped SNPs,
number of significant SNPs, number of independent SNPs, empirical p-value and associated SNP for both LOAD+P vs. LOAD-P and LOAD+P
vs. control analysis. [NB: szgene ‘top results’ numbers 5, 14 and 27 are chromosomal regions].
‘top result* Gene Coverage n SNP
LOAD+P vs. LOAD-P LOAD+P vs. Control
n Sig n Ind Emp P Ass. SNP n Sig n Ind Emp P Assoc SNP
1 DISC1 0.9 31 1 1 0.33 rs 17804163 0 0 1 n/a
2 SLC18A1 0.78 28 1 1 0.40 rs4921691 0 0 1 n/a
3 GABRB2 0.77 55 1 1 0.25 rs664806 1 1 0.64 rs9313879
4 D RD 2 0.85 28 1 1 0.19 rs4938021 0 0 1 n/a
6 AKT1 0.66 4 0 0 1 n/a 0 0 1 n/a
7 G R IN 2B 0.87 184 1 1 0.78 rs2300267 1 1 0.06 rs1861786
8 D G C R 2 0.94 24 0 0 1 n/a 0 0 1 n/a
9 PLXN A2 0.8 12 0 0 1 n/a 0 0 1 n/a
10 R P G R IP 1L 0.9 15 0 0 1 n/a 0 0 1 n/a
11 TPH1 0.87 8 1 1 0.0008 rs17794760 0 0 1 n/a
12 D R D 4 0.53 6 0 0 1 n/a 0 0 1 n/a
13 D AO A 0.71 58 1 1 0.46 rs1041247 0 0 1 n/a
15 DRD1 0.7 24 0 0 1 n/a 0 0 1 n/a
16 H TR 2A 0.8 52 1 1 0.65 rs12584920 1 1 0.31 rs4942576
17 RELN 0.87 189 1 1 0.55 rs4729939 1 1 0.54 rs7794418
18 APOE 0.42 5 0 0 1 n/a 1 1 0.0001 rs2075650
19 NRG1 0.9 284 1 1 0.83 rs12680514 0 0 1 n/a
20 IL1B 0.82 11 1 1 0.18 rs11680809 1 1 0.12 rs11680809
21 M TH FR 0.66 16 0 0 1 n/a 0 0 1 n/a
22 C O M T 0.8 27 0 0 1 n/a 0 0 1 n/a
23 HP 0.78 10 0 0 1 n/a 1 1 0 .27 rs1424241
24 D AO 0.79 15 1 1 0.23 rs10746134 0 0 1 n/a
25 T P 53 0.68 8 0 0 1 n/a 0 0 1 n/a
26 Z N F 804A 0.95 35 1 1 0.29 rs6745533 1 1 0.10 rs1427150
28 DTNBP1 0.79 32 1 1 0.47 rs17391774 0 0 1 n/a
29 OPCML 0.88 419 1 1 0.03 rs750270 1 1 0.13 rs10894589
30 R G S 4 0.77 7 0 0 1 n/a 0 0 1 n/a
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Table 5.6i. Results of the gene based analysis for the genes identified by the O’Donovan et al. GWAS of schizophrenia (O’Donovan et al. 2008).
Table shows gene name, gene coverage, number of genotyped SNPs, number of significant SNPs, number of independent SNPs, empirical p-
value and associated SNP for both LOAD+P vs. LOAD-P and LOAD+P vs. control analysis.
LOAD+P vs. LOAD-P LOAD+P vs. Control
Gene Coverage n SNP N Sig n Ind Emp P Ass. SNP n Sig n Ind Emp P Ass. SNP
AGBL4 0.92 158 1 1 0.47 rs6701767 1 1 0.20 rs590503
CLSTN2 0.87 191 1 0.16 rs6806737 1 1 0.02 rs6806737
CNTLN 0.98 85 1 1 0.02 rs3780256 0 0 1 n/a
CSMD1 0.7 317 1 1 0.25 rs2627283 1 1 0.70 rs2627283
FGFR2 0.8 38 1 1 0.14 rs 1649204 1 1 0.68 rs3135766
IRS2 0.87 15 0 0 1 n/a 0 0 1 n/a
NOS1 0.91 53 1 1 0.12 rs 11068458 0 0 1 n/a
PCSK5 0.67 170 1 1 0.67 rs13288756 1 1 0.94 rs12000040
PLCB2 0.57 13 0 0 1 n/a 0 0 1 n/a
ST6GALNAC5 0.74 26 0 0 1 n/a 1 1 0.18 rs12124645
TRIM71 0.66 16 0 0 1 n/a 0 0 1 n/a
OPCML 0.88 419 1 1 0.03 rs750270 1 1 0.13 rs10894589
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Fourteen genes were identified by the recent meta-analysis of 3 
schizophrenia GWAS (Purcell et al. 2009; Shi et al. 2009; Stefansson et al. 2009), 
conducted by Stefansson and colleagues (Stefansson et al. 2009), as showing 
evidence for association at P  < 1 x 10~5 (Stefansson et al. 2009). These were 
investigated in the LOAD+P GWAS datasets. Only neurogranin (NRGN) showed 
evidence for association (Table 5.6j), at an empirical p-value of 0.03 in the within 
case analysis. This association does not survive Bonferroni correction for multiple 
testing (corrected P = 0.42).
A meta-analysis of three bipolar disorder GWAS (Ferreira et al. 2008; Sklar 
et al. 2008; WTCCC 2007), identified 20 genes showing evidence for association to 
bipolar disorder at a P < 10'6. These genes were investigated by set-based 
analysis using both the LOAD+P datasets. No gene showed any evidence for 
association to LOAD+P at a p-value < 0.05 in either the LOAD+P vs. LOAD-P or 
LOAD+P vs. control analysis (Table 5.6k).
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Table 5.6j. Results o f the gene based analysis for the genes identified by the Stefansson et al. GWAS o f schizophrenia (Stefansson et al. 2009).
Table shows gene name, gene coverage, number of genotyped SNPs, number of significant SNPs, number of independent SNPs, empirical p-
value and associated SNP for both LOAD+P vs. LOAD-P and LOAD+P vs. control analysis.
LOAD+P vs. LOAD-P LOAD+P vs. Control
Gene Coverage n SNP n Sig n Ind Emp P Ass. SNP n Sig n Ind Emp P Ass, SNP
c16orf5 n/a 4 0 0 1 n/a 0 0 1 n/a
FXR1 0.9 9 1 1 0.15 rs1805589 0 0 1 n/a
HIST1H2BJ n/a 6 0 0 1 n/a 0 0 1 n/a
HIST1H2BL n/a 8 0 0 1 n/a 0 0 1 n/a
IFT74 0.72 17 1 1 0.06 rs16910953 0 0 1 n/a
NOTCH4 0.91 78 1 1 0.75 rs3830041 1 1 0.45 rs204987
NRGN 0.95 15 1 1 0.03 rs3830078 1 1 0.08 rs1076095
PGBD1 0.82 12 0 0 1 n/a 1 1 0.27 rs1778507
PLAA 0.72 10 0 0 1 n/a 0 0 1 n/a
PRSS16 0.72 9 0 0 1 n/a 1 1 0.27 rs3800312
SLC06A1 0.89 29 0 0 1 n/a 0 0 1 n/a
TCF4 0.88 74 1 1 0.21 rs 1631486 1 1 0.19 rs17089789
TXNRD2 0.78 36 1 1 0.32 rs17210001 1 1 0.62 rs17210001
VRK2 0.93 21 0 0 1 n/a 0 0 1 n/a
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Table 5.6k. Results of the gene based analysis for the genes identified by the Ferreira et al. GWAS of bipolar disorder (Ferreira et al. 2008).
Table shows gene name, gene coverage, number of genotyped SNPs, number of significant SNPs, number of independent SNPs, empirical p-
value and associated SNP for both LOAD+P vs. LOAD-P and LOAD+P vs. control analysis.
LOAD+P vs. LOAD-P LOAD+P vs. Control
Gene Coverage n SNP n Sig n Ind Emp P Ass. SNP n Sig n Ind Emp P Ass. SNP
ANK3 0.87 187 1 1 0.10 rs 1471247 1 1 0.07 rs1890951
ARNT2 0.79 370 1 1 0.32 rs16972744 0 0 1 n/a
C140RF165 0.71 235 1 1 0.17 rs12589666 0 0 1 n/a
C150RF53 0.69 471 1 1 0.82 rs2643208 0 0 1 n/a
CACNA1C 0.9 190 1 1 0.17 rs4765687 1 1 0.97 rs 10774043
CMTM8 0.72 77 1 1 0.48 rs2053280 0 0 1 n/a
GARNL3 0.81 176 1 1 0.34 rs4350073 0 0 1 n/a
LMAN2L 1 43 1 1 0.05 rs968470 0 0 1 n/a
LRRN1 0.77 27 0 1 n/a 0 0 1 n/a
NPAS3 0.82 588 1 1 0.39 rs1958018 0 0 1 n/a
ODZ4 0.87 347 1 1 0.43 rs565758 0 0 1 n/a
PRSS3 0.48 14 0 1 n/a 0 0 1 n/a
S1PR1 0.52 77 1 1 0.76 rs6577244 0 0 1 n/a
SIAE 0.69 450 1 1 0.47 rs3830078 0 0 1 n/a
SPRED1 0.89 500 1 1 0.08 rs954432 0 0 1 n/a
SVEP1 0.84 324 1 1 0.56 rs10980573 0 0 1 n/a
SYNE1 0.85 175 1 1 0.84 rs214989 0 0 1 n/a
THOC1 0.88 23 0 0 1 n/a 0 0 1 n/a
ZMIZ1 0.67 117 1 1 0.46 rs3740259 0 0 1 n/a
ZNF385D 0.89 183 1 1 0.51 rs13340131 0 0 1 n/a
251
Chapter 5. Genome-Wide Association Study o f LOAD with Psychosis
5.7. Discussion
This is the first LOAD GWAS to condition on the presence or absence of 
psychotic symptoms. The study draws upon 1,671 LOAD cases from the UK with 
comprehensive data on psychotic symptoms and 5,167 controls (before quality 
control). The ‘disease modifier’ hypothesis has been tested by comparison of 
LOAD cases with and without psychotic symptoms. A ‘disease subtype’ model has 
also been tested by comparison of LOAD+P cases to a large control population. 
Aside from the APOE locus, genome wide significant evidence of association with 
LOAD+P, when compared to healthy controls or LOAD cases without psychotic 
symptoms, was not observed. However, large odds ratios (1.5-1.6) were seen for 
numerous loci, particularly in the disease modifier analysis, indicating a large effect 
of these loci in the modification of psychosis in LOAD if the loci prove to be true 
susceptibility loci. The power of the present study to detect loci with effect sizes of 
the magnitude commonly observed in complex traits at a significance level of 0.05 
is modest (e.g. 0.47 for LOAD+P vs. LOAD-P and 0.78 for LOAD+P vs. control for 
a risk allele with a frequency of 0.3 and an odds ratio of 1.3). For rarer variants 
(MAF < 5%), the power to detect true effects reduces considerably to less than 1%. 
In this study, at a genome-wide significance level of 9.5 x 10'8, the power to detect 
common variants decreases considerably to < 0.001 and 0.007 under the disease 
modifier and disease subtype model, respectively. Despite this many SNPs which, 
while failing to reach the stringent genome-wide level of statistical significance, 
were identified and remain interesting as they could reflect true disease loci. Aside 
from SNPs at the APOE locus, the most significant association was observed at 
the RAR-related orphan receptor A (RORA) gene, which showed evidence of 
association in disease subtype and disease modifier analyses. The protein 
encoded by the RORA gene is a member of the NR1 subfamily of nuclear hormone 
receptors. It can bind to hormone response elements upstream of several genes to 
enhance the expression of those genes. The specific functions of this protein are 
unknown, but it has been shown to interact with proteins involved in organogenesis 
and differentiation. RORA has been highlighted as a candidate gene for bipolar 
disorder through a genetic and functional genomics analysis (P = 1.9 x 10-4) (Le-
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Niculescu et al. 2008). In the disease modifier analysis SNP rs2034130 close to the 
microcephalin (MCPH1) gene showed the most evidence of association. MCPH1 
has been implicated in chromosome condensation and DNA damage induced 
cellular responses. It is thought to play a role in neurogenesis and regulation of the 
size of the cerebral cortex. Variant rs2034140 does not lie in a conserved region, 
and is not predicted to lie within a transcription factor binding site (TFBS).
However, duplication of a region of chromosome 8, which includes the MCPH1 
gene, has been associated with autism (Glancy et al. 2009). Perhaps of more 
interest is marker rs11756091 (P =  8.06 x 10'6; OR = 1.53), a non-synonymous 
variant within the potassium channel, subfamily k, member 16 (KCNK16) gene on 
chromosome 6. The rs11756091 variant converts amino acid 301 from a proline to 
a histidine which may have an effect on structure and charge of the protein. This 
SNP is also in high linkage disequilibrium (LD) (D’ = 1, r2 = 0.967) with a 
synonymous variant rs3734618 predicted to be an exon splicing enhancer. Ion 
channel dysfunctions are well-recognized causes of episodic central nervous 
system disease including epilepsies, ataxias and migraine (Gargus 2006); a recent 
meta-analysis suggests they may also be involved in the pathogenesis of bipolar 
disorder (Ferreira et al. 2008). Other SNPs of interest highlighted by the LOAD+P 
versus control analysis include rs1430170 (P = 9.29 x 10'6; OR = 0.71). This is an 
intronic SNP within the Nek associated protein 5 (NAP5) gene on chromosome 2. 
The NAP5 gene is expressed in adult brain and has recently shown highly 
suggestive association (P=9.8 x 10"6) to bipolar disorder in a European American 
GWAS (Smith et al. 2009). Polymorphism rs9289666 (P = 9.29 x 1C6; OR = 1.49) 
is also of interest as it resides within an intron of the solute carrier family 9 
(SLC9A9) gene, which is a sodium/hydrogen exchanger expressed in the brain. 
Multiple studies have shown association of this gene to attention deficit disorder 
(ADHD) (de Silva et al. 2003; Lasky-Su et al. 2008). Also of relevance within the 
top 100 hits are SNPs within the opioid-binding protein/cell adhesion molecule-like 
(OPCML) gene and the tryptophan hydroxylasel (TPH1) gene which are both well 
regarded candidate genes for susceptibility to schizophrenia. Also, the calsyntenin 
2 (CLSTN2), which has shown some evidence for association to schizophrenia in a 
UK GWAS (O’Donovan et al. 2008), and the glutamate receptor, ionotropic, kainate 
2 (GRIK2) gene, which is a strong candidate gene for susceptibility to psychosis.
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The GRIK2 gene is located on chromosome 6q16.3 in a region which shows 
significant linkage to schizophrenia (Cao et al. 1997; Levinson et al. 2000; Martinez 
et al. 1999) and bipolar disorder (Dick et al. 2003; Lambert et al. 2005; Pato et al. 
2004), and was identified by two AD+P linkage screens (Bacanu et al. 2002; 
Hollingworth et al. 2007). Excluding SNPs at the APOE locus, none of the top 20 
SNPs implicated in the LOAD+P versus LOAD-P or LOAD+P versus control 
analyses have been previously associated with LOAD, or LOAD+P. Two SNPs 
showed overlap between the LOAD+P GWAS and previous schizophrenia 
(O’Donovan et al. 2008) and bipolar disorder (WTCCC 2007) GWAS.
Polymorphism rs17443484 is an intergenic marker on chromosome 3. Variant 
rs11122300 is an intronic SNP in the polypeptide N-
acetylgalactosaminyltransferase 2 (GALNT2) gene on chromosome 1. The protein 
encoded by the GALNT2 gene functions in the first step of oligosaccharide 
biosynthesis. While the identification of SNP overlap in LOAD+P, schizophrenia 
and bipolar disorder is interesting, the evidence for association of these variants in 
schizophrenia and bipolar disorder is not striking. Further work is required to 
determine is this degree of overlap could be expected by chance.
Two forms of secondary analysis were undertaken; the first was a SNP 
based analysis investigating SNPs of interest or suitable proxies for these in both 
the LOAD+P GWAS datasets. The second analysis was a gene based/SNP set 
analysis investigating gene regions of interest. The SNP based analysis identified 7 
SNPs of 146 which show evidence for association with LOAD+P; an intronic variant 
in the neuregulinl (NRG1) gene, a synonymous SNP in the glutamate receptor N- 
methyl-D-aspartate receptor subunit 2B (GRIN2B), an intergenic SNP on 
chromosome 9, an intronic SNP in the putative schizophrenia susceptibility gene 
transcription factor 4 (TCF4), intergenic SNPs on chromosomes 2 and 15 and 
rs9870579 an intronic SNP within the CLSTN2 gene. No marker survived 
Bonferroni correction for multiple testing. Marker rs9870579 has shown evidence 
for association to LOAD+P in the MRC genetic resource for LOAD sample. This 
GWAS sample includes a large proportion of the MRC genetic resource for LOAD 
sample. Therefore it is not surprising that rs9870579 shows some evidence for 
association in this study. However, neither association survived Bonferroni 
correction for multiple testing. The OLIG2 SNP rs762237 which has previously
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shown association to LOAD+P was tested in this analysis. No evidence for 
association was found, suggesting that the original finding may be a false positive, 
or that the relaxed phenotype definition utilised in this study maybe too broad to 
identify an association at the OLIG2 locus. The set based analysis identified 6 
genes which show evidence for association with LOAD+P; brain-derived 
neurotrophic factor (BDNF), tryptophan hydroxylase 1 (TPH1), opioid binding 
protein/cell adhesion molecule-like (OPCML), calsyntenin 2 (CLSTN2), centlein, 
centrosomal protein (CNTLN) and neurogranin (NRGN). Only the association with 
TPH1 withstands Bonferroni correction for multiple testing. TPH1 encodes an 
aromatic amino acid hydroxylase which catalyzes the first and rate limiting step in 
the biosynthesis of serotonin, an important hormone and neurotransmitter. 
Mutations in this gene have been associated with an elevated risk for a variety of 
diseases and disorders, including schizophrenia and bipolar disorder. TPH1 is 
associated with LOAD+P in the within case analysis, suggesting that this gene acts 
as a psychosis modifier rather than as a susceptibility gene for LOAD+P as a 
subtype of AD. The OLIG2 gene shows no evidence for association to LOAD+P via 
set based analysis. However, the gene coverage is poor at only 40%.
The future prospects for this dataset are expansive. Imputation may 
highlight additional ‘top hits’ (Hao et al. 2009) and gene ontology (GO) analysis 
may identify interesting gene networks which should be prioritised for investigation 
(Harris et al. 2004). Independent replication of the identified loci in well 
characterised LOAD samples is essential. Fine mapping of the genes of interest 
may then be undertaken in an attempt to identify functional variants. Gene 
screening and sequencing in a limited number of LOAD cases may identify novel 
common variants, while novel rare variants maybe identified by deep sequencing of 
the loci of interest (Mardis 2008). As identified variants may not affect protein 
structure, allelic expression assays may be used to decipher if cis-acting variants 
are present at a specific locus (Bray et al. 2003b). The lllumina HumanHap 
beadchips have proven success in copy number variation (CNV) identification (Lin 
et al. 2009), making this analysis a must in our dataset.
In conclusion, this study does not identify any SNPs which meet strict 
criteria for genome wide significant association with LOAD+P, when compared to 
controls or LOAD cases without psychotic symptoms. However a number of sub
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threshold associations were observed that a) show patterns of effect that are 
stronger than those generally observed in LOAD GWAS studies, b) are interesting 
biological and positional candidates for LOAD+P and c) show some overlap with 
others psychiatric disorders with psychotic features. It is interesting that some 
overlap between schizophrenia, bipolar disorder and psychosis in LOAD was 
observed. There is increased evidence that there is genetic overlap between the 
major psychiatric disorders (Lichtenstein et al. 2009; Purcell et al. 2009). It is 
plausible that this overlap will extend to other disease phenotypes with prominent 
psychotic symptoms. However, the specific SNPs associated with disease in the 
LOAD+P analyses differ from those associated with schizophrenia and bipolar 
disorder. The association of varying genetic polymorphisms within the same gene 
to overlapping phenotypes is not unusual in complex genetics (O’Donovan et al. 
2009), and perhaps, implies that SNPs associated with schizophrenia and bipolar 
disorder are not associated with LOAD+P. Alternatively the LOAD+P sample is not 
adequately powered to detect these associations. Numerous genes have shown 
association to more than one disease/disorder. For example, the Lamin A/C 
(LMNA) gene, which encodes the nuclear envelope proteins lamin A and lamin C, 
has been found to be the causative gene for Autosomal dominant Emery-Dreifuss 
muscular dystrophy (EDMD-AD), in addition to a further eight clearly defined 
phenotypes via differing genetic variations (Rankin and Ellard 2006). A number of 
the loci identified by this study are good functional candidate genes for psychosis 
and warrant further investigation in larger, appropriately powered samples in which 
the presence of psychotic symptoms in LOAD is well characterised. For example, 
the RAR-related orphan receptor A (RORA) gene which is involved in the 
enhancement of gene expression, the potassium channel, subfamily k, member 16 
(KCNK16) gene and the tryptophan hydroxylase 1 (TPH1) gene involved in the 
biosynthesis of serotonin.
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6. Final Discussion
The aim of the research presented within this thesis was to detect a novel 
locus or loci conferring susceptibility to the psychosis observed among LOAD 
sufferers. LOAD is a clinically heterogeneous illness and increasing attention is 
now being paid to utilizing defined subgroups in the hope of unpicking the complex 
aetiology of the illness (Olson et al. 2001; Pericak-Vance et al. 2000; Sweet et al. 
2003). Currently little is known about the underlying causes of the clinical 
differences observed in LOAD. Gaining a more comprehensive understanding of 
LOAD+P may aid both the study of this form of clinical heterogeneity and LOAD as 
a whole, providing a strong platform for the development of future preventative and 
therapeutic strategies.
This thesis is based on the evidence that psychosis in AD is a distinct form 
of AD with heritability estimates of 30-61% (Bacanu et al. 2005). The phenotype 
shows evidence of linkage to specific chromosomal regions (Avramopoulos et al. 
2005; Bacanu et al. 2002; Hollingworth et al. 2007) and evidence for association 
with specific genetic variants (Borroni et al. 2004; Borroni et al. 2006; Borroni et al. 
2007; Go et al. 2005; Holmes et al. 2001; Sweet et al. 1998; Sweet et al. 2005. 
Thus, psychosis in AD is an excellent candidate for gene mapping efforts. The 
published literature highlights an overlap in linkage regions and associated loci of 
neurodevelopmental psychoses and AD+P (Bacanu et al. 2002; Cao et al. 1997; 
Dick et al. 2003; Hollingworth et al. 2007; Lambert et al. 2005; Levinson et al.
2000; Martinez et al. 1999; Pato et al. 2004), supporting the theory that psychosis 
modifier genes act across neurodevelopmental and neurodegenerative disease. 
Under such a ‘disease modifier’ model, genetic variation would not increase the 
risk of developing AD, but could influence the presentation of psychosis in the 
presence of neurodegeneration. Alternatively, psychosis could identify a distinct 
‘sub-phenotype’, or more homogeneous form of the disease. Under such a model, 
genetic variation would increase disease risk but only within those sufferers 
experiencing AD with psychosis. In this thesis both theories as to the development 
of psychosis in LOAD were explored.
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6.1. Thesis Findings
Initial work focused on exploration of the current literature to determine 
criteria to classify psychosis presence or absence in LOAD. The Neuropsychiatric 
Inventory (NPI) (Cummings 1997) was used to assess the prevalence and severity 
of behavioural and psychological symptoms in all participants. Samples were 
classified based on the scores of the NPI, rated to reflect the worst episode of each 
symptom over the lifetime of the illness. Individuals classified as having late-onset 
Alzheimer’s disease with psychosis (LOAD+P) had to meet a frequency threshold 
for presence of symptom(s) > 2, this minimum criterion aimed to exclude those 
patients experiencing very few psychotic episodes which maybe attributable to 
another cause. For individuals to be classified as LOAD+P they also had to 
experience both hallucinations and delusions or experience either hallucinations or 
delusions with a NPI domain score > 3. These criteria were based on similar 
classification definitions of AD+P from previous studies being implicated in AD 
(Cummings et al. 2005). Of the 1,205 MRC genetic resource for LOAD patients,
379 individuals were categorised as LOAD+P (78% females, mean AAO = 76.07 
years). LOAD cases who had not displayed any hallucinations or delusions were 
coded as LOAD-P. As prevalence and severity of psychosis in LOAD has been 
shown to increase with advancing disease progression (Paulsen et al. 2000b; 
Ropacki and Jeste 2005), individuals with mild-moderate LOAD (GDS < 5) were 
considered at unknown risk of developing psychosis and excluded from the LOAD- 
P subgroup. Two hundred and sixty nine individuals were categorised as LOAD-P 
(70% females, mean AAO = 75.97 years). These strict classification criteria were 
employed to isolate a more homogenous phenotype suitable for genetic 
exploration studies. One thousand three hundred and five elderly screened 
controls were also available for genotyping as part of this study.
A 2 stage approach to identifying genes implicated in the aetiology of 
LOAD+P was undertaken. In chapter 3 and 4 of this thesis specific genes and 
genetic polymorphisms which had previously shown evidence of association to 
neurodevelopmental psychoses, specifically schizophrenia, were tested for 
association to LOAD+P. In chapter three 73 variants from 11 psychosis candidate 
genes were investigated. The aim of this study was to elucidate if any ‘historic’
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putative psychosis candidate gene o r  variant contributes to the aetiology of 
LOAD+P. Six of the genes were investigated via a tagging approach to elicit if any 
variation within the locus was directly o r indirectly associated with disease. Specific 
putative susceptibility variants at th e  remaining 5 loci were directly investigated for 
association with disease. Four polymorphisms at the OLIG2 locus showed 
significant association with psychosis in LOAD under a disease modifier model.
The strongest evidence for association was with marker rs762237 (P = 0.002, OR 
= 1.42), an observation that remains significant after correction for multiple testing 
(P= 0.019). This variant is located 6 . 7  kb from the 3’ end of OLIG2. Polymorphism 
rs2834072 (P = 0.004, OR = 1.41) a ls o  shows significant evidence for association 
with LOAD+P and withstands correction for multiple testing (P = 0.05). This variant 
is located 8.9 kb 3’ of the OLIG2 g e n e . Markers rs13046814 (P=  0.03, OR = 1.30) 
and F16GA (P=  0.04, OR = 1.41) s h o w  nominal association with LOAD+P, but 
these do not withstand correction fo r  multiple testing (P = 0.3 and P = 0.39 
respectively). Variant rs13046814 is  located within the 3’ UTR of OLIG2 and 
polymorphism F16GA is located 1 k b  3 ’ of the gene. None of the associated 
variants have an obvious functional relevance and no marker in LD with an 
associated variant resides in a p ro m o ter region, a region of high conservation 
(>80%) or a predicted transcription fa c to r  binding site. The markers which 
associate with LOAD+P differ to th o s e  associated with schizophrenia (Georgieva et 
al. 2006). Implying that genetic va ria tio n  in OLIG2 modifies psychosis in LOAD by a 
varying mechanism to that seen in schizophrenia, and suggests a possible role for 
white matter abnormalities in the a e tio lo g y  of a psychosis subtype of LOAD. 
Numerous genes show association to  more than one disorder. For example, the 
Tripartite motif-containing 32 (T R IM 3 2 )  gene on chromosome 9q33.1 is 
hypothesised to be an E3-ubiquitin-ligase gene (Frosk et al. 2002). The single 
TRIM32 missense variant D487N is associated with autosomal recessive Limb- 
girdle muscular dystrophy (LGMD) (C o s s e e  et al. 2009), while the conserved 
homozygous missense mutation P1 3 0 S  is associated with Bardet—Biedl syndrome 
(BBS) (Chiang et al. 2006). The d iffering  aetiology of psychosis in 
neurodevelopmental and neurodegenerative disease may explain the differing 
presentation of psychosis in these d isorders. Psychosis in AD develops within a 
few years of dementia onset and u s u a lly  persists only a matter of months before 
ceasing (Chen et al. 1991; Paulsen e t  a l. 2000b; Ropacki and Jeste 2005).
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Psychotic symptoms in neurodevelopmental conditions have a common clinical 
presentation. Hallucinations are the most common psychotic symptom which are 
predominantly auditory in nature (Bocker et al. 2000). Delusions of persecution, 
grandiosity and paranoid or bizarre delusions are common (Corner 2004; Tasman 
1997). Despite the differing presentation, the core symptoms of psychosis, 
hallucinations and delusions are common to all phenotypes implicating the same 
loci in psychosis presentation.
In chapter four 21 ‘novel’ variants identified by a recent genome-wide 
association study of schizophrenia (O’Donovan et al. 2008) were investigated for 
association with LOAD+P. No marker showed a significant association, in either 
disease modifier or disease subtype analysis, which survived correction for multiple 
testing. The most significant association was seen with variant rs9870579 in the 
LOAD+P versus control analysis (allelic P = 0.004; OR = 1.48). Marker rs9870579 
is located in intron 1 of the calsyntenin 2 gene. Calsyntenin 2 (CLSTN2) is located 
on chromosome 3q23 and is expressed exclusively in brain. The calsyntenin family 
of proteins are predominantly postsynaptic membrane proteins of excitatory CNS 
synapses with putative calcium binding capacity (Hintsch et al. 2002). However, the 
highest levels of CLSTN2 protein are found in GABAergic neurons (Hintsch et al.
2002). Disrupted GABAergic signalling has been implicated in numerous and 
varied neurological and psychiatric pathologies including schizophrenia. The 3q23 
region has previously shown linkage to AD and the CLSTN2 gene has shown 
significant association to cognitive function (Liu et al. 2007). Thus, CLSTN2 can be 
considered a putative functional and positional candidate gene for psychosis in 
LOAD. Marker rs9870579 does not appear to have a functional role. However, it is 
in high LD with polymorphism rs11927384, which does lie in a conserved region. 
Conservation suggests that this variant or the region in which it lies may have a 
functional role. For example, the conserved region may act as a binding site for 
transcription factors involved in regulation of gene expression. In the schizophrenia 
discovery sample rs9870579 had a significant p-value of 4.72 x 10'5 (O’Donovan et 
al. 2008). This association was the result of an over-representation of the major T 
allele. However, the associated allele in LOAD+P is the minor C allele. Therefore, 
the association seen with psychosis in LOAD is in the opposite direction to that 
seen in schizophrenia. A possible explanation for this finding could be that 
rs9870579 (or a variant in LD with rs9870579) influences susceptibility to psychosis
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in neurodevelopmental and neurodegenerative disease by varying mechanisms. 
Alternatively, at least one of the observed rs9870579 associations could be a false 
positive finding.
In chapter 5 a hypothesis free analysis of genome-wide association data for 
LOAD conditioning on the presence or absence of psychosis was described. The 
analysis studied 526,554 markers in 645 LOAD+P cases, 505 LOAD-P cases and 
5167 controls, including 1,135 elderly controls matched for age, sex and ethnicity. 
No genome-wide significant evidence for association was observed when LOAD+P 
cases where compared to LOAD-P. In the LOAD+P versus control analysis 
genome-wide significance was observed but only with the APOE locus which 
shows a greater association to LOAD alone. Large odds ratios (1.5-1.6) were seen 
for numerous loci, particularly in the disease modifier analysis, indicating a large 
effect of these loci in the modification of psychosis in AD. Therefore, despite not 
observing any SNPs that meet stringent levels of genome-wide significance, many 
SNPs were identified which remain interesting and could reflect true disease loci. 
Aside from SNPs at the APOE locus, the most significant association was 
observed at the RAR-related orphan receptor A (RORA) gene, which showed 
evidence for association in disease subtype and disease modifier analyses. The 
protein encoded by the RORA gene is a member of the NR1 subfamily of nuclear 
hormone receptors. It can bind to hormone response elements upstream of several 
genes to enhance the expression of those genes. The specific functions of this 
protein are unknown; it has been shown to interact with proteins involved in 
organogenesis and differentiation. RORA has been highlighted as a candidate 
gene for bipolar disorder through a genetic and functional genomics analysis (Le- 
Niculescu et al. 2008). In the disease modifier analysis SNP rs2034130 close to the 
microcephalin (MCPH1) gene showed the most evidence of association. MCPH1 
has been implicated in chromosome condensation and DNA damage induced 
cellular responses. It is thought to play a role in neurogenesis and regulation of the 
size of the cerebral cortex. Perhaps of more interest is marker rs11756091 (P = 
8.06 x 10'6; OR = 1.53), a non-synonymous variant within the potassium channel, 
subfamily k, member 16 (KCNK16) gene on chromosome 6 which may affect 
protein charge and function. Ion channel dysfunctions are well-recognized causes 
of episodic central nervous system disease including epilepsies, ataxias and 
migraine (Gargus 2006); a recent meta-analysis suggests they may also be
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involved in the pathogenesis of bipolar disorder (Ferreira et al. 2008). Secondary 
analyses of the disease modifier dataset highlights the tryptophan hydroxylasel 
gene (TPH1).TPH1 encodes an aromatic amino acid hydroxylase which catalyzes 
the first and rate limiting step in the biosynthesis of serotonin, an important 
hormone and neurotransmitter. Mutations in this gene have been associated with 
an elevated risk for a variety of diseases and disorders, including schizophrenia 
(Saetre et al. 2009). These GWAS analyses provide no evidence to support the 
previously identified association with the OLIG2 gene. Suggesting that the original 
association of OLIG2 with LOAD+P could be a false positive finding. However, the 
genetic coverage of the OLIG2 gene is poor at only 40%. This is the first genome- 
wide association study of LOAD+P. Despite the lack of genome-wide significant 
findings some interesting candidate genes have been prioritised for further 
investigations.
6.2. Thesis Limitations
An understandable limit of the work presented in this thesis is power. This 
limitation was partially addressed in chapter 5 where the sample was developed to 
provide a 13% and 21% increase in power for the disease modifier and disease 
subtype analysis respectively. Power calculations show that to achieve a significant 
association with an effect size of 1.2 in a complex genetic disorder a minimum 
sample size of 1300 cases and 1300 controls is required (Faul et al. 2007). Due to 
this a true association may be missed if the effect size is modest, as is often seen 
in studies of complex genetics. A larger sample-set would greatly increase the 
study power. However, this would require recruitment of around 5000 LOAD 
patients with comprehensive data on occurrence of psychotic symptoms to produce 
a dataset with suitable power to confidently access genetic association of 
moderate to strong effect at a given locus. Power to detect smaller effect sizes 
which are proving to be common in complex disease would require a much larger 
data set of 10,000s of samples. However, the sample utilised in this thesis is the 
largest LOAD+P sample of any published study, and is substantial in comparison 
to the datasets studied for genetic association to LOAD+P (Wilkosz et al. 2007).
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Phenotypic classification of LOAD+P is a limitation of any LOAD+P study. 
Research into risk factors for LOAD+P has been plagued with inconsistent results, 
owing largely to methodological variations between studies. There is no 
generalised classification system to assess psychosis in LOAD. The NPI is the 
most commonly used system with established reliability and validity in clinical and 
research settings (Cummings 1997). Despite the NPI being used as the ‘common’ 
classification system, there is no consensus criterion in place to diagnose the 
presence or absence of psychosis in AD. Thus, genetic association studies of 
LOAD+P are often based on varying phenotypic classification making comparisons 
between studies difficult and emphasizing the need for a universal phenotype 
definition. Also, the search for risk factors for neurodegenerative disease is fraught 
with numerous difficulties. For example, endophenotypic information may be 
systematically biased between cases and controls. On the whole data regarding 
dementia sufferers generally comes from an informant, or proxy. It is possible that 
the proxy of an dementia case may recall previous medical history differently to the 
proxy of a control, or the control themselves (Launer et al. 1999).
Another limitation of this study is the methodology of marker selection, or 
gene coverage used in chapters 3 and 4. Ideally each candidate gene would have 
been ‘tagged’ with a minimum r2 of 0.8 and MAF of 0.05 to extract at least 80% of 
the common genetic information from the locus and identify an association signal 
either directly (genotyping the functional variant) or indirectly (genotyping a variant 
in LD with the true susceptibility marker). However, as this study took a novel 
approach to investigate psychosis susceptibility genes it was logical to investigate 
as many of these genes as possible. The only practical way to do this was to 
genotype polymorphisms with either a functional role e.g. reducing gene 
expression, or which had previously shown association to at least one form of 
psychosis. Using this methodology positive association(s) with alternate 
polymorphisms at the loci of interest would be missed. This limitation was partially 
addressed in chapter 5 where a genome-wide approach was utilised. The lllumina 
HumanHap 550k beadchip which was one of the lllumina platforms used in this 
study has been shown to have average coverage of approximately 90% for 
common SNPs with MAF > 5% (Magi et al. 2007). This data is based on the SNPs 
included in phase 1 of the HapMap project (The International HapMap Consortium
2003). However, the distribution of markers across the genome is not even. The
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‘lumpiness’ of marker distribution means that some loci have good coverage while 
others have very poor. For example, the OLIG2 locus, which is of particular interest 
to this study, has poor coverage of 40%. Thus, potential positive associations may 
be missed if they reside at these poorly represented loci. Imputation, which is 
discussed below, may partially resolve this issue by providing genotype data at 
untyped loci.
Also of note is that this study is only designed to identify common variation 
of large to moderate effect size. The genetic risk for LOAD+P may be due to a 
combination of common SNPs of various effect sizes, rare SNPs and copy number 
variants, other unsuspected genomic mechanisms, gene-gene or gene- 
environment interactions, and epigenetic effects.
6.3. Future Work
There is a long way to go to fully characterize the genetic basis of LOAD+P. 
The analysis of genome-wide association data in this thesis suggests that there are 
no loci of large effect contributing to the aetiology of psychosis in AD. However, the 
power of these analyses are inadequate and some loci have not been sufficiently 
interrogated. Further work on this dataset may involve imputation, haplotype 
analysis, gene ontology analysis and copy number variation analysis. The genome- 
wide imputation of genotypes has recently attracted significant attention given its 
broad applicability in the era of GWAS (Hao et al. 2009). Current algorithms can 
accurately impute genotypes for untyped markers, which enables researchers to 
identify evidence for association at these markers, imputation allows the pooling of 
data between studies conducted using different SNP sets and may facilitate the 
interpretation of results through localisation of causal polymorphisms. Imputation 
algorithms are based on the high correlation of linkage disequilibrium (LD) between 
the nearby markers.C onsequently, testing assayed SNPs for association to traits 
of interest will also have some power to capture signals for untyped causal SNPs 
(Hao et al. 2009). Further, if the assayed SNPs are strategically distributed across 
the genome (e.g. tag SNPs), maximal genetic coverage can be achieved (Barrett 
and Cardon 2006). The LD in a reference population, such as the HapMap CEPH
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population, which is genotyped for both the typed and untyped markers in a study, 
is used to determine the LD structure in the study population. From this the 
genotypes of unobserved SNPs can be imputed (i.e. predicted) based on nearby 
markers and then directly tested for association with phenotypes of interest 
(Marchini et al. 2007). Imputing genotypes is surprisingly accurate. However, 
GWAS incorporating imputed genotypes may only have a slight increase in power 
on top of assayed SNPs. The reason for this modest increase in power is likely 
because, adding more markers via imputation only results in modest gain in 
genetic coverage, but worsens the multiple testing penalties (Hao et al. 2009).
Genome-wide association methods based on haplotypes comprising 
multiple SNPs on the same inherited chromosome may provide additional power 
for mapping disease genes and identify associations not seen with single SNPs 
(Zhao et al. 2003). In particular if the common disease-common variant theory 
applies. According to this, the genetic variants related to a complex disease are old 
mutations and are common in the population (minor allele frequencies > 5%). 
Subsequent mutations and recombinations in the ancestral haplotype at which the 
disease mutation occurred shortened the haplotypes that descended from this 
ancestor (Nolte et al. 2007). However, in the current generation the haplotypes will 
still share a fragment around the disease locus (Nolte et al. 2007). Over recent 
years novel methods of haplotype analysis have been implicated or are under 
development, which are fast enough and hence practical to use even for marker 
densities of 500,000 SNPs/genome (Nolte et al. 2007).
Gene Ontology (GO) is a method to describe gene products in terms of their 
associated biological processes, cellular components and molecular functions in a 
species-independent manner (Harris et al. 2004). Numerous methods, such as 
Association List Go AnnoTatOR (ALIGATOR) (Holmans et al. 2009b), and AmiGO 
(Carbon et al. 2009), have been developed to identify GO categories that are 
enriched for association signals in GWAS. ALIGATOR was designed in Cardiff by 
Professor Peter Holmans. The program converts a list of significant SNPs into a list 
of significant genes, applying corrections for gene size and non-independent 
categories, and is not influenced by LD (Holmans et al. 2009b). GO analyses 
identify overrepresented GO categories, and help prioritise genes for investigation.
265
Chapter 6. Final Discussion
Future meta-analysis of GWAS data may prove fruitful in identifying 
common variation for LOAD+P. This will require collaboration between groups with 
large LOAD sample-sets which have comprehensive phenotype data for 
behavioural symptomology. Newer methodologies also include, but are not limited 
to, study of copy number variation (CNV) and deep sequencing of candidate loci 
with the goal of identifying rare risk-influencing variants. We can reasonably hope 
that as this technology is applied to LOAD+P, more small-to-medium-effect risk loci 
will be identified. Copy number variation results from deletions, inversions, 
insertions and duplications. CNVs are inherited but can also arise during 
development. CNVs are usually defined as a DNA segment that is 1 kb or larger 
and present at variable copy number in comparison with a reference genome (Feuk 
et al. 2006). A CNV can be simple in structure, such as tandem duplication, or may 
involve complex gains or losses of homologous sequences at multiple sites in the 
genome. It is estimated that approximately 0.4% of the genomes of unrelated 
people typically differ with respect to copy number (Redon et al. 2006). Multiple 
complementary technologies have been developed to identify and annotate CNVs, 
which include but are not limited to; SNP genotyping arrays, and clone-based 
comparative genomic hybridization. The lllumina HumanHap beadchips have 
proven success in CNV identification (Lin et al. 2009), making this analysis a must 
in our dataset.
Several new sequencing instruments (so-called ‘next generation’ or ‘deep 
sequencing’) are now available and are already transforming the field of genetics. 
When coupled with the appropriate computational algorithms, our ability to answer 
questions about an organism’s mutational spectrum, from single base to large copy 
number polymorphisms, on a genome-wide scale, is likely to radically alter our 
understanding of human genetics (Mardis 2008). Dideoxynucleotide sequencing of 
DNA has been a staple part of molecular genetics since its first description in 1977 
(Sanger et al. 1977), and has undergone a steady metamorphosis from a cottage 
industry into a large-scale production enterprise (Mardis 2008). Dideoxynucleotide 
approaches to focused mutation discovery have used directed PCR to amplify 
selected genomic regions from individual samples, followed by capillary 
sequencing, alignment of the resulting sequence traces and algorithmic detection 
of sequence variants (Nickerson et al. 2001; Wilson et al. 2003). What sets next-
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generation sequencing apart from conventional capillary-based sequencing is the 
ability to process millions of sequence reads in parallel rather than 96 at a time 
(Mardis 2008). Also, next generation sequence reads are produced from fragment 
‘libraries’ that have not been subject to the conventional vector-based cloning and 
amplification stages used in capillary sequencing. As such, some of the cloning 
bias issues that impact genome representation in sequencing projects may be 
avoided, although each sequencing platform may have its own associated biases 
(Mardis 2008). Next generation sequencing, as is the case with most new 
technologies, is still relatively expensive. Sequencing platforms which prioritise 
genome-wide exon sequencing or exome’ sequencing are now readily available to 
allow sequencing of coding regions at workable financial cost.
6.4. Conclusions
Late-onset Alzheimer’s disease is a major cause of dementia and is 
becoming increasingly important in aging populations. The presence of psychotic 
symptoms in LOAD is associated with many serious consequences and may be a 
marker for a more severe form of the disease (Weamer et al. 2009). An obstacle in 
the search for risk factors for LOAD+P is the acquisition of adequately sized and 
phenotypically defined samples. However, previous studies have found that AD+P 
is genetically determined, with the phenotype shown to associate with specific 
chromosomal locations and loci (Avramopoulos et al. 2005; Bacanu et al. 2002; 
Bacanu et al. 2005; Borroni et al. 2004; Borroni et al. 2006; Borroni et al. 2007; Go 
etal. 2005; Hollingworth et al. 2007; Holmes et al. 2001; Sweet et al. 1998; Sweet 
et al. 2005). This study utilised a novel approach of using schizophrenia putative 
susceptibility genes and GWAS results to interrogate psychosis susceptibility 
variants in LOAD with psychosis. This is a conservative hypothesis being tested. 
However, it is a logical approach to undertake in one of the early genetic 
association studies of psychosis in LOAD, drawing vital information from the 
established field of schizophrenia genetics to inform the choice of variants to test. 
This analysis proved fruitful with the identification of the OLIG2 and CLSTN2 loci
267
Chapter 6. Final Discussion
which associate with LOAD+P. This study presents the results of the first genome- 
wide association study of LOAD to condition on the presence or absence of 
psychosis. Despite the lack of genome-wide significant findings some interesting 
candidate genes have been prioritised for further investigations which a) show 
patterns of effect that are stronger than those generally observed in LOAD GWAS 
studies, b) are interesting biological and positional candidates for LOAD+P, and c) 
show some overlap with other disorders with psychotic features. The future 
prospects for this dataset are expansive. Imputation may highlight additional ‘top 
hits’ and gene ontology (GO) analysis may identify interesting gene networks which 
should be prioritised for investigation. This dataset may also provide a useful tool 
for future meta-analyses and gene exploration. The potential of this dataset may be 
maximised by the use of complimentary methodologies. For example, cross 
disciplinary analyses including data from gene expression arrays and inclusion of 
data from comparative genomics which can highlight regions of biologically 
relevant conservation. The hunt for functional susceptibility variants for LOAD+P 
will undoubtedly include the methods discussed and presented in this thesis. Fine 
mapping and the identification of novel susceptibility variants, in conjunction with 
assays to determine the functional relevance of a marker e.g. if the variant is 
related to protein function or gene expression, will be of great clinical importance. 
Psychotic symptoms are associated with many serious consequences in LOAD 
and the identification of these genes would increase our understanding of the 
mechanisms that can cause psychiatric complications in some individuals with AD; 
providing targets for therapy and a platform for future treatment development.
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SNP Forward PCR
rs3738401 ACGTT GGAT GAAAGCT GCC AGCTT GGACG
rs6675281 ACGTT GGAT G AC AACGT GCT GT AGGAAACC
rs821616 ACGTT GGAT GT CTT CT ACAGAC AGGCTT CC
ex12, 4 bp del ACGTT GGAT GACTTT GCCTT GCTT CAT CTG
Reverse PCR Extension
ACGTT GGAT G AG ACCCGT GT AGCC AAGAGA CGACCCGCG AT GT CT CT CT C
ACGTT GGAT GGCCCTT CT CT CT CT GAT GTT TCTGGACGGCTAAAGAC
ACGTT GGAT GG AAGCT GACTT GGAAGCTT G T CCT GGAGCT GTAGGC
ACGTT GGAT GCTT C ACAC AGC AAT CC AC AG GCT GC AAG AT G AAAAGG AT AT G A
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Table 3.2. MAF and genotype counts of tested DISC1 SNPs through female samples. Table shows; SNP ID, minor allele, MAF and genotype counts in
LOAD+P, LOAD-P, LOAD and control samples.
SNP ID MA
MAF Genotype Counts
LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs3738401 A 0.33 0.3 0.32 0.32 31/118/122 13/72/79 69/303/321 79/287/330
rs6675281 T 0.16 0.12 0.15 0.14 5/76/190 3/33/128 16/174/503 13/164/519
rs821616 T 0.27 0.31 0.29 0.28 18/110/143 16/71/77 52/294/347 56/282/358
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Table 3.3. Individual genotyping of DISC1 SNPs through female LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
LOAD+P vs. LOAD-P LOAD+P vs. Control LOAD vs. Control
Alleles Genotype Alleles Genotype Alleles Genotype
SNP ID x2 P OR x2 P x2 P OR x2 P x2 P OR x2 P
rs3738401 1 0.3 1.2 (0.87-1.57) 1.47 0.48 0.28 0.6 1.06 (0.86-1.31) 0.49 0.78 0 0.9 1 (0.86-1.18) 1.23 0.54
rs6675281 2.6 0.1 1.4 (0.93-2.10) 3.44 0.18 1.57 0.21 1.19(0.9-1.57) 2.11 0.35 0.8 0.4 1.1 (0.89-1.37) 0.85 0.65
rs821616 2 0.2 1.2(0.92-1.68) 2.13 0.34 0.36 0.55 1.07 (0.86-1.34) 0.57 0.75 0.1 0.8 1 (0.87-1.20) 0.56 0.75
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Table 3.4. MAF and genotype counts of tested DISC1 SNPs through male samples. Table shows; SNP ID, minor allele, MAF and genotype counts in
LOAD+P, LOAD-P, LOAD and control samples.
SNP ID MA
MAF Genotype Counts
LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD Control
rs3738401 A 0.28 0.3 0.29 0.34 8/25/41 6/28/33 20/122/140 46/198/179
rs6675281 T 0.14 0.18 0.14 0.14 0/21/53 3/18/46 5/71/206 5/106/312
rs821616 T 0.26 0.26 0.25 0.28 5/28/41 5/25/37 17/109/156 32/176/215
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Table 3.5. Individual genotyping of DISC1 SNPs through male LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. control samples.
LOAD+P vs. LOAD-P LOAD+P vs. Control LOAD vs. Control
Alleles Genotype Alleles Genotype Alleles Genotype
SNP ID x2 P OR x2 P x2 P OR x2 P x2 P OR x2 P
rs3738401 0.2 0.7 1.1 (0.66-1.86) 0.98 0.61 2.45 0.12 1.36 (0.92-2.0) 4.82 0.09 4.8 0 1.3(1.03-1.63) 5.06 0.08
rs6675281 0.7 0.4 1.3(0.7-2.5) 4.96 0.08 0.02 0.88 1.04 (0.63-1.72) 1.93 0.38 0.1 0.7 1.1 (0.78-1.43) 0.43 0.81
rs821616 0 0.9 1 (0.6-1.74) 0.03 0.99 0.45 0.5 1.15(0.77-1.71) 0.53 0.77 1.6 0.2 1.2 (0.92-1.48) 1.6 0.45
275
Table 3.6. Relative PCR and extension primers for each DTNBP1 marker tested.
NP Forward PCR Reverse PCR Extension
170454 ACGTT GGAT GCCAAAAC AAGAGGAGGCAAG ACGTT GGAT G AGT CC AAAT C AAGGTGTGGG GG AGG AC AGGTACT GG ATT C AG
19539 ACGTT GGAT GT CTTT G AAG ACTT CCTTT CG ACGTT GGAT GCT ACC ACT AAC AACCAAAAAG G ACAT GGT CTT AAAAT GT ATAAAA
525702 ACGTT GGAT G AAT CT CTACT G AGT AGAGGG ACGTTGGATGAGTGAAACCAGGTTTTAGGC TGTT AAAG ATAAC ATTAAAT CT C ATTAC
13207 ACGTT GGAT GT CTTT G AAG ACTT CCTTT CG ACGTTGGATGCTACCACTAACAACCAAAAAG TCCTTTCGTAAAGCCA
119538 ACGTT GGAT GT CACT GTTTT CATT GCTGGG ACGTT GGAT G AGT G AGGT AAGT AGC AC AAG G AC AG AGC AGTTT ACAT C
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Table 3.7. Results of haplotype analysis at the DTNBP1 locus. Table shows analysis
dataset, number of markers analysed, chi square statistic and p-value.
 Dataset Number of Markers______ ^2_____ Global P
LOAD+P v LOAD-P 5 0.09 0.77
LOAD+P v Control 5 1.88 0.17
LOAD v Control 5 1.17 0.28
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Table 3.8. Relative primers for the GRIK2 variants. The TAA repeat was genotyped by genescan fluorescent PCR. SNP rs6922753 was genotyped by
Amplifluor Uniprim er chemistry.
Variant Forward R everse Label
TAA repeat CAACACC1 1 1 1CTCTAACCCC CTCGGCCAGI I I I IACAACTTG Hex
Variant A llele 1 Allele 2 Reverse
rs6922753 GAAGGT CGGAGT CAACGG ATT C AAGGCAGAT GTT CTT CTCCTG GAAGGT GACCAAGTT CAT GCT G ACAAGGCAGAT GTT CTT CTCCTA GGACCCGCTTT AT GAGT CT AA
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Table 3.9. Relative PCR and extension primers for each GRM3 marker tested.
SNP Forward PCR Reverse PCR Extension
rs 187993 ACGTT GGAT GGTTAAT CT C ACCT CT AATAC
rs13242038 ACGTT GGAT GT G AGG AT GG AAGT CAT GCTG
rs917071 ACGTT GGAT GT AAAGGGCT CCT AGG AAAAC
rs6465084 ACGTT GGAT GT G AC AC AAAGTTCTCTTT CC
rs2228595 ACGTTGG AT G ACG ACT CGCGGG AGCT C ATT
rs1468412 ACGTT GGAT GT GTT CCTT CAGCTTGCAAT G
rs2282966 ACGTT GGAT GTTT CCTT GGGAGGTT GAG AC
ACGTT GGAT GCCCT GCTT GATTAT CACC AC 
ACGTT GGAT GGTT GCT AGGTT C AATTT CT C 
ACGTT GGAT GTACAGCTT CCAAAAGGCCT G 
ACGTTGGATGCCGCTGCTCTTTCCATATTG 
ACGTT GG ATGCTT GAT GAT GCT CT CCT GCG 
ACGTT GGAT GAACT GGAGACTGGTTTT GCC 
ACGTTGG AT GTT AAT CCTT C AAGGGCCC AG
AAACTTT AT AT GTT CT AC AGCA 
AGT CAT GCTGC AAATAT GAG 
GTT GAGACAACAAGACACATA 
GCTCTTTCCAAATTACCATTAAAT 
CTAGCCGCCAGCCGCGCCAATGC 
G AGCTT GC AAT GTTAT AGGC AGT A 
GGGCTCCTAGGAAAACAACTCT
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Table 3.10. Results of haplotype analysis at the GRM3 locus. Table shows analysis dataset,
number of markers analysed, chi square statistic and p-value.
_______ Dataset_________Number of Markers Analysed y2______Global P
LOAD+P v LOAD-P 7 0.007 0.93
LOAD+P v Control 7 1.66 0.2
LOAD v Control 7 4.75 0.03
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Table 3.11. Relative PCR and Extension primers for each NRG1 marker tested.
Variant Forward PCR Reverse PCR Extension
rs12681411 
rs3924999 
SNP8NRG221533 
478B14-848 
420M19-1395
T CTTT GCACT AGC AGGCT C A 
ACGTT GGAT GTT GCCTGGT GAT C AG AGTT G 
T C AATTT AAGGC AT C AGTTTT C AA 
CCAC AT GT CCAACT G AAGAGG 
CTTTTAATCATGAAAGAATAGCAAAAA
T GCAGCCTATT GACTT GGT G 
ACGTT GGAT GCCG ATTCCT GGCTTTT CAT C 
T CT GT GGTT GT CT AAAT CC AG AA 
T CT CC AT GTGT AAAAC AAT ACAT AT C A 
TGTT GTT GTATATTT C AG AATTT CCTT
T CAAGGTACAGCT C AGGTTTT 
GTTAGCCTTGCCTCCCC 
T AAAAAAG AGAT AT AT GAT ATTTGG 
n/a 
n/a
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Table 3.12. Relative PCR and extension primers for the BDNF val/met marker.
SNP Forward PCR Reverse PCR Extension
rs6265 ACGTT GGAT GTTTT CTT C ATT GGGCCG AAC ACGTT GGAT GGCTT GAC AT C ATT GGCT G AC AT CC AAC AGCT CTT CTATC A
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Table 3.13. MAF and genotype counts of tested BDNF SNP through female samples. Table shows; SNP ID, minor alleli
LOAD+P, LOAD-P, LOAD and control samples.
MAF Genotype Counts
SNP ID MA LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD
rs6265 T 0.17 0.2 0.19 0.17 8/82/196 9/54/117 35/241/54-
Table 3.14. Individual genotyping of BDNF SNP through female LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs
LOAD+P vs. LOAD-P LOAD+P vs. Contra
Alleles Genotype Alleles Genotype
SNP ID X2 P OR x2 P x2 P OR x2 P X2 P
rs6265 1.22 0.27 1.21 (0.86-1.69) 1.74 0.42 0.02 0.88 1.02(0.79-1.31) 0.53 0.77 2.5 0.1'
Table 3.15. MAF and genotype counts of tested BDNF SNP through male samples. Table shows; SNP ID, minor allele, M
LOAD+P, LOAD-P, LOAD and control samples.
MAF Genotype Counts
SNP ID MA LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOAD
rs6265 T 0.23 0.2 0.21 0.17 4/29/46 5/20/50 19/106/224
Table 3.16. Individual genotyping of BDNF SNP through male LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD vs. c
LOAD+P vs. LOAD-P LOAD+P vs. Contra
Alleles Genotype Alleles Genotype
SNP ID x2 P OR
CLCMX X2 P OR
Q
.
CMX
x2 P
rs6265 0.53 0.47 1.22(0.71-2.11) 1.83 0.4 4.31 0.04 1.53(1.02-2.29) 4.34 0.11 4.37 0.04
Table 3.17. Relative PCR and extension primers for each DAOA marker tested.
SNP Forward PCR Reverse PCR
3'UTR ACGTT GGAT GAAGACT GACCTT CCAG AT CC
rs1341402 ACGTT GGAT GC AC AC AC AT CTT C AAC ATTT G
rs1421292 ACGTT GGAT GAT GTACTT CCC AGT CCTT GC
rs2391191 ACGTTGG AT GAG AT CCAG ATATACATTGGG
rs3916965 ACGTT GGAT GGGTTTT CTTTT G AAGG AC AG
rs3918342 ACGTT GGAT GCCTTAGG AG AT GGATATAGG
rs778293 ACGTT GGAT GCATAGAAG AAAAGCTT GTG
rs778294 ACGTT GGAT GCGGT GAT G AGGTTACCTTT C
rs954581 ACGTT GGAT GCTATTAGCCTTT ACTTTT CCC
ACGTT GGAT GC AGGCCTTTAT GT CAG AAGC 
ACGTTGGATGGGAAATGTTAACTAACATTA 
ACGTTGGATGTTAAAGGCACTGAGAGGAGC 
ACGTT GGAT GG AGTTTT C AGATTT GCT CAG 
ACGTTGGAT GGGAAAAAAGT GAT GACATT GC 
ACGTT GGAT GGT GCAGT CT C ATT C ACTAT C 
ACGTTGGATGCTAGTTGCCCCCCAAAATTG 
ACGTT GGAT GGCT GCTTACTT CTT C AAGCC 
ACGTT GGAT GTT G ACGT ATCTCTT CT C AGG
K j
Oo
Oo
Table 3.19. Relative PCR and extension primers for each CNP marker tested.
SNP Forward PCR Reverse PCR
3235AG ACGTT GG AT GAG AT CAT GCC ACT GC ACT CC
rs35967904
(7284GA) ACGTTGGATGAACCTGGAAGTAGGGCTCG
rs10540926 ACGTT GGAT GTT GGAAG AGCATCGT GG AAG
rs11079028 ACGTT GGAT G AATAACT G ACCCTCCCTT CC
rs11296 ACGTTGGATGTAGTCTGTGTGCTGTGGTTC
rs12602950 ACGTT GGAT GT GG AG AGGT GAT GCTTAGT G
rs12952915 ACGTT GGAT G AAG AC AGG ATCCG ACTTTGC
rs2070106 ACGTT GGAT GT GGGC ACAGGTTTGCCTTT C
rs4796750 ACGTT GGAT GAGAGGAACAGGGGT GTTAAG
rs4796751 ACGTT GGAT GTT C AGTAAG ACCGG AAGCT C
ACGTT GGAT GGG AGT G ACTACT GCT CAAAG
ACGTT GGAT GCACC ATT CAGG AACCT GG AC 
ACGTT GGAT G ACTT CTT GTT CCCTGTAGCG 
ACGTT GGAT GTT GGT CC AGGTT CCT G AAT G 
ACGTT GGAT GGT G AC AACCCG ATTAGC AAG 
ACGTTGGATGATACCAACATCCGCCACCAG 
ACGTT GGAT GCTTTTT CTGCGT GTT GAGGG 
ACGTT GGAT GTGGCCAAGAAC AT GGAGGT C 
ACGTTGG AT GTT G AAAG AAT GCCTGGCCTG 
ACGTT GGAT GT CCCTGGTGCTT G AAGTTT C
K)vO
Table 3.21. Relative PCR and extension primers for each OLIG2 marker tested.
SNP Forward PCR Reverse PCR
F16GA ACGTT GGAT GGT CTAAGC AAAGGGT GCCTG
rs1005573 ACGTT GGAT GTAAGGTGG AT CCGTTT G AGG
rs1059004 ACGTTGGATGTCCTCACTAGAACTCATCCG
rs11701698 ACGTTGGATGTATTGGGATAGGACTGAGGG
rs11701762 ACGTT GGAT G AAACT GT GC ACCC AGCT GG A
rs13046814 ACGTT GGAT GTAAAAC AG AT GATAC ACT C
rs2834070 ACGTTGGAT GGACAT CT GT CCAG ACAC AT C
rs2834072 ACGTT GGAT GAT GGTT C AG AC AAACCCCT C
rs762178 ACGTT GGAT GCTT CTT GT CCTT CTT GGT GG
rs762237 ACGTT GGAT GGCAT GAT GCACGGTTAGTT C
rs881666 ACGTT GGAT GGTCCCGT CTTAC AAGTAAGG
ACGTT GGAT GGT GC AG AAG ATTT CCCCAG 
ACGTT GGAT GG AAGT G AGGGCCTTT CTTT G 
ACGTT GGAT GCGCTCT C AGGG AAAG AAGTT 
ACGTTGGAT GT GCT GT C AAG ATT GGCT GAG 
ACGTT GGAT G ACT GTGT GCC AGT GT CTTCC 
ACGTT GGAT G AAACT GGGCTTT GTAGCGTC 
ACGTTGGATGAGAGAAAGCACACCAAAGCC 
ACGTT GGAT GTTAT GT AGGG AAGGT ACC AA 
ACGTTGGATGACAAGCTAGGAGGCAGTGG 
ACGTTGGAT GTTT CC AT GTAG AGC AT GGGC 
ACGTT GGAT GCC ACCTT C ATTTACT GGCTG
K jvOK)
Table 3.23. Relative PCR and extension primers for each OLIG1 marker tested.
SNP Forward PCR Reverse PCR
rs17632819 ACGTT GGAT GT CT CT G AAT G ACT C CC AGCC
rs11088236 ACGTT GGAT GT ACCCTT GCCCCTCTCT AAC
rs2834076 ACGTT GGAT GTT AAG AG AC AAT GC ACT CT G
rs10483016 ACGTT GGAT GGCTAAGC ATT GTT GCAGGT G
rs2834079 ACGTTGGAT GGCCT CAGC AT CAGGGAT ATT
rs2834083 ACGTTGGATGTTCACTCCTTTCTGAAAACC
rs928736 ACGTTGGAT GAGGCAGC AT GT GT GT GTTT C
rs7278735 ACGTTGGATGCCCTGGAAAATGGGTTAAGC
rs11088237 ACGTT GGAT GGT AAT AAC AGG ACC C ACCT C
rs8131457 ACGTT GGAT G AACAC ACT CCGG AGT CTTT C
rs7276171 ACGTT GGAT GTAGTT CAGGCAT GGCCTAT C
rs4817527 ACGTT GGAT GCT C AGCCT CAG AT AC ATTT C
rs2834086 ACGTT GGAT GT GGT GT CT GT GTT GATT CCC
rs2834087 ACGTT GGAT GAT GC AGT G AAATT C AGCGT C
rs12481815 ACGTT GGAT GAGACCCT GGCAT GGATACCG
ACGTTGGATGTATTCCATGTTAGCCTACGG 
ACGTT GGAT GT AGGCT AG AGGG AAAAAT GG 
ACGTT GGAT GGT AAG AGT GC AAT CC AT GTG 
ACGTT GGAT GAT GT CT GT GCTT CCG ATTCC 
ACGTTGGAT G AC ACT GCTCCCT GTT CTT AC 
ACGTT GGAT G AAAC AGGCCG AT GT GTTT GG 
ACGTT GGAT G ACTT GT ACGCT CCCC ATTT C 
ACGTTGGATGGCTTCTGTCCAAGGATATAG 
ACGTT GGAT GACAAG AAAAGC ATT GGCAGG 
ACGTTGGATGTTGGGAGATGGTTCACCAAG 
ACGTT GGAT GCTATTT CCT GGCAT CTGCTC 
ACGTTGGAT GCAGCCAG AGGATT GT GACTT 
ACGTT GGAT GG AAAGTT CT GT CT GGT C AAC 
ACGTT GGAT GGTT GGT GCGTTT CCT G AGT G 
ACGTT GGAT GAGCAAAGCCCT GGTCAT GG
K)
Table 3.25. Relative PCR and extension primers for each COMT  marker tested.
SNP Forward PCR Reverse PCR
rs165599 ACGTT GGAT GGGCT G ACT CCT CTT CGTTT C
rs2020917 ACGTT GGAT GAT GAT GAT AT CCC ACCT CCC
rs4680 ACGTT GGAT GTTTT CC AGGT CT G AC AACGG
rs737865 ACGTT GGAT GTCCTACGGTCCCT C AGGCTT
ACGTT GGAT G AC AGT GGT GC AG AGGT C AG 
ACGTT GGAT GCT AACCT CT AG AGTCTAGGG 
ACGTT GGAT GACCCAGCGGATGGT GGATTT 
ACGTT GGAT GCT AAC AG ACCT GCTTTTT GG
Table 3.26. MAF and genotype counts of tested COMT  SNPs through female samples. Table shows; SNP ID, minor alle
LOAD+P, LOAD-P, LOAD and control samples.
SNP ID MA
MAF Genotype Co
LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P L(
rs2020917 T 0.29 0.28 0.29 0.28 20/107/127 17/56/87 54/2
rs737865 C 0.29 0.29 0.29 0.28 21/106/127 18/56/86 56/2
rs4680 G 0.48 0.48 0.48 0.5 59/124/71 39/74/47 165/:
rs165599 G 0.3 0.29 0.3 0.3 20/113/121 10/74/76 55/2
Table 3.27. Individual genotyping of C O M TSNPs through female LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAC
LOAD+P vs. LOAD-P LOAD+P vs. Control
Alleles Genotype Alleles Genotype
SNP ID x2 P OR x2 P x2 P OR x2 P x2
rs2020917 0.06 0.8 1.04 (0.76-1.42) 2.46 0.29 0.36 0.55 1.07 (0.85-1.35) 0.99 0.61 0.35
rs737865 0.01 0.91 1.02 (0.75-1.39) 2.33 0.31 0.31 0.58 1.07 (0.85-1.34) 0.66 0.72 0.35
rs4680 0.001 0.97 1.01 (0.76-1.33) 0.26 0.88 0.82 0.37 1.1 (0.9-1.35) 0.8 0.67 0.94
rs165599 0.05 0.82 1.04 (0.76-1.41) 0.43 0.81 0 0.97 1 (0.8-1.26) 1.92 0.38 0
Table 3.28. MAF and genotype counts of tested COMT  SNPs through male samples. Table shows; SNP ID, minor allele
LOAD+P, LOAD-P, LOAD and control samples.
SNP ID
MAF Genotype Count
MA LOAD+P LOAD-P LOAD Control LOAD+P LOAD-P LOA
rs2020917 T 0.26 0.32 0.29 0.28 2/18/ 39 9/ 25/ 33 31/97/
rs737865 C 0.27 0.32 0.29 0.28 9/17/ 39 9/ 25/ 33 32/96/
rs4680 G 0.48 0.43 0.47 0.44 19/ 24/ 22 12/ 34/21 62/12<
rs165599 G 0.28 0.29 0.31 0.28 7/ 23/ 35 3/ 33/31 27/112
Table 3.29. Individual genotyping of COMT  SNPs through male LOAD+P vs. LOAD-P, LOAD+P vs. control and LOAD v
LOAD+P vs. LOAD-P LOAD+P vs. Control
Alleles Genotype Alleles Genotype
SNP ID x2 P OR x2 P x2 P OR x2 P x2
rs2020917 1.13 0.29 1.33 (0.78-2.27) 1.67 0.43 0.13 0.72 1.08 (0.71-1.64) 2.9 0.23 0.41
rs737865 0.85 0.36 1.28 (0.75-2.18) 2 0.37 0.04 0.84 1.04 (0.69-1.58) 4.35 0.11 0.44
rs4680 0.52 0.47 1.19(0.74-1.94) 3.3 0.19 0.47 0.49 1.14(0.79-1.65) 4.46 0.11 0.55
rs165599 0.01 0.91 1.03 (0.61-1.76) 3.6 0.17 0.01 0.94 1.02 (0.67-1.53) 0.49 0.78 0.91
u>
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Table 3.31. Results of haplotype analysis at the CO M T  locus in males only. Table shows analysis
dataset, number of markers analysed, chi square statistic and p-value.
_______ Dataset________________Number of Markers Analysed__________ ^2_____Global P
LOAD+P v LOAD-P 4 0.23 0.63
LOAD+P v Control 4 0.530 0.47
LOAD v Control 4 1.49 0.22
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Table 3.32. Results of haplotype analysis at the COMT  locus in females only. Table shows analysis
dataset, number of markers analysed, chi square statistic and p-value.
_______ Dataset_______________ Number of Markers Analysed__________ Xi_____Global P
LOAD+P v LOAD-P 4 0.004 0.95
LOAD+P v Control 4 0.3 0.58
LOAD v Control 4 0.26 0.61
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Figure 3.1. Example of Sequenom TyperAnalyser genotyping suite forOUG2 variant rs762237. a.
Is a log height cluster diagram through 384 samples. Red cluster indicates blank/failed samples; 
green cluster indicates T  homozygotes (see e); yellow cluster indicates heterozygotes (see c); and 
blue cluster indicates C homozygotes (see d). b. Is an alternate yield v skew cluster view of the 
same samples. Clusters are as described for a. c. shows an example of heterozygote spectra. 
Remaining extension primer peak is indicated by red dotted line. Peak for the C allele is indicated 
by the left yellow dotted line. Peak for the T  allele is indicated by the right yellow dotted line. d. Is an 
example of C allele homozygote spectra. Remaining extension primer peak is indicated by left red 
dotted line. Expected peak for the T  allele is indicated by the right red dotted line. Peak for the C 
allele is indicated by the yellow dotted line. e. Is spectra for a T  allele homozygote. Remaining 
extension primer peak is indicated by left red dotted line. Expected peak for the C allele is indicated 
by the right red dotted line. Peak for the T  allele is indicated by the yellow dotted line, a and b are 
used to identify suspicious genotype calls, specified by the TyperAnalyser algorithm, and the 
spectra output (c,d or e) is utilised by the user to manually allocate a genotype. [Figure produced 
using Sequenom TyperAnalyser software.]
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Figure 3.2. Example of Amplifluor genotyping cluster through 384 samples for OLIG1 variant 
rs11088236. Schem atic is a plot of red allele fluorescence against green allele fluorescence as 
labelled. Each black spot represents a  sam ple genotype. Cluster below the turquoise lines are the 
blank or failed samples. Cluster above the turquoise line and to the left of the red line are the red 
allele homozygotes. Cluster above the turquoise line, to the right of the red line and the left of the 
green line are the heterozygotes. C luster above the turquoise line and to the right of the green line 
are the green allele homozygotes. G enotypes circled in red are genotypes which were removed 
before statistical analysis. [Figure produced using Microsoft Excel Macro].
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Figure 3.3. Example of genescan fluorescent PCR plot, for the GRIK2 TAA repeat and NRG1 
microsatellites 420M19-1395 and 478B14-848, from genotyper 2.5 software.
Figure shows genotypes for one sample. The  top blue line represents the Fam fluorescent dye and 
shows a hom ozygote genotype for the NRG1 microsatellite 420M 19-1395 . The bottom green line 
represents the Hex fluorescent dye and shows heterozygous genotypes for both the GRIK2 TAA  
repeat (left), and the NRG1 microsatellite 4 7 8B 14 -848  (right). The exact genotypes are determined 
by analysis of the am plim er sizes in comparison to the G enescan™  -500 R O X™  STANDARD, 
which is run in unison with the sample.
27 C04 B...C4 06.fsa 6 Green ml 27
X
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Table 4.1. Chromosome, gene, base position and flanking sequence of each SNP variant tested.
Chr SNP Gene BP Flanking Sequel
1 rs7546928 AGBL4 73023563
1 rs11162231 ST6GALNAC5 77040318
2 rs16984718 intergenic 18430882
2 rs2890738 intergen ic 144273491
2 rs12613195 ZNF804a 185197466
2 rs1344706 ZNF804a 185486673
3 rs12629685 TRIM71 32855082
3 rs9870579 CLSTN2 141162306
8 rs10103330 CSMD1 4167498
9 rs2210539 c9orf39 17158867
9 rs10869675 PCSK5 75819589
10 rs17101921 FGFR2 123143285
11 rs10835482 intergenic 29079278
11 rs1602565 intergenic 29118712
11 rs3016384 OPCML 132078600
12 rs6490121 NOS1 116192578
13 rs4238270 IRS2 109268028
15 rs3784397 PLCB2 38384136
16 rs7192086 intergenic 12969112
16 rs9922369 RPGRIP1L 52205983
18 rs1893146 intergenic 8977427
TGTCCTTACTTTGTCTCCAAATGCTC[A/G]CA 
CAACTGAAACTTGCAACTCTCAAGGC[G/T]CA 
TAT GTAGTT GCTAACTTTT CAT CCTT[G/A]AA1 
TT GTAG AAAG AC AC AG AAGTT CCT CA[C/T]CC 
AGTT CTATATTAC ATTTTT C AG AGC A[C/G]TA< 
TTTGTGACTTTGTTTCTTAGTTTTTG[C/A]TAC 
ATGCAGTGGAGAAGTGAAGTCCTAAC[G/A]C/ 
AGCC AGGGGCT G ACT CAGCTT CATAC[C/T]T G1 
AGGCCCT G AAG AG AGTAAGTAAG ATT[A/T]TG 
T GAT G AATT GT G AAGTTTT GT GTT GG[G/A]T C 
GCCT CTTACTTAAAAAG AG AAAGCGC[G/A] AA 
TTTT CT CTT CT GCG ATACGCT GATAA[A/G] AA 
AGTGGGGCATATT CAT C AAAT GAT G A[T/C]GT 
TTCCATCTTTGTGCTGTAAAGTAGTA[T/C]GG 
CTGTCAGATATGTCTGGCCTTCTCTA[T/C]AC 
AG ACTACT CTTT GC AACT GAAAT GTA[A/G]ACi 
GGAAGGGGCTCCTGAGAGATCCAGAG[G/T]T/ 
CCCTTCCTGAAATGTGCTACAGTAAC[T/C]GGi 
CCT CT CCTAAGT GTAGCT CCTAAAGAfT/AJAT1 
C AGG AGCTAGT G AAC ACTTTTGGGTT[G/A]AA 
ACAC AAGGGAAC AGTT CTCCT G ACTC[G/A]A1
Table 4.2. Nucleotide change, forward primer, reverse primer and extension primer used for genotyping of each variant 
forward and reverse primer are specific to the Sequenom™ assay which has been described elsewhere.
SNP N/C Forward Primer Reverse Primer
rs7546928 A/G ACGTT GGAT GC AAGCCCT GT CCTTACTTT G ACGTTGGATGGTTCACTCCCTTTGCTGTAG
rs11162231 G/T ACGTTGGATGCCTCCI I I I CTTGGCAACTG ACGTT GGAT GCACCTAGG AATAAGCC AC AG
rs16984718 G/A ACGTT GGAT GCTT CGTT CCAT CAT CCAACC ACGTT GGAT GTGT GCAAGGCTGCAAGTTTC
rs2890738 C/T ACGTT GGAT GCCTCTAAAAACTTT GAG ATT C ACGTTGGATGGGGATCGTTTCCAATAACATC
rs12613195 C/G ACGTT GGAT GGT G AGGG AT GT GGTAAGTT C ACGTTGGATGCTTGGCACATATGCTCAGTC
rs1344706 C/A ACGTT GGAT GCCAG ATAG ATAT CCAAGAAG ACGTTGGATGCAAAGCCTTATCTCTTCACAG
rs12629685 G/A ACGTT GGAT G AGCT CCCCTATAT C AACTGC ACGTT GGAT GCAT GCAGT GGAGAAGT GAAG
rs9870579 C/T ACGTT GGAT GT G ACCAT GATAG AAGCC AGG ACGTT GGAT GCCCTTAT CT C AAG AGT CT CC
rs10103330 A/T ACGTT GGAT GTAGGCCCT G AAGAGAGTAAG ACGTTGGATGGTCCAGCAI I I I ICTGCTTC
rs2210539 G/A ACGTT GGAT GT GTT GCT G ACCTGGT CTTT C ACGTTGGATGGGGTTATAGTAGAGTAGGTG
rs10869675 G/A ACGTTGGATGTGAGCCTGTAAGTTCAGAGC ACGTT GGAT GCCCAGAGTATT GAGAATGCC
rs17101921 A/G ACGTTGGATGGI I I ICTCTTCTGCGATACG ACGTTGGATGCCCTGTGCTAGCTAI I I I AC
rs10835482 T/C ACGTT GGAT GGAAT GCTT CCTT GAAAACCAC ACGTT GGAT GTT C AAAT GTTT AAGT GGGGC
rs1602565 T/C ACGTTGGATGGGGTGTTGAAACTAI I I IGC ACGTT GGAT G AAGCTT CCAT CTTT GTGCTG
rs3016384 T/C ACGTT GGAT GAT G ACTTCCCT GGC AAAG AC ACGTT GGAT GTTT GC AAT CCTT GTT GCCT G
rs6490121 A/G ACGTT GGAT GACCCAGAGACTACTCTTT GC ACGTTGGATGCTAATGCCTCAGCCTCAAAG
rs4238270 GH- ACGTT GGAT GCTT GTTCCTTT GGTT CGGC ACGTTGGATGTGAAGTGTGGACTCCTGCTG
rs3784397 T/C ACGTTGGATGGGATTTCCTAGGTGGGCTTG ACGTTGGATGCCCTTCCTGAAATGTGCTAC
rs7192086 T/A ACGTT GGAT GTTT GC AT GT CT CTCTGTGCC ACGTT GGAT GGAGCT CCAAAGCAT CGATT C
rs9922369 G/A ACGTTGGAT GAAT CAGAGGCAGCCAAAGT G ACGTT GGAT GGGGAT CAGGAGCTAGTGAAC
rs1893146 G/A ACGTTGGATGGCTTTGTGAGCAATGGTGTG ACGTT GGAT GCACAC AAGGGAACAGTT CT C
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Figure 4.1. Example of Sequenom TyperAnalyser genotyping suite for variant rs9870579. 
a. Is a log height cluster diagram through 384 samples. Red cluster indicates blank/failed samples; 
green cluster indicates T homozygotes (see e); yellow cluster indicates heterozygotes (see c); and 
blue cluster indicates C homozygotes (see d). b. Is an alternate yield v skew cluster view of the 
same samples. Clusters are as described for a. c. shows an example of heterozygote spectra. 
Remaining extension primer peak is indicated by red dotted line. Peak for the C allele is indicated by 
the left yellow dotted line. Peak for the T allele is indicated by the right yellow dotted line. d. Is an 
example of C allele homozygote spectra. Remaining extension primer peak is indicated by left red 
dotted line. Expected peak for the T allele is indicated by the right red dotted line. Peak for the C 
allele is indicated by the yellow dotted line. e. Is spectra for a T allele homozygote. Remaining 
extension primer peak is indicated by left red dotted line. Expected peak for the C allele is indicated 
by the right red dotted line. Peak for the T allele is indicated by the yellow dotted line, a and b are 
used to identify suspicious genotype calls, specified by the TyperAnalyser algorithm, and the 
spectra output (c.d or e) is utilised by the user to manually allocate a genotype. [Figure produced 
using Sequenom TyperAnalyser software.]
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Figure 4.2. Example of Sequenom TyperAnalyser genotyping suite for variant rs7192086. 
a. Is a log height cluster diagram through 384 samples. Red cluster indicates blank/failed samples; 
green cluster indicates A homozygotes (see d); yellow cluster indicates heterozygotes (see c); and 
blue cluster indicates T homozygotes (see e). b. Is an alternate yield v skew cluster view of the 
same samples. Clusters are as described for a. c. shows an example of heterozygote spectra. 
Remaining extension primer peak is indicated by red dotted line. Peak for the T allele is indicated by 
the left yellow dotted line. Peak for the A allele is indicated by the right yellow dotted line. d. Is an 
example of A allele homozygote spectra. Remaining extension primer peak is indicated by left red 
dotted line. Expected peak for the T allele is indicated by the right red dotted line. Peak for the A 
allele is indicated by the yellow dotted line. e. Is spectra for a T allele homozygote. Remaining 
extension primer peak is indicated by left red dotted line. Expected peak for the A allele is indicated 
by the right red dotted line. Peak for the T allele is indicated by the yellow dotted line, a and b are 
used to identify suspicious genotype calls, specified by the TyperAnalyser algorithm, and the 
spectra output (c,d or e) is utilised by the user to manually allocate a genotype. [Figure produced 
using Sequenom TyperAnalyser software.]
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Mayo / ALS (US)
Coriell / Mayo+ALS (US) 
610 (US) / Mayo+ALS (US) 
610 (US)/Coriell________
n/a = not applicable.
10.0 n/a o.u n/a
25.0 n/a n/a n/a
25.0 n/a 14.0 n/a
20.0 18.5 n/a n/a
312
1 .... ’ \ ' \ / X # ' '
Post QC
n* 999 229 136 48 1412
LOAD+P (%) 374 (37.4) 93 (40.6) 61 (44.9) 15(31.3) 543 (38.5)
LOAD-P (%) 343 (34.3) 52 (22.7) 12 (8.8) 10(20.8) 417(29.5)
Possible LOAD+P# (%) 138(13.8) 60 (26.2) 49 (36.0) 10(20.8) 257(18.2)
LOAD-P, mild LOAD+ (%) 144 (14.4) 24(10.5) 14(10.3) 13(27.1) 195(13.8)
* Total number of LOAD cases with available Neuropsychiatric Inventory and genotype data.
* Mild psychotic symptoms present but do not meet criteria for LOAD+P.
+ No psychotic symptoms present but have not past psychosis risk stages of LOAD.
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Table 5.3. LOAD+P versus LOAD-P. Results for SNPs with p-values ^ 1x1 O'4. Table shows SNP rank, chromosome, b;
associated allele, p-value and OR in LOAD+P vs. LOAD-P and LOAD+P vs. control analyses.
tank Chr SNP BP Gene Type Allele P
1 8 rs2034140 6224172 MCPH1 INTERGENIC G 7.62E-06
2 6 rs11756091 39390784 KCNK16 NON-SYN T 8.06E-06
3 8 rs10956535 131623943 ASAP1 INTERGENIC C 8.79E-06
4 4 rs753129 56363188 AC110611.3-1 DOWNSTREAM G 9.98E-06
5 9 rs960644 105060805 RP11-341 A22.1 INTERGENIC G 1.04E-05
6 12 rs2682778 117544535 SUDS3 INTERGENIC T 1.45E-05
7 10 rs1444400 52904161 PRKG1 INTRONIC G 1.48E-05
8 10 rs1444401 52904934 PRKG1 INTRONIC A 1.50E-05
9 10 rs6480276 52907458 PRKG1 INTRONIC G 1.59E-05
10 2 rs11680774 158954231 CCDC148 INTRONIC C 2.00E-05
11 2 rs2883854 158947298 CCDC148 INTRONIC C 2.07E-05
12 6 rs3734618 39392162 KCNK16 SYNONYMOUS C 2.09E-05
13 1 rs12045777 29301591 EPB41 INTRONIC G 2.18E-05
14 12 rs1520780 117524108 SUDS3 INTERGENIC A 2.75E-05
15 4 rs2695234 24413336 SOD3 DOWNSTREAM T 3.39E-05
16 4 rs12648438 188865648 AC115540.3 INTERGENIC A 3.40E-05
17 6 rs13201744 6071844 F13A1 INTERGENIC T 4.31 E-05
18 4 rs2100889 88917369 IBSP INTERGENIC A 4.51 E-05
19 2 rs3771599 159105674 PK4P;PKP4 INTRONIC G 4.88E-05
20 2 rs11674284 159081135 PK4P;PKP4 INTRONIC C 4.90E-05
21 2 rs6711582 159036181 PK4P;PKP4 INTRONIC T 5.28E-05
22 2 rs2356186 159072718 PK4P;PKP4 INTRONIC T 5.86E-05
23 1 rs2640467 29428745 MECR INTRONIC C 5.91 E-05
24 6 rs9404549 104959117 RP11-427E4.1 INTERGENIC T 5.91 E-05
25 7 rs10235799 149431398 AC006008.2 INTERGENIC C 6.04E-05
26 12 rs11535963 18245787 AC087240.17 INTERGENIC T 6.48E-05
27 12 rs11044223 18675030 PIK3C2G INTRONIC C 6.65E-05
28 1 rs3929673 14225658 C1orf196 INTRONIC T 6.88E-05
29 6 rs7756959 104974286 RP11-427E4.1 INTERGENIC C 6.94E-05
30 4 rs6828769 188885970 AC115540.3 INTERGENIC G 7.01 E-05
31 2 rs3764835 159227614 AC005042.2 INTRONIC T 7.13E-05
32 16 rs17720179 27096354 JMJD5 INTERGENIC T 7.15E-05
33 2 rs3771635 159158409 PK4P;PKP4 INTRONIC G 7.44E-05
34 4 rs1989924 113564134 ALPK1 INTRONIC A 7.49E-05
35 14 rs10143543 23265976 AL160237.4-1 INTERGENIC A 7.53E-05
36 6 rs7740010 104962863 RP11-427E4.1 INTERGENIC A 7.54 E-05
37 6 rs156235 104978232 RP11-427E4.1 INTERGENIC C 7.54E-05
38 16 rs8061432 25762112 HS3ST4 INTRONIC T 7.64E-05
39 2 rs3755365 70798073 ADD2 INTRONIC C 7.74E-05
40 16 rs17674628 8799972 PMM2 INTRONIC A 7.87E-05
41 10 rs11252926 556379 DIP2C INTRONIC A 8.02E-05
42 7 rs17156246 81872957 CACNA2D1 INTRONIC T 8.06E-05
43 3 rs9867560 163153274 AC104471.6 INTERGENIC A 8.26E-05
44 3 rs17443484 163156164 AC104471.6 INTERGENIC T 8.26E-05
45 10 rs11252923 556195 DIP2C INTRONIC T 8.35E-05
46 1 rs1146413 81371728 AL158218.11 INTERGENIC C 8.58E-05
47 3 rs9865618 163165408 AC104471.6 INTERGENIC G 8.87E-05
48 2 rs2080394 70862957 FIGLA INTRONIC C 8.89E-05
49 15 rs17237486 58991573 RORA INTRONIC G 9.03E-05
50 10 rs7089944 13017856 CCDC3 INTRONIC C 9.08E-05
51 2 rs3771408 70834654 ADD2 INTRONIC A 9.24E-05
52 3 rs2139266 142009170 TRIM42 INTERGENIC C 9.32E-05
53 13 rs9512519 26522181 USP12 INTERGENIC C 9.42E-05
54 1 rs1768404 81361200 AL158218.11 INTERGENIC A 9.70E-05
55 8 rs7015252 131624931 ASAP1 INTERGENIC A 9.75E-05
56 2 rs2681031 23084067 AC104807.5-2 INTERGENIC G 9.98E-05
57 2 rs7597989 187935145 CALCRL INTRONIC A 0.0001
58 4 rs6826655 188845047 AC097521.2-2 INTERGENIC A 0.0001
59 14 rs399223 58431254 AL049873.3-2 INTERGENIC C 0.0001
60 13 rs9284246 108125789 MY016 INTRONIC G 0.0001
61 6 rs9377643 105041172 RP11-427E4.1 INTERGENIC C 0.0001
62 2 rs17808559 158880898 CCDC148 INTRONIC T 0.0001
63 2 rs4853462 191832049 MY01B INTRONIC C 0.0001
64 14 rs177726 58447157 AL049873.3-2 INTERGENIC T 0.0001
65 14 rs442555 58365937 AL049873.3-2 UPSTREAM C 0.0001
66 10 rs9664256 83767735 NRG3 INTRONIC G 0.0001
67 13 rs12560710 30053442 AK122825 INTERGENIC A 0.0001
68 5 rs683004 29539692 AC010374.6 INTERGENIC A 0.0001
69 10 rs3903435 83766437 NRG3 INTRONIC G 0.0001
70 10 rs4881399 557325 DIP2C INTRONIC T 0.0001
71 3 rs13070407 25468182 RARB INTRONIC G 0.0001
72 14 rs6573225 58354640 AL049873.3-2 INTERGENIC C 0.0001
73 6 rs267339 104985242 RP11-427E4.1 INTERGENIC A 0.0001
74 11 rs750270 132591508 OPCML INTRONIC A 0.0001
75 5 rs620508 29543052 AC010374.6 INTERGENIC G 0.0001
76 8 rs7842680 56093552 XKR4 INTERGENIC C 0.0001
77 3 rs925665 5101391 AC090955.3 DOWNSTREAM A 0.0001
78 11 rs598829 131247810 HNT;NTM INTRONIC A 0.0001
79 4 rs2303513 119946397 SEC24D INTRONIC A 0.0001
80 11 rs17794760 18012496 TPH1 INTRONIC A 0.0001
81 3 rs4613440 14530815 GRIP2 SYNONYMOUS T 0.0001
82 6 rs775258 101840784 GRIK2 INTERGENIC G 0.0001
83 2 rs3755361 70798759 ADD2 INTRONIC T 0.0002
84 19 rs4805441 34780133 POP4 INTERGENIC C 0.0002
85 9 rs902143 108221732 AL512649.6 INTERGENIC A 0.0002
86 3 rs7614031 118057332 AC069504.7 INTERGENIC A 0.0002
87 12 rs2285831 46411969 RAPGEF3 INTERGENIC A 0.0002
88 7 rs12669501 93832944 COL1A2 INTERGENIC A 0.0002
89 8 rs11781115 26737367 ADRA1A INTRONIC G 0.0002
90 16 rs4548875 25818713 HS3ST4 INTRONIC A 0.0002
91 19 rs3810342 43599425 RASGRP4 INTRONIC G 0.0002
92 2 rs1918901 187851922 AC074020.4 INTERGENIC C 0.0002
93 5 rs4527553 65899491 AC092373.2-2 INTRONIC T 0.0002
94 16 rs2304469 8803595 PMM2 INTRONIC C 0.0002
95 5 rs286969 153301961 FAM114A2 INTERGENIC T 0.0002
96 14 rs11851391 93287901 PRIMA1 INTRONIC A 0.0002
97 5 rs1550825 14961578 AC016575.7 UPSTREAM A 0.0002
98 18 rs7231736 831321 YES1 INTERGENIC G 0.0002
99 8 rs6470563 128777752 MYC INTERGENIC C 0.0002
100 14 rs983449 58481542 AL049873.3-2 INTERGENIC T 0.0002
101 19 rs6509701 58075997 ZNF320 SYNONYMOUS C 0.0002
102 1 rs1894654 7274021 CAMTA1 INTRONIC G 0.0002
103 2 rs7563401 69833697 ANXA4 INTRONIC A 0.0002
104 1 rs12038526 47955182 AL691459.25 INTERGENIC G 0.0002
105 9 rs16922740 105116091 RP11-341A22.1 INTERGENIC C 0.0002
106 10 rs10823083 52925664 PRKG1 INTRONIC A 0.0002
107 9 rs1329771 72964676 TRPM3 INTRONIC G 0.0002
108 9 rs7852394 119611072 TLR4 INTERGENIC C 0.0002
109 19 rs6509698 58050701 ZNF468 INTRONIC T 0.0002
110 7 rs4729127 93846471 COL1A2 INTERGENIC T 0.0002
111 10 rs7079742 19016665 ARL5B INTERGENIC C 0.0002
112 5 rs607077 29531321 AC010374.6 INTERGENIC G 0.0002
113 11 rs2468782 18092218 SAA3P INTRONIC G 0.0002
114 3 rs295464 140789265 NMNAT3 INTRONIC G 0.0002
115 16 rs4362392 25818949 HS3ST4 INTRONIC C 0.0002
116 2 rs3771644 159175252 PK4P;PKP4 INTRONIC A 0.0002
117 13 rs4343137 111113593 RP11-65D24.2 INTRONIC T 0.0002
118 3 rs9823958 141037367 CLSTN2 INTERGENIC A 0.0002
119 2 rs7574570 191806761 MY01B INTERGENIC C 0.0002
120 9 rs10739508 119636032 TLR4 INTERGENIC C 0.0002
121 2 rs7567400 69834799 ANXA4 INTRONIC A 0.0002
122 5 rs905858 29506179 AC010374.6 INTERGENIC G 0.0002
123 13 rs9513354 97550726 FARP1 INTERGENIC A 0.0002
124 18 rs8099057 34021742 n/a INTERGENIC A 0.0002
125 2 rs10445783 191809743 MY01B INTERGENIC G 0.0002
126 2 rs12470671 8420670 AC011747.5 INTERGENIC A 0.0002
127 4 rs7687115 188845851 AC097521.2-2 INTERGENIC G 0.0002
128 19 rs3764640 1158238 STK11 INTRONIC A 0.0002
129 9 rs7854254 119624938 TLR4 INTERGENIC G 0.0002
130 7 rs11767477 77802603 MAGI2 INTRONIC C 0.0002
131 3 rs188423 140773159 NMNAT3 INTRONIC T 0.0002
132 6 rs6931820 93963094 EPHA7 INTERGENIC T 0.0003
133 13 rs1517897 36015431 RP11-56M2.1 INTERGENIC T 0.0003
134 16 rs12049 8797129 TMEM186;C16orf51 3 PRIME UTR T 0.0003
135 8 rs10099199 18422501 PSD3 INTERGENIC G 0.0003
136 9 rs10810562 16387155 BNC2 INTERGENIC A 0.0003
137 3 rs6800179 141050356 CLSTN2 INTERGENIC C 0.0003
138 3 rs6441421 163152503 AC104471.6 INTERGENIC T 0.0003
139 7 rs10954664 81613491 CACNA2D1 INTRONIC G 0.0003
140 3 rs1376967 83584638 AC129415.1-2 INTERGENIC G 0.0003
141 8 rs6559175 6521408 MCPH1 INTERGENIC C 0.0003
142 13 rs11617079 42495865 DNAJC15 NON-SYN G 0.0003
143 13 rs2281782 42496191 DNAJC15 INTRONIC C 0.0003
144 8 rs1441249 87683359 CNGB3 INTRONIC T 0.0003
145 6 rs855250 9716873 OFCC1 INTERGENIC C 0.0003
146 4 rs4699587 95834792 PDLIM5 INTERGENIC C 0.0003
147 12 rs678941 112573616 RBM19 INTERGENIC T 0.0003
148 3 rs7637623 152812216 AC069067.17 INTERGENIC G 0.0003
149 1 rs7556195 230799588 SIPA1L2 INTERGENIC G 0.0003
150 13 rs1927554 35965699 RP11-56M2.1 UPSTREAM C 0.0003
151 13 rs4271475 103916726 RP11-217F17.1 INTERGENIC T 0.0003
152 11 rs4758480 3175285 MRGPRG INTERGENIC T 0.0003
153 10 rs10827186 33413756 RPL7AP53 INTERGENIC G 0.0003
154 1 rs655146 60383617 RP11-575B7.2 INTERGENIC G 0.0003
155 1 rs1041705 80236125 RP11-339A11.1 INTERGENIC C 0.0003
156 3 rs11706561 25430847 RARB INTRONIC T 0.0003
157 2 rs1517443 221268006 AC019051.8 INTERGENIC G 0.0003
158 12 rs1663588 67563432 CPM INTRONIC A 0.0003
159 4 rs16890321 13979845 AC093777.4 INTERGENIC T 0.0003
160 14 rs6573334 23273635 AL160237.4-1 INTERGENIC T 0.0003
161 11 rs10431058 106986728 ELMOD1 INTERGENIC T 0.0003
162 15 rs954432 36753947 C15orf53 INTERGENIC C 0.0003
163 1 rs7515917 14311629 C1orf196 INTRONIC G 0.0003
164 15 rs2711644 51939427 AC066611.6 INTERGENIC T 0.0004
165 7 rs16885938 77798165 MAGI2 INTRONIC T 0.0004
166 11 rs604967 112191202 AP003100.3 INTERGENIC T 0.0004
167 5 rs2074344 136989299 KLHL3 INTRONIC G 0.0004
168 10 rs1930457 59419237 RP11-448K10.1 INTERGENIC A 0.0004
169 6 rs10945617 159872422 RP3-393E18.1 UPSTREAM A 0.0004
170 4 rs4082297 54303520 LNX1 INTERGENIC C 0.0004
171 9 rs10963919 19021231 FAM154A INTRONIC G 0.0004
172 2 rs7593799 187791545 AC074020.4 INTERGENIC T 0.0004
173 7 rs700316 147002743 AC006992.2 INTRONIC A 0.0004
174 10 rs1125478 59289172 RP11-448K10.1 INTERGENIC T 0.0004
175 20 rs2427460 61061227 SLC17A9 INTRONIC C 0.0004
176 16 rs11150535 81644467 CDH13 INTRONIC T 0.0004
177 12 rs621042 18680274 PIK3C2G INTRONIC A 0.0004
178 2 rs2312548 69809264 ANXA4 INTERGENIC A 0.0004
179 3 rs1447721 141038576 CLSTN2 INTERGENIC C 0.0004
180 11 rs868344 117510329 SCN4B 3 PRIME UTR T 0.0004
181 8 rs10088108 20107092 ATP6V1B2 INTRONIC G 0.0004
182 6 rs1544050 39387109 KCNK17 INTRONIC C 0.0004
183 1 rs2990678 13709800 LRRC38 INTRONIC A 0.0004
184 1 rs2365716 154881818 BCAN INTRONIC C 0.0004
185 5 rs329320 133936260 PHF15 INTRONIC G 0.0004
186 5 rs2042243 135611811 TRPC7 INTRONIC A 0.0004
187 9 rs4877108 90573556 NXNL2 INTERGENIC C 0.0004
188 14 rs7160035 23270407 AL160237.4-1 INTERGENIC T 0.0004
189 4 rs9996873 170793421 CLCN3 INTRONIC G 0.0004
190 14 rs17121169 85038905 AL049775.2 INTERGENIC C 0.0004
191 2 rs7564839 158936837 CCDC148 INTRONIC G 0.0004
192 10 rs7094118 11296448 CUGBP2 INTRONIC C 0.0004
193 1 rs10493201 55537080 GOT2L1 INTERGENIC C 0.0004
194 2 rs1583631 211771056 ERBB4 INTERGENIC T 0.0004
195 4 rs4861491 182864573 AC108142.1 INTERGENIC T 0.0004
196 5 rs12189367 9040361 SEMA5A INTERGENIC A 0.0004
197 2 rs1569135 187823643 AC074020.4 INTERGENIC G 0.0004
198 20 rs1016404 50336317 ZFP64 INTERGENIC A 0.0004
199 11 rs643122 112192679 AP003100.3 INTERGENIC C 0.0004
200 13 rs2897319 46665008 RP11-94N9.1 INTERGENIC C 0.0004
201 2 rs3771084 187951878 CALCRL INTRONIC A 0.0004
202 14 rs10484053 95081398 GLRX5 DOWNSTREAM T 0.0004
203 12 rs2130635 82372409 AC090680.11 INTERGENIC C 0.0004
204 16 rs1532472 84743139 AC040170.9 INTERGENIC T 0.0005
205 9 rs7036118 19023376 FAM154A UPSTREAM T 0.0005
206 11 rs4565912 123409605 OR10G8 DOWNSTREAM C 0.0005
207 1 rs1426786 81313972 RP11-2B19.1 INTERGENIC A 0.0005
208 7 rs2520570 112063917 AC005192.1 INTERGENIC G 0.0005
209 10 rs1999505 59413258 RP11-448K10.1 INTERGENIC C 0.0005
210 9 rs7047010 15077382 RP11-54D18.4 INTERGENIC C 0.0005
211 2 rs11690896 118507870 AC009303.3-1 INTERGENIC C 0.0005
212 18 rs1544241 845264 YES1 INTERGENIC T 0.0005
213 16 rs1864 8797034 TMEM186;C16orf51 3 PRIME UTR G 0.0005
214 14 rs1263805 21052472 METTL3 UPSTREAM C 0.0005
215 7 rs2693727 129204966 MIRN183 UPSTREAM G 0.0005
216 2 rs4851161 98823293 C2orf55 INTRONIC C 0.0005
217 10 rs1414395 13374142 PHYH INTRONIC T 0.0005
218 19 rs8102902 3720049 RAX2 INTRONIC G 0.0005
219 14 rs10149208 58313091 AL121819.6 INTERGENIC A 0.0005
220 14 rs7155550 58304017 AL121819.6 DOWNSTREAM C 0.0005
221 1 rs12035356 153020091 KCNN3 INTRONIC C 0.0005
222 6 rs911182 137076157 MAP3K5 INTRONIC G 0.0005
223 11 rs2445290 4976992 OR51L1 SYNONYMOUS A 0.0005
224 18 rs7236716 54318116 ALPK2 INTRONIC T 0.0005
225 11 rs687572 128144543 FLI1 INTRONIC C 0.0005
226 3 rs11712892 142016513 TRIM42 INTERGENIC A 0.0005
227 13 rs9519340 103919432 RP11-217F17.1 INTERGENIC A 0.0005
228 2 rs7596564 70859754 FIGLA INTRONIC A 0.0005
229 2 rs7597155 69838939 ANXA4 INTRONIC T 0.0005
230 3 rs10937074 183120027 AC007547.26-2 INTERGENIC A 0.0005
231 15 rs779885 60549664 AC032011.15 INTERGENIC G 0.0005
232 10 rs7913161 125554890 CPXM2 INTRONIC G 0.0005
233 2 rs12622388 69834530 ANXA4 INTRONIC C 0.0005
234 21 rs12482075 37881096 KCNJ6 INTERGENIC T 0.0005
235 1 rs2481665 62367265 INADL INTRONIC C 0.0005
236 11 rs11030026 27467406 LIN7C INTERGENIC A 0.0005
237 3 rs12638515 164473177 AC104637.5 INTERGENIC G 0.0005
238 1 rs13353041 55546344 GOT2L1 INTERGENIC A 0.0005
239 6 rs12207681 9728632 OFCC1 INTERGENIC C 0.0005
240 2 rs6705773 221286642 AC019051.8 INTERGENIC G 0.0005
241 5 rs255240 123187997 AC008580.7 INTERGENIC C 0.0005
242 3 rs9868790 117961048 BZW1L1 INTERGENIC C 0.0005
243 4 rs1872270 88828705 DMP1 INTERGENIC A 0.0005
244 4 rs7438821 188887227 AC115540.3 INTERGENIC T 0.0005
245 16 rs246174 14287432 AC040173.5 INTERGENIC A 0.0005
246 18 rs12232768 23033599 CHST9 INTERGENIC C 0.0005
247 10 rs16911207 59352070 RP11-448K10.1 INTERGENIC C 0.0005
248 11 rs7939810 27589985 AC104563.14 INTERGENIC G 0.0005
249 3 rs9831813 129961232 RAB7A INTRONIC A 0.0005
250 3 rs4234525 14522806 GRIP2 INTRONIC T 0.0005
251 9 rs10125646 19035502 RRAGA UPSTREAM G 0.0005
252 1 rs7511712 118081431 AL390877.1 INTERGENIC G 0.0005
253 5 rs6555968 171045081 C5orf50 INTERGENIC A 0.0005
254 8 rs10097956 24150656 ADAM28 INTERGENIC G 0.0005
255 16 rs11863067 17701614 XYLT1 INTERGENIC T 0.0005
256 14 rs12889310 82462910 AL163171.4 INTERGENIC C 0.0005
257 6 rs267333 104963333 RP11-427E4.1 INTERGENIC A 0.0005
258 1 rs12569332 209952869 LPGAT1 INTERGENIC C 0.0005
259 10 rs17684713 127942864 ADAM 12 INTRONIC A 0.0005
260 1 rs126013 29092857 EPB41 5 PRIME UTR A 0.0005
261 14 rs8005907 95857500 ATG2B INTRONIC C 0.0005
262 2 rs13407117 158889282 CCDC148 INTRONIC A 0.0005
263 4 rs10516985 97049034 AC093828.3 INTERGENIC C 0.0005
264 5 rs6875311 123207148 AC008580.7 INTERGENIC C 0.0005
265 8 rs2912004 6495247 MCPH1 DOWNSTREAM A 0.0005
266 8 rs11774901 131550501 ASAP1 INTERGENIC T 0.0005
267 8 rs7835207 143205285 TSNARE1 INTERGENIC G 0.0005
268 2 rs3771449 70796926 ADD2 INTRONIC G 0.0005
269 10 rs7067598 23257705 ARMC3 INTRONIC G 0.0006
270 6 rs12213004 9762524 OFCC1 INTERGENIC T 0.0006
271 2 rs6707940 70851745 FIGLA INTRONIC G 0.0006
272 14 rs1112627 82465636 AL163171.4 INTERGENIC T 0.0006
273 13 rs912521 28059336 RP11-57H24.1 INTERGENIC A 0.0006
274 18 rs17805412 9874503 TXNDC2 UPSTREAM A 0.0006
275 14 rs754131 58291699 AL121819.6 INTERGENIC G 0.0006
276 2 rs934287 203416552 ICA1L INTRONIC T 0.0006
277 6 rs10806716 159872442 RP3-393E18.1 UPSTREAM A 0.0006
278 18 rs9807134 33939251 n/a INTERGENIC A 0.0006
279 14 rs1547350 103716079 KIF26A 3 PRIME UTR T 0.0006
280 1 rs2999865 13713882 LRRC38 UPSTREAM A 0.0006
281 6 rs7748110 108025075 SOBP INTRONIC A 0.0006
282 10 rs7897633 52627727 PRKG1 INTRONIC G 0.0006
283 5 rs6873055 153253361 GRIA1 INTERGENIC A 0.0006
284 16 rs896401 8394656 C16orf68 INTERGENIC G 0.0006
285 2 rs3771669 159217221 PK4P;PKP4 INTRONIC G 0.0006
286 16 rs1079348 8780957 ABAT INTRONIC C 0.0006
287 6 rs4707016 84591076 C6orf59;RIPPLY2 INTERGENIC A 0.0006
288 13 rs1360974 101794714 FGF14 INTRONIC T 0.0006
289 1 rs2152391 80281442 RP11-339A11.1 INTERGENIC A 0.0006
290 1 rs10493658 80286294 RP11-339A11.1 INTERGENIC T 0.0006
291 4 rs17615522 38204296 AC096739.3 INTERGENIC C 0.0006
292 2 rs3771604 159123225 PK4P;PKP4 INTRONIC T 0.0006
293 11 rs11234095 83990352 DLG2 INTRONIC G 0.0006
294 11 rs10898274 83990370 DLG2 INTRONIC T 0.0006
295 11 rs4579932 131403489 HNT;NTM INTRONIC C 0.0006
296 3 rs6764249 38705121 SCN10A INTERGENIC G 0.0006
297 1 rs7556538 90666105 AC098656.2 INTERGENIC C 0.0006
298 10 rs4748737 21258985 NEBL INTRONIC G 0.0006
299 19 rs718133 40563547 AC002511.1-2 UPSTREAM T 0.0006
300 14 rs7149631 58303507 AL121819.6 DOWNSTREAM T 0.0006
301 20 rs11574739 42476364 HNF4A INTRONIC C 0.0006
302 15 rs8039372 60409849 AC032011.15 INTERGENIC C 0.0006
303 4 rs9307041 88862789 AC093895.3 INTERGENIC A 0.0006
304 3 rs1499508 65667103 AC121493.1 INTRONIC C 0.0006
305 11 rs532859 106984862 ELMOD1 INTERGENIC A 0.0006
306 17 rs481648 15672648 AC015922.5 UPSTREAM C 0.0006
307 9 rs1124647 105085893 RP11-341 A22.1 INTERGENIC G 0.0006
308 9 rs10811094 18999041 FAM154A INTRONIC A 0.0006
309 10 rs4880336 133783495 JAKMIP3 INTRONIC T 0.0007
310 5 rs10055973 180052524 AC113427.2 INTERGENIC A 0.0007
311 5 rs11738161 180052616 AC113427.2 INTERGENIC A 0.0007
312 5 rs13188129 180052650 AC113427.2 INTERGENIC T 0.0007
313 5 rs11738216 180052755 AC113427.2 INTERGENIC C 0.0007
314 10 rs7908946 127903558 ADAM 12 INTRONIC A 0.0007
315 4 rs12509170 99765951 TSPAN5 INTRONIC G 0.0007
316 4 rs7688470 21781096 AC093735.2 INTERGENIC T 0.0007
317 10 rs7094054 83769819 NRG3 INTRONIC T 0.0007
318 4 rs7655220 21746131 KCNIP4 INTERGENIC G 0.0007
319 3 rs6783373 184440267 MCF2L2 INTRONIC A 0.0007
320 10 rs7079003 1967135 ADARB2 INTERGENIC T 0.0007
321 21 rs4818184 41124301 DSCAM INTRONIC A 0.0007
322 2 rs3771450 70796646 ADD2 INTRONIC C 0.0007
323 2 rs7577964 24451783 AC009228.4-2 INTERGENIC A 0.0007
324 17 rs6503608 33835225 SOCS7 INTERGENIC T 0.0007
325 7 rs2693737 129218230 MIRN183 INTERGENIC C 0.0007
326 13 rs9300636 100362458 NALCN;VGCNL1 INTERGENIC C 0.0007
327 20 rs6067566 48888318 BCAS4 INTRONIC T 0.0007
328 13 rs7327207 19392558 ZMYM2 INTERGENIC C 0.0007
329 12 rs1351681 33589991 AC024153.22 INTERGENIC T 0.0007
330 1 rs11240240 202883128 LRRN2 INTRONIC C 0.0007
331 3 rs9853945 130011320 RAB7A INTRONIC G 0.0007
332 9 rs3780256 17476802 CNTLN INTRONIC T 0.0007
333 15 rs11635381 99488806 CHSY1 INTERGENIC A 0.0007
334 9 rs10867685 82864268 RP11-553J6.1 INTERGENIC G 0.0007
335 6 rs16888746 162010971 PARK2 INTRONIC T 0.0007
336 1 rs4653186 36635516 LSM10 INTRONIC T 0.0007
337 2 rs35907069 69794284 ANXA4 INTERGENIC T 0.0007
338 2 rs12612409 69794791 ANXA4 INTERGENIC A 0.0007
339 18 rs1789597 52003253 AC009271.7 INTRONIC G 0.0007
340 9 rs11142705 72955297 TRPM3 INTRONIC A 0.0007
341 17 rs16968987 52365061 COIL INTERGENIC T 0.0007
342 14 rs9972193 58488475 AL049873.3-2 INTERGENIC C 0.0007
343 4 rs2869703 88845302 AC093895.3 INTERGENIC C 0.0007
344 18 rs11081236 6433601 AP005202.3 INTERGENIC T 0.0007
345 15 rs12443269 51914772 AC066611.6 INTERGENIC C 0.0007
346 10 rs7083429 68973427 CTNNA3 INTRONIC C 0.0007
347 2 rs1157699 187967149 CALCRL INTRONIC T 0.0007
348 13 rs9575351 83049998 AL512782.6-2 INTERGENIC C 0.0008
349 16 rs7188565 6748158 AC125796.2 INTERGENIC A 0.0008
350 13 rs1333464 92629476 GPC6 INTERGENIC T 0.0008
351 18 rs9956147 33926617 n/a INTERGENIC C 0.0008
352 2 rs7603997 24378462 ITSN2 NON-SYN T 0.0008
353 15 rs4778147 25426340 GABRG3 INTRONIC C 0.0008
354 1 rs1752221 81368322 AL158218.11 INTERGENIC T 0.0008
355 3 rs1353021 172573441 TNIK INTRONIC A 0.0008
356 16 rs17671037 6740651 AC125796.2 INTERGENIC C 0.0008
357 16 rs860380 72116684 C16orf47 INTERGENIC C 0.0008
358 13 rs1517881 36027895 RP11-56M2.1 INTERGENIC T 0.0008
359 4 rs9999510 146857486 ZNF827 INTERGENIC C 0.0008
360 1 rs2003046 10955414 C1orf127 INTERGENIC A 0.0008
361 14 rs4569181 75883430 ESRRB INTERGENIC A 0.0008
362 4 rs17211183 92428986 TMSL3 INTERGENIC A 0.0008
363 11 rs871437 132309082 OPCML INTRONIC C 0.0008
364 8 rs2249963 11512635 C8orf14 INTERGENIC C 0.0008
365 4 rs7697101 21783869 AC093735.2 INTERGENIC C 0.0008
366 5 rs7707671 74323498 AC116337.2 UPSTREAM C 0.0008
367 10 rs7912903 1974760 ADARB2 INTERGENIC T 0.0008
368 1 rs12039988 29298420 EPB41 INTRONIC A 0.0008
369 13 rs1927522 26230836 GPR12 3 PRIME UTR T 0.0008
370 5 rs17113869 152355671 GRIA1 INTERGENIC C 0.0008
371 15 rs723988 99496248 CHSY1 INTERGENIC T 0.0008
372 3 rs13096015 183100621 AC007547.26-2 INTERGENIC G 0.0008
373 3 rs6794105 22939325 AC099544.2 INTERGENIC A 0.0008
374 15 rs13380359 24884848 GABRG3 INTRONIC G 0.0008
375 2 rs7599725 221292815 AC019051.8 INTERGENIC T 0.0008
376 4 rs17539365 22323903 GBA3 INTRONIC A 0.0008
377 2 rs2702089 24496795 AC009228.4-2 INTERGENIC A 0.0008
378 1 rs12741645 44335934 RP5-1198020.5 INTERGENIC T 0.0008
379 3 rs2090702 14518673 GRIP2 INTRONIC T 0.0008
380 22 rs2235171 30980200 SLC5A4 NON-SYN T 0.0008
381 3 rs1580800 20914295 AC 104441.2 INTERGENIC A 0.0008
382 5 rs7718958 134121831 DDX46 UPSTREAM C 0.0008
383 5 rs13189947 153050585 GRIA1 INTRONIC A 0.0008
384 11 rs12224791 123424338 AP001884.4 INTERGENIC G 0.0008
385 5 rs1461243 153263155 FAM114A2 INTERGENIC C 0.0008
386 1 rs7513428 165781896 CREG1 INTRONIC A 0.0008
387 9 rs10964182 19484098 AL158206.8-2 UPSTREAM T 0.0008
388 17 rs759974 347709 VPS53 INTERGENIC T 0.0008
389 10 rs1243194 22020520 MLLT10 INTRONIC T 0.0008
390 9 rs16937267 19001300 FAM154A INTRONIC C 0.0008
391 4 rs6829972 14252310 AC093777.4 INTERGENIC G 0.0008
392 7 rs42523 93878935 COL1A2 INTRONIC C 0.0008
393 10 rs6482189 21929144 MLLT10 INTRONIC A 0.0008
394 6 rs9502396 5992248 NRN1 INTERGENIC G 0.0008
395 6 rs1324103 93957737 EPHA7 INTERGENIC C 0.0008
396 3 rs182568 4312312 SUMF1 INTRONIC T 0.0009
397 11 rs4930103 1981120 H19 INTERGENIC G 0.0009
398 7 rs4256491 15384424 TMEM195 INTRONIC A 0.0009
399 6 rs9688888 169462608 XXyac-YX65C7_A.4 INTERGENIC G 0.0009
400 12 rs2555319 118199160 CCDC60 INTERGENIC C 0.0009
401 9 rs7041706 16382810 BNC2 INTERGENIC C 0.0009
402 1 rs7520966 54417850 CYB5RL INTRONIC T 0.0009
403 4 rs13152723 21812805 AC093735.2 INTERGENIC G 0.0009
404 2 rs6730730 228232354 SLC19A3 INTERGENIC G 0.0009
405 8 rs2013265 24148445 ADAM28 INTERGENIC A 0.0009
406 7 rs4615456 15440324 TMEM195 INTRONIC G 0.0009
407 16 rs1369790 59149079 AC018554.7 INTERGENIC G 0.0009
408 8 rs777801 116245300 TRPS1 INTERGENIC T 0.0009
409 8 rs9642799 106326386 ZFPM2 INTERGENIC A 0.0009
410 11 rs1400756 110585670 C11orf53 INTERGENIC C 0.0009
411 7 rs17169762 34361776 AC005582.1 INTRONIC C 0.0009
412 6 rs434310 95061282 RP3-399J4.2 INTERGENIC A 0.0009
413 12 rs10844642 33621635 AC024153.22 DOWNSTREAM C 0.0009
414 5 rs29645 123176335 AC008580.7 INTERGENIC T 0.0009
415 6 rs718868 147892684 SAMD5 INTRONIC T 0.0009
416 11 rs1124847 56712658 LRRC55 3 PRIME UTR G 0.0009
417 3 rs9861350 141971631 TRIM42 INTERGENIC A 0.0009
418 7 rs2392581 38539759 AMPH INTRONIC G 0.0009
419 6 rs7766161 170011280 C6orf70 INTERGENIC G 0.0009
420 13 rs9319313 26241960 GPR12 INTERGENIC G 0.0009
421 16 rs11644878 25820846 HS3ST4 INTRONIC A 0.0009
422 10 rs11014358 18794501 CACNB2 INTRONIC G 0.0009
423 9 rs1411355 109512117 AL389915.19 INTERGENIC A 0.0009
424 9 rs3739482 19497991 SLC24A2 INTERGENIC A 0.0009
425 14 rs1955429 84997096 AL049775.2 INTERGENIC T 0.0009
426 13 rs1517896 36011534 RP11-56M2.1 INTERGENIC A 0.0009
427 11 rs4756930 18076471 SAAL1 INTRONIC T 0.0009
428 3 rs6551273 88258879 ZNF654 INTERGENIC G 0.0009
429 18 rs1944351 52002040 AC009271.7 INTRONIC A 0.0009
430 2 rs6718240 23081861 AC104807.5-2 INTERGENIC G 0.0009
431 15 rs11634818 60143678 FAM148A UPSTREAM G 0.0009
432 4 rs11725282 187194106 AC104070.3 INTERGENIC C 0.0009
433 1 rs1591785 155472908 ETV3 INTERGENIC T 0.0009
434 6 rs421424 8967099 BX255934.7 INTERGENIC A 0.0009
435 9 rs880242 131669653 USP20 INTRONIC G 0.0009
436 5 rs12651858 68613223 CCDC125 3 PRIME UTR C 0.0009
437 5 rs17704210 157961941 EBF1 INTERGENIC G 0.0009
438 13 rs4771929 95650914 HS6ST3 INTRONIC T 0.0009
439 11 rs287756 41688339 n/a INTERGENIC T 0.0009
440 3 rs9843001 120535281 AC092981.3-1 INTRONIC T 0.0009
n/a = not applicable
Table 5.4. LOAD+P versus control. Results for SNPs with p-values £ IxlO"4. Table shows SNP rank, chromosome, base
associated allele, p-value and OR in LOAD+P vs. Control, LOAD vs. control and LOAD+P vs. LOAD-P analyses.
Rank Chr SNP BP Gene Type Allele P OR
LOAD GWA 
P
1 19 rs2075650 50087459 TOMM40 INTRONIC C 3.60E-34 2.47 1.753E-157
2 19 rs157580 50087106 TOMM40 INTRONIC G 1.96E-11 0.62 9.62E-54
3 19 rs6859 50073874 PVRL2 3PRIME_UTR T 3.54E-11 1.54 6.946E-41
4 19 rs439401 50106291 APOE;PKP2 UPSTREAM T 5.94E-08 0.68 2.652E-23
5 19 rs8106922 50093506 TOMM40 INTRONIC G 6.05E-08 0.69 5.373E-39
6 15 rs8038077 58791939 RORA INTRONIC G 1.56E-07 1.78 0.02102
7 19 rs405509 50100676 APOE;PKP2 UPSTREAM A 1.20E-06 1.37 4.884E-37
8 7 rs868055 129222427 MIRN183 INTERGENIC T 1.80E-06 1.62 0.0004112
9 12 rs1906950 25408885 AC092451.12-2 INTERGENIC A 4.88E-06 1.35 0.0009067
10 8 rs4527852 125542605 TRMT12 INTERGENIC T 5.56E-06 1.61 0.1853
11 2 rs1430170 133749869 AC010974.1 INTRONIC G 9.29E-06 0.71 0.01094
12 8 rs10094093 4493322 AC019176.4-2 INTERGENIC T 9.93E-06 0.68 0.06029
13 3 rs9289666 144727672 SLC9A9 INTRONIC A 1.31 E-05 1.49 0.02476
14 19 rs10402948 490266 CDC34 INTRONIC T 1.35E-05 1.63 0.1486
15 2 rs4671328 58788786 IK INTERGENIC A 1.39E-05 0.75 0.004147
16 7 rs4726443 140618341 AC005692.1 INTERGENIC T 1.39E-05 2.51 0.0168
17 8 rs16899656 125602072 TATDN1 INTRONIC G 1.42 E-05 1.58 0.0699
18 16 rs11648322 10082553 GRIN2A INTRONIC T 1.56E-05 1.33 0.02505
19 10 rs6482252 23397218 AL139815.12-3 INTERGENIC G 1.58E-05 1.33 0.003285
20 10 rs7902903 23398083 AL139815.12-3 INTERGENIC C 1.69E-05 1.33 0.008537
21 12 rs12372711 25418920 AC092451.12-2 INTERGENIC G 1.73E-05 1.33 0.0004256
22 2 rs1861410 58787095 IK INTERGENIC C 1.85E-05 0.75 0.006573
23 2 rs1519473 17633576 VSNL1 INTRONIC C 1.87 E-05 1.60 0.1121
24 4 rs753129 56363188 AC110611.3-1 DOWNSTREAM G 2.04E-05 1.36 0.03285
25 2 rs4038129 17638227 VSNL1 INTRONIC C 2.10E-05 1.61 0.3779
26 15 rs8031076 48149784 ATP8B4 INTRONIC A 2.17E-05 1.32 0.0204
27 2 rs1949510 17641610 VSNL1 INTRONIC A 2.35E-05 1.60 0.149
28 16 rs11645153 81676584 CDH13 INTRONIC C 2.63E-05 1.39 0.02804
29 19 rs4919850 507632 GZMM INTERGENIC T 3.05E-05 1.44 0.2901
30 5 rs11740920 132777389 FSTL4 INTRONIC C 3.24E-05 1.36 0.02142
31 2 rs6741951 58812616 IK INTERGENIC T 3.25E-05 0.73 0.006944
32 17 rs9904097 73496579 TNRC6C INTERGENIC G 3.32E-05 1.32 0.006898
33 12 rs4759721 129589514 RIMBP2 INTERGENIC C 3.39E-05 0.76 0.1954
34 7 rs1558542 55101766 EGFR INTRONIC T 3.48E-05 1.38 0.4633
35 16 rs922302 81367787 AC099506.3 INTERGENIC G 3.50E-05 1.37 0.03484
36 8 rs12678035 15315148 AC091559.7 INTERGENIC C 3.72E-05 0.30 0.001775
37 2 rs10176091 58839545 IK INTERGENIC T 3.82E-05 0.74 0.001166
38 6 rs9404549 104959117 RP11-427E4.1 INTERGENIC T 4.04 E-05 1.44 0.2545
39 5 rs6870951 133092859 FSTL4 INTERGENIC A 4.08E-05 1.46 1.027
40 2 rs1978346 217269712 IGFBP5 UPSTREAM G 4.11 E-05 1.31 0.2391
41 11 rs2512152 117392967 AP002962.2 INTERGENIC A 4.18E-05 0.73 0.137
42 19 rs379758 48990002 LYPD5 DOWNSTREAM G 4.21 E-05 1.46 0.1053
43 3 rs578641 147138054 AC055758.23 INTERGENIC C 4.55E-05 0.71 0.394
44 15 rs10519257 48176213 ATP8B4 INTRONIC G 4.63E-05 1.34 0.01263
45 10 rs7079742 19016665 ARL5B INTERGENIC T 4.64E-05 0.76 0.0334
46 10 rs941856 116160015 AFAP1L2 INTERGENIC G 4.68E-05 1.59 0.02923
47 5 rs10474519 76929703 AC108173.1 INTERGENIC T 4.75E-05 1.49 0.00005446
48 17 rs4789523 73524449 TNRC6C INTERGENIC A 4.78E-05 1.33 0.004594
49 16 rs7189966 81371504 AC099506.3 INTERGENIC C 4.93E-05 1.36 0.04047
50 12 rs12366756 49689473 SLC11A2 INTRONIC C 4.97E-05 0.67 0.005768
51 6 rs7756959 104974286 RP11-427E4.1 INTERGENIC C 5.02 E-05 1.43 0.05733
52 3 rs6800179 141050356 CLSTN2 INTERGENIC C 5.53E-05 1.43 0.05311
53 11 rs1400756 110585670 C11orf53 INTERGENIC C 5.61 E-05 1.44 1.018
54 8 rs12543670 4498860 AC019176.4-2 INTERGENIC G 5.67E-05 0.72 0.01861
55 20 rs747680 60977520 DID01 UPSTREAM A 5.71 E-05 1.30 0.00263
56 8 rs10956535 131623943 ASAP1 INTERGENIC C 5.71 E-05 1.30 1.007
57 9 rs9314866 79907769 RP11-336N8.1 INTERGENIC A 5.79E-05 0.76 0.0004003
58 10 rs6585251 115641243 NHLRC2 INTRONIC T 5.80E-05 0.74 0.1915
59 18 rs17240415 64801868 CCDC102B INTRONIC A 6.02E-05 0.74 0.2614
60 18 rs280989 4419639 n/a INTERGENIC G 6.05E-05 0.73 0.003578
61 10 rs2670106 79111719 KCNMA1 INTERGENIC C 6.19E-05 0.63 0.0005924
62 12 rs11169654 49667102 SLC11A2 3PRIMEJJTR A 6.32E-05 0.67 0.008652
63 6 rs156235 104978232 RP11-427E4.1 INTERGENIC C 6.48E-05 1.42 0.1691
64 3 rs7612414 89872049 AC026305.20-3 INTERGENIC G 6.52E-05 1.61 0.2217
65 2 rs848607 36623696 AC007401.2 INTRONIC A 6.61 E-05 0.75 0.979
66 6 rs7740010 104962863 RP11-427E4.1 INTERGENIC A 6.63E-05 1.42 0.2374
67 12 rs831429 102585961 STAB2 INTRONIC C 7.06E-05 1.32 0.351
68 13 rs9512519 26522181 USP12 INTERGENIC C 7.21 E-05 0.49 0.002622
69 18 rs206749 64155406 TMX3 INTERGENIC G 7.23E-05 1.29 0.007995
70 19 rs745952 55189335 VRK3 INTRONIC T 7.39E-05 1.43 0.003302
71 7 rs2693737 129218230 MIRN183 INTERGENIC C 7.51 E-05 1.50 0.02569
72 18 rs4799872 32425512 FHOD3 INTRONIC A 7.89E-05 1.30 0.0218
73 1 rs7520521 70020703 LRRC7 INTRONIC G 8.07E-05 0.77 0.1674
74 15 rs8040030 48163879 ATP8B4 INTRONIC A 8.18E-05 1.29 0.002706
75 16 rs9927466 59162687 AC018554.7 INTERGENIC T 8.28E-05 1.30 1.015
76 6 rs7759504 132108194 ENPP3 INTRONIC T 8.39E-05 0.44 0.4142
77 10 rs1576479 115669955 NHLRC2 INTERGENIC A 8.43E-05 0.77 0.1237
78 7 rs219824 98483453 SMURF1
79 10 rs7913176 115634030 NHLRC2
80 9 rs1328533 79674282 GNAQ
81 10 rs10870210 134597903 C10orf93
82 3 rs2171513 113667617 BTLA
83 9 rs11145589 79662751 GNAQ
84 4 rs10519397 137901725 AC006572.2
85 7 rs17155687 107831342 NRCAM
86 16 rs1436046 59175549 AC018554.7
87 6 rs267339 104985242 RP11-427E4.1
88 19 rs17312204 55249688 AC010624.8-1
89 6 rs9354570 67978123 AL591004.3
90 15 rs8041340 48148130 ATP8B4
91 1 rs6661589 70022134 LRRC7
92 12 rs10745978 102582910 STAB2
93 10 rs1107442 112293585 RP11-73H14.1
94 10 rs1986577 20351249 PLXDC2
95 12 rs1031477 48504911 KIAA1602
96 18 rs4798993 73985341 AC139070.3
97 12 rs7296829 102585727 STAB2
98 2 rs6716814 78229692 AC064872.3
99 6 rs6939897 67969845 AL591004.3
100 19 rs285684 38963499 CHST8
101 15 rs12909131 48174970 ATP8B4
102 10 rs35084455 87559938 GRID1
103 3 rs6806737 141171105 CLSTN2
104 14 rs17558231 69406803 SMOC1
INTRONIC A 8.44E-05 1.30 0.01067
NON_SYN T 8.56E-05 0.74 0.2138
INTRONIC C 8.60E-05 0.76 0.0007377
INTRONIC A 8.77E-05 1.70 0.1317
3PRIMEJJTR T 8.79E-05 0.39 0.0003671
INTRONIC T 8.86E-05 0.73 0.003245
INTERGENIC T 8.87E-05 0.59 0.2014
INTRONIC T 9.00E-05 1.57 0.001551
INTERGENIC C 9.00E-05 1.29 0.3766
INTERGENIC A 9.05E-05 1.38 0.02812
INTRONIC G 9.33E-05 1.53 0.02061
UPSTREAM T 9.59E-05 1.43 0.3268
INTRONIC C 9.72E-05 0.77 0.0001887
INTRONIC A 9.90E-05 0.77 0.149
INTRONIC C 0.0001007 1.29 0.01781
INTERGENIC G 0.0001035 1.34 0.09801
INTRONIC T 0.0001047 1.30 0.1112
INTRONIC C 0.0001054 0.78 0.0541
INTERGENIC T 0.0001066 0.72 0.05808
INTRONIC C 0.0001103 1.28 0.08018
INTERGENIC A 0.0001138 1.32 0.09362
INTERGENIC C 0.0001149 1.43 0.2999
INTERGENIC T 0.0001156 0.75 0.05875
INTRONIC T 0.0001157 1.32 0.02987
INTRONIC T 0.0001208 1.72 0.1177
INTRONIC A 0.0001211 1.40 0.08341
INTERGENIC C 0.0001219 1.52 0.01306
105 2 rs6727330 217271690 IGFBP5 UPSTREAM C 0.0001241 1.29 1.02
106 2 rs1991108 220611959 AC114765.6 INTERGENIC A 0.0001283 1.37 0.005102
107 1 rs11122300 228287788 GALNT2 INTRONIC T 0.000132 1.34 0.0007599
108 6 rs7756211 20661764 CDKAL1 INTRONIC T 0.0001346 1.30 0.2429
109 12 rs17027488 96741146 RNU6-2 INTERGENIC G 0.0001365 1.31 0.02805
110 2 rs12991296 78235370 AC064872.3 INTERGENIC C 0.0001366 1.42 0.01626
111 12 rs755598 102583920 STAB2 INTRONIC G 0.0001378 1.28 0.08816
112 2 rs885640 159783429 TANC1 INTRONIC G 0.0001412 1.29 0.0006816
113 12 rs2398518 129600639 RIMBP2 INTERGENIC A 0.0001446 1.28 0.1045
114 6 rs7773295 107744179 PDSS2 INTRONIC A 0.0001448 1.34 0.1411
115 3 rs6808569 124456196 SEC22A INTRONIC T 0.0001493 0.70 0.3577
116 5 rs620508 29543052 AC010374.6 INTERGENIC G 0.00015 0.76 0.3436
117 2 rs2861264 78220585 AC064872.3 INTERGENIC A 0.0001553 1.42 0.03514
118 10 rs2926872 14058238 FRMD4A INTRONIC G 0.0001598 1.45 0.009523
119 3 rs1915728 89915500 AC026305.20-3 INTERGENIC G 0.0001604 1.65 0.9926
120 3 rs3804592 123461919 CASR INTRONIC T 0.0001627 0.67 0.1962
121 6 rs7758851 20650200 CDKAL1 INTRONIC T 0.0001642 1.29 0.2893
122 13 rs1951898 36404819 RP11-421P11.8 INTERGENIC A 0.0001655 1.42 1.024
123 16 rs2549159 81421748 AC099506.3 INTERGENIC C 0.0001663 1.27 0.04008
124 8 rs777801 116245300 ADD2 INTRONIC T 0.0001671 0.53 0.4034
125 2 rs3755365 70798073 TRPS1 INTERGENIC C 0.0001671 1.30 1.014
126 21 rs2096471 35045555 CLIC6 INTERGENIC C 0.000171 1.33 0.1448
127 10 rs7908946 127903558 ADAM 12 INTRONIC A 0.0001737 0.73 1.006
128 9 rs1926381 7329425 RP11-87M1.1 INTERGENIC T 0.0001752 0.72 0.005402
129 18 rs12454977 74657618 SALL3 INTERGENIC A 0.0001767 0.70 0.9847
130 22 rs760656 31173938 BPIL2 INTRONIC C 0.0001785 0.70 0.0001062
131 17 rs9909561 2687549 GARNL4 INTRONIC A 0.0001795 0.78 0.1619
132 8 rs6578080 141291830 TRAPPC9 INTRONIC G 0.0001801 1.28 1.017
133 5 rs1298248 103436968 AC091894.2 INTERGENIC T 0.0001813 1.29 1.01
134 12 rs7979925 100866032 AC084398.25-2 INTERGENIC C 0.0001817 0.78 0.03238
135 17 rs9889827 73538266 TNRC6C INTERGENIC C 0.0001841 1.28 0.02459
136 9 rs3808720 17654191 SH3GL2 INTRONIC T 0.0001861 0.78 0.002869
137 4 rs2309472 182537727 n/a INTERGENIC A 0.0001912 0.77 0.3867
138 8 rs2034140 6224172 AC026305.20-3 INTERGENIC G 0.0001927 0.46 0.1873
139 3 rs6788646 89915684 MCPH1 INTERGENIC A 0.0001927 1.61 0.9917
140 4 rs13108814 81570062 C4orf22 INTRONIC A 0.0001939 1.33 0.001548
141 11 rs7936316 81924308 FAM181B INTERGENIC A 0.0001966 0.45 0.002175
142 6 rs2745933 20858693 CDKAL1 INTRONIC T 0.0001978 0.78 0.02156
143 2 rs2593708 134695885 MGAT5 INTRONIC T 0.0002009 1.28 0.01839
144 3 rs1533393 124446769 SEC22A INTRONIC C 0.0002022 0.71 0.3762
145 6 rs1338715 87300547 AL391417.7-2 INTERGENIC A 0.0002034 1.29 0.08087
146 4 rs12648767 17167201 LAP3 INTERGENIC A 0.0002035 1.28 0.05669
147 8 rs2702910 6811301 DEFA10P DOWNSTREAM T 0.0002037 0.76 0.01027
148 11 rs7929650 12958762 RASSF10 INTERGENIC G 0.0002062 1.48 0.01913
149 6 rs2674394 93563130 AL589947.3-2 INTERGENIC A 0.0002064 1.37 0.3141
150 5 rs683004 29539692 AC010374.6 INTERGENIC A 0.000207 0.76 0.277
151 16 rs11150535 81644467 CDH13 INTRONIC T 0.000207 1.27 1.02
152 3 rs1520593 89927248 AC026305.20-3 INTERGENIC C 0.0002079 1.61 0.9985
153 18 rs7229111 32432481 FHOD3 INTRONIC A 0.000209 1.27 0.05808
154 6 rs2674371 93553719 AL589947.3-2 UPSTREAM C 0.0002094 1.37 0.3855
155 9 rs3780232 17680180 SH3GL2 INTRONIC C 0.0002097 0.78 0.001098
156 11 rs576825 131200086 HNT;NTM INTRONIC C 0.0002109 1.27 0.08473
157 10 rs4339947 6735491 PRKCQ INTERGENIC C 0.0002158 1.29 0.002172
158 3 rs7653338 90020778 AC095349.10 INTERGENIC A 0.0002219 1.60 0.9985
159 17 rs1122634 45976364 EPN3 UPSTREAM T 0.0002236 1.27 0.1095
160 3 rs7623722 28857984 AC097361.2 INTERGENIC G 0.0002267 1.27 1.012
161 3 rs4580491 124454040 n/a n/a C 0.0002278 0.71 0.383
162 6 rs9342616 67942640 AL590874.6 INTERGENIC T 0.0002292 0.79 0.04672
163 19 rs3764650 997520 ABCA7 INTRONIC C 0.000233 1.47 0.00001556
164 9 rs10981195 113803202 AL138756.23-1 UPSTREAM A 0.000236 1.30 0.4158
165 12 rs11047988 25432786 AC092451.12-2 INTERGENIC G 0.0002379 1.27 0.001824
166 4 rs6834555 9671424 WDR1 INTERGENIC C 0.0002448 0.73 0.04556
167 11 rs2085334 92820698 CCDC67 INTERGENIC G 0.0002456 1.29 0.001077
168 4 rs35495915 54764155 PDGFRA INTERGENIC T 0.0002535 0.73 0.08204
169 2 rs12986742 58828647 IK INTERGENIC C 0.0002593 0.79 0.04324
170 19 rs10402271 50021054 BCAM DOWNSTREAM G 0.0002594 1.27 1.541E-26
171 2 rs13425498 78206058 AC064872.3 INTERGENIC T 0.0002639 1.31 0.2859
172 5 rs3909548 128997514 ADAMTS19 INTRONIC A 0.0002648 1.41 0.07702
173 7 rs2693727 129204966 MIRN183 UPSTREAM G 0.0002665 1.46 0.0374
174 16 rs844395 10010407 GRIN2A INTRONIC A 0.0002678 0.78 0.03064
175 3 rs6770430 90106009 AC095349.10 INTERGENIC A 0.0002685 1.62 1.008
176 19 rs377702 50054507 PVRL2 INTRONIC T 0.0002693 1.27 8.375E-11
177 12 rs1871898 128415853 TMEM132D INTRONIC G 0.0002703 1.27 0.02216
178 18 rs11876226 20907560 ZNF521 INTRONIC G 0.000271 1.34 0.006904
179 3 rs9876068 142901893 RNF7 INTERGENIC C 0.0002728 0.43 0.00002937
180 22 rs5753436 29776921 AC005005.1-1 INTERGENIC G 0.0002784 0.66 0.0361
181 11 rs3096716 86134830 PRSS23 INTERGENIC T 0.000282 1.30 1.02
182 3 rs7648855 89993520 AC095349.10 INTERGENIC G 0.0002892 1.59 0.9928
183 16 rs10492859 81419315 AC099506.3 INTERGENIC G 0.0002893 0.74 0.1008
184 10 rs7089454 127894700 ADAM 12 INTRONIC G 0.0002897 0.75 0.9964
185 16 rs718510 59153108 AC018554.7 INTERGENIC A 0.0002923 0.78 0.04267
186 10 rs821705 108073458 AL133395.21
187 3 rs6766386 147136793 AC055758.23
188 11 rs6592039 81828131 FAM181B
189 19 rs17801681 56368461 SIGLECP3
190 1 rs1258033 46782614 KNCN
191 11 rs2433438 86132394 PRSS23
192 6 rs9473511 49299933 RP1-14209.2
193 6 rs9358383 21107366 CDKAL1
194 12 rs2301529 49676014 SLC11A2
195 6 rs2767576 156921465 AL158033.18
196 8 rs3857946 125675435 MTSS1
197 16 rs837688 10007044 GRIN2A
198 10 rs10904321 4736345 AKR1CL2
199 9 rs12343558 18807951 C9orf94; AD AMTSL1
200 3 rs9869506 111458818 AC117430.3-2
201 6 rs9377643 105041172 RP11-427E4.1
202 18 rs8091319 9674723 AP000902.5
203 10 rs528320 13326337 C10orf49
204 5 rs7702830 111798779 EPB41L4A
205 3 rs966866 141164738 CLSTN2
206 11 rs1949707 81771147 FAM181B
207 10 rs7097356 127901574 ADAM 12
208 14 rs6575028 88503521 TTC8
209 14 rs2369018 95082844 GLRX5
210 11 rs10831608 11361390 GALNTL4
211 8 rs3824110 146142089 ZNF16
212 20 rs6097096 50772458 AL049736.10
INTERGENIC T 0.0002926 1.27 0.007213
INTERGENIC T 0.0002984 0.71 0.9996
INTERGENIC A 0.0003009 0.43 0.06322
3PRIME_UTR A 0.0003016 1.56 0.158
UPSTREAM C 0.000304 0.76 0.006502
INTERGENIC G 0.0003049 1.29 1.025
INTERGENIC T 0.0003103 1.52 0.1599
INTRONIC G 0.0003109 1.29 0.09538
INTRONIC T 0.000312 0.73 0.06983
INTERGENIC C 0.0003122 1.43 0.00006301
INTRONIC A 0.0003135 1.47 0.04825
INTRONIC G 0.0003185 1.26 0.1657
INTERGENIC C 0.0003196 1.27 0.001922
INTRONIC C 0.0003208 1.29 1.012
INTERGENIC G 0.0003234 0.64 0.00153
INTERGENIC C 0.0003256 1.38 0.4068
INTERGENIC T 0.0003258 1.31 0.2576
INTERGENIC C 0.0003269 1.37 0.03679
INTERGENIC C 0.000327 1.34 0.04778
INTRONIC c 0.0003291 1.28 0.01939
INTERGENIC c 0.000331 0.44 0.04758
INTRONIC c 0.0003314 0.76 0.996
INTERGENIC T 0.0003345 1.33 0.002949
DOWNSTREAM T 0.0003345 0.75 0.03062
INTRONIC T 0.0003357 1.26 0.0361
INTRONIC A 0.0003371 0.72 0.004323
INTERGENIC A 0.0003384 1.38 0.001378
213 10 rs3936497 28619975 MPP7 INTERGENIC C 0.0003385 1.51 0.01732
214 12 rs10860757 100544577 MYBPC1 INTRONIC C 0.000339 0.67 0.07681
215 19 rs8103315 49946008 BCL3 INTRONIC T 0.0003412 1.36 2.942E-07
216 10 rs10827932 20351525 PLXDC2 INTRONIC T 0.0003414 1.27 0.002538
217 18 rs1893311 20881576 ZNF521 INTERGENIC T 0.0003425 1.34 0.008352
218 16 rs12922279 59151989 AC018554.7 INTERGENIC C 0.0003445 0.78 0.04185
219 8 rs10104503 6666441 XKR5 INTRONIC T 0.0003454 1.28 0.1771
220 11 rs10837311 39938524 AL591004.3 INTERGENIC T 0.0003466 0.73 0.004395
221 6 rs9294750 67960760 AC021749.6-3 INTERGENIC C 0.0003466 0.79 0.2614
222 15 rs12903325 48140569 ATP8B4 INTRONIC C 0.0003485 1.30 0.03243
223 12 rs12824958 49620342 AC008121.43-2 UPSTREAM c 0.0003488 0.73 0.09133
224 18 rs4799869 32416808 FHOD3 INTRONIC A 0.000353 1.27 0.05578
225 12 rs10745935 100913627 CCDC53 INTERGENIC G 0.0003538 0.61 0.9973
226 9 rs504896 32586503 NDUFB6 INTERGENIC A 0.0003548 1.49 0.08986
227 15 rs6603018 82512023 ADAMTSL3 INTERGENIC T 0.0003548 1.36 1.009
228 9 rs10971038 32582503 NDUFB6 INTERGENIC A 0.0003577 1.49 0.05517
229 12 rs11044223 18675030 PIK3C2G INTRONIC C 0.0003593 0.65 0.3888
230 2 rs1615070 61246679 C2orf74 DOWNSTREAM C 0.0003728 1.26 0.3594
231 15 rs906194 82541642 AC103965.5 INTRONIC A 0.0003748 1.36 1.021
232 14 rs17103033 34626231 C14orf10;PPP2R3C INTRONIC G 0.0003749 1.35 0.0002787
233 10 rs17684713 127942864 ADAM 12 INTRONIC A 0.0003754 0.73 0.9905
234 5 rs1345686 111835478 EPB41L4A INTERGENIC T 0.0003761 1.34 0.03761
235 1 rs34411680 54992999 PARS2 DOWNSTREAM C 0.0003784 1.48 0.04713
236 2 rs10514647 204869721 PARD3B INTERGENIC G 0.0003786 1.46 0.1614
237 2 rs6436883 230213277 DNER INTRONIC T 0.0003815 1.26 0.0001091
238 2 rs17338519 2150112 MYT1L INTRONIC T 0.0003826 1.41 0.1575
239 22 rs80533 39415915 MCHR1 INTERGENIC A 0.0003836 1.29 0.002373
240 9 rs7871498 37374977 ZCCHC7
241 10 rs9888067 96638214 RP11-400G3.3
242 8 rs1893884 99621703 STK3
243 4 rs6848311 187455812 F11
244 2 rs744373 127611085 BIN1
245 14 rs11628156 55409820 AL355773.4
246 14 rs1885186 88499809 TTC8
247 18 rs12454185 74667117 SALL3
248 3 rs6790000 124374854 PDIA5
249 6 rs17445948 54653025 RP3-334F4.1
250 2 rs17338512 2152335 MYT1L
251 3 rs6788684 25937362 OXSM
252 3 rs1705589 171408358 PRKCI
253 11 rs598829 131247810 HNT;NTM
254 1 rs11579916 119589065 AL359915.14
255 8 rs13248917 39918113 AC019129.1
256 2 rs7607908 44160954 ID02
257 9 rs10738482 17650410 SH3GL2
258 2 rs6753886 107992900 SLC5A7
259 14 rs2401785 88487005 TTC8
260 8 rs12541503 6662868 XKR5
261 10 rs9663603 108129695 AL133395.21
262 10 rs11006995 28625502 AC022021.10-3
263 11 rs10899236 70129782 SHANK2
264 3 rs7616301 90102238 AC095349.10
265 3 rs7651217 90099238 AC095349.10
266 7 rs854568 94787737 PON1
INTERGENIC A 0.0003895 1.31 0.1293
INTERGENIC A 0.0003916 0.74 0.4248
INTRONIC A 0.0003924 1.26 0.08192
INTERGENIC T 0.0003949 0.73 0.4312
INTERGENIC G 0.0003959 1.28 0.00000320:
INTERGENIC G 0.0004021 1.27 0.0004217
INTERGENIC T 0.0004042 1.32 0.008811
INTERGENIC G 0.0004094 0.72 0.9905
INTERGENIC C 0.0004111 0.74 0.09121
INTERGENIC A 0.0004122 1.47 0.2397
INTRONIC A 0.0004128 1.41 0.1439
INTERGENIC A 0.0004194 1.35 0.3767
INTERGENIC C 0.0004206 0.74 0.06422
INTRONIC A 0.0004219 1.27 1.006
INTERGENIC T 0.0004256 0.72 0.03498
INTERGENIC C 0.0004293 1.26 0.03945
INTRONIC A 0.0004293 1.36 1.015
INTRONIC A 0.0004318 0.79 0.005816
INTRONIC T 0.000434 0.78 0.2364
INTERGENIC A 0.0004351 1.32 0.002753
INTRONIC T 0.0004398 1.29 0.154
INTERGENIC C 0.0004424 1.29 0.02182
INTERGENIC A 0.0004453 1.55 0.001416
INTRONIC G 0.0004483 0.79 0.04133
INTERGENIC C 0.0004511 1.56 0.9839
INTERGENIC C 0.0004511 1.56 0.9839
INTRONIC C 0.0004566 1.30 0.0008371
267 13 rs4942106 41776392 AKAP11 INTRONIC A 0.0004571 1.29 1.024
268 11 rs7106873 70103491 SHANK2 INTRONIC T 0.00046 1.25 0.08738
269 11 rs10894589 131998236 OPCML INTRONIC T 0.0004603 0.57 0.9747
270 3 rs9863121 173938537 ECT2 INTERGENIC T 0.0004658 1.28 0.3032
271 11 rs1545527 59010971 AP003778.3-4 UPSTREAM G 0.0004683 1.27 1.016
272 14 rs1958018 32646064 NPAS3 INTRONIC G 0.0004684 1.29 1.015
273 16 rs4541063 83783372 FAM92B INTERGENIC C 0.0004731 0.78 0.1542
274 10 rs4748275 6750189 PRKCQ INTERGENIC G 0.0004801 1.28 0.03334
275 15 rs12442068 78463829 ARNT2 INTERGENIC G 0.0004849 1.31 0.07071
276 18 rs12954185 73970814 AC139070.3 INTERGENIC C 0.0004863 0.73 0.007873
277 18 rs4595890 60404482 AC008245.6 INTERGENIC A 0.0004905 0.76 0.0202
278 7 rs17171118 148148237 MYTH INTRONIC T 0.000493 1.36 0.0008541
279 2 rs12467137 2154578 EZH2 INTRONIC T 0.000493 1.40 0.187
280 11 rs12800502 28260001 METT5D1 INTRONIC G 0.0004939 0.72 0.0284
281 10 rs1576480 115669985 NHLRC2 INTERGENIC C 0.0004968 1.25 0.03966
282 6 rs2206579 20733613 CDKAL1 INTRONIC C 0.0004969 1.27 1.019
283 16 rs4889197 71952116 C16orf47 INTERGENIC A 0.0005004 1.25 0.0787
284 12 rs1190655 91124864 AC025164.37-2 INTERGENIC C 0.0005017 1.26 0.01157
285 8 rs17282526 131277125 ASAP1 INTRONIC T 0.0005042 1.25 0.001061
286 1 rs12043001 176073958 SEC16B INTERGENIC G 0.0005045 0.70 0.002307
287 3 rs9289466 135520086 RPL39P5 INTERGENIC C 0.000507 0.79 0.2435
288 4 rs17001970 77589062 SHROOM3 INTRONIC T 0.0005096 1.53 0.1309
289 11 rs1048099 17453092 ABCC8 SYNONYMOUS C 0.0005096 1.31 0.1337
290 6 rs4712540 20871150 STK32B INTRONIC C 0.0005098 1.25 0.01137
291 4 rs1374621 5176625 CDKAL1 INTRONIC T 0.0005098 1.94 0.09377
292 14 rs2363506 76466445 AC007686.5 REGULATORY A 0.0005112 0.80 0.004536
293 17 rs1052507 62497273 HELZ 3PRIMEJJTR G 0.0005151 1.42 0.05301
294 12 rs1861786 13891734 GRIN2B
295 4 rs6850106 151121994 AC096756.3-2
296 12 rs1356083 129575938 RIMBP2
297 5 rs4976217 68437697 SLC30A5
298 17 rs2279966 69232956 C17orf54
299 15 rs2879971 82918472 AC048382.7-2
300 3 rs11707887 140862075 NMNAT3
301 12 rs10842549 25442292 AC092451.12-2
302 6 rs7775523 21063311 CDKAL1
303 5 rs11748946 132775021 FSTL4
304 6 rs4077405 20984662 CDKAL1
305 11 rs1054532 94372055 JMJD2D
306 9 rs7043157 18741638 C9orf94; ADAMTSL1
307 3 rs3774700 62291434 C3orf14
308 11 rs10792830 85516456 AP003097.2
309 5 rs7727192 84447374 AC113412.2-2
310 6 rs17310261 5093162 LYRM4
311 1 rs10925401 235623753 RYR2
312 10 rs3019500 124426520 AL603764.27
313 2 rs3849346 163210967 KCNH7
314 13 rs1891100 94001278 TGDS
315 12 rs11836523 13749151 GRIN2B
316 14 rs7140539 33150659 NPAS3
317 13 rs9512257 26012324 WASF3
318 9 rs960644 105060805 RP11-341 A22.1
319 6 rs1417667 104909883 LSM10
320 1 rs4653186 36635516 RP1-244F1.1
INTRONIC T 0.0005168 0.79 0.9887
INTERGENIC C 0.000518 2.01 0.05634
INTERGENIC G 0.000518 1.25 0.2484
INTRONIC A 0.000521 1.38 0.3614
INTERGENIC A 0.0005224 0.47 0.2279
UPSTREAM T 0.0005269 1.35 1.011
INTRONIC A 0.0005301 1.27 0.06165
INTERGENIC C 0.0005325 1.25 0.2301
INTRONIC C 0.000535 1.26 0.04534
INTRONIC C 0.0005416 1.37 0.1085
INTRONIC G 0.0005424 1.25 0.0851
3PRIMEJJTR A 0.0005451 1.35 0.1376
INTRONIC G 0.0005466 0.80 0.05248
INTRONIC G 0.000547 0.57 0.05512
INTERGENIC T 0.0005483 1.25 0.02034
INTERGENIC G 0.0005535 1.26 0.3575
INTRONIC C 0.0005537 0.65 0.9818
INTRONIC C 0.0005551 0.80 0.0968
INTRONIC T 0.0005553 1.32 0.001085
INTRONIC G 0.0005557 1.30 0.3476
INTERGENIC T 0.0005562 0.78 0.02895
INTRONIC C 0.0005567 1.43 1.033
INTRONIC G 0.0005632 1.26 0.175
INTERGENIC C 0.0005676 0.79 0.03082
INTERGENIC G 0.0005686 0.70 0.9916
INTRONIC G 0.0005708 1.45 0.04004
INTERGENIC T 0.0005708 0.78 0.06372
321 6 rs1012626 20685540 CDKAL1
322 9 rs1123551 133611630 RAPGEF1
323 3 rs10937074 183120027 AC007547.26-2
324 5 rs17733586 73295365 AC093283.3-2
325 16 rs11649643 59206580 AC018554.7
326 5 rs1862310 107153700 AC008586.6
327 8 rs2117085 75973042 PI15
328 4 rs12642995 156776705 GUCY1A3
329 12 rs7967304 83766755 SLC6A15
330 8 rs7002825 101740397 SNX31
331 21 rs1389994 17954750 BTG3
332 4 rs7672650 187508041 AC109517.4
333 6 rs2767577 156938875 AL158033.18
334 4 rs7670038 187615001 AC110761.3
335 14 rs12435645 105108671 IGHA2
336 19 rs1865108 49022693 ZNF283
337 3 rs11708596 14664397 C3orf19
338 1 rs259588 236537568 AL356010.9
339 19 rs11878692 1136924 SBN02
340 12 rs11535963 18245787 AC087240.17
341 13 rs2208932 25124174 ATP8A2
342 1 rs411238 30559814 RP3-357I16.1
343 19 rs10425074 50331964 LRRC68
344 15 rs2242065 56626590 LIPC
345 15 rs10520664 85927717 TMEM83
346 5 rs607077 29531321 AC010374.6
347 8 rs4733037 27149412 STMN4
INTRONIC A 0.0005732 0.79 0.1644
INTERGENIC T 0.0005789 0.57 0.2388
INTERGENIC A 0.0005819 0.79 0.1125
INTERGENIC T 0.0005835 1.59 0.05668
INTERGENIC T 0.0005881 1.27 1.016
INTERGENIC T 0.0005909 1.31 0.01531
INTERGENIC A 0.000591 0.62 0.1869
INTERGENIC G 0.0005941 0.73 1.002
INTERGENIC G 0.0005967 1.26 0.04071
INTERGENIC G 0.0005968 1.29 0.0006819
INTERGENIC A 0.0005983 0.79 0.01101
INTERGENIC G 0.0006017 1.26 0.07013
INTERGENIC G 0.0006031 1.29 0.1033
INTERGENIC A 0.0006042 1.30 0.01637
INTERGENIC A 0.0006047 1.48 0.286
INTRONIC C 0.0006055 1.40 0.3212
UPSTREAM T 0.0006125 1.33 0.08658
INTERGENIC C 0.0006156 0.80 0.04742
INTERGENIC C 0.0006166 1.32 0.09159
INTERGENIC T 0.0006167 0.74 0.4675
INTRONIC C 0.0006181 1.36 1.004
INTERGENIC A 0.0006199 1.27 0.02182
INTRONIC C 0.0006231 1.29 0.0000191
INTRONIC T 0.0006263 1.43 0.225
DOWNSTREAM C 0.0006282 1.54 0.05256
INTERGENIC G 0.0006292 0.78 0.1851
DOWNSTREAM A 0.0006296 1.25 0.1635
348 6 rs4510656 20874676 CDKAL1
349 7 rs7798774 28714056 CREB5
350 17 rs4789551 73722674 BIRC5
351 22 rs1883987 35383415 CACNG2
352 14 rs6572182 42387419 n/a
353 10 rs1890951 61724712 ANK3
354 19 rs12977284 6926032 EMR4P
355 14 rs8005907 95857500 ATG2B
356 4 rs6552500 182579063 n/a
357 16 rs759831 81421161 AC099506.3
358 16 rs1369790 59149079 AC018554.7
359 8 rs11785060 145118650 PLEC1
360 10 rs7077490 108145291 AL133395.21
361 13 rs7320671 19407203 ZMYM2
362 1 rs11806225 11421873 RP11-149P14.1
363 4 rs17004994 81949609 C4orf22
364 5 rs12189436 29518112 AC010374.6
365 17 rs6502823 4638112 GLTPD2
366 12 rs6488565 12883409 DDX47
367 2 rs2664226 220581788 AC114765.6
368 16 rs6497658 10047257 GRIN2A
369 4 rs1803037 100212174 ADH5P4;ADH5
370 20 rs1018443 8574903 PLCB1
371 19 rs8101040 55255711 AC010624.8-1
372 6 rs9470642 37679431 MDGA1
373 3 rs13072512 71496735 FOXP1
374 1 rs12140361 159588622 SDHC
INTRONIC A 0.0006331 1.25 0.0603
INTRONIC G 0.0006369 1.29 0.01249
INTRONIC C 0.0006389 1.43 0.1017
INTRONIC C 0.0006401 1.26 0.3438
INTERGENIC T 0.0006406 1.34 0.03403
INTRONIC A 0.0006415 0.76 0.0213
INTRONIC A 0.0006432 0.60 0.006861
INTRONIC C 0.0006434 0.64 0.3652
INTERGENIC C 0.0006445 1.30 0.09871
INTERGENIC A 0.0006475 0.78 0.1277
INTERGENIC G 0.0006486 1.26 0.9931
INTRONIC T 0.0006516 1.25 0.001063
INTERGENIC G 0.0006533 1.28 0.03651
INTERGENIC C 0.0006583 1.24 1.005
INTERGENIC C 0.0006585 0.55 0.985
INTRONIC G 0.0006591 1.94 0.06421
INTERGENIC C 0.000661 1.41 0.002539
UPSTREAM T 0.0006644 1.41 0.2252
INTERGENIC A 0.0006645 1.29 0.1035
INTERGENIC T 0.0006697 1.33 0.003577
INTRONIC C 0.0006702 1.24 0.3558
3PRIME_UTR A 0.0006706 0.64 0.07578
INTRONIC T 0.0006756 1.28 0.1329
INTRONIC A 0.0006799 1.35 0.0109
INTERGENIC G 0.00068 0.77 0.1246
INTRONIC A 0.0006828 0.80 0.01941
INTRONIC C 0.0006829 1.95 0.003019
375 6 rs12663853 40585151 LRFN2
376 11 rs649931 78375935 ODZ4
377 18 rs8089316 38722881 RIT2
378 6 rs11754558 123292386 RLBP1L2
379 9 rs2181156 10491953 RP11-87N24.1
380 6 rs6935954 26363430 HIST1H2BH
381 9 rs3808708 17684823 SH3GL2
382 14 rs2272550 21661828 AE000660.1-11
383 14 rs12100841 34641402 C14orf10;PPP2R3C
384 12 rs11107270 92834257 CRADD
385 10 rs11006970 28592174 CDKAL1
386 6 rs7747724 20859294 MPP7
387 13 rs2217902 101089435 ITGBL1
388 1 rs437722 30564829 RP3-357I16.1
389 1 rs485660 109824955 SYPL2
390 3 rs340146 113267579 TMPRSS7
391 5 rs11953547 92031385 AC026781.5
392 2 rs2655455 8498335 AC011747.5
393 7 rs1530680 114194632 FOXP2
394 16 rs2304469 8803595 PMM2
395 15 rs2412621 39621697 RPAP1
396 8 rs7815950 101728344 SNX31
397 20 rs2145280 55788630 CMA1
398 14 rs12589666 24062459 PMEPA1
399 8 rs4275231 26137422 PPP2R2A
400 12 rs6580784 49754578 CSRNP2
401 3 rs6790913 45058525 CLEC3B
INTRONIC G 0.0006836 2.67 0.00169
INTRONIC T 0.0006863 0.50 0.216
INTRONIC C 0.0006911 1.35 0.1073
INTERGENIC A 0.0006912 1.84 0.02305
INTERGENIC G 0.0006913 1.25 0.02215
UPSTREAM A 0.0006935 0.80 0.315
INTRONIC A 0.0006937 0.79 0.002237
NON_SYN A 0.0006938 1.26 0.9932
INTRONIC C 0.0006941 1.31 0.0005634
INTERGENIC C 0.0006951 1.83 0.09337
INTRONIC T 0.0006961 1.40 0.02723
INTRONIC C 0.0006961 1.25 0.04912
INTRONIC C 0.0006961 1.45 0.3725
INTERGENIC A 0.0006965 1.27 0.01147
3PRIMEJJTR A 0.0006972 1.28 0.3963
INTRONIC T 0.0006981 1.43 0.01303
INTERGENIC T 0.0007003 1.34 0.434
INTERGENIC A 0.0007011 1.24 0.2486
INTERGENIC T 0.0007013 1.30 0.002356
INTRONIC C 0.0007046 1.25 0.2075
INTRONIC C 0.0007076 0.79 0.004308
INTRONIC c 0.000709 0.65 0.1029
INTERGENIC A 0.0007094 1.29 0.01981
INTERGENIC A 0.0007094 1.25 0.03523
INTERGENIC T 0.00071 1.32 0.284
INTRONIC A 0.0007106 0.75 0.1233
INTERGENIC T 0.0007202 1.41 1.008
402 18 rs169455 4416360 n/a
403 10 rs988011 117587767 ATRNL1
404 8 rs7815631 101728102 SNX31
405 14 rs204984 76624887 KIAA1737
406 7 rs1557780 27961372 JAZF1
407 8 rs4397386 141294034 TRAPPC9
408 5 rs25923 110824997 CAMK4
409 14 rs7142488 55317763 AL355773.4
410 17 rs16950116 47022532 CA10
411 3 rs1242061 144859179 SLC9A9
412 8 rs13277804 18848961 PSD3
413 2 rs10187702 58723279 IK
414 4 rs4485803 148270902 TTC29
415 5 rs1428609 66716372 AC008459.7
416 15 rs3098538 25501132 GABRG3
417 2 rs1177265 61192336 KIAA1841
418 2 rs17750151 171266344 AC007277.2
419 6 rs381480 105039869 RP11-427E4.1
420 5 rs9918231 29669784 NAGK
421 2 rs6724815 71138848 AC010374.6
422 5 rs10042848 92035583 AC026781.5
423 6 rs9371581 152671279 SYNE1
424 6 rs3778279 26433442 H3F3AP1
425 11 rs4406832 130077513 C11orf44
426 17 rs578065 15705232 AC015922.5
427 5 rs10491314 141535648 NDFIP1
428 19 rs3764640 1158238 STK11
INTERGENIC T 0.0007286 0.77 0.01042
INTRONIC A 0.0007308 1.38 0.01353
INTRONIC T 0.0007329 0.65 0.02219
INTERGENIC A 0.000733 0.77 0.02934
INTRONIC C 0.0007332 0.80 0.08359
INTRONIC C 0.0007339 1.25 0.998
INTRONIC C 0.0007341 1.25 0.4336
INTERGENIC C 0.0007374 1.26 0.00155;
INTERGENIC T 0.0007383 1.44 0.9888
INTRONIC A 0.0007388 1.31 0.03286
INTRONIC A 0.0007399 0.67 0.1476
INTERGENIC G 0.0007408 0.71 0.00143C
INTERGENIC A 0.0007409 0.47 0.193
INTERGENIC G 0.0007418 1.24 1.002
INTERGENIC A 0.0007423 1.30 0.1398
INTRONIC G 0.0007438 0.80 0.218
INTERGENIC G 0.0007442 0.69 0.05135
INTERGENIC T 0.00075 1.34 0.1703
INTERGENIC A 0.0007506 1.27 0.1345
INTERGENIC A 0.0007506 1.46 1.001
INTERGENIC G 0.0007512 1.34 0.3285
INTRONIC G 0.0007551 0.80 0.07961
UPSTREAM C 0.000756 1.24 0.2104
INTRONIC A 0.0007569 0.73 0.004991
NON_CODING G 0.000757 1.25 0.0733
INTERGENIC A 0.00076 1.31 0.01036
INTRONIC A 0.0007603 0.75 0.9791
429 2 rs1035601 220593213 AC114765.6
430 4 rs717435 108452512 AC104663.3
431 12 rs11057929 124006284 DHX37
432 6 rs9366354 20653447 CDKAL1
433 18 rs8098687 30773270 DTNA
434 8 rs2008555 96802870 AC116154.2
435 10 rs11244887 127892517 ADAM 12
436 17 rs790097 69115102 SDK2
437 2 rs16856529 217281937 IGFBP5
438 20 rs6011530 61112293 AL121673.41
439 2 rs7597992 70797524 ADD2
440 6 rs12207523 132027750 ENPP3
441 2 rs888182 217280090 IGFBP5
442 15 rs7177318 48159823 ATP8B4
443 12 rs3217907 4277097 CCND2
444 6 rs16893540 28066090 RP3-408B20.4
445 10 rs1471247 61744286 ANK3
446 3 rs651165 173895581 AADACL1
447 12 rs4471501 49711619 SLC11A2
448 6 rs11155004 139160262 C6orf91;ECT2L
449 15 rs7176145 66490322 ITGA11
450 6 rs1395633 54665623 RP3-334F4.1
451 10 rs11015633 19019475 ARL5B
452 6 rs9480754 107656140 PDSS2
453 3 rs4684237 14685592 C3orf19
454 1 rs2294642 11644280 FBX044
455 15 rs16940650 85926915 TMEM83
INTERGENIC G 0.0007618 1.32 0.004481
INTERGENIC T 0.0007631 0.80 0.01781
INTRONIC C 0.0007656 1.30 0.2553
INTRONIC G 0.0007676 0.79 0.2312
INTERGENIC A 0.0007677 0.73 0.003418
INTERGENIC T 0.000768 0.76 0.3338
INTRONIC T 0.0007682 0.76 1.011
INTERGENIC A 0.0007683 0.66 0.1797
INTERGENIC G 0.0007691 1.33 0.1497
INTRONIC A 0.0007736 1.36 0.385
INTRONIC C 0.0007741 1.32 0.09461
INTRONIC T 0.0007759 0.56 0.1299
INTERGENIC C 0.000776 1.32 0.06355
INTRONIC T 0.0007764 1.24 0.0006585
INTRONIC A 0.0007766 1.25 0.00359
INTERGENIC T 0.0007824 2.08 0.001104
INTRONIC A 0.0007824 0.80 0.06508
INTRONIC A 0.0007867 1.28 0.1087
UPSTREAM A 0.0007868 0.77 0.09591
INTRONIC T 0.000787 0.80 0.2207
INTRONIC G 0.0007882 1.33 0.000597
INTERGENIC T 0.0007902 1.45 0.1954
INTERGENIC G 0.000792 1.24 0.08936
INTRONIC G 0.0007928 1.27 0.07712
INTRONIC T 0.000799 1.29 0.07652
3PRIMEJJTR T 0.0008012 0.60 0.2628
DOWNSTREAM T 0.0008016 1.53 0.04957
456 18 rs9304251 37534376 AC011225.1 INTERGENIC A 0.0008073 1.45 1.007
457 6 rs2753977 66176184 EGFL10;EYS INTRONIC C 0.0008138 1.34 0.007076
458 10 rs1475418 6730153 PRKCQ INTERGENIC A 0.0008229 1.26 0.003404
459 6 rs9349437 48017897 C6orf138 INTRONIC T 0.0008239 1.33 0.3785
460 1 rs953517 36682864 C1orf102 INTRONIC C 0.0008244 0.79 0.1432
461 21 rs2838000 41568388 BACE2 INTRONIC T 0.0008251 1.29 1.011
462 12 rs4768967 49792595 TFCP2 INTRONIC A 0.0008266 0.75 0.1117
463 4 rs931602 79704900 ANXA3 INTRONIC C 0.0008271 1.27 0.1524
464 12 rs10444509 100738161 GNPTAB INTRONIC G 0.0008275 0.73 0.04093
465 1 rs4073574 11725021 AGTRAP INTRONIC G 0.0008322 1.25 0.9827
466 3 rs968628 156299605 MME INTRONIC G 0.0008367 1.24 0.001567
467 3 rs10460808 106986819 CBLB INTRONIC C 0.0008437 1.42 0.004538
468 11 rs516431 131301209 HNT;NTM INTRONIC T 0.0008462 1.28 0.3687
469 8 rs12679771 140971097 TRAPPC9 INTRONIC T 0.0008481 0.75 0.132
470 18 rs623966 30715894 DTNA INTRONIC C 0.0008515 0.74 0.0008519
471 13 rs7983069 38379318 RP11-7B3.3 DOWNSTREAM A 0.0008536 0.80 0.06151
472 3 rs1111516 135552894 RPL39P5 DOWNSTREAM T 0.0008539 0.79 0.1707
473 10 rs10901559 127888676 ADAM 12 INTRONIC T 0.0008637 0.76 1.014
474 1 rs12408243 46762631 DMBX1 INTERGENIC C 0.0008653 0.81 0.007723
475 2 rs2392820 221661777 AC019208.8 INTERGENIC T 0.0008678 1.26 1.02
476 10 rs4747272 6753766 PRKCQ INTERGENIC T 0.0008683 1.33 0.03274
477 22 rs7292528 25046227 SEZ6L INTRONIC T 0.0008688 1.42 0.2794
478 19 rs7259059 55206290 VRK3 INTRONIC T 0.0008727 1.29 0.1893
479 3 rs2667469 124371327 PDIA5 INTERGENIC G 0.0008751 0.76 0.9791
480 7 rs3735219 148144400 EZH2 INTRONIC A 0.000877 1.34 0.02664
481 16 rs1155970 81422728 AC099506.3 INTERGENIC C 0.0008791 0.79 0.05162
482 3 rs1461762 111465959 AC117430.3-2 INTERGENIC A 0.0008797 0.72 0.06479
483 4 rs17039589 110105816 COL25A1
484 6 rs995291 105032852 RP11-427E4.1
485 3 rs7623367 193713253 AC026671.18
486 2 rs13032780 191930845 MY01B
487 8 rs4872211 23983658 AC023202.8
488 6 rs1885275 136160513 PDE7B
489 18 rs11080606 12857969 PTPN2
490 7 rs7783459 148204831 EZH2
491 22 rs11704749 33942297 HMGXB4
492 7 rs38519 28004411 JAZF1
493 11 rs7938094 39904380 AC021749.6-3
494 9 rs2860101 70293226 PGM5
495 10 rs10751569 128361479 AL512272.15
496 12 rs10859283 91145168 AC025164.37-2
497 14 rs12885638 56461434 AL137100.4
498 5 rs13165786 83892156 EDIL3
499 11 rs7118622 11355982 GALNTL4
500 3 rs9852993 134093286 TMEM108
501 1 rs12132152 97523004 DPYD
502 21 rs7280677 20549970 AP000431.2
503 1 rs17109254 83289801 RP4-601K24.1
504 8 rs4240188 12685435 LONRF1
505 11 rs7943388 39966521 AC021749.6
506 12 rs149411 51380232 SLC11A2
507 6 rs195850 99297801 POU3F2
508 4 rs998091 5687628 EVC2
509 3 rs500193 182846387 LAMP3
INTRONIC A 0.0008874 1.39 0.05128
INTERGENIC A 0.0008879 1.34 0.216
INTERGENIC G 0.000888 0.58 0.02673
INTRONIC T 0.0008932 0.77 0.000455
INTERGENIC A 0.0008945 0.71 0.2349
INTERGENIC T 0.000896 1.27 0.123
INTRONIC G 0.0008982 1.26 0.2259
INTRONIC A 0.0008991 1.34 0.01738
INTERGENIC A 0.0009009 0.64 0.157
INTRONIC T 0.0009025 1.24 0.009706
INTERGENIC C 0.0009057 0.75 0.03027
INTRONIC T 0.0009092 0.69 0.00955
INTERGENIC A 0.0009097 0.80 0.02037
INTERGENIC T 0.0009147 1.27 0.08521
INTERGENIC C 0.0009156 1.25 0.1334
INTERGENIC C 0.0009195 1.24 0.04904
INTRONIC c 0.0009246 0.77 1.016
INTERGENIC T 0.0009254 0.75 0.9886
INTERGENIC A 0.0009284 2.05 0.00914
INTERGENIC C 0.0009307 0.79 0.3572
INTERGENIC A 0.0009324 1.96 0.02495
INTERGENIC A 0.0009327 1.24 0.3855
INTERGENIC T 0.0009331 0.71 0.08051
3PRIME_UTR T 0.000935 0.80 0.05944
INTERGENIC T 0.0009362 0.72 0.5548
INTRONIC T 0.0009367 1.25 0.08107
INTRONIC G 0.0009377 1.48 0.05818
510 1 rs6425838 34254416 CSMD2 INTRONIC T 0.0009379 1.26 0.1339
511 2 rs7577925 134040519 AC010890.1 INTRONIC T 0.0009384 0.79 0.01804
512 5 rs10462823 6891874 AC122710.3 INTERGENIC A 0.0009444 0.70 0.1031
513 6 rs9356756 20844151 CDKAL1 INTRONIC G 0.0009445 1.24 0.02786
514 5 rs11959584 151854302 NMUR2 INTERGENIC C 0.0009474 1.24 0.2172
n/a = not applicable
Table 5.5. Breakdown of minor allele frequencies for SNPs <10^ in either LOAD+P vs. LOAD-P or LOAD+P vs. control a
irrespective of analysis. Table shows chromosome, SNP ID, gene name, minor allele, and minor allele frequency in LOAI
Chr SNP Gene Minor Allele MAF LOAD+P MAF LOA
19 rs2075650 TOMM40 C 0.30 0.29
19 rs157580 TOMM40 G 0.29 0.31
19 rs6859 PVRL2 C 0.48 0.48
19 rs439401 APOE;PKP2 T 0.27 0.30
19 rs8106922 TOMM40 G 0.30 0.31
15 rs8038077 RORA G 0.11 0.07
19 rs405509 APOE;PKP2 C 0.43 0.42
7 rs868055 MIRN183 T 0.12 0.08
12 rs1906950 AC092451.12-2 A 0.41 0.35
8 rs4527852 TRMT12 T 0.11 0.08
8 rs2034140 MCPH1 G 0.02 0.07
6 rs11756091 KCNK16 G 0.48 0.42
8 rs10956535 ASAP1 C 0.44 0.33
2 rs1430170 AC010974.1 G 0.23 0.29
8 rs10094093 AC019176.4-2 T 0.16 0.20
4 rs753129 AC110611.3-1 G 0.30 0.21
9 rs960644 RP11-341 A22.1 G 0.11 0.18
3 rs9289666 SLC9A9 A 0.15 0.10
19 rs10402948 CDC34 T 0.10 0.07
7 rs4726443 AC005692.1 T 0.05 0.03
2 rs4671328 IK A 0.39 0.43
8 rs16899656 TATDN1 G 0.11 0.08
12 rs2682778 SUDS3 T 0.17 0.25
10 rs1444400 PRKG1 G 0.37 0.28
10 rs1444401 PRKG1 A 0.37 0.28
16 rs11648322 GRIN2A T 0.42 0.38
10 rs6482252 AL139815.12-3 T 0.45 0.49
10 rs6480276 PRKG1 G 0.37 0.28
10 rs7902903 AL139815.12-3 T 0.44 0.49
12 rs12372711 AC092451.12-2 G 0.41 0.35
2 rs1861410 IK C 0.39 0.43
2 rs1519473 VSNL1 C 0.10 0.07
2 rs11680774 CCDC148 C 0.21 0.29
4 rs753129 AC110611.3-1 G 0.30 0.21
2 rs2883854 CCDC148 C 0.23 0.32
6 rs3734618 KCNK16 T 0.48 0.43
2 rs4038129 VSNL1 C 0.10 0.06
15 rs8031076 ATP8B4 A 0.43 0.40
1 rs12045777 EPB41 A 0.47 0.44
2 rs1949510 VSNL1 A 0.10 0.06
16 rs11645153 CDH13 C 0.23 0.18
12 rs1520780 SUDS3 A 0.18 0.27
19 rs4919850 GZMM T 0.17 0.13
5 rs11740920 FSTL4 C 0.26 0.22
2 rs6741951 IK T 0.24 0.25
17 rs9904097 TNRC6C G 0.39 0.34
4 rs2695234 SOD3 T 0.05 0.10
12 rs4759721 RIMBP2 C 0.40 0.46
4 rs12648438 AC115540.3 A 0.23 0.16
7 rs1558542 EGFR T 0.24 0.19
16 rs922302 AC099506.3 G 0.24 0.21
8 rs12678035 AC091559.7 C 0.01 0.03
2 rs10176091 IK T 0.28 0.29
6 rs9404549 RP11-427E4.1 T 0.17 0.10
5 rs6870951 FSTL4 A 0.15 0.11
2 rs1978346 IGFBP5 G 0.41 0.35
11 rs2512152 AP002962.2 A 0.23 0.27
19 rs379758 LYPD5 G 0.15 0.12
6 rs13201744 F13A1 T 0.08 0.15
4 rs2100889 IBSP A 0.27 0.35
3 rs578641 AC055758.23 C 0.17 0.22
15 rs10519257 ATP8B4 G 0.30 0.27
10 rs7079742 ARL5B T 0.36 0.44
10 rs941856 AFAP1L2 G 0.09 0.06
5 rs10474519 AC108173.1 T 0.13 0.10
17 rs4789523 TNRC6C A 0.33 0.27
2 rs3771599 PK4P;PKP4 G 0.34 0.43
2 rs11674284 PK4P;PKP4 C 0.25 0.34
16 rs7189966 AC099506.3 C 0.24 0.21
12 rs12366756 SLC11A2 C 0.16 0.18
6 rs7756959 RP11-427E4.1 C 0.17 0.10
2 rs6711582 PK4P.PKP4 T 0.33 0.42
3 rs6800179 CLSTN2 C 0.17 0.11
11 rs1400756 C11orf53 C 0.16 0.11
8 rs12543670 AC019176.4-2 G 0.18 0.20
20 rs747680 DID01 G 0.45 0.50
8 rs10956535 ASAP1 C 0.44 0.33
9 rs9314866 RP11-336N8.1 A 0.31 0.35
10 rs6585251 NHLRC2 T 0.23 0.27
2 rs2356186 PK4P;PKP4 T 0.34 0.43
1 rs2640467 MECR C 0.39 0.31
6 rs9404549 RP11-427E4.1 T 0.17 0.10
18 rs17240415 CCDC102B A 0.25 0.30
7 rs10235799 AC006008.2 C 0.37 0.45
18 rs280989 n/a G 0.36 0.40
10 rs2670106 KCNMA1 C 0.08 0.11
12 rs11169654 SLC11A2 A 0.16 0.18
6 rs156235 RP11-427E4.1 C 0.16 0.10
12 rs11535963 AC087240.17 T 0.24 0.32
3 rs7612414 AC026305.20-3 G 0.09 0.06
2 rs848607 AC007401.2 A 0.25 0.31
6 rs7740010 RP11-427E4.1 A 0.16 0.10
12 rs11044223 PIK3C2G C 0.07 0.13
1 rs3929673 C1orf196 T 0.32 0.41
6 rs7756959 RP11-427E4.1 C 0.17 0.10
4 rs6828769 AC115540.3 G 0.24 0.16
12 rs831429 STAB2 C 0.32 0.28
2 rs3764835 AC005042.2 T 0.13 0.20
16 rs17720179 JMJD5 T 0.11 0.17
13 rs9512519 USP12 C 0.03 0.07
18 rs206749 TMX3 G 0.44 0.37
19 rs745952 VRK3 T 0.16 0.14
2 rs3771635 PK4P;PKP4 G 0.25 0.34
4 rs1989924 ALPK1 A 0.46 0.37
7 rs2693737 MIRN183 C 0.12 0.07
14 rs10143543 AL160237.4-1 A 0.39 0.30
6 rs7740010 RP11-427E4.1 A 0.16 0.10
6 rs156235 RP11-427E4.1 C 0.16 0.10
16 rs8061432 HS3ST4 T 0.09 0.05
2 rs3755365 ADD2 C 0.36 0.27
16 rs17674628 PMM2 A 0.23 0.16
18 rs4799872 FHOD3 A 0.40 0.35
10 rs11252926 DIP2C A 0.31 0.40
7 rs17156246 CACNA2D1 T 0.16 0.10
1 rs7520521 LRRC7 G 0.34 0.39
15 rs8040030 ATP8B4 A 0.49 0.46
3 rs9867560 AC104471.6 T 0.11 0.18
3 rs17443484 AC104471.6 A 0.11 0.18
16 rs9927466 AC018554.7 T 0.41 0.33
10 rs11252923 DIP2C T 0.31 0.40
6 rs7759504 ENPP3 T 0.02 0.04
10 rs1576479 NHLRC2 A 0.43 0.47
7 rs219824 SMURF1 A 0.38 0.34
10 rs7913176 NHLRC2 T 0.23 0.27
1 rs1146413 AL158218.11 C 0.38 0.46
9 rs1328533 GNAQ C 0.32 0.36
10 rs10870210 C10orf93 A 0.11 0.07
3 rs2171513 BTLA T 0.02 0.03
9 rs11145589 GNAQ T 0.20 0.25
4 rs10519397 AC006572.2 T 0.06 0.10
3 rs9865618 AC104471.6 G 0.11 0.17
2 rs2080394 FIGLA C 0.44 0.47
7 rs17155687 NRCAM T 0.09 0.09
16 rs1436046 AC018554.7 C 0.48 0.40
15 rs17237486 RORA G 0.21 0.14
6 rs267339 RP11-427E4.1 A 0.19 0.13
10 rs7089944 CCDC3 C 0.22 0.30
2 rs3771408 ADD2 A 0.42 0.49
3 rs2139266 TRIM42 T 0.46 0.45
19 rs17312204 AC010624.8-1 G 0.10 0.09
13 rs9512519 USP12 C 0.03 0.07
6 rs9354570 AL591004.3 T 0.15 0.11
1 rs1768404 AL158218.11 A 0.38 0.46
15 rs8041340 ATP8B4 C 0.35 0.37
8 rs7015252 ASAP1 A 0.39 0.48
1 rs6661589 LRRC7 A 0.34 0.39
2 rs2681031 AC104807.5-2 G 0.48 0.39
5 rs683004 AC010374.6 A 0.27 0.35
5 rs620508 AC010374.6 G 0.27 0.35
3 rs925665 AC090955.3 A 0.31 0.39
4 rs6826655 AC097521.2-2 A 0.41 0.50
14 rs6573225 AL049873.3-2 C 0.15 0.09
14 rs442555 AL049873.3-2 C 0.15 0.09
14 rs399223 AL049873.3-2 C 0.17 0.11
14 rs177726 AL049873.3-2 T 0.17 0.11
2 rs7597989 CALCRL A 0.42 0.48
2 rs17808559 CCDC148 T 0.25 0.34
10 rs4881399 DIP2C T 0.31 0.40
6 rs775258 GRIK2 G 0.10 0.16
3 rs4613440 GRIP2 T 0.50 0.41
11 rs598829 HNT;NTM A 0.34 0.26
13 rs12560710 n/a A 0.11 0.06
13 rs9284246 MY016 G 0.44 0.35
2 rs4853462 MY01B C 0.36 0.28
10 rs3903435 NRG3 G 0.42 0.49
10 rs9664256 NRG3 G 0.43 0.49
11 rs750270 OPCML A 0.10 0.05
3 rs13070407 RARB G 0.25 0.33
6 rs267339 RP11-427E4.1 A 0.19 0.13
6 rs9377643 RP11-427E4.1 C 0.16 0.10
4 rs2303513 SEC24D A 0.26 0.34
11 rs17794760 TPH1 A 0.15 0.23
8 rs7842680 XKR4 C 0.17 0.11
12 rs10745978 STAB2 C 0.48 0.44
10 rs1107442 RP11-73H14.1 G 0.25 0.20
10 rs1986577 PLXDC2 T 0.40 0.34
12 rs1031477 KIAA1602 C 0.42 0.47
18 rs4798993 AC139070.3 T 0.18 0.19
12 rs7296829 STAB2 C 0.48 0.44
2 rs6716814 AC064872.3 A 0.28 0.24
6 rs6939897 AL591004.3 C 0.15 0.11
19 rs285684 CHST8 T 0.25 0.29
15 rs12909131 ATP8B4 T 0.29 0.25
10 rs35084455 GRID1 T 0.10 0.07
3 rs6806737 CLSTN2 A 0.17 0.12
14 rs17558231 SMOC1 C 0.10 0.09
2 rs6727330 IGFBP5 C 0.41 0.35
2 rs1991108 AC114765.6 A 0.20 0.17
1 rs11122300 GALNT2 T 0.23 0.21
6 rs7756211 CDKAL1 T 0.37 0.30
12 rs17027488 RNU6-2 G 0.29 0.24
2 rs12991296 AC064872.3 C 0.15 0.12
12 rs755598 STAB2 G 0.48 0.44
2 rs885640 TANC1 G 0.39 0.34
12 rs2398518 RIMBP2 A 0.46 0.39
6 rs7773295 PDSS2 A 0.24 0.22
3 rs6808569 SEC22A T 0.14 0.17
5 rs620508 AC010374.6 G 0.27 0.35
2 rs2861264 AC064872.3 A 0.14 0.12
10 rs2926872 FRMD4A G 0.13 0.11
3 rs1915728 AC026305.20-3 G 0.07 0.05
3 rs3804592 CASR T 0.10 0.14
6 rs7758851 CDKAL1 T 0.36 0.30
13 rs1951898 RP11-421P11.8 A 0.16 0.12
16 rs2549159 AC099506.3 C 0.49 0.46
8 rs777801 ADD2 T 0.04 0.07
2 rs3755365 TRPS1 C 0.36 0.27
21 rs2096471 CLIC6 C 0.25 0.20
10 rs7908946 ADAM12 A 0.18 0.25
9 rs1926381 RP11-87M1.1 T 0.16 0.20
18 rs12454977 SALL3 A 0.13 0.18
22 rs760656 BPIL2 C 0.18 0.24
17 rs9909561 GARNL4 A 0.44 0.48
8 rs6578080 TRAPPC9 T 0.50 0.46
5 rs1298248 AC091894.2 T 0.39 0.34
12 rs7979925 AC084398.25-2 C 0.35 0.42
17 rs9889827 TNRC6C C 0.41 0.35
9 rs3808720 SH3GL2 T 0.33 0.32
4 rs2309472 n/a A 0.34 0.37
8 rs2034140 AC026305.20-3 G 0.02 0.07
3 rs6788646 MCPH1 A 0.07 0.05
4 rs13108814 C4orf22 A 0.25 0.19
11 rs7936316 FAM181B A 0.03 0.03
6 rs2745933 CDKAL1 T 0.37 0.43
5 rs905858 AC010374.6 G 0.37 0.44
5 rs607077 AC010374.6 G 0.28 0.35
2 rs12470671 AC011747.5 A 0.36 0.44
5 rs1550825 AC016575.7 A 0.35 0.43
16 rs9927466 AC018554.7 T 0.41 0.33
3 rs7614031 AC069504.7 A 0.45 0.36
2 rs1918901 AC074020.4 C 0.40 0.50
5 rs4527553 AC092373.2-2 T 0.15 0.22
4 rs7687115 AC097521.2-2 G 0.41 0.49
2 rs3755361 ADD2 T 0.42 0.49
8 rs11781115 ADRA1A G 0.29 0.37
14 rs983449 AL049873.3-2 T 0.11 0.06
9 rs902143 AL512649.6 A 0.42 0.50
1 rs12038526 AL691459.25 G 0.13 0.20
2 rs7563401 ANXA4 G 0.47 0.44
2 rs7567400 ANXA4 G 0.47 0.44
10 rs7079742 ARL5B T 0.36 0.44
1 rs1894654 CAMTA1 G 0.29 0.37
3 rs9823958 CLSTN2 A 0.14 0.08
7 rs12669501 COL1A2 A 0.08 0.14
7 rs4729127 COL1A2 C 0.08 0.14
5 rs286969 FAM114A2 T 0.43 0.35
13 rs9513354 FARP1 A 0.24 0.17
16 rs4548875 HS3ST4 A 0.18 0.12
16 rs4362392 HS3ST4 C 0.18 0.12
7 rs11767477 MAGI2 C 0.27 0.19
8 rs6470563 MYC C 0.07 0.12
2 rs7574570 MY01B C 0.36 0.28
2 rs10445783 MY01B G 0.36 0.28
18 rs8099057 n/a A 0.15 0.22
3 rs188423 NMNAT3 T 0.47 0.39
3 rs295464 NMNAT3 G 0.47 0.39
2 rs3771644 PK4P;PKP4 A 0.25 0.33
16 rs2304469 PMM2 T 0.48 0.43
19 rs4805441 POP4 T 0.47 0.44
14 rs11851391 PRIMA1 A 0.13 0.08
10 rs10823083 PRKG1 A 0.32 0.40
12 rs2285831 RAPGEF3 A 0.12 0.07
19 rs3810342 RASGRP4 G 0.20 0.13
9 rs16922740 RP11-341A22.1 C 0.07 0.12
13 rs4343137 RP11-65D24.2 T 0.29 0.21
11 rs2468782 SAA3P G 0.16 0.23
19 rs3764640 STK11 A 0.17 0.23
9 rs7852394 TLR4 C 0.48 0.40
9 rs7854254 TLR4 G 0.48 0.40
9 rs10739508 TLR4 T 0.48 0.44
9 rs1329771 TRPM3 G 0.41 0.49
18 rs7231736 YES1 G 0.46 0.38
19 rs6509701 ZNF320 C 0.33 0.25
19 rs6509698 ZNF468 T 0.17 0.11
2 rs2593708 MGAT5 T 0.43 0.38
3 rs1533393 SEC22A C 0.14 0.17
6 rs1338715 AL391417.7-2 A 0.33 0.28
4 rs12648767 LAP3 A 0.37 0.33
8 rs2702910 DEFA10P T 0.24 0.28
11 rs7929650 RASSF10 G 0.11 0.09
6 rs2674394 AL589947.3-2 A 0.18 0.15
5 rs683004 AC010374.6 A 0.27 0.35
16 rs11150535 CDH13 T 0.49 0.41
3 rs1520593 AC026305.20-3 C 0.07 0.05
18 rs7229111 FHOD3 A 0.40 0.36
6 rs2674371 AL589947.3-2 C 0.18 0.15
9 rs3780232 SH3GL2 C 0.33 0.32
11 rs576825 HNT;NTM C 0.39 0.34
10 rs4339947 PRKCQ C 0.34 0.32
3 rs7653338 AC095349.10 A 0.07 0.05
17 rs1122634 EPN3 C 0.50 0.44
3 rs7623722 AC097361.2 A 0.45 0.48
3 rs4580491 n/a C 0.14 0.17
6 rs9342616 AL590874.6 T 0.42 0.47
19 rs3764650 ABCA7 C 0.12 0.11
9 rs10981195 AL138756.23-1 A 0.28 0.24
12 rs11047988 AC092451.12-2 G 0.40 0.35
4 rs6834555 WDR1 C 0.17 0.20
11 rs2085334 CCDC67 G 0.32 0.25
4 rs35495915 PDGFRA T 0.23 0.28
2 rs12986742 IK C 0.43 0.45
19 rs10402271 BCAM G 0.38 0.39
2 rs13425498 AC064872.3 T 0.27 0.22
5 rs3909548 ADAMTS19 A 0.15 0.12
7 rs2693727 MIRN183 G 0.11 0.07
16 rs844395 GRIN2A A 0.35 0.37
3 rs6770430 AC095349.10 A 0.07 0.05
19 rs377702 PVRL2 T 0.43 0.43
12 rs1871898 TMEM132D T 0.48 0.46
18 rs11876226 ZNF521 G 0.21 0.17
3 rs9876068 RNF7 C 0.02 0.04
22 rs5753436 AC005005.1-1 G 0.11 0.14
11 rs3096716 PRSS23 T 0.29 0.28
3 rs7648855 AC095349.10 G 0.07 0.05
16 rs10492859 AC099506.3 G 0.18 0.20
10 rs7089454 ADAM12 G 0.21 0.27
16 rs718510 AC018554.7 A 0.33 0.40
10 rs821705 AL133395.21 T 0.36 0.32
3 rs6766386 AC055758.23 T 0.20 0.26
2 rs1517443 AC019051.8 G 0.36 0.45
3 rs7637623 AC069067.17 G 0.42 0.50
4 rs16890321 AC093777.4 T 0.19 0.25
3 rs6441421 AC104471.6 T 0.34 0.42
3 rs1376967 AC129415.1-2 G 0.20 0.14
14 rs6573334 AL160237.4-1 T 0.13 0.08
9 rs10810562 BNC2 A 0.15 0.10
15 rs954432 C15orf53 C 0.37 0.29
1 rs7515917 C1orf196 A 0.47 0.45
7 rs10954664 CACNA2D1 G 0.46 0.38
3 rs6800179 CLSTN2 C 0.17 0.11
8 rs1441249 CNGB3 T 0.43 0.49
12 rs1663588 CPM A 0.10 0.15
13 rs11617079 DNAJC15 G 0.20 0.27
13 rs2281782 DNAJC15 C 0.20 0.27
11 rs10431058 ELMOD1 T 0.37 0.45
6 rs6931820 EPHA7 T 0.29 0.37
8 rs6559175 MCPH1 C 0.22 0.29
11 rs4758480 MRGPRG T 0.36 0.45
6 rs855250 OFCC1 C 0.11 0.17
4 rs4699587 PDLIM5 C 0.04 0.08
8 rs10099199 PSD3 G 0.12 0.18
3 rs11706561 RARB T 0.15 0.21
12 rs678941 RBM19 T 0.10 0.16
13 rs4271475 RP11-217F17.1 T 0.45 0.37
1 rs1041705 RP11-339A11.1 C 0.40 0.32
13 rs1927554 RP11-56M2.1 C 0.38 0.46
13 rs1517897 RP11-56M2.1 T 0.37 0.45
1 rs655146 RP11-575B7.2 G 0.12 0.18
10 rs10827186 RPL7AP53 G 0.18 0.24
1 rs7556195 SIPA1L2 G 0.16 0.23
16 rs12049 TMEM186;C16orf51 C 0.49 0.43
11 rs6592039 FAM181B A 0.02 0.04
19 rs17801681 SIGLECP3 A 0.08 0.05
1 rs1258033 KNCN C 0.22 0.27
11 rs2433438 PRSS23 G 0.29 0.28
6 rs9473511 RP1-14209.2 T 0.09 0.07
6 rs9358383 CDKAL1 G 0.31 0.25
12 rs2301529 SLC11A2 T 0.16 0.18
6 rs2767576 AL158033.18 C 0.20 0.18
8 rs3857946 MTSS1 A 0.11 0.08
16 rs837688 GRIN2A G 0.45 0.41
10 rs10904321 AKR1CL2 C 0.49 0.43
9 rs12343558 C9orf94;ADAMTSL1 C 0.30 0.27
3 rs9869506 AC117430.3-2 G 0.09 0.13
6 rs9377643 RP11-427E4.1 C 0.16 0.10
18 rs8091319 AP000902.5 T 0.25 0.21
10 rs528320 C10orf49 C 0.16 0.12
5 rs7702830 EPB41L4A C 0.20 0.15
3 rs966866 CLSTN2 c 0.33 0.28
11 rs1949707 FAM181B c 0.02 0.04
10 rs7097356 ADAM 12 c 0.21 0.27
14 rs2369018 GLRX5 T 0.19 0.24
14 rs6575028 TTC8 T 0.22 0.20
11 rs10831608 GALNTL4 T 0.43 0.39
8 rs3824110 ZNF16 A 0.21 0.25
20 rs6097096 AL049736.10 A 0.15 0.11
10 rs3936497 MPP7 C 0.09 0.08
12 rs10860757 MYBPC1 C 0.09 0.12
19 rs8103315 BCL3 T 0.17 0.16
10 rs10827932 PLXDC2 T 0.45 0.40
18 rs1893311 ZNF521 T 0.20 0.16
16 rs12922279 AC018554.7 C 0.34 0.41
8 rs10104503 XKR5 T 0.35 0.30
6 rs9294750 AC021749.6-3 C 0.43 0.47
11 rs10837311 AL591004.3 T 0.15 0.18
15 rs12903325 ATP8B4 C 0.28 0.25
12 rs12824958 AC008121.43-2 C 0.16 0.18
18 rs4799869 FHOD3 A 0.38 0.34
12 rs10745935 CCDC53 G 0.05 0.09
15 rs6603018 ADAMTSL3 T 0.17 0.12
9 rs504896 NDUFB6 A 0.09 0.07
9 rs10971038 NDUFB6 A 0.10 0.07
12 rs11044223 PIK3C2G C 0.07 0.13
2 rs1615070 C2orf74 T 0.50 0.45
15 rs906194 AC103965.5 A 0.17 0.12
14 rs17103033 C14orf10;PPP2R3C G 0.18 0.14
10 rs17684713 ADAM 12 A 0.15 0.21
5 rs1345686 EPB41L4A T 0.20 0.15
1 rs34411680 PARS2 C 0.17 0.14
2 rs10514647 PARD3B G 0.11 0.07
2 rs6436883 DNER T 0.44 0.40
2 rs17338519 MYT1L T 0.13 0.10
22 rs80533 MCHR1 A 0.28 0.25
9 rs7871498 ZCCHC7 A 0.25 0.19
10 rs9888067 RP11-400G3.3 A 0.16 0.21
8 rs1893884 STK3 A 0.49 0.45
4 rs6848311 F11 T 0.16 0.20
2 rs744373 BIN1 G 0.33 0.31
7 rs700316 AC006992.2 A 0.14 0.21
15 rs2711644 AC066611.6 T 0.41 0.33
2 rs7593799 AC074020.4 T 0.41 0.50
2 rs1569135 AC074020.4 G 0.41 0.49
12 rs2130635 AC090680.11 C 0.11 0.16
4 rs4861491 AC108142.1 T 0.12 0.18
14 rs17121169 AL049775.2 G 0.12 0.07
14 rs7160035 AL160237.4-1 T 0.13 0.08
2 rs2312548 ANXA4 A 0.42 0.50
11 rs604967 AP003100.3 C 0.50 0.42
11 rs643122 AP003100.3 T 0.50 0.42
8 rs10088108 ATP6V1B2 G 0.17 0.23
1 rs2365716 BCAN C 0.32 0.24
2 rs3771084 CALCRL A 0.38 0.46
2 rs7564839 CCDC148 G 0.29 0.37
16 rs11150535 CDH13 T 0.49 0.41
4 rs9996873 CLCN3 C 0.18 0.24
3 rs1447721 CLSTN2 T 0.13 0.08
10 rs7094118 CUGBP2 C 0.30 0.23
2 rs1583631 ERBB4 T 0.28 0.35
9 rs10963919 FAM154A G 0.14 0.09
14 rs10484053 GLRX5 T 0.16 0.11
1 rs10493201 GOT2L1 C 0.15 0.10
6 rs1544050 KCNK17 C 0.39 0.47
5 rs2074344 KLHL3 G 0.11 0.06
4 rs4082297 LNX1 C 0.18 0.12
1 rs2990678 LRRC38 A 0.31 0.39
7 rs16885938 MAGI2 T 0.23 0.16
9 rs4877108 NXNL2 C 0.33 0.26
5 rs329320 PHF15 G 0.22 0.16
12 rs621042 PIK3C2G A 0.43 0.49
10 rs1125478 RP11-448K10.1 T 0.23 0.30
10 rs1930457 RP11-448K10.1 A 0.06 0.11
13 rs2897319 RP11-94N9.1 C 0.21 0.15
6 rs10945617 RP3-393E18.1 A 0.24 0.17
11 rs868344 SCN4B C 0.39 0.31
5 rs12189367 SEMA5A A 0.07 0.13
20 rs2427460 SLC17A9 C 0.45 0.47
5 rs2042243 TRPC7 A 0.13 0.08
20 rs1016404 ZFP64 A 0.44 0.48
14 rs11628156 AL355773.4 G 0.39 0.35
14 rs1885186 TTC8 T 0.22 0.20
18 rs12454185 SALL3 G 0.14 0.18
3 rs6790000 PDIA5 C 0.17 0.22
6 rs17445948 RP3-334F4.1 A 0.10 0.08
2 rs17338512 MYT1L A 0.13 0.10
3 rs6788684 OXSM A 0.18 0.16
3 rs1705589 PRKCI C 0.17 0.22
11 rs598829 HNT;NTM A 0.34 0.26
1 rs11579916 AL359915.14 T 0.14 0.16
8 rs13248917 AC019129.1 T 0.45 0.49
2 rs7607908 ID02 A 0.17 0.14
9 rs10738482 SH3GL2 A 0.34 0.33
2 rs6753886 SLC5A7 T 0.32 0.37
14 rs2401785 TTC8 A 0.22 0.20
8 rs12541503 XKR5 T 0.28 0.24
10 rs9663603 AL133395.21 C 0.28 0.26
10 rs11006995 AC022021.10-3 A 0.08 0.06
11 rs10899236 SHANK2 G 0.42 0.44
3 rs7616301 AC095349.10 C 0.07 0.05
3 rs7651217 AC095349.10 C 0.07 0.05
7 rs854568 PON1 C 0.26 0.24
13 rs4942106 AKAP11 A 0.27 0.22
11 rs7106873 SHANK2 T 0.48 0.46
11 rs10894589 OPCML T 0.04 0.07
3 rs9863121 ECT2 T 0.32 0.27
11 rs1545527 AP003778.3-4 G 0.34 0.33
14 rs1958018 NPAS3 G 0.27 0.20
16 rs4541063 FAM92B C 0.28 0.34
10 rs4748275 PRKCQ G 0.31 0.29
15 rs12442068 ARNT2 G 0.23 0.20
18 rs12954185 AC139070.3 C 0.15 0.17
18 rs4595890 AC008245.6 A 0.40 0.45
2 rs12467137 EZH2 T 0.13 0.10
7 rs17171118 MYT1L T 0.17 0.14
11 rs12800502 METT5D1 G 0.13 0.15
10 rs1576480 NHLRC2 T 0.45 0.49
6 rs2206579 CDKAL1 C 0.38 0.31
7 rs2520570 AC005192.1 G 0.14 0.19
3 rs10937074 AC007547.26-2 A 0.30 0.38
5 rs255240 AC008580.7 C 0.42 0.49
5 rs6875311 AC008580.7 C 0.34 0.42
2 rs11690896 AC009303.3-1 C 0.09 0.05
2 rs6705773 AC019051.8 G 0.31 0.39
15 rs779885 AC032011.15 G 0.37 0.30
16 rs1532472 AC040170.9 T 0.29 0.36
16 rs246174 AC040173.5 A 0.35 0.42
4 rs10516985 AC093828.3 C 0.09 0.14
11 rs7939810 AC104563.14 G 0.38 0.30
3 rs12638515 AC104637.5 G 0.02 0.05
4 rs7438821 AC115540.3 A 0.19 0.13
10 rs17684713 ADAM 12 A 0.15 0.21
8 rs10097956 ADAM28 G 0.23 0.31
2 rs3771449 ADD2 A 0.49 0.42
14 rs7155550 AL121819.6 C 0.21 0.15
14 rs10149208 AL121819.6 A 0.43 0.35
14 rs12889310 AL163171.4 C 0.47 0.39
1 rs7511712 AL390877.1 G 0.31 0.38
18 rs7236716 ALPK2 T 0.10 0.06
2 rs12622388 ANXA4 C 0.34 0.27
2 rs7597155 ANXA4 C 0.47 0.45
8 rs11774901 ASAP1 T 0.04 0.08
14 rs8005907 ATG2B C 0.06 0.11
3 rs9868790 BZW1L1 C 0.34 0.27
2 rs4851161 C2orf55 c 0.06 0.03
5 rs6555968 C5orf50 A 0.44 0.48
2 rs13407117 CCDC148 A 0.29 0.37
18 rs12232768 CHST9 C 0.03 0.06
10 rs7913161 CPXM2 G 0.09 0.14
4 rs1872270 DMP1 T 0.28 0.35
1 rs126013 EPB41 A 0.41 0.33
9 rs7036118 FAM154A T 0.44 0.36
2 rs7596564 FIGLA A 0.45 0.37
11 rs687572 FLI1 C 0.29 0.37
1 rs13353041 GOT2L1 A 0.15 0.10
3 rs4234525 GRIP2 T 0.48 0.40
1 rs2481665 INADL C 0.38 0.46
21 rs12482075 KCNJ6 T 0.28 0.35
1 rs12035356 KCNN3 C 0.01 0.04
11 rs11030026 LIN7C A 0.19 0.13
1 rs12569332 LPGAT1 C 0.14 0.09
6 rs911182 MAP3K5 G 0.50 0.42
8 rs2912004 MCPH1 A 0.26 0.33
14 rs1263805 METTL3 C 0.22 0.29
7 rs2693727 MIRN183 G 0.11 0.07
6 rs12207681 OFCC1 C 0.11 0.16
11 rs4565912 OR10G8 C 0.35 0.27
11 rs2445290 OR51L1 A 0.13 0.19
10 rs1414395 PHYH T 0.36 0.44
3 rs9831813 RAB7A A 0.08 0.13
19 rs8102902 RAX2 G 0.16 0.23
13 rs9519340 RP11-217F17.1 A 0.46 0.39
1 rs1426786 RP11-2B19.1 A 0.31 0.38
6 rs267333 RP11-427E4.1 A 0.42 0.34
10 rs16911207 RP11-448K10.1 C 0.07 0.12
10 rs1999505 RP11-448K10.1 C 0.06 0.11
9 rs7047010 RP11-54D18.4 C 0.24 0.32
9 rs10125646 RRAGA G 0.45 0.37
16 rs1864 TMEM186;C16orf51 G 0.39 0.31
3 rs11712892 TRIM42 A 0.34 0.42
8 rs7835207 TSNARE1 G 0.14 0.20
16 rs11863067 XYLT1 T 0.05 0.09
18 rs1544241 YES1 T 0.49 0.42
16 rs4889197 C16orf47 G 0.48 0.48
12 rs1190655 AC025164.37-2 C 0.37 0.34
8 rs17282526 ASAP1 C 0.49 0.46
1 rs12043001 SEC16B G 0.11 0.13
3 rs9289466 RPL39P5 C 0.32 0.38
11 rs1048099 ABCC8 T 0.46 0.49
4 rs17001970 SHROOM3 T 0.08 0.06
4 rs1374621 CDKAL1 T 0.06 0.05
6 rs4712540 STK32B T 0.44 0.50
14 rs2363506 AC007686.5 A 0.42 0.48
17 rs1052507 HELZ G 0.12 0.09
12 rs1861786 GRIN2B T 0.33 0.38
4 rs6850106 AC096756.3-2 C 0.05 0.04
12 rs1356083 RIMBP2 T 0.48 0.47
5 rs4976217 SLC30A5 A 0.23 0.19
17 rs2279966 C17orf54 A 0.03 0.05
15 rs2879971 AC048382.7-2 T 0.17 0.12
3 rs11707887 NMNAT3 A 0.32 0.26
12 rs10842549 AC092451.12-2 C 0.46 0.41
6 rs7775523 CDKAL1 C 0.39 0.33
5 rs11748946 FSTL4 C 0.26 0.22
6 rs4077405 CDKAL1 A 0.47 0.46
11 rs1054532 JMJD2D A 0.18 0.14
9 rs7043157 C9orf94; AD AMTSL1 G 0.44 0.46
3 rs3774700 C3orf14 G 0.04 0.06
11 rs10792830 AP003097.2 T 0.50 0.47
5 rs7727192 AC113412.2-2 G 0.39 0.33
6 rs17310261 LYRM4 C 0.07 0.11
1 rs10925401 RYR2 C 0.39 0.44
10 rs3019500 AL603764.27 T 0.39 0.37
2 rs3849346 KCNH7 G 0.25 0.22
13 rs1891100 TGDS T 0.28 0.32
12 rs11836523 GRIN2B C 0.12 0.09
14 rs7140539 NPAS3 G 0.37 0.33
13 rs9512257 WASF3 C 0.37 0.43
9 rs960644 RP11-341 A22.1 G 0.11 0.18
6 rs1417667 LSM10 G 0.11 0.07
1 rs4653186 RP1-244F1.1 T 0.28 0.35
6 rs1012626 CDKAL1 A 0.32 0.38
9 rs1123551 RAPGEF1 T 0.04 0.06
3 rs10937074 AC007547.26-2 A 0.30 0.38
5 rs17733586 AC093283.3-2 T 0.06 0.05
16 rs11649643 AC018554.7 T 0.31 0.25
5 rs1862310 AC008586.6 T 0.23 0.20
8 rs2117085 PI15 A 0.05 0.07
4 rs12642995 GUCY1A3 G 0.14 0.19
12 rs7967304 SLC6A15 G 0.36 0.31
8 rs7002825 SNX31 G 0.26 0.21
21 rs1389994 BTG3 A 0.36 0.40
16 rs1079348 ABAT C 0.32 0.25
19 rs718133 AC002511.1-2 T 0.21 0.28
17 rs481648 AC015922.5 C 0.33 0.26
15 rs8039372 AC032011.15 C 0.29 0.36
4 rs9307041 AC093895.3 A 0.28 0.35
4 rs17615522 AC096739.3 C 0.04 0.08
1 rs7556538 AC098656.2 C 0.08 0.12
3 rs1499508 AC121493.1 A 0.25 0.18
14 rs754131 AL121819.6 G 0.20 0.14
14 rs7149631 AL121819.6 T 0.21 0.15
14 rs1112627 AL163171.4 T 0.40 0.32
10 rs7067598 ARMC3 G 0.28 0.21
16 rs896401 C16ort68 G 0.28 0.21
6 rs4707016 C6orf59;RIPPLY2 A 0.37 0.45
11 rs11234095 DLG2 T 0.07 0.12
11 rs10898274 DLG2 G 0.07 0.12
11 rs532859 ELMOD1 T 0.48 0.44
9 rs10811094 FAM154A A 0.43 0.49
13 rs1360974 FGF14 T 0.35 0.27
2 rs6707940 FIGLA G 0.44 0.36
5 rs6873055 GRIA1 A 0.19 0.13
20 rs11574739 HNF4A C 0.23 0.16
11 rs4579932 HNT;NTM C 0.42 0.50
2 rs934287 ICA1L T 0.14 0.20
14 rs1547350 KIF26A G 0.48 0.44
1 rs2999865 LRRC38 A 0.22 0.30
18 rs9807134 n/a A 0.18 0.25
10 rs4748737 NEBL G 0.36 0.29
6 rs12213004 OFCC1 T 0.11 0.16
2 rs3771604 PK4P;PKP4 T 0.37 0.45
2 rs3771669 PK4P;PKP4 G 0.26 0.33
10 rs7897633 PRKG1 G 0.44 0.48
1 rs2152391 RP11-339A11.1 A 0.40 0.32
1 rs10493658 RP11-339A11.1 T 0.40 0.32
9 rs1124647 RP11-341 A22.1 G 0.08 0.12
13 rs912521 RP11-57H24.1 A 0.29 0.22
6 rs10806716 RP3-393E18.1 A 0.24 0.17
3 rs6764249 SCN10A G 0.18 0.12
6 rs7748110 SOBP A 0.06 0.10
18 rs17805412 TXNDC2 A 0.12 0.18
4 rs7672650 AC109517.4 G 0.36 0.31
6 rs2767577 AL158033.18 G 0.26 0.24
4 rs7670038 AC110761.3 G 0.46 0.50
14 rs12435645 IGHA2 A 0.14 0.12
19 rs1865108 ZNF283 C 0.13 0.10
3 rs11708596 C3orf19 T 0.20 0.16
1 rs259588 AL356010.9 C 0.40 0.43
19 rs11878692 SBN02 C 0.20 0.18
12 rs11535963 AC087240.17 T 0.24 0.32
13 rs2208932 ATP8A2 C 0.17 0.13
1 rs411238 RP3-357I16.1 A 0.30 0.28
19 rs10425074 LRRC68 C 0.26 0.23
15 rs2242065 LI PC T 0.11 0.09
15 rs10520664 TMEM83 C 0.07 0.05
5 rs607077 AC010374.6 G 0.28 0.35
8 rs4733037 STMN4 A 0.38 0.34
6 rs4510656 CDKAL1 A 0.50 0.46
7 rs7798774 CREB5 G 0.25 0.23
17 rs4789551 BIRC5 C 0.11 0.08
22 rs1883987 CACNG2 C 0.39 0.36
14 rs6572182 n/a T 0.17 0.15
10 rs1890951 ANK3 A 0.34 0.41
19 rs12977284 EMR4P A 0.05 0.05
14 rs8005907 ATG2B C 0.06 0.11
4 rs6552500 n/a C 0.24 0.20
16 rs759831 AC099506.3 A 0.25 0.26
16 rs1369790 AC018554.7 G 0.37 0.30
8 rs11785060 PLEC1 T 0.41 0.37
10 rs7077490 AL133395.21 G 0.29 0.26
13 rs7320671 ZMYM2 C 0.46 0.38
1 rs11806225 RP11-149P14.1 C 0.03 0.06
4 rs17004994 C4orf22 G 0.06 0.04
5 rs12189436 AC010374.6 C 0.12 0.08
17 rs6502823 GLTPD2 T 0.12 0.08
12 rs6488565 DDX47 A 0.25 0.22
2 rs2664226 AC114765.6 T 0.19 0.17
16 rs6497658 GRIN2A C 0.47 0.43
4 rs1803037 ADH5P4.ADH5 A 0.08 0.10
20 rs1018443 PLCB1 T 0.28 0.25
19 rs8101040 AC010624.8-1 A 0.17 0.15
6 rs9470642 MDGA1 G 0.22 0.27
3 rs13072512 FOXP1 A 0.44 0.49
1 rs12140361 SDHC C 0.05 0.05
6 rs12663853 LRFN2 G 0.03 0.03
11 rs649931 ODZ4 T 0.03 0.04
18 rs8089316 RIT2 C 0.16 0.13
6 rs11754558 RLBP1L2 A 0.06 0.05
9 rs2181156 RP11-87N24.1 G 0.44 0.43
6 rs6935954 HIST1H2BH A 0.38 0.40
9 rs3808708 SH3GL2 A 0.32 0.31
14 rs2272550 AE000660.1-11 A 0.35 0.28
14 rs12100841 C14orf 10; PPP2R3C C 0.22 0.17
12 rs11107270 CRADD C 0.06 0.04
10 rs11006970 CDKAL1 T 0.12 0.10
13 rs2217902 ITGBL1 C 0.10 0.08
6 rs7747724 MPP7 C 0.50 0.46
1 rs437722 RP3-357I16.1 A 0.30 0.28
1 rs485660 SYPL2 A 0.28 0.24
3 rs340146 TMPRSS7 T 0.11 0.08
2 rs7577964 AC009228.4-2 A 0.33 0.41
18 rs1789597 AC009271.7 G 0.25 0.19
12 rs1351681 AC024153.22 T 0.39 0.31
15 rs12443269 AC066611.6 C 0.40 0.33
4 rs7688470 AC093735.2 T 0.18 0.24
4 rs2869703 AC093895.3 C 0.28 0.35
5 rs10055973 AC113427.2 C 0.29 0.23
5 rs11738161 AC113427.2 T 0.29 0.23
5 rs13188129 AC113427.2 A 0.29 0.23
5 rs11738216 AC113427.2 A 0.29 0.23
10 rs7908946 ADAM12 A 0.18 0.25
10 rs7079003 ADARB2 T 0.37 0.30
2 rs3771450 ADD2 A 0.49 0.43
14 rs9972193 AL049873.3-2 C 0.25 0.19
2 rs35907069 ANXA4 A 0.06 0.11
2 rs12612409 ANXA4 T 0.06 0.11
18 rs11081236 AP005202.3 T 0.41 0.48
20 rs6067566 BCAS4 T 0.08 0.12
2 rs1157699 CALCRL T 0.38 0.31
15 rs11635381 CHSY1 A 0.48 0.41
9 rs3780256 CNTLN C 0.49 0.43
17 rs16968987 COIL T 0.06 0.09
10 rs7083429 CTNNA3 C 0.35 0.28
21 rs4818184 DSCAM A 0.11 0.16
10 rs4880336 JAKMIP3 T 0.20 0.27
4 rs7655220 KCNIP4 G 0.26 0.32
1 rs11240240 LRRN2 C 0.05 0.02
1 rs4653186 LSM10 T 0.28 0.35
3 rs6783373 MCF2L2 A 0.31 0.24
7 rs2693737 MIRN183 C 0.12 0.07
13 rs9300636 NALCN;VGCNL1 C 0.34 0.42
10 rs7094054 NRG3 T 0.42 0.50
6 rs16888746 PARK2 T 0.16 0.10
3 rs9853945 RAB7A G 0.08 0.13
9 rs10867685 RP11-553J6.1 A 0.49 0.43
17 rs6503608 SOCS7 T 0.39 0.47
9 rs11142705 TRPM3 A 0.38 0.46
4 rs12509170 TSPAN5 G 0.48 0.40
13 rs7327207 ZMYM2 C 0.38 0.46
5 rs11953547 AC026781.5 T 0.17 0.14
2 rs2655455 AC011747.5 G 0.50 0.43
7 rs1530680 FOXP2 T 0.23 0.19
16 rs2304469 PMM2 T 0.48 0.43
15 rs2412621 RPAP1 C 0.31 0.34
8 rs7815950 SNX31 C 0.07 0.09
20 rs2145280 CMA1 A 0.24 0.21
14 rs12589666 PMEPA1 A 0.42 0.35
8 rs4275231 PPP2R2A T 0.20 0.16
12 rs6580784 CSRNP2 A 0.16 0.18
3 rs6790913 CLEC3B T 0.12 0.09
18 rs169455 n/a T 0.40 0.42
10 rs988011 ATRNL1 A 0.13 0.09
8 rs7815631 SNX31 T 0.07 0.09
14 rs204984 KIAA1737 A 0.22 0.26
7 rs1557780 JAZF1 C 0.34 0.40
8 rs4397386 TRAPPC9 C 0.50 0.45
5 rs25923 CAMK4 C 0.40 0.34
14 rs7142488 AL355773.4 C 0.36 0.32
17 rs16950116 CA10 T 0.10 0.07
3 rs1242061 SLC9A9 A 0.45 0.42
8 rs13277804 PSD3 A 0.08 0.12
2 rs10187702 IK G 0.11 0.12
4 rs4485803 TTC29 A 0.02 0.03
5 rs1428609 AC008459.7 G 0.49 0.43
15 rs3098538 GABRG3 A 0.21 0.18
2 rs1177265 KIAA1841 G 0.41 0.45
2 rs17750151 AC007277.2 G 0.09 0.13
6 rs381480 RP11-427E4.1 T 0.17 0.12
2 rs6724815 AC010374.6 A 0.09 0.07
5 rs9918231 NAGK A 0.29 0.24
5 rs10042848 AC026781.5 G 0.17 0.14
6 rs9371581 SYNE1 G 0.42 0.46
6 rs3778279 H3F3AP1 T 0.49 0.47
11 rs4406832 C11orf44 A 0.14 0.16
17 rs578065 AC015922.5 G 0.41 0.35
5 rs10491314 NDFIP1 A 0.21 0.18
19 rs3764640 STK11 A 0.17 0.23
2 rs1035601 AC114765.6 G 0.19 0.17
4 rs717435 AC104663.3 T 0.40 0.42
12 rs11057929 DHX37 C 0.22 0.19
6 rs9366354 CDKAL1 G 0.32 0.38
18 rs8098687 DTNA A 0.13 0.16
8 rs2008555 AC116154.2 T 0.19 0.25
10 rs11244887 ADAM 12 T 0.19 0.24
17 rs790097 SDK2 A 0.07 0.10
2 rs16856529 IGFBP5 G 0.19 0.15
20 rs6011530 AL121673.41 A 0.15 0.13
2 rs7597992 ADD2 C 0.18 0.14
6 rs12207523 ENPP3 T 0.03 0.06
2 rs888182 IGFBP5 C 0.20 0.16
15 rs7177318 ATP8B4 T 0.46 0.43
12 rs3217907 CCND2 A 0.40 0.34
10 rs1471247 ANK3 A 0.35 0.42
6 rs16893540 RP3-408B20.4 T 0.04 0.04
3 rs651165 AADACL1 A 0.27 0.23
12 rs4471501 SLC11A2 A 0.22 0.24
6 rs11155004 C6orf91;ECT2L T 0.45 0.49
15 rs7176145 ITGA11 G 0.30 0.25
6 rs1395633 RP3-334F4.1 T 0.10 0.08
10 rs11015633 ARL5B G 0.47 0.40
6 rs9480754 PDSS2 G 0.31 0.30
3 rs4684237 C3orf19 T 0.25 0.21
3 rs13096015 AC007547.26-2 G 0.30 0.38
2 rs2702089 AC009228.4-2 A 0.36 0.44
2 rs7599725 AC019051.8 T 0.26 0.34
4 rs7697101 AC093735.2 C 0.44 0.48
4 rs6829972 AC093777.4 G 0.12 0.17
3 rs6794105 AC099544.2 A 0.35 0.43
3 rs1580800 AC104441.2 A 0.10 0.15
5 rs7707671 AC116337.2 C 0.26 0.33
16 rs17671037 AC125796.2 C 0.32 0.25
16 rs7188565 AC125796.2 A 0.41 0.34
10 rs7912903 ADARB2 T 0.03 0.06
9 rs10964182 AL158206.8-2 T 0.27 0.20
1 rs1752221 AL158218.11 T 0.42 0.48
13 rs9575351 AL512782.6-2 C 0.06 0.10
11 rs12224791 AP001884.4 G 0.35 0.28
16 rs860380 C16orf47 C 0.40 0.47
1 rs2003046 C1orf127 A 0.26 0.19
8 rs2249963 C8orf14 C 0.42 0.50
15 rs723988 CHSY1 T 0.47 0.39
7 rs42523 COL1A2 C 0.21 0.27
1 rs7513428 CREG1 A 0.18 0.13
5 rs7718958 DDX46 C 0.22 0.16
1 rs12039988 EPB41 A 0.39 0.47
6 rs1324103 EPHA7 C 0.43 0.50
14 rs4569181 ESRRB G 0.50 0.43
5 rs1461243 FAM114A2 C 0.19 0.13
9 rs16937267 FAM154A C 0.15 0.09
15 rs13380359 GABRG3 G 0.06 0.03
15 rs4778147 GABRG3 T 0.50 0.43
4 rs17539365 GBA3 A 0.42 0.35
13 rs1333464 GPC6 T 0.16 0.11
13 rs1927522 GPR12 T 0.17 0.12
5 rs17113869 GRIA1 C 0.22 0.29
5 rs13189947 GRIA1 A 0.15 0.10
3 rs2090702 GRIP2 T 0.47 0.39
2 rs7603997 ITSN2 T 0.31 0.39
10 rs6482189 MLLT10 A 0.35 0.28
10 rs1243194 MLLT10 T 0.33 0.26
18 rs9956147 n/a C 0.18 0.24
6 rs9502396 NRN1 G 0.15 0.21
11 rs871437 OPCML C 0.13 0.08
13 rs1517881 RP11-56M2.1 T 0.36 0.44
1 rs12741645 RP5-1198020.5 T 0.12 0.17
22 rs2235171 SLC5A4 T 0.05 0.02
4 rs17211183 TMSL3 A 0.03 0.06
3 rs1353021 TNIK A 0.43 0.48
17 rs759974 VPS53 C 0.47 0.45
4 rs9999510 ZNF827 C 0.42 0.34
1 rs2294642 FBX044 T 0.05 0.06
15 rs16940650 TMEM83 T 0.07 0.05
18 rs9304251 AC011225.1 A 0.10 0.06
6 rs2753977 EGFL10;EYS C 0.17 0.12
10 rs1475418 PRKCQ A 0.31 0.29
6 rs9349437 C6orf138 T 0.19 0.14
1 rs953517 C1orf102 C 0.31 0.38
21 rs2838000 BACE2 T 0.25 0.20
12 rs4768967 TFCP2 A 0.16 0.18
4 rs931602 ANXA3 C 0.30 0.24
12 rs10444509 GNPTAB G 0.13 0.14
1 rs4073574 AGTRAP G 0.39 0.33
3 rs968628 MME G 0.47 0.46
3 rs10460808 CBLB C 0.11 0.08
11 rs516431 HNT;NTM T 0.26 0.22
8 rs12679771 TRAPPC9 T 0.17 0.22
18 rs623966 DTNA C 0.15 0.18
13 rs7983069 RP11-7B3.3 A 0.34 0.38
3 rs1111516 RPL39P5 T 0.31 0.37
10 rs10901559 ADAM 12 T 0.19 0.24
1 rs12408243 DMBX1 C 0.45 0.50
2 rs2392820 AC019208.8 T 0.32 0.25
10 rs4747272 PRKCQ T 0.30 0.28
22 rs7292528 SEZ6L T 0.11 0.10
19 rs7259059 VRK3 T 0.22 0.20
3 rs2667469 PDIA5 G 0.19 0.25
7 rs3735219 EZH2 A 0.17 0.14
16 rs1155970 AC099506.3 C 0.28 0.29
3 rs1461762 AC117430.3-2 A 0.11 0.16
4 rs17039589 COL25A1 A 0.13 0.12
6 rs995291 RP11-427E4.1 A 0.17 0.12
3 rs7623367 AC026671.18 G 0.05 0.06
2 rs13032780 MY01B T 0.21 0.25
8 rs4872211 AC023202.8 A 0.11 0.15
6 rs1885275 PDE7B T 0.29 0.26
18 rs11080606 PTPN2 G 0.33 0.29
7 rs7783459 EZH2 A 0.17 0.14
7 rs17169762 AC005582.1 C 0.08 0.13
5 rs29645 AC008580.7 T 0.35 0.43
18 rs1944351 AC009271.7 A 0.45 0.47
16 rs1369790 AC018554.7 G 0.37 0.30
12 rs10844642 AC024153.22 C 0.41 0.33
3 rs9843001 AC092981.3-1 T 0.20 0.14
4 rs13152723 AC093735.2 G 0.21 0.15
4 rs11725282 AC104070.3 C 0.15 0.10
2 rs6718240 AC104807.5-2 G 0.30 0.38
8 rs2013265 ADAM28 A 0.22 0.29
14 rs1955429 AL049775.2 T 0.19 0.14
9 rs1411355 AL389915.19 A 0.24 0.18
7 rs2392581 AMPH G 0.45 0.38
9 rs7041706 BNC2 C 0.27 0.20
6 rs421424 BX255934.7 A 0.25 0.32
11 rs1400756 C11orf53 C 0.16 0.11
6 rs7766161 C6orf70 G 0.15 0.21
10 rs11014358 CACNB2 G 0.17 0.11
5 rs12651858 CCDC125 C 0.10 0.06
12 rs2555319 CCDC60 C 0.37 0.30
1 rs7520966 CYB5RL T 0.23 0.30
5 rs17704210 EBF1 G 0.09 0.14
1 rs1591785 ETV3 T 0.38 0.46
15 rs11634818 FAM148A G 0.09 0.05
13 rs9319313 GPR12 G 0.17 0.12
11 rs4930103 H19 G 0.43 0.50
16 rs11644878 HS3ST4 A 0.43 0.49
13 rs4771929 HS6ST3 T 0.03 0.06
11 rs1124847 LRRC55 G 0.46 0.38
11 rs287756 n/a T 0.39 0.46
13 rs1517896 RP11-56M2.1 A 0.37 0.45
6 rs434310 RP3-399J4.2 A 0.24 0.31
11 rs4756930 SAAL1 T 0.41 0.48
6 rs718868 SAMD5 T 0.36 0.29
2 rs6730730 SLC19A3 G 0.09 0.15
9 rs3739482 SLC24A2 A 0.36 0.43
3 rs182568 SUMF1 T 0.11 0.06
7 rs4256491 TMEM195 A 0.11 0.16
7 rs4615456 TMEM195 G 0.45 0.37
3 rs9861350 TRIM42 A 0.38 0.46
8 rs777801 TRPS1 T 0.04 0.07
9 rs880242 USP20 G 0.44 0.37
6 rs9688888 XXyac-YX65C7_A.4 G 0.10 0.16
8 rs9642799 ZFPM2 A 0.32 0.26
3 rs6551273 ZNF654 G 0.17 0.11
22 rs11704749 HMGXB4 A 0.06 0.09
7 rs38519 JAZF1 T 0.46 0.40
11 rs7938094 AC021749.6-3 C 0.15 0.18
9 rs2860101 PGM5 T 0.09 0.10
10 rs10751569 AL512272.15 A 0.42 0.45
12 rs10859283 AC025164.37-2 T 0.28 0.27
14 rs12885638 AL137100.4 C 0.34 0.29
5 rs13165786 EDIL3 C 0.46 0.41
11 rs7118622 GALNTL4 c 0.22 0.27
3 rs9852993 TMEM108 T 0.16 0.20
1 rs12132152 DPYD A 0.04 0.03
21 rs7280677 AP000431.2 C 0.29 0.36
1 rs17109254 RP4-601K24.1 A 0.05 0.03
8 rs4240188 LONRF1 A 0.44 0.37
11 rs7943388 AC021749.6 T 0.11 0.13
12 rs149411 SLC11A2 T 0.38 0.40
6 rs195850 POU3F2 C 0.13 0.14
4 rs998091 EVC2 T 0.36 0.32
3 rs500193 LAMP3 G 0.08 0.06
1 rs6425838 CSMD2 T 0.33 0.29
2 rs7577925 AC010890.1 T 0.31 0.35
5 rs10462823 AC122710.3 A 0.10 0.13
6 rs9356756 CDKAL1 G 0.46 0.40
5 rs11959584 NMUR2 T 0.46 0.50
n/a = not applicable.
Table 5.6. Full results for the SNP based analysis of the szgene markers. Table shows gene name, gene position in ‘top
r2 values, p-value and OR in within case analysis and case-control analysis, and szgene OR and 95% confidence interva
Gene
‘top result’ 
position D' r2
LOAD+P vs. 
LOAD-P
LOA
C<
SNP Proxy P OR P
DISC1 1 rs3737597 rs16856351 1 1 0.76 1.09 0.29
DISC1 1 rs821597 rs864752 1 0.97 0.95 0.99 0.32
DISC1 1 rs821616 rs821596 1 1 0.76 1.03 0.36
DISC1 1 rs6675281 n/a n/a n/a 0.53 1.09 0.44
DISC1 1 rs3738398 rs1417585 0.93 0.78 0.19 1.14 0.55
DISC1 1 rs2812393 rs2812389 1 0.84 0.17 1.14 0.58
DISC1 1 rs1322784 rs2255340 1 0.95 0.33 1.11 0.62
DISC1 1 rs2255340 n/a n/a n/a 0.33 1.11 0.62
DISC1 1 rs2738864 rs2255340 1 1 0.33 1.11 0.62
DISC1 1 rs3738401 n/a n/a n/a 0.70 1.04 0.66
DISC1 1 rs1000731 n/a n/a n/a 0.81 0.97 0.78
DISC1 1 rs2492367 rs17766087 0.74 0.31 0.69 0.95 0.84
DISC1 1 rs1322783 n/a n/a n/a 0.35 1.05 0.86
DISC1 1 rs9432024 rs9431714 1 0.89 0.81 0.98 0.89
DISC1 1 rs1934909 n/a n/a n/a 0.85 1.03 0.95
DISC1 1 rs999710 rs1073179 0.96 0.69 0.95 1.01 0.96
DISC1 1 rs1984895 n/a n/a n/a n/a n/a n/a
DISC1 1 rs751229 n/a n/a n/a n/a n/a n/a
SLC18A1 2 rs2270637 n/a n/a n/a 0.95 1.01 0.47
SLC18A1 2 rs2270641 rs1497022 1 1 0.25 0.89 0.93
GABRB2 3 rs6556547 rs7702598 0.73 0.26 0.46 1.14 0.40
GABRB2 3 rs187269 rs173766 1 1 0.87 0.98 0.83
GABRB2 3 rs1816072 rs252957 0.93 0.83 0.67 1.04 0.84
GABRB2 3 rs1816071 rs252957 0.93 0.83 0.67 1.04 0.84
GABRB2 3 rs194072 n/a n/a n/a 0.72 0.95 0.89
GABRB2 3 rs252944 n/a n/a n/a n/a n/a n/a
DRD2 4 rs1079597 rs2471857 1 1 0.42 0.90 0.07
DRD2 4 rs1800497 n/a n/a n/a 0.50 0.92 0.29
DRD2 4 rs6275 rs2242592 1 1 0.35 1.10 0.37
DRD2 4 rs6277 rs754672 0.96 0.81 0.75 1.03 0.83
DRD2 4 rs1801028 n/a n/a n/a n/a n/a n/a
DRD2 4 rs1799732 n/a n/a n/a n/a n/a n/a
10q26.13 5 rs11248526 n/a n/a n/a 0.86 1.03 0.85
10q26.13 5 rs17101921 n/a n/a n/a n/a n/a n/a
AKT1 6 rs1130214 rs4983559 1 0.66 0.26 1.11 0.24
AKT1 6 rs2498799 n/a n/a n/a n/a n/a n/a
AKT1 6 rs3803300 n/a n/a n/a n/a n/a n/a
AKT1 6 rs3730358 n/a n/a n/a n/a n/a n/a
AKT1 6 rs2494732 n/a n/a n/a n/a n/a n/a
GRIN2B 7 rs1806201 n/a n/a n/a 0.16 1.16 0.046
GRIN2B 7 rs7301328 rs2216344 0.96 0.69 0.54 1.06 0.11
GRIN2B 7 rs1805502 n/a n/a n/a 0.57 0.93 0.25
GRIN2B 7 rs1019385 n/a n/a n/a n/a n/a n/a
DGCR2 8 rs2073776 rs2238743 0.95 0.54 0.86 0.98 0.15
DGCR2 8 rs807759 n/a n/a n/a n/a n/a n/a
PLXNA2 9 rs841865 n/a n/a n/a 0.87 0.98 0.12
PLXNA2 9 rs752016 n/a n/a n/a 0.59 0.94 0.45
PLXNA2 9 rs1327175 n/a n/a n/a n/a n/a n/a
PLXNA2 9 rs2498028 n/a n/a n/a n/a n/a n/a
RPGRIP1L 10 rs9922369 rs2111119 1 0.25 0.78 0.96 0.85
TPH1 11 rs1800532 rs2670765 1 1 0.07 1.19 0.31
TPH1 11 rs1799913 n/a n/a n/a n/a n/a n/a
DRD4 12 rs4646983 n/a n/a n/a n/a n/a n/a
DRD4 12 rs1800955 n/a n/a n/a n/a n/a n/a
DRD4 12 120-bp TR n/a n/a n/a n/a n/a n/a
DRD4 12 48-bp VNTR n/a n/a n/a n/a n/a n/a
DAOA 13 rs778293 n/a n/a n/a 0.42 0.80 0.24
DAOA 13 rs3916966 n/a n/a n/a 0.76 1.03 0.36
DAOA 13 rs3916967 rs3916966 1 1 0.76 1.03 0.36
DAOA 13 rs2391191 n/a n/a n/a 0.81 1.02 0.40
DAOA 13 rs1421292 rs1362886 1 0.88 0.58 1.05 0.65
DAOA 13 rs947267 rs701567 1 1 0.64 1.04 0.73
DAOA 13 rs3916970 rs2893229 0.96 0.77 0.81 0.98 0.78
DAOA 13 rs778294 n/a n/a n/a 0.17 1.03 0.87
DAOA 13 rs3916971 n/a n/a n/a 0.47 0.93 0.90
DAOA 13 rs3918342 rs9519707 1 1 0.58 1.05 0.98
DAOA 13 rs3916965 n/a n/a n/a n/a n/a n/a
11p14.1 14 rs1602565 rs7938219 1 1 0.99 1.00 0.45
DRD1 15 rs4532 n/a n/a n/a 0.24 1.08 0.55
HTR2A 16 rs6314 n/a n/a n/a 0.55 0.91 0.46
HTR2A 16 rs6311 n/a n/a n/a 0.72 1.04 0.74
HTR2A 16 rs6313 n/a n/a n/a 0.77 1.03 0.75
RELN 17 rs7341475 n/a n/a n/a 0.58 0.93 0.73
APOE 18 rs7412 n/a n/a n/a n/a n/a n/a
APOE 18 rs429358 n/a n/a n/a n/a n/a n/a
NRG1 19 rs4733376 rs3757934 1 1 0.15 1.25 0.038
NRG1 19 rs6988339 n/a n/a n/a 0.47 0.93 0.66
NRG1 19 rs10503929 n/a n/a n/a 0.71 1.05 0.80
NRG1 19 rs2466058 rs4602844 1 0.67 0.99 1.00 0.88
NRG1 19 rs3924999 n/a n/a n/a 0.33 0.91 0.96
NRG1 19 rs2439272 n/a n/a n/a n/a n/a n/a
NRG1 19 rs35753505 n/a n/a n/a n/a n/a n/a
NRG1 19 rs6994992 n/a n/a n/a n/a n/a n/a
NRG1 19 420M9-1395 n/a n/a n/a n/a n/a n/a
NRG1 19 478B14-642 n/a n/a n/a n/a n/a n/a
NRG1 19 478B14-848 n/a n/a n/a n/a n/a n/a
NRG1 19 SNP8NRG22132 n/a n/a n/a n/a n/a n/a
NRG1 19 SNP8NRG241930 n/a n/a n/a n/a n/a n/a
NRG1 19 SNP8NRG433E1006 n/a n/a n/a n/a n/a n/i
1L1B 20 rs1143634 n/a n/a n/a 0.09 1.20 0.2
1L1B 20 rs16944 rs10169916 1 1 0.36 1.10 0.4
MTHFR 21 rs1801131 n/a n/a n/a 0.21 0.88 O.C
MTHFR 21 rs1801133 n/a n/a n/a 0.98 0.99 0.6
COMT 22 rs4633 rs4680 1 0.97 0.93 0.99 0.3
COMT 22 rs4680 n/a n/a n/a 0.93 0.99 0.3
COMT 22 rs737865 rs2020917 1 1 0.40 0.92 0.5
COMT 22 rs165599 n/a n/a n/a 0.67 1.06 0.8
COMT 22 rs4818 n/a n/a n/a n/a n/a n/<
COMT 22 rs769224 n/a n/a n/a n/a n/a n/«
HP 23 Hp1/2 n/a n/a n/a n/a n/a n/i
DAO 24 rs3741775 n/a n/a n/a 0.98 1.00 0.4
DAO 24 rs4623951 n/a n/a n/a 0.87 1.02 0.4
DAO 24 rs3825251 n/a n/a n/a 0.67 0.95 0.6
DAO 24 rs2111902 n/a n/a n/a 0.60 0.95 0.9
DAO 24 rs3918346 n/a n/a n/a n/a n/a n/i
TP53 25 rs1042522 rs7141 0.81 0.31 0.59 0.95 0.4
ZNF804A 26 rs1344706 rs1366840 1 0.69 0.23 1.12 0.9
16p13.12 27 rs7192086 rs7189560 1 0.96 0.16 0.87 0.9
DTNBP1 28 rs1018381 rs9296985 1 1 0.25 1.20 0.0
DTNBP1 28 rs2619538 rs9296985 1 0.92 0.67 1.20 0.0
DTNBP1 28 rs742106 n/a n/a n/a 0.97 1.00 0.1
DTNBP1 28 rs2619539 rs4236167 1 0.97 0.51 0.94 0.2
DTNBP1 28 rs1011313 n/a n/a n/a 0.32 0.85 0.4
DTNBP1 28 rs2619522 rs1474605 1 0.95 0.82 0.97 0.5
DTNBP1 28 rs2619528 rs1474605 1 0.95 0.82 0.97 0.5
DTNBP1 28 rs3213207 rs1474605 1 0.56 0.82 0.97 0.5
DTNBP1 28 rs760761 rs1474605 1 1 0.82 0.97 0.5
DTNBP1 28 rs1047631 n/a n/a n/a 0.14 0.83 0.5
DTNBP1 28 rs760666 rs875462 1 1 0.90 0.99 0.9
DTNBP1 28 rs2005976 n/a n/a n/a n/a n/a n/i
DTNBP1 28 rs909706 n/a n/a n/a n/a n/a n/
OPCML 29 rs3016384 n/a n/a n/a 0.76 1.03 0.2
RGS4 30 rs951436 rs961437 1 1 0.93 0.99 0.6
RGS4 30 rs951439 rs6678136 1 1 0.93 1.01 0.7
RGS4 30 rs2661319 n/a n/a n/a n/a n/a n/
RGS4 30 rsi 0917670 n/a n/a n/a n/a n/a n/<
n/a = not applicable.
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Figure 5.1. Example of quantile-quantile plot when comparing different sets of controls. In this 
exam ple, screened controls from the UK and Ireland, genotyped on the lllumina 610-quadchip  are  
com pared with controls from  the 1958 British birth cohort, genotyped on the lllumina  
H um anH ap550. T h e  observed association x test statistics (y-axis) have been plotted against those  
expected under the null expectation (x-axis). The y-axis was limited at 30 although higher values  
w ere observed. T he  line of equality is colored red. An exclusion x2 threshold of 11 w as em ployed  
(indicated by the dotted horizontal line). [Figure taken from Harold et al. 2009}.
391
Chapter 5 Appendix
o ©
t o
o
o
0 5 10 15 20
Expected
Figure 5.2. Example of quantile-quantile plot when comparing different sets of controls. In this 
exam ple, 1958 British birth cohort population controls, genotyped as part of the W T C C C  study are  
com pared with 1958  British birth cohort population controls, genotyped as part of the T 1 D G C  study. 
The observed association x test statistics (y-axis) have been plotted against those expected under 
the null expectation (x-axis). The  line of equality is colored red. No exclusion x2 threshold was  
warranted.
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Abbreviations
Abbreviations
AAO age at onset
AP42 amyloid-peta 42
AD Alzheimer’s disease
AD+P Alzheimer’s disease with psychosis
AD-P Alzheimer’s disease without psychosis
ALIGATOR Association List Go AnnoTatOR
AMPA a-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
APOE apolipoprotein E
APP p-amyloid precursor protein
Arg arginine
ARID4A AT rich interactive domain 4A
ARP affected relative pair
ASAP1 development and differentiation enhancing factor
ASP Affected Sibling Pair
BBS Bardet-Biedl syndrome
BDNF brain-derived neurotrophic factor
bHLH basic helix-loop-helix
Blat basic local alignment tool
BLOC-1 biogenesis of lysosome-related organelles complex 1
bp base pairs/base position
CAMDEX Cambridge mental disorders of the elderly examination
CCDC60 coiled-coil domain containing 60 gene
CDS protein-coding regions
CEPH centre d'etude du polymorphisme humain
CEU centre d'etude du polymorphisme humain from Utah
CHRNA7 nicotinic acetylcholine receptor gene
Cl confidence interval
CLSTN2 calsyntenin 2
CLU clusterin
CNP 2', 3'-cyclic nucleotide 3' phosphodiesterase
CNTLN centlein, centrosomal protein
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Abbreviations
CNV copy number variation
COMT catechol-O-methyltransferase
cM centimorgans
CNS central nervous system
CSF2RA colony stimulating factor, receptor 2 alpha gene
CT computerised tomography
Cx31 connexin 31
Cys cysteine
c16orf5 chromosome 16 open reading frame 5
DAOA D-amino acid oxidase activator
ddH20 double distilled water
DISC1 disrupted in schizophrenia 1
ddNTPs dideoxy-nucleotide triphosphates
DLB dementia with lewy bodies
DLPFC dorsolateral prefrontal cortex
dNTPs deoxy-nucleotide triphosphates
DPC dystrophin-associated protein complex
DRD1 dopamine receptor D1
DRD2 dopamine receptor D2
DRD3 dopamine receptor D3
DRD4 dopamine receptor D4
DTNBP1 dystrobrevin binding protein 1/dysbindin 1
DZ dizygotic
DSM-IV 4th edition of diagnostic and statistical manual of mental 
disorders
DNA deoxyribonucleic acid
ECR evolutionary conserved region
EDMD-AD autosomal dominant Emery-Dreifuss muscular dystrophy
EDTA ethylenediaminetetraacetic acid
EM expectation-maximization
ENCODE ENCyclopedia Of DNA Elements
EOAD early onset Alzheimer’s disease
ERE6 oestrogen response element 6
Exo I exonuclease I
Abbreviations
FDR false discovery rate
GABA gamma-aminobutyric acid
GALNT2 polypeptide N-acetylgalactosaminyltransferase 2
GDS global deterioration scale
GJB3 connexin 31
Gin glutamine
GO gene ontology
GRIK2 glutamate receptor, ionotropic, kainate 2
GRIN2B N-methyl-D-aspartate receptor subunit 2B
GRM2 glutamate receptor metabotropic 2
GRM3 glutamate receptor metabotropic 3
GWA genome-wide association
GWAS genome-wide association study
GWS genome-wide significance
HD Huntington’s disease
HIST 1H2BJ histone cluster 1, H2BJ
HIST1H2BL histone cluster 1, H2BL
hr hour
HWE Hardy-Weinberg equilibrium
IBD identity by descent
IBS identity by state
IL-ip interleukin-1 p
IL3RA interleukin 3 receptor alpha
Kb kilobase
KCNK16 potassium channel, subfamily k, member 16
kDa kiloDalton
LASER-AD London and the south east region AD
Leu leucine
LGMD Limb-Girdle muscular dystrophy
LMNA lamin A/C
LD linkage disequilibrium
LOAD late onset Alzheimer’s disease
LOAD+P late onset Alzheimer’s disease with psychosis
LOAD-P late onset Alzheimer’s disease without psychosis
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Abbreviations
LOD logarithm of the odds
MAF minor allele frequency
MALDI-ToF matrix assisted laser desorption ionisation -  time of flight
Max maximum
Mb megabase
MCPH1 microcephalin
MDS multi-dimensional scaling
Met methionine
MgCI2 magnesium chloride
Min minute/minimum
MLS maximum LOD score
mM micromole
MMSE mini mental state examination
MRC medical research council
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
MS mass spectometry
MZ monozygotic
NAP5 nek associated protein 5
NCBI national center for biotechnology information
NHS national health service
NIMH national institute for mental health
NINCDS-ADRDA national institute of neurological and communication disorders
and stroke and the Alzheimer’s disease and related disorders 
associations 
nanogram 
nk2 homeobox 2 
nanometre
N-methyl-D-aspartic acid 
neuropsychiatric inventory 
neuregulin-1 
neurogranin
obsessive compulsive disorder 
oligodendrocyte lineage transcription factor 1
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ng
NKX2-2
nm
NMDA
NPI
NRG1
NRGN
OCD
OLIG1
Abbreviations
0LIG2 oligodendrocyte lineage transcription factor 2
OMIM online mendelian inheritance in man
OMR oligodendrocyte/myelin related
OPCML opioid binding protein/cell adhesion
OR odds ratio
PC principal component
PCA principal components analysis
PCLO piccolo
PCR polymerase chain reaction
PD Parkinson's disease
PDE4B phosphodiesterase 4B
Phe phenylalanine
PICALM phosphatidylinositol binding clathrin assembly protein
PLXNA2 plexin A2
pmol picomole
PS power and sample size calculation
PSEN1 presenilin 1
PSEN2 presenilin 2
QC quality control
QQ quantile-quantile
RELN reelin
RORA RAR-related orphan receptor A
RPGRIP1L retinitis pigmentosa GTPase regulator interacting protein 1
like
rpm revolutions per minute
SAP shrimp alkaline phosphatase
Ser serine
SLC9A9 solute carrier family 9
SNAP SNP annotation and proxy search
SNP single nucleotide polymorphism
STRING known and predicted protein-protein interactions database
Szgene schizophrenia gene
Taq Thermus Aquatics
TBE tris borate ethylenediaminetetraacetic acid
Abbreviations
TCF4 transcription factor 4
TCF7L2 transcription factor 7-like 2
TE tris ethylenediaminetetraacetic acid
Tm melting temperature
TPH1 tryptophan hydroxylasel
TRIM32 tripartite motif-containing 32
T1DGC type 1 diabetes genetics consortium
T2D type 2 diabetes
UCSC University California, Santa Cruz
UK United Kingdom
USA United States of America
US United States
UTR untranslated region
UV ultraviolet
V version
Val valine
VCFS Velocardiofacial syndrome
WGA whole genome association
WTCCC Wellcome Trust case control consortium
ZNF804A zinc finger protein 804A
°C degrees centigrade
pg microgram
pi microlitre
pM micromole
1958BBC 1958 British birth cohort
5HT-2A serotonin receptor
5HTTLPR serotonin gene-linked promoter region
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